1 - Cade
Transcription
1 - Cade
o SERVIÇO PÚBLICO FEDERAL JdvnJ INTERESSADO:RFØLJFRFNTF& PFZIER. INC. ("PFIZER") - e WYETH rYVYt 1 02 ASSUNTO: CÓDIGO: no 0 op O OUTROS DADOS: o o o MOVIMENTAÇÕES: SIGLA DATA EQ 01 / / 03 / , p o o. CÓDIGO 04 I SIGLA CÓDIGO 15 17 18 05 / / 19 06 / / 20 07 / /" 21 08 / 1) 22 09 / f 23 10 / / 24 II / » 25 12 / / 26 13 / / 27 / 28 'IMENTAÇÕES DEVERÃO SER COMUNICADAS AO PROTOCOLO ANEXOS DATA - - - t FRANCESCHTNT e MIRANDA 4dvogados José Inácio Gonzaga Franceschiní Custodio da Piedade U. Miranda Fernando Eduardo E. Ferreira Thays R. Martins Fontes Moreira José Alberto Gonçalves da Motta Gianni Nunes de Araujo Ana Carolina Pinto Couri Smith Paulo Messias Pedrassoli Walter Basílio Bacco Júnior Camila Castanho Girardi Sandra Gomes Esteves Maria Eugênia Dei Nero Poletti Camila Pimentel Porto Daria Bruno Greca Consentino Flávia Maria Pelliciari Salum Bruna Cantergiani Martineili Crlsthiane Helena Lopes Ferreiro André Pissolito Campos Silvia Cristina Landi Bernardes Marcos Paulo Amorim Claudia Nastari Capanema Patricia Bandouk Carvalho Av. Brig Faria Urna, 1461- 13 and&- São Paulo. SP .01480.! Tal.: +5511 3095-2566-Fax: +5511 3813-9693 fl-frntfndvooaios wn br SECRETARIA DE DIREITO ECONÔMICO - SDE 11 DEPARTAMENTO DE PROTEÇÃO E DEFESA ECONÔMICA MINISTÉRIO DA1JUSTIÇA - MJ § Recebidgsm- VIs 8 'Ramo de Atividade: Indústria Farmacêutica. Operação: Aquisição da WYETH pela U PFIZER. - SDEJGJÍCAPRO oorden*çIO de Apoio Procotuti 1 1M111111111 08012.001157/2009-71 PFZIER, INC. sociedade com sede em 235 East 42 Street, Nova lorque, Estados Unidos (doravante designada "PFIZER") e WYETH, empresa co m sede em 5 Giralda Farns, Madison, Es tados Unidos (doravant e designada "WYETH"), por seus advogados, vêm, respeitosamente, ad cautelam, em observância ao disposto no § 40 do artigo 54, da Lei n.° 8.884/94, apresentar para exame e aprovação do Egrégio Conselho Administrativo de Defesa Econômica - CADE, após a realiúção de instrução e devida manifestação, nos termos da Lei, das Ilustradas Secretaria de Acompanhamento Econômico - SEAE, do Ministério da Fazenda, e Secretaria de Direito Econômico - SDE, do Ministério da Justiça, em 03 (três) vias, o Agreement and Plan of Merger ("Contrato"), em 25 de janeiro de 2009, além do Anexo 1, a que se refere a ResolLção CADE n.° 15/98. 11 1 r FRANCÊS CHINI e MIRANDA 4dvogados / (F.. iÇ DA OPERAÇÃO A operação eni referência trata da aquisição da WYETH pela PFIZER, empresas de produtos farmacêuticos e veterinários, as requerentes celebraram o Agreement and Plan of Merger ("Contrato"), em 25 de janeiro de 2009, mediante o qual a PFIZER adquirirá a WYETH, pelo valor aproximado de US$ 68 bilhões. Para a realização da operação será pago determinado montante em dinheiro, bem como realizada troca deH ações. Observados os termos e as condições dispostos no Contrato, as empresas irão fundir, conforme detalha o Artigo 1 ("Fusão"). O Contrato prevê condições costumeiras para o féchamento, incluindo a aprovação pelos acionistas da WYETH, bem como a aprovação de órgãos de defesa da concorrência. O fechamento está previsto para ocorrer no final do terceiro ou quatro trimestres de 2009. DOS EFEITOS A PFIZER é uma empresa farmacêutica global que produz medicamentos destinados á saúde humana e animal. No Brasil, a PFIZER produz e comercializa ampla gama de produtos para a saúde humana, para diversas aplicações terapêuticas. O mesmo ocorre no campo da saúde animal, em que a PFIZER possui atividades de produção e comercialização de produtos para bovinos, suínos e animais de companhia. Ademais, no Brasil, o grupo PFIZER desenvolve atividades relacionadas à fabricação e , comercialização de cápsulas gelatinosas para medicamentos, fertilizantes, defensivos, fungicidas e produtos antibacterianos para a agricultura, além de arrendar sistemas de vacinação in ovo. De outro lado, a WYETH, também é uma empresa que tem atuação mundial dedicada ao tratamento da saúde humana, produzindo 'A FRANCE,SCHINI e MIRANDA F;$ 03 -~ppo~-_ Ádvogados comercializando produtos farmacêuticos que exigem ou não prescrição médica, 9 bem como produtos para a saúde animal. As atividades das Requerentes, no Brasil, sobrepõem-se em duas áreas, conforme se verifica na tabela abaixo: Linha de Produto' i Pfizer Wyeth Medicamentos para Saúde Humana X X - Medicamentos com Prescrição - X X - Medicamentos sem Prescrição X Medicamentos para Saúde Animal X Cápsulas para medicamentos X Produtos para nutrição e proteção foliar X Sistemas de vacinação in ovo X X t Os Anexos 1 e ;II contêm a lista de todos os produtos para a saúde humana e animal que são atualmente comercializados pelas Requerentes no Brasil, separadamen e. Conforme doravante se verá, as Requerentes permanecem diligenciando io sentido de obter informações precisas sobre os efeitos da operação no mercadc brasileiro e sobre as áreas em que possa informações requerido, bem como a haver concentração. Dado o volume extensa lista de produtos de cada Requerente, não foi possível concluir o trabalho até o momento. De toda a sorte, as Requerentes informam que despenderão os O melhores esforços para concluir, tal tarefa, comprometendo-se, desde logo, a submeter informações acuradas eladicionáis nestes autos tão-logo quanto possível. Como é sabido, a identificação precisa de mercados relevante, bem como produtos substitutos, quando se trata da indústria farmacêutica, não é uma tarefa trivial. Produtos para a Saúde Humana Tendo-se tocante a medicamentos para a conta a complexidade envolvida, no humana, as autoridades de defesa da (1 FRANCESCHINI e MIRA$IDA Advogados ORDE concorrência contrataram uma áonsultoria especializada, a ser prestada pela Associação Nacional dos Centros de Pós Graduação em Economia - ANPEC, que contou com a colaboração técnica'do Instituto de Pesquisa Econômica Aplicada IPEA, para desenvolver um estudo, econômico,bem como métodos quantitativos no tocante à política concorrencial e regulatória, além de preparar base de dados para ser empregada e fundamentar os referidos estudos'. Em termos gerais, o estudo, que vem sendo adotado pelos órgãos do Sistema Brasileird de Defesa da Concorrência - Si para definir •mercado relevante em operações envolvendo medicamentos, propõe uma metodologia cujo ponto de partida é aplicação da Classificação Química uro pean Anatômica (ATC) da E Pharmaceutical Market Research Association (EphMRA), utilizada pelo Intercontinental Marketing Services (IMS) e, posteriormente, desenvolve-se para o agrupamento devido à indicação terapêutica do produto. De fato, a apliciação da referida classificação (ATC4), em determinados casos, não é a metodologia mais acurada para se definir mercado relevante. Isso porque há situações em que é mais indicada a combinação de uma série de produtos classificados em subclasses distintas da ATC, por serem substitutos para o tratamento de uma mesma doença. Por outro lado, produtos 11 agrupados na mesma subclasse: podei ter aplicações e indicações terapêuticas distintas. Assim sendo, existirão casc em que a análise da substitutibilidade deverá desenvolver-se no sentido de as aplicações terapêuticas do produto e as doenças para as quas ele Produtos para a Saúde Animal A definição é determinação das sobreposições, no tocante aos produtos veterinários também é complexa. As difiduldades residem, especialmente, na inexistência de fonte de dados oficial, nas diversas aplicações do mesmo produto, na forma de administração das doses prescritas, quS podem variar substancialmente entre os 1 'Procedimentos para a Definição e Análise Antitkiste de Mercados Rélevàntes de Medicamentos". Contrato SDE/MJ n° 1 ANPEC/IPEA. 4 / FRANCESCHINI e MI RANDA Advogados k _o.a_ OPD produtos e, finalmente, nas diferentes reações provocadas pelo produto no tratamento do animal. O PAIVET, Painel da Indústria Veterinária, elaborado pela empresa SINAPSE, que também já foi objeto de adoção pelos órgãos brasileiros de defesa da concorrência, para definir mercado relevante no setor de saúde animal, também pode ser, dependendo do caso, bastante impreciso. Em determinadas situações, sua aplicação isolada não é recomendada, diante das distorções analíticas que provoca, distanciando os resultados da realidade do mercado, pelas razões retro discutidas. Nessas hipóteses, a análise antitruste deve ser mais aprofundada, considerando-se ás indicações terapêuticas do produto e as doenças para a quais ele é prescrito. Considerando-se as discussões e complexidades envolvendo a definição de mercados relevantes para produtos farmacêuticos de forma geral, tanto para a saúde humana, quanto para a veterinária, como dito, não foi possível identificar as concentrações de mercado resultantes da operação até o momento. Mais que as dificuldades mencionadas à aplicação da metodologia, mencione-se que as partes comercializam uma ampla lista de produtos (Vide Anexos 1 e II) em ambos os segmentos no Brasil. Nestes termos, dado o tempo disponível, desde a celebração do contrato, não foi possível determinar com precisão as áreas em que ocorrerá, sobreposição de atividades entre as Requerentes. É certo, todavia, que as Requerentes se encontram despendendo todos os esforços para identificar as características de substitutibilidade de cada produto envolvido no ato, demandando tempo suplementar para tanto. Isto posto, as Requerentes comprometem-se a apresentar tão-logo possível o resultado desta tarefa, peça esta em que conterá tanto as áreas de sobreposição, como as respectivas estruturas de mercado, para melhor instruir o presente ato. Informa-se, ainda, que as linhas de produtos comercializadas pelas Requerentes, no Brasil, considerando-se as indicações terapêuticas mais abrangentes dos produtos, são, de forma geral, complementares. Finalmente, sobÊé as relações verticais, informa-se que as Requerentes não vendem principiosi ativos no Brasil. No tocante às cápsulas gelatinosas vendidas pelo grupo PFIZER, informa-se que elas poderiam ser 11 empregadas pela WYETH para a fabricção de medicamentos, todavia, conforme 5 1 ÇpEi FRANCESCUINI e MIRANDA Advogados \--- dito, informações adicionais sobre os efeitos da operação serão submetidas brevemente, tão-logo possível. DO PEDIDO _______________ lnicialménte, requer-se seja concedido tratamento 1 EONFIDÉNÕjiL às informações/documetos abaixo relacionados, por se tratar de segredos de negócio e, portanto, protegidos por Lei, em especial pelas Portarias n.° 4/2006ISDE e n.° 4612006/SEAE, dos Ministérios da Justiça e da Fazenda, respectivamente: • Faturamento das Partes, constantes dos itens 1.9 e IV.3, do Arjexo 1, a que se refere a Resolução CADE n.° 15/98, nos termos do art. 26, inciso VI da Portaria n.° 412006/SDE; • Clientes e fornecedores listados no item Vl.1 do Anexo 1, nós termos do art. 26, inciso Xl da Portaria 11 n.° 4/2006/SDE; e o Contrato, anexo, nos termos do art. 26, inciso VIII da Portaria n.° 4/2006/SDE. 1 Requer-se, outrossim, a posterior juntada, no prazo legal, dos seguintes documentos: (i) instrumento de mandato outorgado pela PFIZER, (ii) cópias autenticadas dos competentes comprovantes de recolhimento da Taxa Processual de Apresentação de Atos de Concentração, além do original deste; e (iii) a tradução do Contrato para o vernáculo, para os devidos fins de direito. Isto posto, tendo-se em conta que o presente Ato de Concentração é não gera preiuízos à Loncorrência, merece ser aprovado sem restrições e é o que ora se requer. Solicita-se, ror fim, que toda e qualquer notificação, intimação, convocação ou comunicação,relativa ao presente Ato de Concentração seja endereçada aos advogados das Requerentes, qualificados no anex2er 11 r / £ FRANCESCHINI e MIRANDA Advogados .5. instrumento de mandato, a saber: Franceschini e Miranda - Advogados, alc José Inácio Gonzaga Franceschini e Camila Castanho Girardf, Av. Brigadeiro Faria Lima, ri.0 1461, 130 andar, Torre Sul, São Paulo SP, CEP 01452-904, telefone: (11) 3095 2566, fax: (11) 3813 9693, e-maiL cgi rara ifm-advogados. com. br. Termos em que, Pede Deferimento, De São Paulo para Brasília, 13 de fevereiro de 2009. PFIZER, INC. Pp. José Inácio Gonzaga Franceschini OAB/SP h.° 28.711 Pp. _______________________________ Camila Castanho Girardi OAB/SP ri.° 175.500 .._res2 Ip Assessoria Econômica de: EDGARD PEREIRA & ASSOCIADOS Edgard Antônio Pereira CORECON 17.677 2a Região 7 Fiz n.o PARTE 1— DAS REQUERENTES 1.1. Nome de acordo com o estatuto sodial, nome dos estabelecimentos, 1 nome do representante legal, CGC/MF e inscrição estadual Requerente A Razão social: PFIZÉR, INC. ("PFIZER") Representante legal: Marc Brotman CNPJ: Não se aplica. Empresa estrangeira. Inscrição estadual: Não se aplica. Êmprõsã estrangeira. Requerente B Razão social: WYETH ("WYETH") Representante legal.- Gesilaine Macedo Chaves CNPJ: Não se aplica. Empresa estrangeira. Inscrição estadual.- Não se aplica. Empresa estrangeira. il 1.2. Principal setor de atividades das Requerente A - PFIZER 14.01 - Indústria Farmacêutica - Pr 14.99 - Indústria Farmacêutica - D Farmacêuticos e Veterinários; Requerente B -WYETH 14. 01 - Indústria Farmacêutica - Produtos Farmacêuticos e Veterinários. F ANEXÕ 1 \ç7' 1.3. Endereço da sede, número do telefonõ e do fax e endereço do correio eletrônico Requerente A - PFIZER 235 East 42 Street, Nova lorque (NY) 10017, EUA. Tel. / Fax: 1212 733 6098 1573 0768 C www.pfizer.com Wyeth 5 Giralda Farms Madison, (NJ) 07940, EUA. Tel / Fax: 1 973 660-5000 www.wyeth.com 1.4. Nome dos acionistas ou quotistas com as respectivas participações no o capital social, discriminando a natureza da participação societária Requerente A - PFIZER A PFIZER é a sociedade controladora do Grupo PFIZER. As ações são negociadas na Bolsa de Valores de Nôva Iorque e estão pulverizadas. A Pfizer não é controlada por qualquer pessoa jurídica ou indivíduo. Requerente 8— WYETH Acionista Wyeth Wyeth Pharmaceuticals Inc. 1 F 1 1 Ações 581.880.2891 85,65421% 116.6721 0,01717% H ANEXO 1 Wyeth Advertising Inc. 1.5. Grupo de empresas da qual faz parte Requerente A - PFIZER Grupo PFIZER Requerente B WYETH Grupo WYETH 1.6. Nacionalidade de origem do grupo Requerente A - PFIZER Grupo PFIZER - norte-americano Requerente B - WYETH Grupo WYETH - norte-atnèricano. 1.7. Principal setor de atividades do g Grúpo da Requerente A - PFIZER Vide item 1.2. deitem 1.2. 1.4951 0,00022% a ANEX 1.8. Relação de todas as empresas direta grupo, com atuação tio Brasil e no M nas quais pelo menos uma das participação no capital social superior Mercosul. indiretamente componentes do osul, bem como das empresas tegrantes do grupo detenha 5%, com atuação no Brasil e no Requerente A - PFIZER Brasil Pharmacia do Brasil Ltda. Laboratórios Pfizer Ltda. Uruguay :1 Argentina Pfizer Corporation S/A 11 Pfizer SRL Pfizer Health AB (Argentina Warner Lambert dei Branch) Uruguay S.A. Searle Argentina S. R. L. Requerente 8 -WYETH Brasil São Cristóvão Participações Ltda. Fort Dodge Saúde Animal Ltda. .. Fort Dodge Manufatura Argentina Cyanamid de Argentina S.A. Argentina Fort Dodge Sanidad Animal S.A. Argentina Wyeth S.A. Uruguay Whitehall Laboratorios S.A. Ltda. RMV Produtos Veterinários Ltda. 1.9. Faturamento, no último exercício, da(s) Requerente(s), da totalidade das empresas do grupo no País, no Morcosbl e no mundo. Requerente A - PFIZER 4EI\ (Fie. ANEXO i Participante (2007) Grupo - Brasil (2007) 5 Grupo - Mercosul* (2008) Grupo - Mundo (2007) Grupo - Mercosul (2007)* Grupo - Mundo (2007) (*) Valor não inclui o Brasil Requerente - WYE Participante (2007)* Grupo - Brasil (2007) (*) Faturamento em dólares convertido para reais a taxa de lt3b2/Ub$ 1,UUU tiO. Relação das aquisições, fusões, associações e constituições conjuntas de novas empresas efetuadas pelo gkpo no Brasil e no Mercosul, nos últimos 3 anos Reauerente A - PFIZER - Em Junho de 2006, o Grupo J&J adquiriu os ativos e ações do negócio da 11 Pfizer referentes à divisão de cohsume1 healthcare, incluindo produtos para cuidado e higiene pessoal e medicamentos de venda livre (Ato de Concentração n°08012.007138/2006-14 L Operação aprovada pelo CADE). - Em 14 de novembro de 2006, Embre, Inc. tornou-se uma subsidiária da Pfizer, Inc. mediante a celebração do Agreernent and PIan of Merger (Ato de Concentração n° 08012.011008/2006-78 - Operação aprovada pelo CADE) Requerente B - WYETH Não houve. U í E ANEXÓ 1 e PARTE II— DO ATO OU CONTRATO NOTIFICADO 11.1. Descrição resumida da operação indiàando sua modalidade (aquisição fusão, constituição de nova empreia, contrato, associações / joilU ventures etc.) As Requerentes celebraram o Agreement1 and Plan of Merger ("Contrato"), em 25 de janeiro de 2009, mediante o quala PFIZER adquirirá a WYETH pelo valor aproximado de US$ 68 bilhões. Fara a realização da operação será pago determinado montante em dinheiro, em como realizada troca de ações. Ambas as Requerentes têm ativos e operàm no Brasil li Observados os termos e as condições dispostos no Contrato, as empresas irão fundir, conforme detalha o Artigo 1 ("Fusão"). O Contrato prevê condições costumeiras para o fechamento, incluindo a aprovação pelos acionistas da WYETH, bem como a aprovação de órgãos de defesa da concorrência. O fechamento está previsto para ocorrer no final do terceiro ou quatro trimestres de 2009. 11.2. Setor(es) de atividade em que ocorreu o ato ou contrato notificado 14.01 - Indústria Farmacêutica - Podutos Farmacêuticos e Veterinários. 11.3. Esclarecer se o ato ou contrato é conseqüência de operação realizada entre empresas/grupo de empresas fota do País Operáção realizada envolve as operações das Requerentes no mundo, inclusive no Brasil. (111, is J__) 7 11.4. Relação de ativos envolvidos e sua A operação envolve todos os ativos pertencentes ao grupo WYETH no mundo. 11.5. Data e valor da operação Data: 2510112009. Valor da Operação: Aproximadamente US$ 68 bilhões 11.6. Nas operações que envolvem alteração da composição do capital social, 1 apresentar quadro contendo sua estrutura antes e após a realização do ato ou contrato notificado PFIZER, após a satisfação das Haverá a fusão dos grupos WYETH condições contrâtuais. A operação envolve troca de ações, bem como pagamento de quantia em dinheiro. Para maiores detalhes, vide Contrato. 11.7. Razões consideradas decisivas' para a realização do ato ou contrato notificado A operação possibilitará a criaçãode uma empresa diversificada no universo globalizado da indústria farmacêutica. É esperado que ela possa oferecer uma ampla gama de produtos para` todos, os estágios da vida, em áreas terapêuticas essenciais, incluindo drogas para o tratamento cardiovascular, doenças oncológicas, da mulher, do sistema nervoso central, bem Como infecto-contagiosas. A operação também possibilitará que as' Requerentes agrupem os negócios de produtos para saúde animal como os biológicos, os antibióticos e os destinados a animais de companhia. ANEXO 1 III - DA DOCUMENTAÇÃO /11. 1. Cópias dos documentos que Segue anexa cópia do Agreement and 111.2. Cópia do último relatório anual o ato ou contrato notificado ofMerger de 25/01/2009. para acionistas ou quotistas. Seguem, anexas, cópias dos seguintes • • Relatório de Responsabilidade Corpoiativa do grupo PFIZER relativo ao ano de 2007, e Relatório Anual do grupo WYETH relativo ao ano de 2007. 111.3. Quaisquer atos e contratos ou adicionais firmados entre as partes Não há. 111.4. Relação dos membros da direção do grupo que, igualmente, sejam membros da direção de quaisquer outras empresas com atividades nos mesmos setores das Requerentes Requerente A - PFIZER Não há. Requerente B - WYETH Não há. T 'E. 1; iii;s. Acordos de acionistas, quot:stas todas e quaisquer: acordos que incluam reqras relacionadas com a administração 10 Au 1' PARTE IV 4- FIS DOS MERCADOS DE ATUAÇÃO IV. 1. Relação das linhas de produtosl serviços ofertados por cada uma das Requerentes no Brasil e no Mercosul Requórénte A - PFIZER A PFIZER é uma empresa estrangeira e Çiolding que desempenha operações no Brasil, indiretamente, medianteas subsidiárias brasileiras pertencentes ao grupo PFIZER. Vide item 1.8. Requerente 8— WYETH A WYETH é uma empresa estrangeira quê desempenha operações no Brasil, indiretamente, mediante as subsidiárias brasileiras pertencentes ao grupo WYETH. Vide item 1.8. IV.2. Relação das linhas de produtos / serviços ofertadõs pelas demais empresas que pertencem aos mesmos brupos das Requerentes no Brasil e no Mercosul Grupo da Requerente A - Grupo PFIZER Brazil / Mercosur Produtos para a Saúde Humana Produtos para a Saúde Animal Cápsulas gelatinosas para a indústria farmacêutica Defensivos, Fungicidas, Antibacterianos e Fertilizantes para a Agricultura Grupo da Requerente B - Grupo WYETÀ Brazil / Mercosur Produtos para a Saúde Humana li 1 Produtos para a Saúde Animal IV.3. Identificar os produtos / éerviç& em que se verificam relações horizontais ou verticais entre os grupo das Requerentes. A PFIZER é uma empresa farmàcêutic global que produz medicamentos destinados à saúde humana e animall No Brasil, a PFIZER produz e comercializa ampla gama de produtos pára a saúde humana, para diversas aplicações terapêuticas. O mesmo ocorre no campo da saúde animal, em que a PFIZER possui atividades de produção é comercialização de produtos para bovinos, suínos e animais de companhia. Ademais, no Brasil, o grupo PFIER desenvolve atividades relacionadas à 11 fabricação e comercialização de 'cápsulas gelatinosas para medicamentos, fertilizantes, defensivos, fungicidas e [produtos antibacterianos para a agricultura, além de arrendar sistemas de vacinação iii ovo. De outro lado, a WYETH, também é umaempresa que tem atuação mundial 11 dedicada ao tratamento da saúde humana, produzindo e comercializando produtos farmacêuticos que exigem ou ião prescrição médica, bem como produtos para a saúde animal. As atividades das Requerentes, !no Brasil, sobrepõem-se em duas áreas, conforme se verifica na tabela abaixo: IL Linha de Produto Medicamentos para Saúde Huriana 11 - Medicamentos cm Prescrição - Medicamentos sem Prescrição Medicamentos para Saúde Animal Cápsulas para medicamentos « Produtos para nutrição e proteção foliar Sistemas de vacinação in ovo Pfizer X X X X X X Wyeth X X X X Os Anexos 1 e II contêm a lista de todos os produtospara a saúde humana e animal que são atualmente com&cializados pelas Requerentes no Brasil, ANEXO 12 ( r13 separadamente. Conforme doravante se 'ierá, as Requerentes permanecem diligenciando no sentido de obter informáções precisas sobre os efeitos da operação no mercado brasileiro e sobra as áreas em que possa haver concentração. Dado o volume de informaçbes requerido, bem como a extensa lista de produtos de cada Requerente, não foi possível concluir o trabalho até o momento. De toda a sorte, as Requerehtes informam que despenderão os melhores esforços para concluir tal tarefal,1 comprometendo-se, desde logo, a submeter informações acuradas e adicionais nestes autos tão-logo quanto possível. Como é sabido, a identificação precisa de mercados relevante, bem como produtos substitutos, quando se trata da 'indústria farmacêutica, não é uma tarefa trivial. Produtos cara a Saúde Humana Tendo-se em conta a complexidade envolvida, no tocante a medicamentos para a saúde humana, as autoridades de defesa da concorrência contrataram uma consultoria especializada, a ser prestada pela Associação Nacional dos Centros de Pós-Graduação em Economia - ANPEC, que contou com a colaboração técnica do Instituto de Pesquisa Econômica Aplicada - IPEA, para desenvolver um estudo econômico, bem como métodos quantitativos no tocante à política concorrencial e regulatá1ia, além de preparar base de dados para ser empregada e fundamentar os referidos estudos'. Em termos gerais, o estudo, que vem sendo adotado pelos órgãos do Sistema Brasileiro de Defesa da Concorrência - SDC para definir mercado relevante em operações envolvendo medicamentos, propõe uma metodologia cujo ponto de partida é a aplicação da Classificação Química Anatômica (ATC) da European Pharmaceutical Market Research Association (EphMRA), utilizada pelo Intercontinental Marketing Services (I MS) e, posteriormente, desenvolvese para o agrupamento devido à indicação terapêutica do produto. 1 'Procedimentos para a Definição e Ariáliei Antitruáte de Mercados Relevantes de Medicamentos". Contrato SDE/MJ no 1 ANPEC/IPEA. _m 11 E/ ANEXO 1 ( 13 1 -- O OPDE De fato, a aplicação da referida classificação (ATC4), em determinados casos, não é a metodologia mais acurada parase definir mercado relevante. Isso porque há situações em que é mais indicada a combinação de uma série de produtos classificados em subclasses distintas da ATC, por serem substitutos ,para o tratamento de uma mesma doença. Por outro lado, produtos agrupados na mesma subclasse podem ter aplicações e indicações terapêuticas distintas. Assim sendo, existirão casos er 1i que a análise da substitutibilidade deverá desenvolver-se no sentido de examinar as aplicações terapêuticas do produto e as doenças para as quais ele é indicado. Produtos para a Saúde Animal A definição e determinação das sobreposições, no tocante aos produtos veterinários também é complexa. As dificuldades residem, especialmente, na inexistência de fonte de dados ofYcial, nas diversas aplicações do mesmo produto, na forma de administração 11 das doses prescritas, que podem variar substancialmente entre os produtos e, finalmente, nas diferentes reações' provodadas pelo produto no tratamento do animal. O PAIVET, Painel da Indústria Veterináriai elaborado pela empresa SINAPSE, que também já foi objeto de adoção pelos órgãos brasileiros de defesa da concorrência, para definir mercado relevante no setor de saúde animal, também pode ser, dependendo do caso, bastante impreciso. Em determinadas situações, sua aplicação isolada não é recomendada, diante das distorções analíticas que provóca, distanciando os resultados da realidade do mercado, pelas razões retro discutidas. Nessas hipóteses, a análise antitruste deve ser mais aprofundada , considerando-se as indicações terapêuticas do produto e as doenças para a quais ele é prescrito. Considerando-se as discussões e complexidades envolvendo a definição de mercados relevantes para produtos farmacêuticos de forma geral, tanto para a 11 saúde humana, quanto para a tveterinária, como dito, não foi possível 11 identificar as concentrações de mercado resultantes da operação até o momento. Mais que as dificuldade mencionadas á aplicação da metodologia, li mencione-se que as pàrtes comercializari uma ampla lista de produtos (Vide ANEXO 1 Anexos 1 e II) em ambos os segmentos no Brâsil. Nestes termos, dado o 11 tempo disponível, desde a celebração do contrato, não foi possível determinar com precisão as áreas em que ocorrerá obreposição de atividades entre as Requerentes. È certo, todavia, que as Requerentes se encontram despendendo todos os esforços para identificar as características de substitutibilidade de cada produto envolvido no ato, demandando tempo 1 suplementar para tanto. Isto posto, as Requerentes comprometem-se a apresentar tão-logo possível o resultado desta tarefa, peça esta em que conterá tanto as áreas de sobreposição, como as respectivas estruturas de mercado, para melhor instruir o presente ato. Informa-se, ainda, que as linhas de produtos comercializadas pelas Requerentes, no Brasil, considerando-se as indicações terapêuticas mais 1 abrangentes dos produtos, são, de forma geral, complementares. Finalmente, sobre as relações verticais, informa-se que as Requerentes não vendem princípios ativos no Brasil. N9 tocante às cápsulas gelatinosas vendidas pelo grupo PFIZER, informa-se que elas poderiam ser empregadas pela WYETH para a fabricação de medicamentos. Todavia, conforme dito, 11 informações adicionais sobre os efeitos da operação serão submetidas brevemente, tão-logo possível. EI PARTE V L DOS'MÈRCADOS RELEVANTES V.1. Estimativa dos mercados relevantes identificados em termos de valor (R$) e quantidade das vendas no último ano li 1 Vide item IV.3, acima. •V.2. Valor (R$) e quantidade das vendas eu de cada Requerente, em cada mercado Considerando-se o elevado númerà Requerentes no País e pelo fato de qi identificar as eventuais sobreposições ex se apresentar as vendas, separadament Anexos 1 e II, informação que, além de presente análise. As vendas das Reque em que se verificarem concentraçõe informadas, tão-logo possível. termos absolutos e percentuais, levante, no último ano produtos comercializado pelas não foi possível, até o momento, entes, não há por ora condições de )aratodos os produtos listados nos istosa, data venia, não auxiliará a ites, considerando-se os produtos de mercado serão prontamente V.3. Estimativa da participação de: mercado dos principáls concorrentes (mais de 55/5) em valor (R$), tio último ano. Caso não seja possível, apresente estimativa em quantidade. Indicar endereço, número do 11 telefone e fax de cada um dos concorrentes, além da metodologia e fonte utilizadas na estimativa. Até o momento, nãõ foi possívêl apresentar as estruturas de oferta, nos termos que constam do item lV3. Todavia, de forma a melhor instruir o presente ato, encontre-se, abaix8, os principais concorrentes que atuam no mercado brasileiro, considerando-se, seprãdamente, os produtos para saúde animal e para saúde humana. Concorrentes ANEXO 1 Produtos para a Saúde Humana Eh LilIy do Brasil Ltda. Av. Morumbi, 8264 - Brooklin São Paulo - SP CEP: 04703-002 Astra Zeneca Brasil Ltda. Rodovia Raposo Tavares, km 26,9. Cotia — SP Tel.: 11 3737-1200 Môrõk Sharp Domme Alexandre Dumas, 2092. São Paulo - SP tél.: 11 5189-7700 Novartis Biociência S.A. Avenida Professor Vicente Rao, 90: São Paulo - SP Tel.: 11 5532-7122 Roche Brasil Endereço Av. Engenheiro Billings, 1729 - Jag ré São Paulo - SP CEP: 05321-900 Tel.; 11 3719-4566 Fax: 11 3719-4981 Sanofi-Aventis Farmacêutica Ltda. Av. Major Sylvio de Magalhães Padilha, 5200 São Paulo - SP Tel.: 11 3759-6000 ANEXO 1 Produtos para a Saúde Animal Merial Saúde Animal Av. Carlos Grimaldi, 1701, 40 andar.. Campinas - SP CEP 13091-000 Schering-Plough Saúde Animal Indústri e Comércio Ltda. e lntervet Sõhering Plough Animal Health Av. Sir Henry Wellcome, 335 - Jd. Moinho Cotia - SP CEP: 06741-050 Tel.: 1146134000 Fax: 1146134098 VaIlée S.A. Av. Eng. Luis Carlos Berrini, 716, 2° a São Paulo - SP CEP: 04571-000 Tel.: 11 5504-4333 Fax: 11 5505-5448 Ouro Fino Agronegócio Rodovia Anhanguera SP 330, km 298. Cravinhos - SP CEP: 14.140-000 TeI./Fax: 16 3518-2000 Industrial. 17 ( Fla DPty DPfla PARTE VI— CONDIÇÕES GERAIS NOS MERCADOS RELEVANTES VI. 1. Os 5 (cinco) maiores cIientes e fornecedores independentes nos 11 mercados relevantes de cada: requerente (indicar nome, endereço, número do telefone, número do fax e e-mail de pessoa para contato) ANEXO 1 - 5 nrinrinn,c rlinntnc 50 ANEX e -4 ANEXO 1 e Fiz. ID PC E PFIZER - 5 principais fornecedores AN c ANEXO ,cá__ -C b ANE4I Vt2. Código da Tarifa Externa Comum imposto de importação. Incluíras ali Em virtude do exposto no item V13 2 e a respectiva alíquota do previstas na alíquota os códigos TEC não são relevantes para a análise desta operaçãi e VL3. Estimativa da participação das independentes no mercado nacional A comercialização de produtos de saúde humana e animal depende do registro perante o Ministério da Saúde e o Ministério da Agricultura, Pecuária e Abastecimentos, o que dificulta a importação independenté na maior parte desse mercado. VL4. Identificação dos fatores que influenciam positiva e negativamente a entrada nos mercados relevantes As Requerentes não têm ciência de barreiras significativas para o ingresso ou à expansão das atividades no Brasil nos egmentos de produtos para a saúde humana e animal objeto do presentJ Nota-se que existem diversos e significativos concorrentes, em ambos os segmentos analisados, que também têm atuação global, conforme se veem listados no item V.3. Após a operação, a nova empresa continuará enfrent ando pressão competitiva das referidas concorrentes, bem como da indústria de genéricos. 4E/47 1 ANEXO 1 VII INFORMAÇÕES FINAIS V11.1. Informações adicionais que serem consideradas empresas julgarem relevantes a Não há. VlI.2. Informar as demais apresentado em que este ato ou contrato foi O ato também está sendo notificadô às autoridades de defesa da concorrência nos Estados Unidos, Canadá, Comunidade Européia, China e Austrália. V11.3. Nome, endereço, número do telefone, número do fax, endereço eletrônico do funcionário da empresa encarregado de gerar informações referentes à notificação. No caso de apresentação por meio de procurador dotado de mandato, apresentar as mesmas informações acompanhadas da procuração. Franceschini e Miranda Advoaàdos José Inácio Gonzaga Franceschini -Advogado Camila castanho Girardi - Advogada Av. Brig. Faria Lima, 1461, 13° andar São Paulo - SP Telefone: (11) 3095-2566 (11)3813-9693 Fax: E-mail: cgirardkâfm-advogados. com.br cuyaiu nrituuiuu reteita - cçuiiuriiis Rodrigo Hussne - Economista Av. Brig. Faria Lima, 1461, 70 andar São Paulo - SP Telefone: (11) 3037-3777 Fax: (11)3032-7861 E-mail: edpardedap.com.br càdgob RecStiwt MINIVTtRIO DA FAZENDA - NúnwadeRdascta .4- S 145000 caprt IbA DO 1E$OURQ CIOMAI. -- 1) - C2 OuI do Piocoltà,fl daçmfló CRU IVOV2O à;; Nome d3 tiflicade Çwtwo: ~EIXO ADMINISTRATIVO DE DEFESA ECQNa4ICA 30 001130211 45.000.00 AS friom'.çÕn ,medss nnsa gula %24S s*.'a tøo.t,*dade do conotoks. Que deà..m a.w de 0Ú4%d5. oonctna' e 1~Favorecida dc, rnc,. 4.) LIOW** $G$Øõ* (.) CRU SIMPLES - / vi Pagamento excIu&vo no Cnn do Brasa SÃ. f$NFFDfl44SIISCE4O4BSBEFBffC1 2t1MZal 4500&O0 S903004504 000000010104 fl1231S145*0 0045352300*0 - BANCU - t4;5Q38 0450 $5t9t97 CDHPRtVAUW W. PA!A Cotwcvio flRU4tflf, Ccdtn de irra ft%tli da PIRIORnto *IRO de Referencia Ccwaeteacia 1*VAAAA COM CUtl.SARRA 5. UNIÃO !i5-9 •flt$nteto -3 49e@45!s23eee-4 1410212n? i e2feo9 flata de Venciir,to cnn Valor Ptindit Valor Total • flttoe: NR,WJTEIITTCACAO 45,940.00 tn .D.F5, 437• !73.ryt . 2007 Corporate Responsibflity Report Stirong Actions Partnering for Positive Change fG7 (ris. .j DPD 1 We lursue Innovative Solijtioi+. to Heaith Chailenges Aroiind the World. Medical innovation is the core of our business. Tt's a fdrceforoõd—for patients, for those who seek to stay, healthy, and for society at large. Yet, our respon.sibiIities and potential impact go far beyond Lhe medicine4we discovei and develop They mclude providing the value that our stakehoideis seck. We enage our stakeholders and partners to address socieiy's evo1vng needs on broad social, ethical and environrnental fronts. There are many ópportunities to par+ier on the sàfety of and access to our medicines, 011 new cures and treatments, and on better health for people around tbe world. We ai.sÇ beije that good ccirporate responsibihty can be a soürce o] .isiness innovation. New partnerships that acldress iai needs through busiuess practices can foster sw inable healthcare solutions. Pfizer seeks more ofthese ikageè so we can heip make the world better foicúr mmunities, our keystakeholders, and ali thoe who int a healthier tornorrow. OVERV!EW Pfi?qr , 2007 Go,pora, Respon.5ihility R.'porL -r 1 C FS ? CHAIRMANS LETTER TO STAKEIIOLDERS a. . lfl lIkÇ Á ávIN 1I -' , JeffKindler C)iairrnan o! flu iloard and Chie! Exocutive Oøtc ir 4 - 1t ' - To Our Stakeholders, Pfizer's most important contrbutjon to society Oremarns d1scovenng, developing and brrnging to market new medicines. But producing even a great treatment is not enough. What's li also essential is how responsibly we use our skills and resources to invest in health around the w6rld. 2 Pfizer 2007 ('orporol,R..ponsibility fte.púrt OVERVI EW c OPOE OCR VALUES INTEGR[TY RESPECT FOR PEOPLE CUSTOMER FOCUS COMMUNITY INNOVATION That's why Iam pleased to share with you Pfizer's 2007 Corporate Responsibility Report. It is much mre detailed than Lhe previous report because our commitment to serving socity reaches farther, includes more arcas, and involves more partners than ever b'fore. Of course, sustainable programs of corporate responsibility work best when wè invest in Lhe health of communities and invest ia the health of our businees. This means that for ïfizer, corporate responsibility must be Lhe work of every department—on eve#y day. And so you will see ia these pages the tangible results, throughout our company, of commitr,ent to one of our chief priorities Lhis 'eár: collaborating with and providing +0Te value to stakeholders—whether patients, doctors, healthcare payers, nhngovernmental organizations or Lhe community. You will see in this report aoL jusL rhetoric huL resulta, whether in reducing accidents ia the workplace ar reducing Lhe energy we use. You will see us reach out to the communities in which we operate, whether helping schools, or promoting good health. You will see Lhe ways Pfizer colleagues partner with stakeholders to supp11 innovative public health programa in oncology and li tobacco independeric volunteer for work combating infectious diseases in Lhe least-developed arena of Lhe world. You will see inLius report new partnership and phiianthropy modela, creating 11 initiativesLhat ansvver questiona we've asked ourselves: How can we enhance the healthcare nvai1ab1eLo Lhose in Lhe poorest arcas of Lhe world? Iiow do we malte sare LhaL our custoners cnn be confident our medicines are safe and effectiveand LhaL we inform them al,out benefita and risks? Ia a world concerned about greenhouse gases, how can we reduce our environmental footprint? 1 And while laws a d regulations mandate responsible acLion, at Pfizer we are determined Lo go beyond compliance. We want aoL just to follow the lawbut lead the way: ThaL's especially true when iL comes to becoming more LransparenV—in plan English, letting you know what we're doing. And ao in Lhis report, you will algo soe ways to go online at www.pfizer.com and discover how wq: • PoaL Lhe status oÇour post'marketing studies—the first company todo ao • Provide resulta of aD our registered clinical Lrial studies ii • Open to public view what's in our pipeline Disclose US polit\cal contributions twice a year Plan to disclose grants to US medical associations and patient groups, beginning next ydar. We cannot forgeLhaL as we Lalk abouL Lhe programa and initiatives described here, Lhey stem frond Lhe work of real people, dedicated to change. These are my Pfizer colleagues working in more than 100 countries. 1 applaud Lhem alI. They symbolize Lhe Pfizer: moving quickly to Lalce Lhe lead, embracing li innovation, achievin resulta responsibly—and improving life for others around Lhe world. 11 TEAMWORK PERFORMANCE LEADERSHIP QUALITY Sincerely, JeffKindler Chairman of Lhe Board and Chief ExecuLiv Officer 0V E RV tE W Pfl:er 2007 (rporatv Ruponsibi/iry Report li Who We Are Founded in New York iii 1849. Pfizer is the world's largest research-based pharmaceutical company. Taking new approaches to betier health, we discover, develop and cle].iver innovative medicines to Lreat and help prevent disease in both people and animais. Through consistent, high-quality manufacturing and distribution operations, our medicines reach pati.ents iii more than 100 countries. We also partner roviders, governments, organizations, local commurnties and other stakeholders around the world to expand access to our medicines !nd to provide better-quality healthcare heaith system support. AL Pfizer, our agues work every day to h.elp people happier and heaithier longer. and to reduce the human. and econoinic burden of disease worldwide. t PFIZER FACTS LEADING MEDICINES Headquarters in New York City Oncology Meiabolic & Endocrine 89,000 employees worldwide Lines of Business - Human Hea!th Pharmaceuticals - Animal Health Pharrnaceuticals and Vaccines AROMÃSIN CANPTOSAR SIJTENT Pain LV A ICA' RELPAX' Operates in more than 100 countries lnflammation $48.4 billion in revenues, the world's largest pharmaceutical company $7.6 billion in Research & Development CE LE A A E 11 Allergy & Respiratory IRfectious Diseases 11 R&D therapeutic areas CHANTIX / CHAMPIX' 'E A IS' FEND' One of the world's leading medicines, Lipitor', which is a treatment for high cholesterol Ophthalmology XALATAN' / XALACOM World's largest animal health company and leader in annual animal health R&D investment US EPA Climate Leader member TO CONTACT IJS $1.7 billion in Pfizer Inc philanthropic contributions Accolades ai www.pfizer.com/accolades P.iease see www.pfizer.com/contact or write to our li corporate mailing address ai Corporate Responsibility, 235 East 42nd Street, New York, NY 10017. 'Ali numben are for fiscal year 2006 4 .P/üer 2007 Q'rp.'rate !kspon,ih,liiy Jkpr,rL E OVERVIEW Pfizer Corporate Responsibility Why Corporate Responsibility (CR)? In today's world, being a responsible company is the only smart way to operate in both the short-term and long-terni. To be responsible and accountable—socially, ethically and environmentally—is to be trusted. We need that trust to serve our dverse stakeholders and support a sustainable enterprise. We know trust is built over time with actions, not words. This report reflects progress in our actions and acknowledges areas where we still need to improve. Corporate Responsibility and the Board of Directors The Pfizer Board of Directors' Corporate Governance Conimittee charter requires directors to 'consider the perspectives of stakeholders in the company's decisions regarding current and emerging political, social and public policy issues." The Board receives information about stakeholder perceptions and opinions by varlous means including direct ernail from the public (see www.pfizer.com/ corpgov), Pfizer senior executivas' reports, annual shareholder proposais, and Directors' own personal and protessional networks. Integration of Corporate Responsibility lntegrating our corporate responsibility is not just updating data and meeting certain social responsibility codes. It is about changing our behavior and resource allocationchanging the way we operate, communicate and partner with stakeholders. On a daily basis, Pfizer Corporate Responsibility is managed giobally by a team that is part of Worldwide Public Affairs and Policy. The team is responsible for developing this CR report, establishing Pfizer's CR partnerships with vadous soclally responsible investors, nongovernmental and multilateral organizations, and coordinating with different global Pfizer functional and business areas. The team's focus isto foster and support integration of CR throughout the cornpany with a strong emphasis on stakeholder engagement. The team siso serves as an Internal-external bridge to foster communication for new ideas. We integrate corporate responsibility into how we engage on policy issues and even how we develop our medicines. For example, see page 91 on the introduction of our smoking cessation niedication Chantix® (called Champix' in Europe). OVERVIEW the Report We are pleased to issue Pfizer's second report on our corporate responsibility approach and activities. We decided to publish this longer report to address key issues in detail, supplemented by a sunimary of our corporate responsibility activities in two printed documents—a 24-page summary report and a brochure. Please note that even more information about our corporate responsibility activities is available on our website at www.pfizer.com/responsibility. Scope of Reporting. This report covers Pfizer's pharmaceutical and animal health businesses. Pfizer's consumer products business was sold' to Johnson & Johnson at the end of 2006. This Corporate Responsibility Report includes activities and data from the calendar year 2006, including data from our consumer products business. The envlronmental performance data does not include our consumer products business. Additional updates from 2007 are referenced where relevant. We remain cory-imitted to internatlonally recognized standards for CR reorting and we will continue to review our reporting practices in Iight of evolving standards including external assurance standards. Materiality The content of this report is based on a materlality analysis tocusing on two key factors—the importance to stakeholders and the potential to influence business strategy. Materiality was assessed by an interna] cross-divisional team representing the key businesses and by an externai advisory group. Stakeholder lnclusiveness We listen to our stakeholders and value their perspectives. In keeping with the principie of stakeholder inclusiveness, we have identified our stakeholders in this report, the feedback we have received, and how we have responded to their expectations and interests. To contact us, please se www.pfizer.com/contact. Global Reporting Initiative Sustainability Reporting Guidelines We considered the Global Reporting !nitiativé (CRI) Sustainability Reporting Guidelines (03) in preparing this report and Include a comprehensive CRI index. We self-declare this report to CRI Aflplication Levei A. For information on CRI, please see www.globalreporting.org P/i:er 2007 £01) orWv R'npcn.ihllitv R.'por Global Public/Civil Sector View To bailar understand the global civil sectoron a wide range othealthcareissues n2pqad?P96th, global research flrm Globescan conducted intervi~on behalt of Pfizer with 350 healthcare opinion leaders from China Gret Britiin Japan Mexico South Afnca and the US with representatives from government health policy, NGOs and multilateral organizations as shown below. Ttie results trom the 2004 survey were included li our 2005 Corporate Ci~ Report. • Respondente were asked for mutOple menlions; te measureis caiculeted as a percenlage cii total responderas sndne total can exceed 100. OK! MA- Doei Kriow / Not Avaflabla lhe sempia elas lo, ~ Orei tfly, oondiced e Selo. lia Us SineVW., FI.eO: lo 2re0 Ir. USiWle lias Orc,eaeSIo n-Io0.k enwn000re.sbIlty010re 24 flMO das. ires ss.re,ed Ore., te 2®4das J5— mes hesonleo W 'o IDO 'ewe,denls O,aI.eS ol 50. lo 1.m. ai ir. lotei .a.,eie, DE. IS ,espoed.nts teve moi. mei0ir O,.., note corei.. wtse 50 ai.tddea ores itnel..sl lo EDOI ad 20l. UM 6 T5Çztr 20117 Coi -p,rote T€o'aoponsihtlity Rep'M 0V E 11V 1 E W Our Corporate Responsibility Standards and Evaluation Partners The Business Róun tãbi&s S.E.E. (Social, Environmentai Economic) Change initiative is a voiuntary program for rnernber companies to adopt rsustainabihty principies as a business planning tooi its of the Btjsines Roundtabie's Ciiniate Resolve initiative and in 2007 agreed to a new statement ohciimate change. 4; 00w Jones SustainableAsset Managemeni (DJSAM) www.s-group.com/htrnte/ain.cfm a) DJSAM is a research organization that evaluáesÇ companies as sustainable investments Pfizer has been seiected to be in the DJSAM Index since 20d0)Last year, Pfizer had leading scores in corporate governance, environmentai reporting taTent attraction and retention and stakeholder engagement Trnsparency International (Ti) www.trans parency,o rg An WGO wfth a ketwork of local chapters in more than 90 countnes, TI's goal isto combat corruption and :bribery. Pfizer tias served on.Tl's Steering Cornmittee on Busiiess Principies for Countering Bilbery since 2003, and in 2005 j6irõdthe Board of Ti-USA FTSE4dood www.ftse49ood.com US EPA Climate Leaders www.epa.gov/staiepiy Thiá index sedes, creatêd by the UK FTSE medsures the performance of companies giobaily recognized corporat responibiht Pfizer has rnet FTSE4Good Sodial Resri&i criteda since March 2002. 5 Global Accountability Project (GAP) www oneworidtrust org 1~1.1U1101% JN Pfizer is a charter member company under the US Environmental Protection Agency Chmate Leaders Prograni1 This is a voluntary industry government partnership that works with climate change strategies and tf&house si i[&edõction dàTt 11 r 22 1 11H'1; GAP is part of the Accountabiiity Prograrn at One World Trust an NGO that anis to generate wider commitrnent to the principies and values of accountability in eceniber 2006,the GAP index rated Pfizer as among the most transparent and accountabie organizations of the 30 reviewed in detail 2r. Institute for Suppiy Chain Managenient (ISM) www.isrn.wsindex.ctm PP A rnember organization of supply chain professinaIs, iSM deveioped suppiychaid standards for sociai~ 111M responsibiiity that focus on community, diversity, environment, ethics, human rights, íinanclei responsibiiity and sàfety. Pfizer sighed on to these principies in 2005. 0V E RV 1 E W 1'frrir 2007 Gorporafr Rea;'õnibititt RporL Progress on 2006 Commitments FOCUS MEà 2006 COMMITMENTS PROGRESS 1 -. I--- Submit 20 new medicinas for FDA approval belw?en 2001 and 2006 t.Ilt1tfW Disclose resulls cl ali late-stag clinical trais on cur marlçeted products E É Pfizer has and continues to disclose lhe results of its late-alago clinloal tnais on markeled producta. in additâon, in 2007, we expanded ou, commnilmont to Include ever9 rer-sponsored clinical study in patienls on the NIH-sponsored website www.clinicahrlals.gov. This includes Phase 1 trais and non-Interventional studies with prospectNe data. • t1rnlIFyh.,dlr, Appltvancedscicnpe and technolcgy fn lhe manufacture of medicines lo produce cosieffeclive high-quality products l - • A compreiteve Technology & innvFaion strategy is In place aimed at saving $5 biflion over years through the introduction of new technologies and processes. • . Extensive use of enzyniesiristead of chemical reagents is an iniportani coniponent and wili yield s gnificant environmental henefita as weli as cost reduction. For example, a new procries oy acture which s not s has b e siniflcn cheaper but will eliminate up to 5 mullloale ons p of o solvent usage. Pfizer submkteà 19 new niedicines for approval by lhe end of 2006. I Continue to reduce injuries, eney use, wastes and emissuons, relatuve to production leveis and lhe number of coileagues EE -- ,, Ensure that contract manufacturers and key suppliers 1. have responsuble envuronrnent, health and safely (EHS) management relaled to productuon of materiais for Pfizer à • Conipared to 2005, Plizer Global Manufacturing (PGM) Iost time accldent rate decreased by 12 percenl and total injury rate went down by 8 perceno. CM energy consumplion was redtuced by 10 percent compared to 2005. bringing CO2 emiastons down by 9 peroent adjusted for asquisutions and duvestitures. PGM hazardous waste was reduced by 18 percent and nonhazardous waste by 9 percent. Excludlng duvested and closed sitei, hazardous waste was reduced by 10 percent and nonhazardous waste by 2 pekent. •1 --'Mrx'r-' —--- — ' ---'----'------ We review key suppliers of active pharmaceutical lngredlents (API) and ali contract manutacturers til either API ar final 6wg products. In 2006, 100 EHS reviews were completed k0 assure the respons'biiily til these key suppluers Reviews were done giobally, with a partucular)-oc'u's on China açid Gidla. The results are consldered ,n our supplier decusions. - r, e Support lhe communitles in whih we aparato nianufacturing plants through communuty oulreach activuties focuaed on education public health, safety and improvement of lhe envtronment — • Ali PGM sltes, lncludlng majorioçlstics centers, established community outreach programa. Over 140 projecta were umpiemented as pari of tênis effort. • PGM altas obtalned 39 EHS awards from governnient and other externai ii ri organiatuons. - Offer our resoumoes and talent to respondi to global disasters, such as we dld wlth lhe Soulheast Aslan tsunamu and 1-lurrícanes Katrina and R We continue to offer ourcoileagues and resouutes though the Pfizer Global Health Feliows program, to combat infectious duseases In arfas where lhey aro most endomuc. For more unformation on thus program plase see pagos 43-44 and 49. 1 1 - i * - Ii S - - __*eP*tfNatn__ •y lutnr Follow internaluonaJty reoognuzed standard for corporate responsibiluty repartirá, such as the Global Reporlung inutuative 1 i Develop corporate responsubiluty perfomiance measures As slated in Pflie?s 2005 Corporate Cutizeqishp Report. Gtvert Ota tans4lion Pfizer cl werar.ptzercom/mesponsibi5ly ln 2008. J'fizmr 2007 Cuirporote Respoaauhilily Report Pfizer consldered the GRI Sustainabiluty Reporling Guldelines (G3) in preparing thus report and included accmprehensive GRI Index. We seil-declare thls report to GRI Application Levei 8. [Pfizer tuas worked wuth internai and oxternal stakeholders lo betler understand ou' CR ig tinis esnh Liruformation lo develop metrlcs for use in ou, next reportung cycle. 5 -1i*i *J ,r 8 undergoing, commttTents for 2008 wuii te posted on our Coporate AesponSbiity cobaIa tiVE RVIEW FOGUS ÁREA PROGRESS 2006 COMMITMENTS • Az of June 2007, Pfizer will have spent 11 months foliowing the commerclal . availabdity'of Chantix in lhe US educating physicians about this product without ,' rur'ining any branded consumar TV or prini advertising. We wili continuo to educate heailhcare professionals for sovraI moro months prior to beginning any brandod $ consumer adverlising. • Exubera randod advertlsing b gan In 2007, more than 9 months foliowing the first * cornmercial availability of lhe product in lhe US. During thls time, Pfizer has invesled significanl rasources in educating yslcians and educators aboul Exubera and lhe use of inhaled insulin. Educate physlcians for a minimum ai aix months aboul a new prescription medicina prior lo beginning TV and pfint advertising Include language In prodúct' TV and pnnl ads lnforming consumos lhat doctos may recornmend alternativo Ireatments, including litestyle changes, when appropriate e Pfizer rnedicines aro not for everyone and our advoitising makes that doar. wr ou ngge in ai our advetsingto ensure lhal consumers know that lhelr physiclan may recommend something other than lhe advertised product, lncluding díat and exercise. - HN IR Stop ustng remlnder ads" on in 2006. Pflz& has nol run anyjv or pnnl reminder advertsemenls. 1 TV and in consume, magazines with lhe exceplion ofs related activities I p 1 ______ — Use a new consumer-fdondlyF ~The_ majorily of Pfizer print advertisements have an Important Fada brlef summary and and consumep-tested prinl brief are in developmenl. summary in ali product pdnt adE RO ORIM e*mtsut*qr , mms , j Increase advertising eftorts behind disease awarenese and r. Pfizer Heipfui Answers Plizereclucates people about pfizer Ijeiprul ,4nswers na nLjmber o? ways, including campaigns cri radio, púnl and anime advertising and local avente to he1p uninsured 1 ,Aj'ner(can iearn ab'out 'programa that can holp thom to save on medicines. Through ur outreadi offorts, Pfizer is enrolling many new patienls in our patient assislance P? ograma. Pfizer submils ali new DTC TV advertising campaigns to lhe FDA for review in advance 1 of aiiing. Pfizer supports lhe FDA having lhe appropriate resources lo conduct these ' reviews and has been a proponent ai advertising review fees as outlined in FDAIRA legislalion - Submit tolhe FDA for review ali new OTc TV ads in advance e? ainng Ensure ada ara trgeied to approprlate audiences wmll air erectile dysfunctmon ads cnly during programa wilh moro than 90 percenl aduil viewership Wfl'7flflfl,'.i,,r*- .rnesn.spurnasprssrn.rnaslr Viara advertising is placed on TV programming that has a rnínimurn of gopercent adult v]ewprship. '' 1 jiTP - Provido lraining for empioyees to 1Lflizer commissioned indopendent monitonng and ovaIualior studies thiough lhe most effeclively work wilh NGOs Isoslon Universily $chool of Pubiic Heaith lo understand program impacta and how to In developing countries lincroase lhe program yalue for beneficiaries. As a result, a three-day Iraining has been tincorporaled mio Pfizer's Global l-Iealth Feliows (GHF) program operations. ,s,,.wiew.waiaur - ne.aasaa seimum, ejii a, eu i ease'ms,,,eeefl Presenl Global Healtb Feliows rnodel and provide suppoit to privale sector to repiicate 11 kwss*tnuarusie ------5 - - Provido 35 miflion doses of' aniibiolic to lreal active trachoma Infeclion worldwide i, ,e'e-eta-usesa ' Through a partnership wilh lhe Brookings lnslitulion's inlernalional Volunleerlsm i ,iniliative, Pfizer has beert working to promote inlernalional Corporate Voiunteetlsm. Meanwhiie; Ffizer has advised and supporled soveral companies in their efforls to establ ah Fellowship programs, lnciuding 60 and Ernst & 'Young. - 1 uOh lhe Internationai Trachoma Initiativo QTfl, 17 million trealmenls ol Zithromax rornycir) wero proided in IS countries in 2006. The shortfail was due to delays in-~ling up lhe progra in some counlries duo to bureaucratic or customs cleararVce ,r s, lhe roducod incidence ai trachoma and zonas ai armed conflict. in 2007, asaS time, lhe TI is on targel to reach 35 rniflion doses by yearend.jj As siated in Pfizer's 2005 corporal. citzaui,Jiip Report Given ffie irnsibon Pfizer is undergoir,g, oomrnilrnenls for 2008 wa be poafled 0,1 Dor Corporal. Rasporeibety website ai www.pflaerconilresponsiblrty In 2008. OVE RVI EW Pfrz,er 2007 Goiporcfe Jk,põnnihilitv R.*pori 9 4vEf F13 odel Operating with a New Stake c Stakehoiders are peopie or groups who affect, or are affect by, Pfizer's business activities. We share with them an overarching goal—good health for ali people aI manageable cosls, and a heaithcare systern that is sustainabie. Our relalionships with stakeholders are at the heart of our corporate responsibihty because they define what il means for Pfizer to create value. That is why Jeff Kindier, afler being named CEO in Juiy 2006, and the new senidr management team met with a variety of stakeholders. They wanted to find out what was on stakeholders' minds, what worked weu—and what needed to be strengthened. Some of the cornpany's new priorities and actions are a result of these discussions. Here are just some of the stakeholders our senhor management mel with in the past year: • • • • • • • • • • • • • • • • American Heart Association American Lung Association American Medical Association Campaign for Tobacco Free Kids Easter Seals (disabihly services) Instilutional and other sharehoiders international Alhance of Patienls' Organizations National Alliance for the Mentaily iii Nationai and local government leaders Organizalion for Economic and Cooperation Development (OECD) Oxfarn Great Britain and Oxfam Arnedca Pfizer coUeagues around the world Pharmaceutical lndustry Labor Management Association Sheel Metal Workers International Association Women impacling Public Poiicy World Health Organizalion works as pari: of wider healthcare systems. We ong and Irusting partnerships to make progress on improving global heailh. Given this reality, we wiili continue to engage stakeholders regularly and continue to share knowledge, skiils and goais on how to prevent or manage diseases, gel medicines to lhe people who need them, and prornote good heaith aniong diverse populations. These partnerships take many forrinsas described in this report. 1 for Engagirig Stakeholders: • Advisory boards on isaues and producta • Assoclallons and networks for palienl advocales Conferencias aI internationai, regional and nationai leveis •' • Dialogues with multicultural slakehoider groups •' Email and leItar responses Externai compliance hollines e' Focus groups with different stakeholders • Grassroots outreach programs within communitles •jl Managemenl-employee advisory counciis and "lownhalis" Media briefings and intervlews with journalisls • Meelings, briefings and feedback sessions with inveslors, Ii cuslomers, iegislators and regulators ' Partnerships in lhe fieid with NGOs and MI-Os • • Pfizercom website interactive features • Professlonai Irade associatlons for sclence and business • Seles cails to physicians •, Surveys of colieagues and customers Senior manaõement heard a spectrum of comments from a stakeholders ranging fromPfizer being seen as an inflexible business pariner, to questions about lhe stock price and from awe at Pfizer s scientists for their skilis and dedicalion to surprise at lhe scope of our partnerships in improving access to medicines However, most stakeholders agree lhat given lhe compiexuly of public health probiems facing lhe world loday, no single entity—governmenl corporalion academic instilulion nongovernmenlai organization civic organizaluon or others—can solve heallhcare ussues alone 1 takes ali of us workung together, contnbuting our respectiva strengths Some stakeholders have dilferenl views on how to achieve heallhcare goais Our chalienge is to buuid on amas of agreement and find common ground To achieve this, we seek to constanlly improve our communications and transparency to listen and respond better to stakeholders, and to learn from them. We siso share insights on how lhe pharmaceutical 10 Pfi:er 2007 Qnporate Rcapon,ih,Iity —1V4 RÁ WI-10-Hálg Évidence Network www euro ho nIJHEN UM Pfizer supports lhe important work of lhe World Heaith Upr0arization MHO) Heaith Evidence Nelwork (HEN) Which pVordiolicymaketwith independent and readyto use evidence based infomal,on on publicNJI health and heaithcare issues HEN providesisy access to olhar internalionai dalabases and sour&s of lnforrnalion The scope of HEN s work oorresponds wuth Ithe 14;straleguc technicai objectives of WHO in 2007 Pibased on stakehoider dialogue we ofereci suggestuons on potential heaithcare topics and lhe crealion of work groups and pohcy bnefs lo upport publuc healthcare decus,on-makers while respectung their undependence We siso supporl HEN with an unreslricted granl and with an scientifcpxpertise. siso -11.11 E 0V E RV 1 E W \ 4j. Pfizer's old StàkéholdéYModel a Previously, we engaged with stakeholders one on one in amas of shared interest gI a S 1 2- Pfiz&r's New Stakeholder Modal TodayinahetworkedworId,wefocus on mutual goals—on pursuing innovativo solutions to global health challengos with our slakeholders as partners. This also helps build ec000mic prosperity. 'UàÁgi1034 p, RW t 3 AT ENTS Rk FM IM 51 ru ir, 0V E B VI E W im:rr 2007 (Mrparofr J.pon.thilttv Repõrt 11 EdI Changing How We Integrate StakehoMer Needs We are seeking to provido more social value today, as well as medica] resuits, because that is what society is asking of us. By better serving our key stakeholders, we ultimately better serve our shareholders. For a macro view of this change, please soe the chart on pago 11. We are hiring a diverso world orce to refiect the diversa societias in which we operate. This Is one way to give society a stronger "voice" within Pfizer—to employ in influential positions coileagues from biotech firmo, patient advocacy groups, health professionals' organizations, insurance providers, governments, think tanks and academia who influence our dialogue. This diversity changes how we Õ • think and operate at the very core of our business. Changes on the day-to-day levei, for example, are evident in our ACE (Aiigning Customer Exceilence) Program in Europe (pago 84). We also engage directly with stakeholdei's through issuo advisory boards, employee surveys, conferences, small meetings and public-private partnerships. Some approaches have predefined feedback and follow-up methods. Other approaches are more informal and help shape futuro goals and activities. Foliowing are two new initiatives from early 2007: to nficit partner uable worlç partners to provide financial support and other..skill for their activitiesThis is one way wd contributo to the improvementof patients' lives beyond our core business of developung unnovatrve médicunes For 92 In theVK..ye áfJréquire, as a berofthe itical lndustry, :ations we work vorkung with theseÇ 'ayPfizer.UK has]J; ind described theq full naturapt our relationships with ese groups, as i noted on above. In the US: in 2008,'w&will dev for educational grants and ind planning process as noted on wili enuFuikeholders' vie MI 12 Pízor 200fl Corporate Tksp.'nsihsfitv Repori ove our and abáve. Thi red as the medical 0V E E vi E W Cf4 sol DPDE j Our Coliective Action Some social ar environmental problems can only be solved by coilective action, when stakeholders from an entire industry ora cross-section of society band together for the greater good—when "ali hands on deck" can provida solutions mo effectively. We Iry to demonstrale our corporate responsibikty by taking a leadershlp role in such collective actions, either within lhe biomedical community ar in cross-sector initiatives. We know thal working with our colleagues from other conipanies and civil institutions resulls in more effective, iong-lerm solutions. - - Examples include: - Partnership for Quality Medical Donations www.pqmd.org E E E t 1 IE PQMD is dedicaled to advancln the quality óf rhdichi producls deliverod to urfderservedpeole and eri' viclims around the world. Pfizer sponsorod Iwo key ' PQMD projects. We lunded a study to develop a' p melhodology for estimating the nurnber of patients treated based on lhelu vomes of medicinas shipped to developing countries by PQMD members. We also funded and direcled lhe creation of an educational fim thal teaches lhe basics of medica] inventory ET!?a9omont and raises awarenoss of lhe supply chain management professuon globaily. The fimsaable o lhe webbv mPior colieaguo. E E a e OVERVI EV h -, Wârking to Provida Coverage for theUninsured www.coalitionfortheuninsured.org 4, UMIPiu E, With approxinialely 47 million Americans still lacking healthcare coverage, Pfizer joined a hi y diverse IM h grãup of 16 public-private Sartners tti rethink lhe issue and lay out a path for progress. Over the pasl two yearè, t,thisi' oalition, the Health Coverage Coalition for the Unlnsured (HCCU), cornprised of healthcare providers, E trade associations and activist groups, developed consensus recornrnendalions for covering a signlficant number ot the uninsured. On January 18, 2007, the coalilion releasod an agreemenl which ali the parties Eendorsed in whal we think is a national heailhcare first in tle liS. For more information on lhe key principies aridrecobrnendations, please soe pago 89, 1 '.EE 1 'E WEtIWE, E .- Thé Glóbal Environnientál Management lnitiative J wwgemi.orgIwaterpIanner/ E E - GEMI is a coahtion of companies committed to WNg E improving suslainabie business practices. The initiative's recent effort is calied "Coilecting the Drops: A ater Suslainability Plajiner." Pfizer piayed a loading rSd in develop wa inabihly bel by providing strateguc direclion on lhe approach and technicai dontent, based on our own successos and chalienges with maiagínb water. The planner is designod te heip guide a facility through lhe process of asssslng and idenlifying specific water uses and Eneeds inèomparison to the availability of water in the region; lhe impacto! operalions on the available water E resources, and those factor; that may pose a risk to the Pfizer 2007 Corporafv Reponsihitif ,- Report 13 L j finãltng CURES AND TREATMENTS 0w, rnost important e dntfibution is discovering, developing and de1iering innovative medicines that society values to.prevnt and freat disease. To achieve these goals, we arecornmitted to improing R&D produqtivity, increasing the transparency of our pipeline and chnical frial practices, improvihg druíg safety monitoring, and workingin partneshíp m, ith ourstakehoiders to advancethe dWcoveryand deyelopment of effective.new medicines. } 16 f'fize.r 207 Corpurote Rnponsibilitv Report Fia DPDE ii 2006/2007 KEY ACTIONS Launched innovativõ new médicines totreat major diseases—for two -t hard-to-treat cancers, diabetes, tobacco dependence and blàodstream infections. Received FDA approval foreizentryTM Ïmaraviroc), a breakthrough treatment for HIV/A!DS. unched www.pfizer.com/pipeline improve R&D transparency. Established astem ceil research policy t6 guide ourexternal partnerships beginnihg .in 2007. artneréd with the National Institutes ofHealth (NIH) and biotech firms to dnravei the genetic causes of common Established a couaboration with the World Healthorganizatidn tálhélp t: find new compounds for diseases of thedeyeloping world. Continued to develop 242 reearch prorams—the most Pfizer hãs ever had—spanning 11 therapeutic areas. d the mainstream :eutical industry's first r" to supportearly-stage start-ups. Expanded disclosure of our4 clinical triais. SeIzent" will ba known as CaisanthO in ali countdes ouIsde the US pending reguiatory approval: 18 J'ficor 2007 corjmrrae Rrspanihility Reperi R&D: FINDINO CURES AND TREATMENTS Launching Medicines for Unmet Medical Needs Continuous hiomedical iimovation is essential, not oniy to find cures and effective treatments for patients, bui also to reduce the direct and indirect costs of disease ou society. which includes such things as Iost job productivi.ty. In 2006, Pfizer introduced several innovative medicines that are expected to have significant beneflis for patients and societ•v They are: H1 Sutent' is the flrst medicine ever to be approved simultaneously by the FDA to treat two types of deadly cancer—advanced renal cell carcinoma, a tye of kidney cancer,and gastrointestinal sttomal tumor, I2nbn s GIST. Also approved to treM these diseases by the European Union, Sutent not only kilis cancer 10. celis but starves the tumors of blood and nutrients. Pfizer is now investigatingeits e a in .breast,lung and colorectal cancers. R&D FINDING CURES AND TREATMENTS Ier2ÜO7Grpôrafef?epo,nzhitity.Rpon 19 Eraxis treats candidemitho mosfdéadIÇTfth JW common hospital-acqurred bloodstream nfe6uons which can spread qu'ckly especrally for patients with weakened ínimune systeins Eraxis' san irrqortant newtreatment for, the approximately60 000 patients in the US who contract thisdangerous ínfeclinhJfl9 1 flfl n % eaoh year. Mi!O P.qP, In June 2007, the FDA approved Lyifor thê management of fibromyalgia, a cornmo&chronic and t widespread pain condition. The a?&àI Mresents a breakthrough for the more than six rnillion Arnedcans , indibâtion. Ii waíiiitiaIIyapproédfóitiõWián of neuropathuc pain associated with1diabetic pe neuropathy and postherpetio neuralgia and for adjunctive use in the treatrnenfofepilepsy 20 J'/jr 2907Gorp,rte Prspo,u,,h,iitvReoori R&D FINDINO CURES AND TREATMENTS OFO Expanding Research for Diseases of the Developing World We believe we have a responsibility to conduct and support research for diseases that affectt the developing world and are expanding our efforts to help meet this global health. chaileuge. As a single cornpany, however, we are Iimited in our ability to solve such universal health problema and recognize that multisector sotttioits are needed. Today, pubhc-pnvate partnersh.ips are essential te inaking progress ou this front. proving Treatments for MaIana Through our Zithromax/chloroquine clinicai trial prograni, Pfizer scientists are developing a potential ralaria treatment based on our widely used antibiotic, Zithrornax. Dosed in conibination with chloroquine, Zithromax' démonstrated positive results in the treatment of adults with mataria in Africa. Currently, clinicai studies are ongoing at cantara in South Arnenica, India and Africa. Opening a New Front Against Infections We expanded our commitment to fighting infectious diseases in 2007 by acquiring UK-based PowderMed Ltd, whose proprietary, DNA-based technology is designed to deliver a new generation of vaccines. This vaccine development program, with a needle-freo delivery system, is at the forefront of a scientific effort to overhaul a vaccine manufactuning systern that has remained largely unchanged for the last 50 years. While the research is at an early stage, this new DNA-based technology is quickly adaptable to changing strains of influenza. The pipeline also includes vaccines in phase 1 developrnent for herpes simplex vitus (HSA as well as other vital diseases. Collaborating with the World Health Organízation Our coliaboration with the World Health Organization's Special Prograrn for Research and Training in Tropical Diseases (WHO/TDR), announced in October 2006, is an unprecedented partnership for a public company. We are opening our library of medicinal compoundsthe world's largesi—to help search for new antiparasitic medicines against such deadly diseases of the developing world as maIana, leishmaniasis, African trypanosomiasis, onchocerciasis, schistosomiasis, and Chagas' disease. We will also bring scientists from developing countries into our laboratonies for training in drug discovery technlques. fl "This collaboration is a stop forward in expanding worldwide capacity in tropical disease research, because it enhances access to research tools for developing country researchers and expands access to large .numbers of compounds for screening to identify new Ieads." DR. ROBERT RIDLEY DIRECTOR OF WHO/TDR R&D: FINDING CURES AND TREATMENTS E Pfi,.'r2OO7UorporateR.onibÜityReport 21 Bringing an R&D Pipeline Strategfy to bife Our broad and diverse pipeline of new medi&ines will help drive the development of new medicines for a wide variety of therapeutic areas over the next severa! years. We determine our R&D priorities accrding to medical need, fo!!owed by breakthrough potential, obstacles and comnïercial opportunities. The depth of our -----rnid-stage pipelme gwes tis contidence that À ---1 --À--- Cardiovascular, Metabolic and Endocrine Disease Qncology There are seven main areas o! Iocus—atherosclerosis, hypertension, obesity, diabetes, bane and muscle health, thrombosis and growth hormone deficiency.' Pfizer is building on its traditional strengths in cardiovascular research and is The number of oncology R&D projects at Pfizer has increased four-foId over the past tive years. At the annual Association of Clinical Oncology meeting in .June 2007, we presented 52 abstracts on 10 different medicines. These presentations expanding research in metabolio and endocrine diseases. Drug candidates in late-stage development include a potential new treatment for obesity now in Phase III studies. highlighted 212 clinical triais under way in oncology, the most in the industry. Late-stage development projects Include Fhase III triais against melanoma and pancreatio, breast, and Iurig cancers. 22 .T%cer 20117 Co,-porote Tkap,,naíh,litv Report R&D: FINDINO CURES AND TREATMENTS new medicines that will address significan unrnet medical needs. We now have more drug candidates, more clinical triais, and more research programs than ever before—a total of 242 programs spanning 1 therapeutic arcas. Our four major arcas of concentration include: N eu rosc i ence This portfolio includes new drug targets in areas of critical medical need—Alzheimer's disease, pain, cognition and attention-deficit/tiyperactivity disorder, depression and anxiety, and sleep disorders. Pfizer's Lyrica', the company's new medicine for neuropathic pain, was recently approved by the FDA for the treatment of fibromyalgia, which is characterized by chronic, widespread pain that affects tens of miflions of people worldwide. R&D: FINDING CURES AND TREATMENTS Diseases We are targeting key bacterial agents and key vira? diseases. Pfizer is breaking new ground in our approaches to the treatment of HIV/AIDS, especially with the recent FDA approval of Selzentry". We are siso exploring a nurnber of other R&p approaches to find new treatments for HIV/AlDS. Pftter 2007 (Jorporafe ReeponíhiUtv Report 23 • 7 iRIMgr Increasing Pipeline Transparency Pfizer's Eleven Therapeutic Areas :Wifh aggressive targets, vlrtually across the board, we have irnportant research programs underway in atherosclerosis, oncology,diabetes, obesity, rheumatoid arthritis, HIV/AIOS, schizophrenia, liver disease, and Alzheimer's, arnong others. As a Ssuit, our portfolio of newmolecular entities (potential new medicines as yet untested and unapproved) has aimost trip!ed sihce the beginning of the decade. We now expect that our Phase iii portfolio (when compounds are tested in Iarge-scale clinicai triais) will grov dramatically over the next three years. Four new programs advanced into Phase III in Iate 2006 are:- t Vàrious stakeholders have told us they would like a broader picture o! our pipeline and its potential, as weB as a'transparent assessment of our opportunities and chaIIènes. We are now posting infornation about our pipeline on www.ptizer.com/pipclíne —where doctors, patients, investors and tho public can track our progress over time. With a pipeline that is 250 percent larger than it was just six years ago, the new website provides details on ali major projecta iii ali key disease areas. - II • Axitinib, a prornising new treatment for thyroid cance CP-945,599, to treat obesity and its complications SutentO for the treatment of metastatuo breast cancer Pediatric studies of Zithromax'/chloroquine to treat the single greatest kilierof chiidren in Africa. . R o 1 tINFECTIOUS DISEASES ÁLi1r& & IESPIRATORY' ONGOLOGY PAJN .............. DERMATOLOGV 4; -. - 24 -- 11fiSf2O7 ( ji,,+te fl jonsibftity E-w,rt R&D: F1ND1t4OCURES AND TREATMENTS t t. ÇF 4 What Is a Clinical Trial? Clinical Inala are crucial to discovering and developing new medicines. This section desenhes what clinical triais are and how they work.A clinical tual is a research study perfoi.rned with hurnan volunteers to answer specific health questiona and to prove the relative safety and effectiveness of a potential medicine. Patients in clinical triais are car efully selected by healthcare professionalsfphysicians and closely monitored to ensure their safety and the integrity aí the resulta. Government agencies regulate ali phases of clinical research up te the approvai of a new drug. Carefu.Hy conducted clinical triais are Lhe safest way to fimd new or i.rnproved treatrnents. advance medical knowledge, and improve clinical practice in many areas of medicine. ft&D. FINDING CURES AND TREATMENTS What are the different phases of clinicai triais? Clinical triais are divided into the foliowing phases: { M P9 PhaseI Iriais are the first studies of a drug in human subjects. Phase 1 triais test the safety and tolerability of a prospective medicina, helping to determine which dosages are safe and well tolerated. The studies are typically in a sniall sample of study subjects, who are usuaIIyheIthy volunteers, although for some tÇipes of drugs. Phase 1 triais niay be conducted in patients who have the condition that the drug is intended to treat. Pfivr 2007 Uo,poratv Re;'on,ibiUtv Report 25 ~Ê S5 Iç 1 Maintaíning Clinical Trial Standards in the Developing World -C - In recent years there has been an increase in clinical triais conducted in developing and emerging countries. While we still conduct most of our triais in Worth Arnerica and Europe, others are dono in advanced countries in Asia and Latin Arnerica. Around 10 percent of study participants come from Eastern Europe and another 10 percent from Asia, excluding Japan. A very small percentage come from the Middle East and Africa. There are several reasons for this changing trend. Some countries require local clinical triais before a medicine can be registered there, even if it lhas been approved by regulators elsewhere. There are siso specilic medical reasons, like targeting certain diseases according te global incidence and prevalence. We conduct clinical triais in accardance with local laws and regulations, and recognize internationai standards, like the internationa! Conference cl Harmonization, Good Clinical Practices (GCP) Guidelines (www.ich.org/LOB/niedial ME0lA482.pd1) and the Declaration of Helsinki. We also have the responsibility to ensure that GCPs are followed by contract research organizations we hire. Inereasing Clinical Triai Transpare Ethicai standards for clinical researchare evolving and stakeholders have a growing interest in greater transparency. W1tEI the expansion of our pollcy In Janua& 2007, wen e p NlH-sponsoredwebsite www.clinh Thls Includes Phase 1 trlals and nc studies with prospectivo data. For registers, we also disclosé the resi Msults database (vi*.àlinicalstuc ãpproval. As 01 Auõlist 8, 2007, 842 tudies on thNiH site and on lhe PhRMA resulta sito. Jhis e on our previous clinicai trials disc which was based on the January of the internationalederaionp 26 J'1zer 2007 tJo,porrste Rcsponihrhtv Rcp.rI ovan Facing Chalienges in the Leveloping World Addresslng Stakeholders Pharmaceutical companies face unique chailenges when conducting drug triais for potentially Iife-saving medicines in countries with weak, ambiguous ar nonexistent medical and regulatory infrastructures. In recent years, companies have been chailenged legaily and in the media regardless of their scientific success ar failure, ar the humanitarian nature of tleir elforts. Pfizer is currently facing such a legal issue. The case concerns a clinical fria! aI Pfizer's antibiotic, Trovan, and children suffering from meningitis during a severo meningitis epidemia in Mano, Nigeria in 1996. Eleven years later, in June 2907, Mano and federal autharities Iiled civil and criminal Iawsuits in Nigeria against Pfizer. One of the aliegations is that Pfizer failed to obtain proper informed cansent from lhe children's families. As Pfizer stated inEits responso to this action, Pfizer acted in lhe best interest of1 the children and used lhe best medical knowledge available tol treat patients. Bef ore any child was admitled ta the study, tte entire process for conducting the trial was explained to each parent ar guardian in their nativo language, and consent was obtained oraiiy. The parents ar guardians were allowed to re~nain with and soe their children during the treatment. The study was conducled with the necessary approvais from lhe relevant government agencies and in a responsible and ethical way consistent with lhe company's commitment to palient s4y. felTrovan proved safe and elfective. The study's survival rato lar both Trovan and the comparative drug exceeded lhe sdrvival rato of any other treatment being adminislered at the lnfectious Disease Hospital in Kano. Addressing the Epidemia Nieria's 1996 meningitis outbreak was the most serious meningitis epidemia ever recarded in the country. It took lhe lives of almost 12,000 people over aix months, and significantly strained the country's health system. Pfizer's goal vias te bring a lile-saving and innovative form of antibiotic that could be used effectively in à meningitis epidemic. Trovan was not only demonstrated in pre-clinical studies to be effective at treating the meningitis pathogen, its oral form a'joided lhe use of intravenaus administration ar intramuscular injections. At lhe lime of lhe study, Trovan was in late-stage development and had been tested ciinically in more than 5.900 patients in lhe United States, Europe and eisewhere. Pfizer was getling ready to begin a global pediatria meningitis clinical study when the 1996 epidemic broke out. This pediatria meningitis study was evenlually canducted in 1998 and the study concluded that Trovan raised no new sal ety R&D: FINDING CURES AND TREATMENTS .04 05 1 R,:, QIJICK DECISION TRANSPARENCY i MAKING - jov e * * STAKEI-1OLDER COST OF . "!! Torcetrapib: A Case $tdd ihRsponsibIe Actions ÇNw F6r5years, our scíentists had been i; 1 w&kihg on a compound to dramaticaily imrõve the treatnient of cardiovascular disease. The compound, torcetrapib, aimed to raise "good" cholesterol, and the research iooked very promising. this medicine. Deveioping torcetrapib required innovation across ali amas of, Pfizer—from biology and chemistry, to manufacturing. . When we decided to terminate the trial, our medical team immediateiy, Then, in December 2006, to the surprlse L reached out to hundreds of clinical of many, we immediately terminated ali t , 1 ,investigators to notify them of clinicai triais for torcetrapib With our the decislon, and we coritactedother focus on patient safety, we knew we -MIgkey audiences, nciuding regulatory had to stop the triai wVen the Data and agencies around the world. We Safety Monitoring Board (DSMB), an siso were open and accessible iii •independent body overseeing the drug's communicating with the media and morbidity and mortahty study,aierted us financial communities as weli as with flbout a statistical irnbalance in rnortality our employ'ees. ali-cause and cardiovascuiar events il ÈPI U1~ $ k&oe il\3r liníng in ali of Uns ws among triai participants. te Çeraiiublic rectlon to The data was both surprising and Whiie our, stbk içt aproxirrt%i) disappointing. We hád Óreat hopes for 10 percent of itsvaiue bythe end the freatment and had aiready spent of that first day, we receked praise more than $1 bdii6n doflars deveioping for our swift response from some of our harshest media critics. As one newsaper described it, the way we 1 1111 . . QP handied the crisis heiped to "restore our faith in the íntegrity of corporationsthat play such a big role in safeguarding our heaith and satety." The stock price later recovered. The torcetrapib story is a reminder of the profound risks associated with biomedicai R&D. The fact is, 75 percent of ali biomedicai research ends in faiiure, 50 the average cost to discover and deveiop one approved medicine has increased to more than $800 miflion, according to the Tuftsen Cter for te Study of Drug Development As Pfizer's head of global R&D said "We dá sêience to heip cure the world'ieases, and when it works, it's fantast ic. But no project advances withoti a hitch and nothi ng do is truly unsuccessfui ... this is one of te most important projects we've eyer workecJ on and we wili iearn frorn this? ...y . ZW ilp1iPb R&D FINDING CURES AND fl er2afltorparai, T'spôinth'Iih Ri pari 27 4 agâ Pfizer's Stem Ceil Research Policy When people th.ink of human embryonic stem cells, they don't often imagine the pover of these cel].s in drug d.iscõvery. For more than a decade, Pfizer has been using animal or adilt stem cells in its laboratories to help screen new compounds and identify safer and more elfective medicines. With compelling evidence from this research, Pfizer has begun to explore accessing drug development technology from leading academic, biotechnology or pharmaceuticãl partners around the world, who also have experience with currently-available, human embryonic stem cell lines that meet the highest ethical standards set by leading scientific authorities. This Pfizer Stem Ceil Policy guides the company's • research activities and its exploration of new external partnerships. The policy summary foliows: Pfizer acknowledges the sensitive issues raised by this research, and we support proper ethical safeguards that take Into account both the moral Issues and public sensitivities. Pfizer will only engage in stem cell research projects that meet the highest ethical standards set by leading scientific authorities around the world, including the Guidelines developed by the National Academy of Sciences in the USA. Pfizer strongly opposes any efforts to clone human belngs. • Pfizer recognlzes the enormous potential of stem cell research. Stem celis are important tools for modern biomedical research, including Pfizer's search for innovative new medicines. • Pfizer has mede significant investments in animal stem cells and in human adult hematopoietic (somatic) stem cells. The company will continue to invest in these stem cell technologies. • Pfizer recognizes that human embryonic stem cells may provide even greater potential dueto their increasd ability for self-renewal and capacity to form a wide variety of cells and tissues. A human sten, cell culture. 28 J'/ÇT 2007 Corpo,cto tcspi,n,ihilityf?eport R&D: FINDING CURES AND TREATMENTS E/ Fia ORDE Pursuing a Humane Approach to Animais in Research J Weltare Policy Ô We understancl our stakeholders' concerns atout the use of animais in research testing. .Based on our Animal. Welfare polícy, we proactively look for alteruatives that reduce, replace or refine our work with animaIs. Tu orcier to adopt new nonanimal test met;bods, we engage in and Iead crossindustry efforts aimed at developing new testing and inforniation systems that may help accurately predict medical outeomes and reduce the use of anjmals in testing. necessary to use animais in the anim ,such as and in vit and where animais must be'used: the numbers of animais used in eaclt the number of studies invóMng animais, to minirnum necessary to obtain vaiidresuits our research objectives; and Currently and for the foreseeabie future, it is only through the combination of animal-based research and alternatives that we can understand the fundamental biology of the diseases we are trying to treat, discover new medicines and assess their safety. While new technologies can reduce our use of animais, most are applicabie only for safety evaluations, which are the smalier portion of our animal use. The rnajority of lhe animais utiiized in testing are used to understand basic causes of disease and to test the efficacy of new candidate compounds for medicines. A range of studies measure how a new medicine is absorbed and how the body distributes and breaks it down. Exploratory studies of this kind can be done in tissues, but the pivotal studies have to be dono in whole animais before we can conduct them in hurnans. We work through pharmaceutical trade organizations and relevant scientific boards, and directly with global regulatory authorities, to increase the common understanding and acceptance of appropriate aiternative methods. One example of this is our strategic investment in the work of lhe International Life Sciences lnstitutes/Health and Environmental Sciences Institute. We are also members of the In Vitro Testing Industrial Platforn, (IVTIP). Pfizer cannot eiiminate our use of animais in research at this time. But we can make sure that the tests we need to carry out—some of which are required for.regulatory purposes and others because it's the only way to get the necessary medical answers—are cone tolhe very highest ethical standards of animal weif are. R&D: FINDINO CURES AND TREATMENTS oi brocedure nvoivincj aniralso minimize Improving Animal Health Pfizer Animal Health (PAH) is dedicated to improving the safety, quafty and productivity of the food supply and helping pets live longer, heaithier lives through innovation in products for livestock and companion animais. In 2006, PAH spent $270 million on research to improve the health and welfare 'of animais. One recent Pfizer iaunch, lrnprovac—a novel alternativo to surgicai castration of boars—is a good exam,ie. The animal weifare community is appiauding this product for its humane approach to a necessary animal husbandry practice. To advance canine cancer research, PAH announced that it wili donate $1.1 million over two years to heip ostablish a national canino tumor tissue bank. The Pfizer Ganine Tumor Biospecimen Bank wili be housed at the Nationai Cancer institute (NCI) in Bethesda, Maryland, and wilil be managed by the Morris Animal Foundation (MAF)—the world's iargest charitabie rionprofit organization funding research to •protect, treat and cure animais worldwide. With this tissue •bank, veterinary and medical investigators can explore the mechanisms of cancer, evaluate promising new dnjg candidates and possibiy deveiop a better understanding o! •the reiationship between human and animal cancers. E Pfirer2OO7C,rporah'Re*;'onihilitvRepofl 29 Expanding Scientific Coliaborations and Partnerships V/e are increasingly open to new and different approaches to maximize Lhe potential of our R&D activi.ties—in the form of scientiflc alliances and partnerships wíth academia, publie research institutions, foundations, nongovernmental organizations, biotechirniogy compani.es and governments, Effective partnerships not orily help na achieve scientific advances, but they J' also help us streamline the com plex and expensit'e R&D proceas. Pflzcïs aliiance portfolio is large but focuseci, involving parfners with expertlse that spans th.e entire irocess of discovering, developing and delivering new medicines for patents in need. 30 TYieer 2107Corpor<te Rcspon,rbiütyReprt 1h R&D; FINDING CURES AND TREATMENTS ORnE AND RECOGNITION Two Pfizer scientists, along with a non-Pfizer scientist, were presented inMarch 2007 with the PhRMA Discoverers Award. These three scientists are responsible for the discovery of Zyvox®, the first member of an entireiy new class of antibacterial agents to reach the market in Pie 35 years prior to its approval in 2000. A Pfizer scientist was appointed to Pie US National Human Genome Advisory Council in 2006. In 2006, Pfizer La Joila was presented with the Most Innovative Product Award for Sutent® by CONNECT, a nonprofit group focusing on technotogy growth. Pfizer India won the 2006 Pharma Exceilence •Award for Exubera* in the "Innovative Products of the Vear" category. R&D: FINDINO CURES AND TREATMENTS I'ti;er 2007 torporrjfe Rçlpon.bi&ititv Report 31 1- - • inves,ting IN HEALTH Improving access tomedicihe and strengthening healthcare systems for lunderserved peopl.e aroun.d the world are arnongthe•standaiMs by whiêh our success as a pharrnaceuticàllúõi4ipany is measured. Te that end, we are Árorking on newsolutions with our partners. We are ihve'ting 1h effective and sustainabie healthcafe delivSy resources, and working with national governbierits, frntet national agencies, nongoverurnental organizations, multilateral organ.izations, acadernic institutionsand others to heip people get the rnediéines and servicës thõy need. 32 flzer 2007 Go,-porate Responiihility Repr,rt 4Ei4' r EW 2006/2007 KEV ACTIONS Launched "Mobilize Against MaIana" with NGO partners and three African governments to help in maIana treatment. aunched Global Health Partnerships support innovative public health rograms in the areas of oncology and bacco dependence. Launched ConnectHlV to support 20 community-based AIOS service organizations working to stop the spread of HIV/AIDS in the US. eveloped disease management rograms in the US, Italy and the UK. § Joined a new coalition created by The Brookings Institution to increase the number of US volunteers involved in international service. Implementing a Holistic to Healthcare Delivery broach Making medicines acces around the world requires a commitment on ffiany fronts: engaging and educati.ng providers anã patients about diagnosis and treatment, bdilding healthcare capacity, delivering the:me4cines where they need to be and when they nted to be there, and partnering effectively with çrganizations treating patients on the ground. 34 Pfizer 2007 Co,porate Fkipon*ihihtv R,,,,1 k INVESTI NG 1H H EALTH ) Treat, Teach, Build, Serve To invest in effective and sustainable delivery of healthcare resources and expertise to underserved people around the world, Pfizer coordinates its efforts under four major arcas of support. We define thein as: * O. TREAT Improving access to medicines and heaithcare services. • TEACH Increasing patient education and healthworker training on health issues and prevention. • BUILD Working to strengthen healthcare organizations and expand their ability te serve their patients and communities better. • SERVE Advocating for improved heaithcare for the underserved and sharing best practices to improve healthcare delivery to this populati.on. This and the next two pages include examples of programs that contribute in ali Ibur arcas. INVESTI NG IN H EALTH 1 Pftn.r 2007 Umparote Jkaponsihilitv Report 35 na 9' 36 Pficer 2007 Coporate Rnpon,ih,lity Report INVESTING 1H HEALTH Pfizer Global Health FelIow Elizabeth Gesierich with Irene Njoroge, an administrator at the knu,1 HIV/AIDS Orphans Day Caro Centre in Nairobi, Kenya. Pfizer Global Health FelIow O,. Ponni Subblah tralned new physlclans at Mulago Hospital In Kampala, Uganda, with I-lealth Volunteera Overseaa. INVESTING IN HEALTH l>flrer , 2007 ('mporot,' R,;'on sihi!itv Report 37 Additional Programs Around the World We support a range of sustaínable healtbcare delivery resources in countnes where we operate to help un.derserved peopie get the care and treatments they need. Below is a sample of these prograrns. More information may be found on the Pfizer country-specific» websites on www.pfizer.com. Improving access to medicines and healthcare services 38 , 07 Coiporate tkRpúníhTlttv Eeport TYier 20 UNITEDSTATES «I.lPiiiIWt In the Unitéd States, the Pfiz& Helpful M of patient assistance progranis h&ps Ame presdription drug coveáeéave on man ttfl medicina s;no ae,eageo timited income may quIi tet thelPfi for free In the past tive years Pfizer had hc tive mitlion patients receive nearly 50 rnhhic prescriptions for free orat a savings. Pfizer is also a member of the Partnersl Prescription AssistanceQPA—a national sponsored bíAmerica'spharrnaceuticaI r cornpanies that heTps Iow-income, uninsur underinsured individuàlsáteS pré&iti medicines. The PPA cdhiects patiéhts in r more than 475 publie and private patientpr8ams 'ncluding re than 180 progra t by pharmaceutical compnies As ofs se aniversary in Apnl 2007rWie PPA has hi than 3.6 mullion patients nationwide find pr that provido more than 2,500 prescription for free or nearly free. The PPAIso offers toinform patients about free healthcare di 1communities and há connected moretha tients with thesinis in their 5;000 t reach the age of 65. That's why Pfizérfion-6d With the Hungaiian Society of Hypertension and a national health program oy a pUbhc private partnership between Italy's Puglia regional government ind Pfizer Italy. lhe program takes a proactive approach to ide ntifying and treating patients with such chronic diseases as diabetes, congestive heart failure, and other cardovascuIar conditions—as well as patients with rsk tactors for cardiovascular disease. Pfizer provides detailed operational, technical and clinical consultation. This patient-centered prograrn is designed to reduce cardiovascülar risk by modifying patient Itt estyles, improve continuity of cará and appropriate access to needed services, and implement consistent caro guidelines for thd program staif dnd physicians' E involved intheproiect. i&ieasurmentwith an arteriograph, which'measures arterial stiffness, Pfizeïis helping to increàse aWáréhés ab6üt tiTe early phase of athero- and artenosclerosis datiformation, andyesults of the workinjgroups will bepubhhed in national specialist Journais. Y tt IWVESTING IN HEALTH Su P(i:er 2007 (jorporafe Re.ponsibilif v Report 39 QPOE TEACH Inoreasing patient education and health worker trainiqg on health issues and prevention Soulherriuni4d States, we have responded to In lhe an alarming trend in lhe rales of HIV/AIDS infectlons by partnering with community-based organizalions in the regionto help prevent lhe spread ai HIV/AIDs lhrough our Sàulhern HIV/AIDS Prevention lnitiative. The Pfizr Foundalion and Pfizer commilled a total of $6 iplilioçi over lhree years, beginning in 2004, to stípport a nelwork ai more lhan 60 innovative HIV/AIDS prevenlion programs across nine Soulhern slales. By, provi ding training for heallh workers, educators and Volunlears, lhese prograrns strengthened lhe capacity ai cornmunlly-based organizations la reach and serve â.lheir cammuniiies Alter lhree 'ers ai &ants and intensive capacitybuliding support, lhe majority aI granlees demonslraled sironger service dehvery, rmproved organizational •capacity, and expanded nelworks with local and regional AIDS service organizations. In addition, lhe social impact of the initialive nas been significanl: • More than 1,000 individuais were trained as a peer educator or mentor, • 3,000 individuais were provided with lesting and/or counseiing, • Morethan,11,000 rei errais were made to tesling, i"' counseling and healthcare services, and • More than 50,000 community rnembers were reached with SA Tiompo," Iaúnched 1h Novemb&r 2006 ht lhe Afehtihe Congress of Clinical 0nc4logy, is an awareness cem paign deslgned to inforrripaple abou of early detion 4Pf'zer s obje peoplá to get peno icei mediçz to encourageeopfe tãrriakd li quit smokihàrid ëát hâlthiéF1 that maytgFtie diee This campaign is béing carri with Lalceo (Argentino League noroV&nmentaI organization working on behalf of cancer pai In Argentina. 40 Jcer 2007 Co'porate fkpôn,h,Uiv Jkpr,r Hvrrtt to A nationwide mobile informalion campaigri called lhe TMMemory Bus" began in 2003. Witb physicians, psychotherapists and biher mental heallh experts on the bus stops in 24 cities ll pyr Aulria every year, oflenng help and information hd the tbpic ai momory weakness, ilh a focus on educaling the populalion aboul lhe importance of early diaghosió ol dementia. Tbe bus enables visitors to speak cardidly and anonymously with a doctor and gaiA knowledge aboul this sensitivo subjecl. The Memory Bus has become one of Auslria's mosl popular disease awareness campaigns. INVESTINO IN HEAI,TH Childhood obesity 'San epidemic in Ireland as it is other developed countnes ' Way2Go For a Healthier Vou" is a national public health information prograrn designed tc help familiesh,ake healthier cho The focus ai this çirogrim is Õnj parents,where strategiés on h6T obesity are discussed. Neas co, communIcation physical activit) factors Another elernent is an e' for the schools Way2Ga1materi 747 secondary schoals used w,th students age1iji SYA 224,000 students have the prgram throuáh helihhon and/ar physical education classi cancer , India group their childreiv, meetings foi Idress childhood ir eseu em -ii!r TEAR Project is an initíitive strengthening their relationshiptk &i network through work The r partnership between Pfizer, Guarulhos City Hall andj the Cornelia VilegAssociation strives to directly benetil patients by helping themPedeern theWself-esteem, encourage their incluston in society, and generate income for their farn,l,es since they are often adults in low income JObS Backed by a team ai psychiatnsts psychologcsts social workers occupationat therapists nstructors in industrial trades and nurse practitioners the prograrrofferz seven different workshops printe 1P1 participants and to help sústain INVESTING IN HEALTH enfion, detectionandearly diji 1Al$ edwere awareness sessions run byoncoI6glsts orations that have a largo populationbffemale Kéy goals included traininggynecoIogists ydetection, inoreasing refehàlé to onéolagists, iorming patients about the írnpdrtance of early dng. initiative 0 0 As ii bnàny developed cour,tries, dementia is an emerging chalienge for the German healthcare and Iong-terrn care system. To oífer salutions for 1 Germany and co-proniotion partner Eisal developed and init,ated a caro management project together with Germany's largest statutory health insurance cornpany AØK. The idcu of lhe projoct, which partners with stkeholders, is to impróve theearly diagni os' ai Alzheimer's, delay the reductian af cognitive sk,lIs and entry into nursing home care, and reduce the cost of caro. IDA was launched in July 2005 and in January 2007 the recruitment ai physicians and patients was completed. Now 129 physicians in theregion ci middle Franconia (part ai Bavaria) are contributing with 390 patients for the project. The caremanagementproject Is based on a broad perspective to evalüate real-life quality of caro, complement drug treatment with other , treatmerit aooroaches. and iritearate the efforts ai Pfi:er200Tta,porah'Rc,ponübílity &'porl 41 Tbe Pfuzerbain Foundation createdaichool-based obesity programtoproniote and spread health habits for schooi children. The program iifocüsed on diet, exerãise and obesity prevention and hetps to reaóh lOto 12-year-old children with a tR with tliiHõalth and Education Regional Ministríes from Madrid and Valencia and trains elderly peopTe (above age 60) as program instructors to provide educational materiais and promote discussions with the children. in the past year this program has reached 1 alrnost 40,000 children in more than 1,700 classrooms 1,1 and trained 45 instructorâMIOROL .11 Pfier Sweden, in cooperation with 22 ophthaimologusts, developed an education program in 2006 for general practitioners andopticians. Tbe objective was to help tinem make better referrais to eye cliniès, with a focus on the niost common eye disea&es—glaucoma, age-related macula! degeneration, dry yes and diabetic retinopathy lhe goal: "The right patient, at the righf time, with the right levei of cara." In the program's first year, 36 nieetings were held with more than 500 attendees, who sald fim prograrn was very heiptul and wouid heip mprove ref errais. Additional proof of its initiai success was that 90 percent of participatingophthalmoiogists signed up for another year. H t Foliowing the ávastatii tsunaml in2ôO4tthe pfi Foi.jndation donated $1 helptrairtfiVe psychiatd Mákh rio reclplenls.:itietraining was conducted )OS at the University of Pennsyivania: Pfizer isted the psychiatnsts in the socialization watotreat RTSÕ at the Nationai Congress (Bàtani;No'Jemb4y2006). PfizeïlndbIeiá i a media briefing on PTSD, conducted in which generated ctverage in 19 ottibts he second patbf the program, àurrently ;iudes the deveiopment of a nat!bnai a center, since indonesla Is prone to ffite ;' 42 J%er 2007 (]orporato Ueapon*rh,?ily Report -R INVESTING IN H EALTH 40E 8Q_ \ DPE Pfizer holds a workshop each year,for volunlary healthcare mi organizations to discuss healthcare issues including I5P awareness, comnunications and improvements for patients, families and healthcare professional The two-day worksfiop is in its sevenitjyearand volves participante from more than 50 voluntary IÇealthc e organizations. Activieslinderwaji nciu&ëstudsí diagnosis notes, àn education book fomSialtud ts, andá focus on KA tearn-based healthcare. VII 2 BUILD Working to strengthen healthcare organizations andexpand their ability to serve their patients and communities better Pfiier Global Health Followsare poileagues called upon to apply their professional skills to help improve access to healthcare in local communitíes throughout the developing world. The program was launched in 4 2003 and continues to hélio me-et the need for stronger nted in partnership with nõhgovernnintal eral organizàti6ri, Global Health Fellow s are designed ând implemented according s. The fellowships last for a period of months, allo4ing Feliows time to integrate LI community and host organization and ie contnbutions. During their assignments, rain and support their local counterparts, skills so that the contributions they make to and INVESTINO IN HEALTH Pti2vr 2007 Corporuh' ResponübiIiiv Report 43 Taking Healthcare on the Road Siovenia For those citizens ôf Siovenia who ddnot live near a healtn conter. Pfizer hÉís teamed up with the Sloveniân Heart Foundatin and the Siovenian Diabetics Association to Iaunch lhe Cardicmoble. aspecially converted camper Qan dedicated to reducing cdrdicvascula disease. The van offers free lectures, an exhibition cn Malaysia Mi ihitiative endorsed by Malaysia's Ministry ot Healthj the Care-A-Van piovides troe health screenings hea educa{on througiout lhe country lo frnprove lhe standardièbf fieallh a Qrig t e population, espeçiatly(he Iess privileged inírural and sernl-urbari cornmunitles Tie god ís lo indease awareness about the importante of prevention. Since its Iaunch in 1999, the Care-A-Van has visited more tha 186 ocations and screened rridre than 80000 pàtients natio nw ide e 44 fler 2007 Corporate !.pnnsih'lity Rezw,rt INVESTINU IN UEALTU 1 Advocating for improved healthcare for the undE to improve healthcare delivery to this population and sharing best practices E INVÉSTING IN HEALTH Pft:er 2007 (J,ipor&e R.epnnthíi&ty Rgport 45 4 Pfizer Health So Ef um IP . •. Chronic diseases-din "esses ! k!esr diabet heart disease asthma and abesity thatcariÇ be managed butnot cüred—are thefr adig 4 causes of death and disabdity in the Uited States. inaddition tothe human cost of sunerindand prematur54ath thatr7% accompãnchronic diseãseíthe h'dàitcà4 ............................................ system cannot effectiveiy address escaiatipg costs without heiping peopie iearntprpnage : and prevent these diseases. In thischauenging éhvironmentPir Heaith Soiutcons (PHSÏriners governments, payers and providers lo impiement and support cuituraily senItive, community-based programs that he!p peopie engage in heaithy behaviors and be9ínore 4 4 active participants inmanaging theirpwn health These partnerships have proen tobe effective in hétping people preent compilcations and ábute events. This, iniurn, saves heaithcare yoCi rces by préQentin the need for expensive services such as the 444 use of emergency rooms and hospitais For,more on these paitherships; 't piéàse see www.j5fi2erheaithsolutions.com. . . 11 1 - q 4 i4j :d!jhl Nw gá 46 Pfizcr 2007 Corporal., Responsibility Repon :I$ 1 HO ¶5Tf I.partnerihip with local heali dèsigned and implementedt and peersupport program to ;services provided in six loW4i commúnities aroijnd th&US. cúlturall9 àppro*iate edüáati k tíiiR?idually and in groupsrír1 %community. Peer hlthe 'a, "7 eral, and a rRroniddiseas ;úblic healtFnitiati l06,is designed td id their fârfimlles, tlr by addressing tisk wíth the, ¼'4" I'a ••C •,,!w I of the Amigos erj Salud prograrfl avallable jr th'epUbllc domam. • 1 behavlor Arkan pssesm edlrnyc Ni -; - From 2001 through Septeber 2005, 0,15 partnerskip between the State of Florida and Pfizeryeduced , healthcare costa by improving the health ofohronicaily mil beneficlaries of Medicaid, state-sponsored Jiealthcare assistanceJiThrough a netork of cbminunit hospitais, physicians, civicorganizations and atient groups Flokdas Ageno for CareAdministration (AHCA) and Pfizer designe 0" a prograir that pro'Mded care managementnewa!th benefs, and ealtdare h support. in its fourth year, Florida' A Healthy State saved the Stateof Florida $34.6 million ri medical cost reductions. This is in addition to $7,4 milt(on in investrnents that Pfizer mede to support prograni operations across the state Frorn program Inception through Septernber 2005, Florida: A Healthy State generated $139,5 millíon in savins ànd rogram investments and provided tcess to prviously unavailable healthcare resourças to over 180,000 Mediçaid beneficiaries with chrond conditioris.The State of Floria managed the Çloçid: A kea)thy State program for an additional 15 mohths (Octdbé?200 through December 2006), during whiclqtlme Pfizer provIdeatchnlcal and prograrn support. INVESTINO IN HEALTH mntLmSL9lilhSts$qL_ pl1l ? Y OII1i DPOE Improving Access to Medicines IMPACI ON SOGIETY PARTNERS TYPE OF PROGRAM & ACTIVITY A famfty of patient prescr(ption assistance progranis tini hdps patlenh without. Pr ri dru cpyerage save on Pfizer madto nos, no piatter th sg income PabeMs witI bmhej incpm4erwrsly 'Iess ftian'io-bmes lhe Federal Poveay)IPr Levei, adjustea for mIIy size me>' q&iifytor Ires Pfizer medidnes, Programs 1hat pmvt& Iree Pfizer medicines unclude' Connectlo-n to C" Siwinp ahe08y0tM• and lhe Pflzer C Hospital Partnership Pragram A'Pfizer initiatrve, Nailonal Governora Association, NatonaI Assoozation o? Community Health liters. r tiiva2z na. " Provides Pfizer niedicines lor free lo quabfied patients throogh their doctors' offices. -,4.,.,,,..,-,-. ii _aat,it._iunma 4.2oan$aaads.___,,tnLam More tSan IDO 000 physic ano currently have patients partloipatirig in tbe program. 1,1 2006, Pfizer helped nearly 650,000 patienta More tian 40 larga urban hospitais Ii jo 2006, Pfizer helpeal moro than 142,000 patients receive 500,000 Pfizer prescriptions for free through.the Pfizer Hospital Partnershim( 5jJj fifi i A patronal etfort sponsored ) Larica harmaceutic& reshetch Coulpanles, lo partnership v$th more eo national organizations including lhe Mierican Acad o? Famlly PhyslclansEaster Seals, National laoce for Hispan(c Health National Urban ______ ague1 Uriited Way o? Amorlca and NAACP !p:nto;accohspc5uieet patients In lhe (IS to more tÇan 475 pubáic and jrivate patient assistanoe progranis. Inoíuing Pfizer HeipluI Mswers. Regional Ireatment and training fcility in '? Uganda that strengthens local capaciW ir HrV/ AIOS, maiana and tubercuTosis. 48 lo 2006, Pfizer hetped more than 600,000 patients recelve more than 2 millíon Pfizer prescriptions for freiethrough the Shanng Lhe Cara program. receive more than 6 mullion Pfizer prescriptions for troe lhrough lhe Corinection to Caro prograni. i Provides Pfizer medicines for troa through disproportionate share hospitais across lhe US. e 6, Pfizer, Holpful Mswêrs halped oer 1,500,000 pailents r000ive over 9 million Pfizer prescriptions and saved patients àver $800 million.' 'Oased on wholesale ecqu sfin cosi 10 troe medicina progranis and actuei savkigs recervod by salienta kr progamt. _________________________ Onro,11 Providas Pfizer medicines for me o eligibie padents moro than 40 participating federaily qualified community health centers across the lis, r r 9 ['fizer 2007 Corporais Rnpoiisifiilltv &piit MakereU,niversiy lhe Acadni?0 AllaÀ Foundation, Mulago Hospital, San Francisco AIOS FoundatsorvPangaea Global AIOS Foundatjon lnfectious Diseases Soclety of %nerlca, Tho AIOS Sopport Organlzatioo (rASO). 1 In ZOOÇ, lhe Partnershrp for Prescription Asslstance rniatched more than 2 million patienis to prescription assistance programs. Soca 200 , DI has trauried mora thaA 1400 heathoare provudars from 26 Átrlcan countries lhe cantar currently providas cara lo appmimately 1O,C00 pationts INVESTI N O IN O EALTH e «SprIng 2007 AWARDS AND RECOGNITIONS e Pfizer was voted the top corporate giver by The Chronicie af Phi/anthropy in 2006. ........................................ Pfizer Hong Kong received the Gold Award from the Hong Kong Social Welfare Department in recognition of its commitment to volunteerism. Pfizer Global Health Feflows received the first annuat Corporate Citizenship award from Global HF? News in May 2007. INVESTI NO IN li EALTH E P/i:er 2007 Voiporah' Rç,ponsibititv Rpon 49 1: 1 H 1 strengt4'iening 1 PATIENT SAFFJTY Patient safety is om top commitment To make. skre our medicih4 are safe. and effective, we have a ugoioits cva1ciiation process that starts at the ear1iest stageL of drug discovery and continues long after our ibedicines are on the market. We continue to tak4new actions to improve our transparency andi cornmunicatiõhs about safety. -ç 1 i 50 .P[u.r 2007 Qirjiorate Rv,ponaih,Iitv Rcj'c,'t - k Fia. 7 r- A, 1 t í n FW 2006/2007 KEY ACTIONS Established a new medical governance process that strengthens internai coordination and accountability throughout product Iifecycles. Launched a website to disclose safety studies on our medicines after they are on lhe market. O lntroduced new packaging and shipping technology to support anticounterfeiting efforts. 52 flcer 2007Corporate &spon,;h'iityRejw,rt lidentifying, Analyzing and Reporting Safety Data We ernploy about 2.000 professionaisincluding physicians, nurses, pharinacists, medical research scientists, and statisticiansare dedicated to patient safety. Their sole responsibility is to identifv, analyze and report potential safety issues at every poit in the life of a medicine—from a cornpound's Jàrly discoverv phase, through clinical t.rial.s and regulatory approval, and for as long as i is prescribed by physicians. P? fizer scientists use information i.eportecl hy physicians, patients and caregivers, as as peer-reviewed journais and medical li.terature, tu detect heaith risks as early in a ihedicine's lifecycle as scientificaily possible. In partnership with outside experts and lkalth authorities, we thoroughly evaluate dil reported potential safety concerns and communicate risks to physicians and patients in the most timely way possible. 1 STRENOTHÈNING PATIENT SAPITY Strengthening Pfizer Medical Governance In response to new chalienges and siakeholder concerns aboul the safety of medicines, we have estabIished a new medical governance process that strengthens coordination and accountability among the medical and safety organizations responsible for the benefitlrisk profiles of our investigati.onal and approved medicines. These procedures refiect Pfizer's i.ncreased - scale, the critical importance of reaching clear medical decisions on a timely basis, and Lhe need for transparency in Pfizer's medical decision-making process, both internally and externally. This new process is comprised of a three-tiered Medical Review Comniittee structure: t The Executivo Medical Review Committee is chaired by the Chief Medical 0ff cor and senior managernent. This ccmrnittee providés oversight, direction and resolution of conflicts arising from the legitimate diversity of medical opinion that can otten exist. t The Therapeutic Moa Medical Review Committees are composed of senhor therapeutic arca medical, safety, regulatory and legal management. These committees provide prirnary oversight and support of the Product Medical Review Cornmittees, as needed. e I N The Product Medical Review Committees are composed of our product teams, as well as medical, safety, regulatory and legal representativos. These committees oversee lhe development and maintenance of the benefit/risk profile of specific compounds. STRENOTIIENING PATIENT SAPETY Pfi:er 2007 tarpnr&v Rc.ponsibilkv Repor: 53 'e Communicating About Safety to Key Stakeholders In addition to assuring besl practices internally, Pfizer is taking steps to broaden safety awareness and contlnuously improve safety comrnunications. These include: • Makirig information on our medicines' labeling easier to understand • Developing and continuatly updating brochuras for doctors and patients that explain the appropriate use of our medicines • Producing safety trainlng materiais for physicians who conduct clinical triais • Providing clearer safety inforniation on our product websites to help patients understand the safety issues invoived with lhe medicinas they are taking. Working with Regulators We wanl to make sure lhe medicinas we develop and produce are approved and monitored by strong, effective and rigorou regulatory agencies. We support a drug regulatory framework that is well funded and effeclively managed, bolh pre- and post-approval. We are committed to working with regulalory agencies, governments and olher stakehoiders to address concerns about drug safety. Regulatory guidelmnes provide a checks and balances system for safety reporting. We niusl notify the FDA in lhe (iS, for exampie, of adversa fmndings within seven days of becoming aware of an unexpected life-lhrealening safety issue and within 15 days for a serious unexpected health risk. Non-serious events are aggregated and reported periodically. Meanwhiie, in the US, we support proposais that will slrengthen the FDA's ability to conduct regular surveiliance, identify new safety signais and hypotheses, and comrnunicale risks to patients and heaith professionais. We also beijava the FDA should have access to safety data from large sludy popuiations so that risks and benefits can be evaivated with the rnost rigorous statislical methods. And we strongly support proposais that require niandatory risk rnanagement plans, which we aiready include in our drug applicalion submissions. 54 J'fueryOO7Qn-rnW RtgponsilnljtyRepi,rt Conducting Post-Marketing Studies Oür safety research and assessment continues throughout lhe life of a drug because additionai risks ar benefits can become aparenl after a medicine is approved for markeling and raches a broader and larger patient popuialion. in this poslmarkeiing effort, Pfizer spends miiiions of doilars and employs ataff of medical professionais around the world who work with outside experts to evaluate potentiai concerns, using lhe bst scientific methods at our disposai; including lechniques tiiàt look at real-world, post-approvai patient experiences with our medicines. We empioy new technologies to gather patient eperiences with our medicines as quickly and accurateiy as p!ossibie. , increasingiy, regulators are requiring a plan to monitor patient safety posl-approvai. As part of our commitment t6 patients and regulators, Pfizer proactively proposes comprehensive medicine safety pians before they become aequiremenl. Working with regulators, we develop longlemi studies of large patient popuiations in real-world clinicai pactice environrnenls to help further ensure patienl safety dnce a medicina is availabie. For exampie: Our clinicai program for Exubera, inhaied insulin, inciudes studies evaluating ils long-term safety. The studies are run by an independent governance structure and are designed to further evaluate lhe effects of iong-terrn exposure to Exubera' on the lungs. independent physician investigators wili continue to sludy lhe effects of lhe medicina in thousands of patients in severai countries, in real-world settings, over the long term. Our medicina for arthritis pain, Ceiebrex, is being reviewed in an independenl sludy conducted by the Cleveland Ciinic. We have invested $300 million in lhe study, which is overseen by an independent Data Monitoring Board, and compares cardiovascular effects of Celebrex' against ibuprofen and naproxen in a doubieblinded, rwidomized program that wili invoive more than 20,000 patients. STRENGTHENING PATIENT SAFETY W Transparency 7. 11`11 ti SCE - fdr more nonlhe ãafQty dfmédicines ihe maiketp1ace. T took:j1rnportant € pübhcacéàiintabihi May 2007 of our dn .A 31, tliis, we .cling uzich In g • 1 Thi'ir heips.d •.•;r. - 10 ted after a as a requir regiIatoïapproVai or continued marke •arüd,Tgned to pro medicinas safety; e ffrsf&f itá kind for a website pro FDA post-marketinç IistedPfizer PMCs, process. It is avaiial a medica] r deeIbpment, aná'I medicines;undegõ ahd evaluation in cc Afie worlq," said Pfi Eeczko. "Thís kincí tne status of our tJS .• . keting comrniÏmonls edicine receives ent for approval i ias. Thd st ias nlitioh abdLjt lhe• . Tile A •. FDA first posted a database of aI[ the inc ng commtrnents on its public wBte in zer site expands the informationavailabi approval date update the sie 1 ENT 8Á jo j4 - - •. treatrnE th3$ Ç pr. thev- of d Deterring Medicine Couriterfeiting to Protect Patient Safety Pharmaceuticai counterfeitíng is on Lhe risc around Lhe giobe, potentially putting at i.i.sk inillions of patients Mio take for granted that Lhe prescription medicines they buy are safe and effective. Counterfeit drugs are dangerous by their very nature—they are not produced uncler safe manufacturing practices and they are not inspected by the regulatory authorities. Many are producçd by criminais with sophisticated equiprnent capable of duplicating near-perfect copies of the medicines and their packaging. - Because counterfeiters are frequently more concerned with lhe appearance than the effucacy of their counlerfeits, it is impossible for palienls to know whal ingredienls lhese fake medicines actually contam. Some may conlain norte of lhe active pharmaceutical ingredient, depriving palients of lhe therapeutic benefil they expected from the product. Others may contain lethal ingrediente, mncluding heavy metal, arsenic, boric acid, Ieaded paint and floor polish. To address this issue, Pfizer Iaunched a focused anticounterfeiling program in 1998 to delecl and disrupt major counlerfeíling operations, in response to the detection of counlerfeil Vlagra. Since their, counterfeit Pfizer medicines have been found in at Ieast 73 counlries, with more than 25 million counlerfeit lablets seized by authorilies in the past three years alone. In response to this growing prõblem, lhe staif devoted to combaling counlerfeiting has increased to 17 fuli-time coileagues, most of whom have prior Iaw enforcemenl experience. We have partnered with Iaw enforcement around lhe world, developing Ieads, providing those Ieads to Iaw enforcemenl and regulatory agencies, and then assisting in those investigations as requested. We have siso lnvesled 56 Pfieer 2007 Crparo trprn,sih,Ti&v Reprrl irS slate-of-lhe-art forensic facilities to support lhese efforts. Supporting these agencies includes lhe tesling of suspected counlerfeit products to determine their aulhenlicity, and entering resulte in a dalabase, which nas; helped to trace the flow of counlerfeit producls. In addition, Pfizer has rovided 40 training programs for enforcernent and regulatory aijlhorilies in 17 counlries. Our partnerships with those agencies have conlributed to the dismantling of counlerfeiting operations in more lhan 20 counlries, lncluding Belgium, Bulgarla, Canada, China, Colombia, Costa Rica, Egypt, India, Israel, Jordan, Mexico, lhe Netherlands, Paraguay, Peru, Poland, Catar, Russia, Taiwan, Thailand, Turkey, Ukraine, the United Kingdom and lhe Uniled Stales. . Pfizer partrrera with Iaw enlorcement agencies around lhe world and has invested in slate-of-lhe-arl forensic facilities and Iraining programe. lhese partnerships have helped te dismãnlle counterteitlng operatiohs in more than 20 countnes. STRENGTHENING PATIENT SAFETY Using New Tocis and Techniques In addition to investigating and prosecuting counterfeiters, we also review the integrity 01 the suppiy chain and have consequently introduced new high-security measures to differentiate between genuine and counterfeit products. In high-risk markets, such as the UK, we have changed the way our medicines are distributed, opting to move away from lhe Iess-secure wholesahng modei to supply directiy to pharmacies. On rnany of our products, we have introduced color-shifting ink logos and tamper-evident packaging as authentication bois for pharrnacists, doctors and patienls. e Using Radio Frequency ID to Combat Counterfeiting I-low do you know lf you've purchased a counterfelt medicina? In some cases, patients latem identified counterfeita as having a different lasle, odor, conslslency or appeàrance. Patients may siso have a diffe,ent reaction to die counterfeil drug. In our latest initiative to combat pharmaceutical counterfeiting, we have begun a pilot program to ship a medicine containing radio frequency identification (RFID) tags to custoniers in the United Stales. RFID technology is being added to ali Viagra tablets sold in the US 50 pharmacies and wholesaiers can verify the unique eleclroníc product code, or EPC, on Viagra® packaging. We are lhe firsl pharniaceulical company to put in place a program of this type, focused on EPC authentication as a means of deteriing counterfeiting. Pfizer lias invested several million dollars to date in the technology, which discourages counterfeiting because itis bolh difficult and expensive to duplicate. Pharmacists and wholesalers use specially-designed electronic scanners that communicate lhe code over the Internet to a secure Pfuzér website. The companys app!ication ai RFID is not yel capabie of "tracking and tracing" medicines lhrough lhe distribution: system. "Track and trace" requires lhal ali parIs of the suppiy chain invesl in compatibie technology and agreo to capture and share informalion about producl movernent. Pfizer wili continue to explore lhe uses of this technology—inciuding "track and trace" in 2007 and beyond. Pfizer's apphcalion 01 RFID does not allow for lhe coliection of any palient information. We are also working cooperaliveiy with standards-selting bodies, stale governnients, the FIDA, industry groups and customers to estabhsh policies for lhe widespread application of RFID in lhe futuro. STRENGTHENINO PATIENT SAFETY Pfirer 2007 Corporuh' Eepon,ihi1ity Rvpoti 57 OPUE Improving Safety in the Drüg Distribution Chain Eveiy yearÀmericans flul more than three biHion prescriptions through reputable pharmacies. The vast majority of these medicines are disti'ibuted through top-quahty wholesalers. But in the last few years, counterfeit drugs have entered the nation's supply chain. ti e This probtem is exacert,ated by the split jurisdiction of drug sal ety. While the US FIDA oversees the approval and manufacture of drugs, each of the 50 states is in chaie of licensing and inspecting the wholesalers who distribute and dispense them. And now the Internet complicates matters even more. To help prevent counterfeit medicines from entering the pharmaceutical distribution system, Pfizer has helped shape model legislation that imposes criminal background checks and criminal penalties for counterfeiting. It also establishes licensing requirements for secondary wholesalers, and requires "change of ownership" documentation if medicines leave the traditional distribution chain. Working with iaw enforcement agencies and many other stakeholders since 2004, anti-counterfeiting legislation has passed in 25 states, with the remaining 25 states either considering or introducing similar laws. Stakeholders working with Pfizer on this legislation include the Hcalthcare Distribution Management Association (HDMA), the National Association ci Chain Drug Stores (NACDS) and the National Association cl Boards cl Pharmacy (NABP). One change spurred by the legislation is a significant reduction in the number of transactions (the number cl times a medicine changes hands) in the distribution process, from 15 to 20 transactions to three or four. And when a medicine leaves the normal distribution chain, it would require a "pedigree"—a document or electronic file that would include defined data elements that established the medicine's change cl ownership. By 2010, Pfizer expects to implement "e-pedigrees" for ali our medicines, and those most susceptible te counterfeiting may also carry a unique serial number. 58 Pua, 2007 Gnrporate Rrsponsih,Iitj' Report DS AND RECOGNITION •received, in 2007, an Internationai ;iation of Business Communicator's Quili Award for communication materiais oped for the Coaiítion Against Fake izer was chosen by CIO (Chief information ficer) magazine to receive its CIO 100 award 2007, for using information technoiogy rectively to create value. lood & Drug Packaging magazine named Ifizer's Amboise, France, manufacturing facility a 2006 Piant of the Year for its RFID pilot program used for \flagra' packaging. STRENGTHENINO PATIENT SAFETY sfi!N DSAYÍI 49E/4> 9€ _1• Advancing good health ocjcurs not only through the discovery, developmerit and distribution of medicines, but also by Dreserving and creating a healthy environment. Pfier is dedicated to addressing environmént, IeaIth and safety (EHS) issues rõlevant to our industry and our stakeholders through !inn4vative policies and programs. 2006/2007 KEY ACTIONS .Endorsed lhe UN Global Compact's "Caring for Clímate: The Business Leadership Platform" in May 2007 to advance climate change solutions. Reduced greenhouse gas (GHG) emissions in 2006 by about 179,400 tCO2eq from the previous year; on track to achieve longterm goal of reducing carbon dioxide (CO2) emissions per milhon doltars of saies by 35 percent in 2008. Mel Volatile Organic Compounds (VOC) emission reduction goal twa years in advance of our 2008 target. lmpiemented more than 400 energy conservatian measures in 2006 resulting in an improvement in energy efficiency and reduction of 69,000 metric tons of COz emissions. ENVrR0NMENT, HEALTH AND SAFETY •Decreased water usage in 2006 by over 21 million cubic meters. Achieved ISO 14001 certification for 34 facilities, OHSAS 18001 certification for 21 facilities, and OSHA VPP status o for three facilities. Participated in the US EPA National Envirorimental Performance Track at eight facilities. Partnered with the Alliance to Conserve the Maya Forest to promote sustainabie growth and conservation in the second largest rainforest in lhe Americas. Completed our second year using 30 percent post-consumer content recycled paper as the preferred paper for ali US-based operations. Pfi.-er2007Gorporafekeapõrsibétity R,port 61 E TO DATE WE HAVE EsTABUSaED FIVE COMPANYWIDE GOALS: * Climate Change To reduce carbon dioxide emissions by 35 percent per mililon dollars of saies by 2007 from our baseline year 2000. * Clean Energy To meet 35 percent of our global electricity needs by 2010 through "clean" energy sources C * Ozone Depieting Compounds (ODCs) Te phase out the use of Class 1 ODCs ri large heating, ventilation and air conditioning (HVAC) and industrial process eq u i pment * Ozone Depletion Potential (ODP) Te reduce our ODP from ODC releases by the end of 2007 by 80 percent from our 2002 baseline * Volatile Organic Compounds (V0CS) Te reduce our releases of VOOs by 40 percent on an absolute bagis from the baseline year of 2002 by the end of 2008 62 fizer 2007 Ck'rporai. Rapon.ihility Repert Climate Change: Reducing Greenhouse Gases and Using Energy Wisely The weight of scientific evidence indicates that global climate cFange is prirnarily caused by emissions related to burning fossil fuels—cornmonly referred to as greenhouse gases (GHG). Because this significant global environmental problem wUl have potential impact on the health of millions of people, Pflzer is not waiting for mandatory programs and has been pràactive in reducirig its emissions. Pfizer's Climate Change and Energy Prograni seeks CLI MATE minimize the cost and LEADERSÁÂUQ to operational restrictions ansing is. E,wfronrn,ni.ipyci.ctionAgancy from a carbon-constrained environrnent, reduce Pfizer's contribution to GHG emissions, and assess the risk presented to Pfizer's operations from the potential physical dhanges resulting from a warming global climate. Pfizer has had a company standard requiring the conservation of energy and the reduction of GHG since 1996. 19 2002, we became a charter member of the us EPA Climate Leaders Program, a government-industry partnership that works with companies to develop long-term, comprehensive climate change strategies. As a Climate Leader, we established a companywide goal of reducing carbon dioxide (CO2) emissions by 35 percent per nillion doliars of saies by the end o! 2007 from the baseline year of 2000. In 2003, we expanded our goal te include a cFmnhitment te meet 35 percent of our eiectricity needs by 2010 through the use of clean energy technologies such as wind power, solar power, and cogeneration. In addition to reducing GHG emissions fiem our facihties, Fizer is working to better understand the impact of our nearly 38,000 vehicies worldwide. In this regard, we are conducting apiIot program in 2007 to field-test hybrid vehicles to help increase fuel economy and reduce potential GHG emissions. We are siso entering into a partnership with fuel providers to sLipport clean energy projects that would offset the carbon emissions from our fieet. ENVIRONMENT, HEALTH AND SAFETY Absolute GHG Ernissionsmst.,, 3.0 — me- Diroot Ind iria • Actual U AdJusted • Actual E Adjusted • Actual • A4ustS From bssolin. 2000 to 2006, Pfizer reduced 0H13 enlissions by 32.7 percemt por milton doliars cri saies. Ouring lhe sarne time peried, our absoluta CO. ernissions decreased approximately 11 percent. TIre company ia on track to meel cur goal of reducing CO. emissiens 35 p.rcert por nillion dcliars ef saies by the ind ei 2007 trem the baselino year 2000. o Data Scop. a Pfizer calcijations of 0H13 emisalons we.a comploted referenclnç the WRl 0H13 Pretecol. using file Opersllonal Cont,ol 0TanizationaJ Boundasy method and a materlalily threshold ol 5 percent. b lhe data is based àn facity-specific utihty invoices for purctiaaed quanfihies ei eleclricity, fuel ou, natural gas and aleani. o Direct CO, omiasioria—emisalons reaultirig from flue combustion ol fossil fuels ai our faculities te provide ates.,, for manutacturing processes, hiesting and cooling. d indirect CO; emissions—emisaiens resulting primarily trem lhe cembustion ei foaail tueta for purchased oiectrtcity and steam. o Fleel orniesiens—emissions resulting from the oparation ei our global saies iloel. En4ronmantai performance data included in this report haa bem deveioped using practices that ahgn witi, te World Resources Institute Ri) protocol for 13H13 erniasiona. Principaily, data tuas bean atandardtzed and baaeline adjusted te more aocurateiy accounl for changes in ou, environmentai footprint duo te alt. ciosures, divestitures, and acquisitiens. The double bar graphs lncluded for lhe envlrenmentai p&ennance data róresent lhe originei data sot reported and aubsequent baseline adjustments. Satety performance data in tia report, which is rate-based, is tíne actual data set at lhe time ei coilection. ENVIRONMENT. HEALTII AND SAPETY P/i:er2007C'orporolvRe.pon,bililyRepor1 63 DPOE Planning for Change Effectively managing the financial implications and opportunities associated with reducing climate impact is another Irnportant componont of our program. We are piloting projects to secure and preserve carbon credits (e.g., Energy Efficiency Credits, Renowable Energy Credits) in preparation for emissions trading programs. In 2006, we were ano of the first companies to successfuily trade energy officiency credits generated in the State of Connecticut. In lhe longer temi, we are striving to identify operating risks and business opportunities prosented by a changing global climate, such as pianning for severo stornis and restricted wator availability, and evaluating our response as à leader in healthcare to changing disease pattorns. We will report on these risks and opportunities in more dotail in future years. O Pfizer's Green Building Program Pfizer owns ar operates over 70 million square foot of faciiity space worldwide—and with it comes a significant environmental responsibility. We have mede a commitment to BUILDINGS develop environmentaily responsible facilitios through a program called "Green Buildings: Local Action, Global Results." Tho goal is to promoto the best alternativos to standard building materiais and office interiors that support heaithior, moro oco-friondly business onvironmonts in addition to conserving natural resources and reducing energy consumption. Our Green Buildings Tear is also showcasing best practices across Pfizer to help coileaguos make inforrned green and lifocycle cost docisions. GREEN Tho team has: • • • • 64 Deveioped lifecycle cost analysis tools Created a Green Buildings evaluation process Publiclzed caso studios lntroducod a rocognition program. fizer 2007trporate Rcspone,h,Iity Report AI tie end of 2006, Pfizer obtined llpercent of its ,egy neds frorn dean energy aources, wÍth an eatlmated 7 percent contribulion froin Mure cogenoratron. lhe company Is on track co mel te goal of 35 perceni afta eneiy consuniption from clean energy sources by 2010 but continues to be cha!Ienged by facility clàsures, energy purchase considerations, capital inveslnieni decisions, and the operatlng costa and technical Iln,itations associated with running cogeneration unite 1' ENvIRONMENT, HEALTH AND SAFETY Ma Conserving Water The availability of clean potable water is one of the rnost important health issues of our time—and one that may be further exacerbated in coming years by clirnate change. Our commitment is not only to advance good health through our medicines, but siso to advance good health in the communities in which we operate by conserving water and protecting water quality. While Pfizer's use of water in its research and manufacturing facilities is relatively small compareci to some other industries, our responsibe management of water is an important element of our global EHS program. Our EHS Guideline on Water Gonservation requires facilities worldwide to: • Review and quantify their water use • ldentify and prioritize water conservation measures • Develop, implement and report on water conservation action plans and targets • Support cornmunity efforts during drought conditions. Although Pfizer's overali water use continues to decrease, the consumption (net use) has remained fairly constant over the past four years, annually at approxirnately 30 million cubic meters. We see this as an area to improve and are working to better understand our global water use— needs, demand, potential impact—and will subsequently focus appropriate water conservation measures in these areas. OsisJteWeU. Offsfte Water • Actual • 4usted • Actual U A4usted Onalte surlace Water Not VisIble on Chart On average. Pfizer obtaina Ita water equally from offsite and anSI, resources. welis are the primary source onsite wlth only a few thousand galiona taken htm onsite surface water. With plant conalderations and production changes, total water use should continue to decine, resulting Ina relativa change to source. ÔO: 100'. reo NRé '101H MMIR.E Rq 40 20 W!.. 1 W. Noncontact 000ling water Consumptlon nei use) • Actual E Adjusted 0 Actual U Adjusted Pfizer's total water use continues to decline, showing an overali reduction 0133 percent from 2003 to 2006.01 dia total water used in 2006, approxlmat&y 57 percent was r,turned to ha original soube subsequent to lia use as one-pesa, nonoontact coollng water. In general, nonconlact cooling water impacta water resource availability rninirnelly, sovas energy and reducea COa emisaions. ENVIBONMENT, HEALTH AND SAFETY i'fi?er2OO7C:orporoteRolonsibiüfyRepart 65 CPDE Continuing to Reduce our Footprint: Reducing Air and Waste Emissioris Pfizer's commitment to reduce the environmental impact of our operations inciudes reducing our emissions to the air, rninimizing the waste we produce and nlaxirnizing our use of recycled materiais. We are also committed to effectively nianaging any waste we generate to elirninate its potentiai impact on human heaith and the envirõnment. Eliminating Ozone Depieting Compounds (ODCs) and Volatile Organio Compounds (VOCs) To help protect the Earth's ozone iayer, we are committed to eliminating 000 releases from Pfizer operations woildwide. Once released into the atmosphere, ODCs riso into the stratosphere where they prornote reactions that destroy the Earth's protective ozone layer, allowing more harmfui solar radiation (primarily ultraviolet radiation) to reach the Earth's surf ace. Class 1 ODCs are known to be more harmful to the ozone iayer than Class II compounds. Pfizer's use of Class 1 ODCs is sornewhat hrnitedprincipally found in chillers and refrigeration units (CFCs) and in flre-suppression systems (Halons). We met our 2005 goal to phase out the use of Class 1 ODCs in large HVAC and industrial process equipment for specific faciliities with the exception of those sites pending closure or those with major production changes, which would trigger taking Class 1 equipment out of service. Pfizer is working to meet its 2007 goal in which we pledged to phase out the remaining use of Class 1 ODC equipment. Pfizer is not oniy committed to the phase-out of 000s, the company set a public goal to reduce the ozone depletior potential (ODP) by 80 percent at the end of 2007 from baseline year 2002. We are pleased to report that through various measures which include 000 substitution and an aggressive maintenance and repair program, Pfizer has met the ODP goal a year in advance and is poised to retain lts target. 66 Iii "ir 2007 Go'por4k Rspón.iMiitr Rcporl Pfizer uses VOCs primarily as soivents in our manufacturing processes. We have a long-standing strategy for reducing loses of VOCs to the environn,ent through process inprovements, in-line controis, and end-of-!ine devices. To realize further reductions, Pfizer set a public goal to further control VOO emissions by committing to reduce oir11 relesses by 40 percent on an absoluto basis from the baseline year o! 2002 by the end of 2008. We are pleased to re°port the company has met its absolute goal o! a 40 percent VPC ernission reduction, two years in advance of its target date 2008. Efforts attributed to this achievement include an aãgressive solvent reduction program, production changes ahd installation of additionai thermal oxidizer units. Reducing our Waste We classify our waste as either special waste or non-special w'este. Special waste is defined as waste that could adversely impact public health or the environment if mismanaged, and includes such waste strearns as biomedical waste, solvent and hazardous chemical wastes, returned pharmaceutical poducts and heavy metais. Non-special waste includes papar, cafetaria waste, and recyclabies such as giass, metal ahd plastic. A]though there is a trend toward decreasing our total waste footprint (a 24 precent reduction from 2003 to 2006), our recycling rates remain consistent at 26 percent. Compared with others in our industry, there is opportunity to improve. To help drive improvement in our waste and recycling performance, we continue to critically examine our global program and performance data associated with waste generation, as well as our onsite and offsite recychng programs. Fdr example, Pfizer teams are focused on reducing solvent Waste and promoting solvent recovery and recycling. At the site levei, many facilities have found smart ways to reduce total waste generated, reuse material and recycle on- and offsite. ENVIRONMENT. HEALTH AND SAFETY L Goa]: Total Ozone Depieting Potential dcflogrtma R li eq vs soco 7,000 . 6.000 4.000 •.' 1 NI 'i 3.000 ii toco :T402 02 Froin Production HCFC Loas Primrny 000 Loas • Actual E A4usted • Actual S Aousted • Actual U AdJusIed AI lhe end of 2006, we reduced our ODP (tom ralasses of ODGa by 82 percent againat our baseline year of 2002, me.tir,g ou' public goaJ one year in advance. A 57 percent reducllon was acheved (tom 2005 to 2006, as a result of 000 substitulion, an aggresslve rnainlenanàe and repair plogram, and plant considerations. Non-special Waste Generated 60 Air Pfizer achieved the VOO pubtic goal twa yeass in advance afta targetour woddwide relesses (lo air and watar) were reducad by 43 percent troo, our baseline year 2002 102006. pecataStLFSled alto 200 M uft '30 ~i4iiiJ em 15 0 ,100 v- 20 IM 10 03 Recycled Oflslle 1. • Actual • Adjusted j; 015 04 :1:! • Actual • Adiusted S Actual U MjuSted [ - 03 04 J Ii IT 7T 0 06 Dispoaed Recyoled Otfsite Dlsposed • Actual • Adusted • Actual U Adjuated • Actual E A4usted Pfizer reduced lhe generation ol non- apaclal waste by approximately 16 percent (tom 2003 to 2006, with a alight increasi, of 4 percant (tom 2005 to 2006 — attçibuted loa mole compreheflaive data acope (te., data cotacted (mm mofa oflicea). Oftaite recyctng ratas inctoased 49 percent in 2006 (mm 33 parcent In 2003. ENVIRONMENT. HEALTH AND SAFETY Pfizer reduced lhe generailon of speclal waate by approxlmately 27 percent trorn 2003 lo 2006 and 12 pircant (tom 2005 to 2005. lhe offaita racycling rata, however remains conalatent over Iha paat lour yean at an sverage of 22 percenl. Sino* our onsite racycling eftofls am aignhtioant, there is a focus on retining data collectiort of tNs meftic to advance lhe aolvent recovezy and reoycling program further. Pfi2vr 2007 fl'rporofe Reaponsibitih' Repori 67 Understanding the Impact of Pharmaceuticats in the Environment o Pharmaceuticais and their by-products have found their way into lhe environment by way of patient use for as long as medicines have been used to treat disease. However, our awareness ai this issue has increased with lhe developnient of new anaiytical teóhnoiogies that detect minute traces of pharniaceuticais and other organic chemicais in the environment. Patienl use ai prescription and over-lhe-counter niedicalions is the most significant palhway by which trace amounts ai pharmaceuticais enter lhe environment. Because peopie excrete medicines that are not fuily metabolized or absorbed by lhe body, and because sewage treatmenl planta are generaliy nol equipped to remove these conslituents, trace amounts of medicines are present in rivers, streams and other surface waters. A small quantily of pharrnaceuticals may be introduced into the environment when patients dispose ai unused prescriplion and OTG medications in iandfffls and sewage systems, bul disposal is not believed to be a major pathway. Severa] studies to date indicate that lhe presence of trace concentralions of pharrnaceuticais in surface water and drinking waler present no appreciabie risk to human heaith, but scientific knowledge on the cumuiative ar long-term impact of these trace leveis on both human heallh and aquatic ecosystems is in the earliest stages of development. Because Pfizer is cornmitted to adhering to principies of responsible environmental stewardship, we are working in dose cooperation with the scientific community, reguiatory agencies, patient groups and NGOs to develop and advance the body of knowiedge reiated to pharmaceuticais in the environment and their potentiai lmpacts. For instance, Pfizer was an aclive participanl in lhe pharmaceuticai industry's development of lhe PhATE model, a scientific boi that can be used to more reahsticavy estimate the concentration and distribution of active pharmaceulicai ingrediente discharged into US surface waters. Pfizer aiso participates in producl take-back programs in countries that have iniliated them. We are committed to minimizing lhe disposai ai pharmaceuticais frorn palients and to investigating unused medicine disposai ailernatives. Realizing the Promise of Green Chemistry Pfizer has been at the forefronl of developing and rranufacluring drugs using environmentafly-friendiy Green Chemistry (GC) praclices. By appiying GC principies, Pfizer has improved lhe way it produces many products, sibslàntia!ly reducing waste, saving moncy, and winning reàognilion for ils environmentai efforts. For exampie, Lyrica, which lreats neuropathic pain associated with diabetes or shingles, is being manufactured using a lhird-generation synthesis ai lhe producl that eiiminates five muiihon gaflons of waste per year. Similarly, a green chemislry GREENCHEMISTRY modification for lhe manufacture of Vfend', an antifungal medication, 15 years in lhe màking, ied to a reduction of 25,000 tons of waste per year. In arder to share knowiedge within our organization, c'oileagues meel monthly to produce cornmon education naleriais for chemists and engineers. The tiraI of these materiais—a guide in lhe seleclion of environmenlaDy-friendly saivents—has been rofled oul to chemists throughout Pfizer's R&D organization and is subsequenlly used by chemists and engineers in lhe manufacluring organization. Similariy, reagenls guide has been deveioped and is expected to be dislributed over the next few months. Pfizer teams aiso actively coVaborate to promote lhe principies of Green Cheniislry lhrough a number of community dutreach activities, inciuding workshops, conferences and 6urricuia for mlddie schooi, hlgh schooi and universities. fl Recognized as a Green Chemistry Leader 1, jOL in 2002,Pfizr reçeived the US Environmentai Pdlection gency Presidential Green Chemistry Award for appiying Gren Chemistry lo lhe nianufacturing ol ZoIoft. Pfizer doubied lhe producl yieid and significantly reduced EHS impact in the process. Pfizer's efforts lo enhance lhe EHS profiie of Viaga were honored in 2903 'Wibhthe receipt of the UK iriélilúle ai Chemict Enginers (iChemE MCryslal 1 1,Farabay Award for Gree'p Chernicai Technoiogy? Pfizer reducedthiamounl of organlc process wastes generafed from4,30d tons per year lo oniy 300 tons 41 par yearr in Otober 2006, 1 hmE once again recagnized Pfizer fâr Green Chemislry practièes for Lyrica' and Vfep&. Lyrlca° won lhe top European Green Ghemistry award—theExcetience in Green Chemistry 'and Englneering Award —and Vfend' was a finabat for lhe Faraday Award. - 68 Pjiccr 2007 Q'rporate Rcspon,ilility Rezw,rt ENVIRONMENT, HEALTH AND SAFE?? 7 Workplace Safety: Enhancing Strong Safety Performance Across the Business Attaining workplace safety across a business as diverso as Pfizer's is a chailonge. With offices, laboratories, manutacturing facilities, warehouses, and other working environments, ensuring safety exceDence requires the focus and attention 01 the entire business. "Workplace safety" includes: • Providing a workptace where chemical and physical hazards are appropriately rnanaged • Establishing a culture where ali coileagues prioritize safety and constantiy demonstrate caro and safe behavior • Ensuring the medical well-being of our cofleagues In the workplace • Making cortam that our operations are not at risk of an accidental chemical release, firo, explosion or any other unexpected process upset • Safeguarding those In the workpiace from adverso exposure to chemical hazards and • Protecting the safety of our drivers and those who share lhe roads with our drivers. Pfizer is committed to ensuring lhe safety of its coiloagues and others and promoting a safety cultura in ali our areas of operalions. o 1. ENVIRONM ENT, HEALTH AND SAFETY fi i'fier 2007 £'rnporoteRprrnibititv Report 69 e Reducing Injuries and Promoting a Culture of Safety guidelines that establish baseline performance criteria. Fé,r example, each Pfizer facility is required to establish ahd implement a safety managemenl system that includes workplace risk identification and control, management and coileague safety cornmillees, safety training, incident reporting and invesligation systems, safety procedure implementation apd docurnenlalion, managernenl system review, and p:erformance expectations. Every person who works at or visits a Pfizer site expects to cave lhe work environrnent unharmed by their activities. This simpló tenet is the goal of Pfizer's coileague safety program, and underlying this goal are two priniary objectives —to continuously improve our safety performance and to maintain a strong safety cultura throughoul lhe company. To further improve our safety performance, Pfizer has developed and implemenled a comprehensive seI of safety 1ttJ* : MI ø1 1 õW 'h.p Poij IÍr!ib t 0 :1. ENVIRONMENT, HEALTH AND SAFETY 4Ç1E147\ As. t icR DP'X ases and Injuries II '4uryratay a 7É ml02 ti K1 11 04 OS Coe ar our prinary lnjury and Ilineas mesaures is tire Leal Tinia lnury and Iiinew rata (LTIR), me number of iniuries and moesses Incidente par 100 colleagues) mal result lo one ornara leal work days par 100,000 hoursworked. From 2003 to 2006, we reduced our leal tine lnjury and ilmneas rata by 21 percenl. However, trem 2005 to 2006 lhere was an approxinale decrease 01 onty 5 percent. We recognize 0w LTIR Ia abova lhe 2006 pharmaceutical lnduat.y average o! 0.47. We continue to avstuate lhe reasona behind lhe rale and In parailel, have mnplemented several programa In 2007 te advanca cor aalely cultura. e ENVIRONMKNT, HEALTH AND SAFETY As-rother coe ei our key netries to hetp determine lhe adequacy ei our satety programs is me Total lnJury Rale (TIR). conmonly reterred to as lhe 051-IA recordatile rale. II is expressed as lhe nunber 0f racordable injurias ffiat occur par 100 enployees par year. We Irack lbis information ln addition te lhe LTIR bacause lI captures nora lntornation on injwies, enabllng us to baIlar ldentity and locus on aram lo naad o! k'nprovsnent. Pfizer successlully reduced tis TIR by 43 percent trem 2003 to 2006, and 20 parcent Irem 2005 te 2006, although wa still remain above lhe 2006 phannaceutical industry avarage o! 1.04. As wilh lhe LTIR, lheie are signiticant afforta underway to bring this rale lowa, decraaslnú the 051-IA recordables. ifiter 2007 €.'orporrjfe Rewon uihilify R,'pori 71 OPDE Process Safety Fieet Safety The production of Pfizer's medicines requires the uso ai complex R&D and manufacturing processes and techniques that have certain inherent risks. To address these risks and ensure the safety of our conimunities, coileagues and others, Pfizer lias a niature and sophisticated process safety prõgram designed to maintain safe and environnientaily sound operations worldwide. This moans taking the necessary steps to prevent the risk aí an accidentai cheniicai relesse, tire, explosion ar any other unexpected process upset. In addition to tuli cornp!iance with ali laws and reguIation, we use te EHS Guideline on Process Safety to make sure R&D and manufacturing facilities worldwide implement programs to protect our coileaguos and conimunities from the threat of an accident. Those operations must develap and maintain a management system that, at a minimum, addresses process and equipment operating practices and controis together with site and community emergency preparedness and responso. Mono ai the world's loaders devoted to healthcare, our saies fome íleet is among the largest in the world. With aiestimated fleet of 38,000 veludos worldwide and and 11 etimated 910 milhon mitos traveled last year, driving is rdbognized as a significant risk, and safety continues to be a focus for the organization. accident rate (accidents por miltion miles) is dose to—but above—the pharmaceutical industry average. This is not where we would like it to be and we aro c&mmitted to doing better. Performance improvement iritiatives include efforts to standardize practices, increase diver safety awareness, conduct mandatory motor vehicle record reviews, and imprave driver training. Safeguading olir drivers and thoso who share the roads with them is paramount to our program. Greenng Pfizer's FIeet"—The Us fleet is piloting the 2007 Toyota camry Hybrid this year. a vehicle alternativo that meets our safety selection criteria and cnsiders envirorunental and economic benetits. 72 flzer 20)7Gorporote Rtspon..;hz?ityRc'p'jrt ENVIRONMENT, HEALTU AND SAFETY íris. j\ \ AWAROS ANO RECOGNITION Received our third successive Missouri Water Environmental Association "GoId Star Certificate" for pretreatment achievements by our St. Louis R&D facility. For more information bout Pfizer's Environment, fr HeaIth and Safety Program, p!ease visit www.pfizer.com/ ! respõnsibility. Honored with the National Award from the Irish National Safety Organization to our Ireland-based manufacturing sites. Achieved program recertification for the Kalamazoo, Michigan site from the Wi!dlife Habitat Council. Recognized by the "Labs for the 21 st Century," a coilaborative partnership between the US EPA and US DOE, the Ann Arbor B520 Renovation Project was first in its class for Pfizer. r Earning the first Silver-rated award in Leadership in Energy and Enviromental Design in Connecticut our Clinical Research Unit Iocated in New Haveri was also the first industry project to receive three (out of four) Green Globe certifications. ENVIRONMBNT, HEALTH AND SAFETY J'fi:er 2007 (Joiporat Repon,ihilily R.'port 73 o) Fb Over the iast few years, thS business community has been revamping its côrporate governance procedures in response to shareholder demands for increased transparenc,. In 1992 we became the first major com pany td form a department devoted exciusiveiy to co orate governance. We have worked steadily buiid a solid foundation of Jeadership 1 Board effectiveness and accountabiiity to sha hoiders and ali stakeholders. This year, ' took new actions to buiid on that iegacy. 2006/2007 KEY. ACTIONS The lmpact of Culture and Values Elected Jeff Kindier as Chairman and CEO. improvements in corporate governance alone will not generate trust ar restore invostor confidence. Good corporate governance must be rooted in lhe culture and values of the organization and lhe way we do business every day. Our coueagues understand that these values apply to everyone, everywhere around the globo. Our ability to be viewed as a trusted nieniber aí society begins with lhe Pfizer Policies on Business conduct. In addition, Pfizer Directors are required to comply wilh a cade of Business conducl and Elhics designed specifically to cover ali areas aí professionai conduct relaling to service on our Board. These policies and cade, as well as athers menlioned In this seclion, can be found at www.pfizer.com/carpgav. Elected Constance J. Horner as Lead Independent Director. Strengthened the link between executive comperisation and Pfizer's financial performance through several actions by the Board of Directors. lnitiated face-to-face meetings between institutional investors and the Board. Adopted a new international procedure to improve our implementation of the US Foreign Corrupt Practices Act and local anti-bribery laws. GOVERNANCE & COMPLIANCE ii! Pfi:er 2007 Co,porub' )?ponihiIiiy J*port 75 DPOE Ensuring Board Independence The Board is comprised of a rnajority of independent directors, and has elected a nonmanagement director to serve in a iead capacity. The current Lead independent Director, Constance J. Horner, presides at executive sessioris, functions as principal liaison on Board-wide issues between the independent directors and the Chairman, assures an appropriate agenda and flow of information to the Board, and recommends lhe retention of outside advisors and consultaria who report directly to the Board. If requested by shareholders, the Lead Independent Director will be available, as appropriate, for consultation and direct communication. The Board of Directors adopted a formal set of Director Qualification Standards, which outline guidelines for director independence that either meet or exceed the independence requirements of the NewYork Stock Exchange. Strict guidelines for Directors and their immediate families must be followed with respect to past employment or affiliation with Pfizer or lts independent registered public accounting firrn. Ali of our Directors are independent, with the exception of our Chairman, Jeff Kindier and our Chairman Erneritus, William C. Steere, Jr. The Board foliows a defined set of Corporate Governance Principies and conducts an annual evaluation to assure that the guidelines are timely, effective, and best represent lhe Board's oversight and accountability on behalf of shareholders. Each Board committee has a charter outlining its responsibilities, and a checklist of oversight responsibilities to be covered throughout lhe year. As part of the annual nornination process for directors, the Corporate Governance Committee reviews the qualifications of each director, evaluatirig skilis and talents to assure a balance of expertise in various disciplines and perspectives. Encouraging Shareholder and Stakeholder Participation Pfizer's Corporate Governance Committee Charter requires directors to "maintain an informed status on Cornpany issues related to corporate social responsibility and the Cornpany's participation and visibility as a global corporate citizen." To assure effective communication, Pfizer was among the first companies to expand communication via the Internet, $0 shareholders and ali stakeholders can contact members of the Board directly. Relevant communications are distributed to the Board or Individual directors, and the Board receives a quarterly summary of ali shareholder and stakeholder communications. This practice serves as an early warning system, $0 the Board can identify and respond to shareholder and stakehoider concerns. 76 I''ieer 2,90, Qirparate Rcspon.fh,lisy Rcpert Pfizer is the flrst company to initiate a regular meeting between its Board and institutionai investors on governance. The Board wilI invite representatives who evaluate governance ractices and who vote the proxies of the company's largest institutional investors. These representatives wiv have an opportunity to provide comments and perspective on Pfizer's governance policies and practices including executive c,ompensation. They own in aggregate approximately 35 perceni of Pfizer's shares. The initial meeting is pianned for the fali of 2007. Pfizer has been in the forefront of corporate governance for over two decades. it has taken the lead in the elimination its poison pio; the declassification of the Board, 50 that ali directors are elected at each annual meeting; the adoption df majority voting pohcy; and expanded disclosures on executive compensation well ahead of new SEO regulations. The company was siso among the first to use SEC "Piam Enghsh" rules to make disclosures more understandabie to investors. GOVERNANCE & COMPLIANCE Fis Prevenling Bribery and Corniption The Foreign Corrupt Practices Act (FCPA), which became 1.15 iaw in 1977, conlains lhree key provisions that pertain to our business: Complying•with Ali Laws, Committed to the Highest Ethical Standards Pfizer's Board of Directors established our Corporate Compliance Program to support the company's unyielding con,niilmenl to high standards of legal and ethical conduct. Our corporate ethics and compliance officer and staif provida oversight and guidance to ensure compliance with applicable laws, regulations and company policies, and foster a positive, ethical work environment for ali employees. Colleagues worldwide siso receive the Suffimary of Pfizer Policies on Business Conduct, orthe Blue Book" as it is known, and must sign a statement acknowledging that they have read it and will abide by it. The Blue Book has been translated into 45 languages. Our commitment to operate with inlegrlty is supported by comprehensive and coordinated processes, policies, communications and training, which enable coileagues to act lawfutly, meet internai expectations and promote transparency. Our compliance program cascades frorn our Chief Compliance Officer to Depuly Compliance Otficers and a network 01 compliance liaisons aI each site worldwide, with 24-hour toII-free hotlines. For a detailed overview of Pfizer's corporate governance policies, procedures, managemenl structure and staff, please visil www.pfizer.com/corpgov. ,. Ai, anll-brlbery provislon, which maRes it uniawfui to bribe foreign governmenl officials direclly ar indireclly to oblain ar relain business • The books and records provislon, which Imposes requiremenls on pubiic companies to maintain accurate s and records, and to implement stringent accounting b and financial contrais and ,. The system of internal contrais provision, which imposes requiremenls on public companies to impiemenl stringenl accountíng and financial contrais. To continually improve on our ability to adhere to ali provisions of lhe FCPA, we implemented, in Apr'd 2007, the International Mti-Bribery and Anti-Corruption Corporate Procedure. This procedure estabiishes anli-bribery standards and processes designed to support compliance with the FCPA, as weil as local anti-bribery laws. Pfizer siso deveioped an impiementalion piatform to help local leams train coDeagues and adopl local procedures. This platform is divided into 12 separale sections, which covers such lhings as third-party Iransaclions and consultancy agreements to gifts, hospitahly, inlernalional meeling support and sile visits, to educational grants, invesligalor-initiated research grants, charilabie contributions 'and poiilicai contributions. To support compliance even furlher, lhe company has also established lhe foliowing bois and systems: Advancing Coileague Underslanding: Pfizer Compliance Education Center The legal environment is becoming more complicated with each passing year, so we addressed the need for additionai coileague education by creating the Pfizer Compliance Education Center. The Center offers a series of interactive' programs, delivered through the web and other available means, which are customized to meet individual needs in lhe areas of greater risk. For exampie, saies representatives lhroughout lhe Uniled States receive annuai training in the varlous healthcare laws and Pfizer policies which affect their interactions with healthcare professionals These programs cover topics of corporate compliance, as well as ethical and legal responsibility, primarily complemenling the many programs already in place within the organizalion. The goal is to give coVeagues access to compliance information aI ali times and to make sure, to lhe exlent possibie, that they are appropriateiy grounded in lhe key compliance issues that affect service to patienls and customers Every year we ask Pfizer coileagues, including the company's senior Ieadership, to lake the Pfizer integrity Piedge and certify that they understand and are abiding by lhe standards described in the "Blue Book". Online guidance and 24-hour support are available to any colteagues with questions ar concerns in their area of lhe business. E. A compFance hotline in 70 countries Global compliance liaisons In ali n,arkets • Trainlng for ali coDeagues, with materiais available in 45 languages • Auditing procedures for ali saies and marketlng programs. Evaivating Corporate Regulatory Compliance To maintain and enhance lhe value of our internai audit aclivities—and to make sure lhe company is able to identify and evaluale any potenlial galos in lhe overali status of Pfizer's compliance systems—lhe Legal Division broughl four Regulatory Compliance Audil funclions logelher under a singie umbreila and redesigned the audil process. The new organization, called Corporate Regulatory Compliance, identifies audil targets and deploys audil resources based on risk analysis, and assesses systems that support compliance. The funclionai audit groups that comprise Corporate Regulatory Compliance are Environmenl, Health and Safety Compliance Assurance, Corporate Quality Assurance, Research and Developmenl Oversight, and Research Quality Assurance. [ COvERNANCE & COMPLIANCE I,er 2007 ()o,porot' R,t31,on.ihilitt Report 7 1P 4: lês (iII - Si y e a0 *Jifli FIt!! IWI a2=üz Jo e Fui 1kTJ - PXiIØ tvJ$n 10 , SEI jo mum EADDFPEMDNTmRFCTOt iÇI 1 Iip 78 fl&zw &O7Lrppmce !rsponsrtiilttyfkvorL GW PO lj $ GOVERNA :*PLIAN C Er am c DPDE AWARDS ANO RECOGNITION FflOMLEFTTORJÇHT: FSTROW • Dennis & Ausielio, MD. çk Michaci S. Bwn, M.D. Dis*ngutsf$,d ebair, BiorneaSaisices, flegntai rofeso, Unft'erftg oL1ess So'tithw4strfl elictil Ceri !Rated the top company in our peer group by Governance Metrics International, a New York-bâsed research firm that provides corporàte governance ratings for almost 4,000 publie companies worldwide (April 2007). M. MthonyBums h,irman Lmentu& ydorSysirnlhc, SECONDROW 1 Robert N. Burt 1eIIred Chairman and CEO MCCopor oq W DoriCorriwell Chaimian Md CEO, Gronite Btoa Içat'ng Coporson Im »dilliarn H Gray III Chalrtnan MiarGroup 41, pilo THIRD R0W William R. Howell Chainnan EmeMus, J O. enney Company n" .InffrAvR '- kip ' JwK Windlpr George Lorch,JL Oh Çeus tro WI!* ÀlIp - FOURTH 110W MI* 4 , P$ DanaGMeadhD Oj,aIrmi Cotóti rr r WiIiiaib. SeerejTr2i.,. cSj& the o i: ii •4•. '9 !110 J GOVERNXNCE & COMPLÏÁ i,er 2007 C'o,porale Re*;'ontíbiIiIy Report 79 [Fia - Pfizer is cornmitted to res onsible Sales and Marketing practices that Jdress physician and patient needs by próvidin fuli and accurate information about our mei icines. Sales and Marketing practices were tt the forefront of the change proõess at Pfi rjaIiEIIIErlI[s 2007. Changes that were iplemented include endorsing and implement g guidelines for prescription medicine adxj rtising, committing to and rolling out a global ode of conduct on interactions with healthca professionais, and reducing staff to better aiin with physician need. We reinforce our comrnitrïfient with ongoing training, monitoring and cêmpliance with ali healthcare ethics, law arcÇ regLlation. 2006/2007 KEY ACTIONS Ranked Number One overail in the US industry in 2007 by physicians and customers for an unprecedented 12th consecutive year. Rolled out a code of conduct on interactions withhealthcare professionais in 45 languages in more than 100 countries. SALES AND MARKETING lmplemented guidelines for more beneficial 'prescription medicine advértising. Launched PfizerPro website, a one-stop resource information site for healthcare professionais on Pfizer's products ranging from pipeline to post-marketing studies. J'fier2fiOiCoJporafrRceponsibiIityRdpofl 81 vE/ IFI3 Advancing a Track Record in Training Ranking Number One for 12 Consecutive Years For an unprecedented 1 2th consecutive year, physicians and customers in 2007 ranked Pfizer's US saies force Number One overaV in the industry, according te an annual survey conducted by Verispan, a pharmaceuticai research firm. Pfizer's US seles force was named the best by 10 specialties and by nurse-practitioners and physicians assistants. Categorias included quahty, faniiharity and physician speciaity. Speciaities giving top scores to Pfizer's fieid force inciuded Uroiogy, internai Medicine, General Practitioners, Cardioiogy and Orthopedic Surgery. The company was arnong the top three in 15 specialties—the best in the industry. This recognition reflects Pfizer's commitnent to its customers and heaithcare providers, and to consistentiy dehver against our goai to provide disease and product knowiedge and support the vaiue of our current medicines and newiy avaiiabie therapies. t=fll iwat. Cw Si 'LL.I =- z d'ur abihty to consistentiy rank Number One is rooted in our ijng track record in professional deveiopment throughout eãch seles coiieague's career. We focus our training on poduct knowiedge, different diseases, heaithcare ethics and law, and fieid ieader coaching. A primary objective of our sâies force isto provide physicians with accurate medicai and product information, inciuding ali avaiiabie data on benefits and risks, so physicians can make more informed treatment d'ecisions. Ali rnembers of the seles force are expected to know the medica] foundation of diseases and treatments as dell as the iatest research findings on Pfizer and competitors' pkducts. Self-study, instructor-Ied, classroom style and on-the-job courses are offered. Speciflc heaithcare iaw compliance, irciuding effective documentation, is a major part of the tiaining for every seles colieague and seles manager around tle world at Pfizer. Colieagues are required to take an onhne training course and pass a test on ethics and compliance every year. 1 1ooking for new ways to interact with US Falthcare professionais, Pfizer set out to totalty revarnp its web-based approach for healthcare providers. Pfizer for Professionals (PfizerPro), Pfizer's new one-stop shop for heaithcare 9rofessionals, is an innovative online resource tiat not only communicates to providers about inline products and patient education but also about the company's pipeline, post-marketirig studies and more. Www.pfizerpro.com/content/home.jsp 82 Jker 2007 Cr.rp.,ratc tksp,,n,ihilitv Jtep'irl SALES AND MAREETINO P1, lmplementing a Global Marketing Code of Conduct In 2006 we rolled out the Pfizer Global Policy on Interactions with Healthcare Prol essionais throughout Pfizer. This poiicy incorporates comrnon legal and ethical standards from many of Pfizer's major markets, inciuding the US and Europe, and applies them to every country in which we operate. The pohcy, written in 45 languages, provides specific guidelines on appropriate behavior for Pfizer coHeagues who have direct contact with physioians and other healthcare .professionals. It covers such topics as the guidelines for Pfizer-hosted educationai or prornotional meetings, medical communications, marketing activities, confidentiality of patient data, and use of giveaway items. Seles professionais, in particular, are required to complete and pass a self-study course oh the poiicy. In Sales, the pohcy was roiled out through a process coordinated by the Seles Leadership and Compliance Senior Seles Management which was responsibie for completion of the training and monitoring. Restructuring the Sales Force In 2006, we reduced the size of our seles torce in the (iS by 20 percent, and management by up to 30 percent, with similar cuts in Europe and other parts of the world. The restructuring was undertaken to better aiign Pfizer with physician needs and other changes in the marketplace—changing products and services, and changing stakehoider expectations-to. become a better partner with heaithcare professionais. The saies force was reorganized into four operating units focused on products, with a fifth focused on customers. The saies force became more entrepreneudal; increased its speed of decision-making in the fieid, and coordinated better with the Pfizer leadership team. As a result, physicians said they feit they had been heard and that their patients could be better served. in addition, we improved our internei efficiencies. SALES AND MARKETING E Pfi:er 2ÜO7Yn,porue Rta;'on,tbiütyR'port 83 1 (, 1,7M W é M 1 LJNITEDSTATES Deflvering Beneficial Prescription Medicina Advertisin impienienting New Prescdptioi Med;cine Consumar We beijava that responsible consumar advertising educates Advertising Guidelines patients and is a critical conversation starter that results in life-changing diagnosis and troa rnent decislons. Dataj 4 we comrnitted to change some of our consumar dá supports that consumers value the information pro'ded by avertislÁgprctices in the liS by: advertising that alerts them about potential health conditions • Educating physicians about our new medicinas for and available treatment options. Not ali advertising is relevant a mirjimum of at ieast six rnonths prior to beginning to ali people,but It is of critical interest to those who suffer or consumer television and print advertising are at risk for an advertised condition. lmportantly, advertising • Subniltting ali new television ads to the FOA for comment motivates patients to seek additional inforniation and to taik in ávaAce of airing to their doctors, and it is only through consultation with a , • lncreasing advertisirig efforts behind disease awareness physician that a treatment can be evaluated and prescribedJ and Pfizer Helpful Answers to provido more information We recognize that this type of communication reaches a on access to medicina (see pagas 39, 48). i broad audience and thus requires a responsible approach. Jr To continuously improve the usefulness of this form of communication, we embarked on a serias of changes over 'in 2007 wemade the foliowing changes: 1 the past two years to make sura our prescription medicine i Lipitor advertising now reinforces the role of alternativa 1— 1 1 advertising encourages patients to have appropriate treatments for high cholesterol, such as exercise and diet, conversations with their doctors, heips consumers understand and advises patients that physicians rnay recornmend other ithe risks and benefits of prescription medicines, and motivates l treatment options peopletoovercomesigni • . Pnnt campa gnsfor Lyr ca', Lpitors, Zyrtec' and others include eay-to-read facts aboutsks, and ali print ads include Pfiíer Helpful .Answers inforrnation OuFdvàtising now prornotés disease awareness, nciuding awareríess of heart health, overactive bladder and chronic obstructi,e puimonary disease (COPO) • Ournewest Celebrex commercial, pèeviewed by the FDA, 01 provides a broad context of the risk-benefit profiies of URROU 0910 various prescription pain rnedications. r . 1 - EUROPE 1 ) The AC (Allgnjng O stomer Exeelience) P%qgram in Euçppe, is Pfizerinitiativtdestgned tá alfgn Pfizer Europe to 9 IV .- m i~tíw .piqI, 4Iii' 11 i:.1jjj$jj • 8empowenrig physicians-and patients se costs apot the oniy fac(or in défermlningjie9jth doais the burden oldisease. -1 4 - SE Through AOL we )lave reailocated jesourcs in Éurope so wà can jnteract more flexibly with a range ai ata ehoiders WhaErovide direct eedbacilthat heps,N suddres th& concer siand interests. Patidht g?oups, the pubiic at iare,payers, governrnent and haltiofficiais and ph siõians' ari ti rses' group are'all increasrngjy i organ zed to advise us in thiscapacity . . - WW i - 84 Jj#r2QoO?Ç'nprat,Re.ypot4qjüiRq,a 1 - iIr, w. 11 rk ffiN 4 SALES ANO MARKETING . 1. ÁRINI 41 - 1 no \;4~ %o We believe that effective pthblic policies can help create an environrnenf in which innovative medicines are more effectitiely brought to market, and natients are aMe to receive the medicines they need. For 1 s reason, we believe it's our responsibility to en ge in public policy discussions. This includes sues that affect regulatory guidelines, mec me safety, and a range of business practice around the world. We engage in ways that ar transparent and consistent with our value.sj 2006/2007 KEV ACTIONS Worked with the Health Coverage Coalition for the Uninsured to develop recommendations to address the uninsured in the US healthcare system. ER Worked around the world to strengthen healthcare policies, increase patient access to care and protect against counterfeit medicines. Requested US trade associations to disclose any portion of our dues used for political purposes. 86 J'fizer 2007 Gorp,rutq Rrspo,,,íhility Rcpor Éxpanded the Pfizer Europe Advisory Council, Vvhich includes a range of stakeholders who advise Pfizer on healthcare issues. Supported proposed legislation with the çampaign for Smokefree Air to help make Michigan the 30th US state to protect citizens from exposure to secondhand smoke. Supported increased access to medicines and safety monitoring in the US through policy ádvocacy. PUBLIC POLICY Contributing to the Political Debate Publie policies—on such issues as access to medicine, Lhe futuro of Medicare, iliegal importation and inteilectual pi.operty proteciions—have enormous impact ali our ability to ineet patient need.s and create shareholder value. For this reason we actively participate in public policy discussions, sharing our knowledge about healthcare, global public health, dísease prevention and health education, and contributing ideas about improving efficiency and effectiveness. Public Policy in the United States Different parts of the world face different public policy issues based on their healthcare systems, mailets and economic • strengths. In the US, for exanipie, we participate in one of the most • heavily regulated industries, and comply with ali federal and state lobbying registration and disclosure laws. We demonstrate transparency by publicly disclosing on our website our corporate political contributions and employee Political Action Committee contributions. In addition, we have agreed to disciose any portion of our trade association dues that are used for political purposes. To access Pfizer's Political Action Report, visit www.pfizer. comlresponsibiiity/lobbying_and_political_contributions.jsp. We strongly believe in contributing to public policy activities in ways that are appropriate, ethical and trai.isparent. This approach is applied giobaily, wherever we engage with governrnents, private ar public institutions. PUBLIC POLICY Pfi:er 2007 (Ja,poro!e Rej'onjhliSy Report 87 vE/ Supporting Healtti Reform Pfizer is part of a larger healthcare system in the US. We ara working along with other companies to heip make policy reforme that strengthen the current system, Improve quaiity and stabilize esoalating healthcare costs. Here are some primary exemplos: FDA Revitalization Act (FDARA) This legislation is an expansion of the reauthorization of the Prescription Drug User Fee Act (PDUFA), a Iaw requiring lhe lndustry to pay fees tolhe FDA in return for predictable regulatory review limes and processes. With this special funding, the FDA has been able to double its review staif and bring median review times for new drug applications down by about haif—to aliow for a 10-rnonth review cycle (six rnonths for priority applications). Usar fees were first estabiished in 1992, then re-enacted everyfive years. User fees make up 42.5 percent of the FDA's Center for Drug Evaluation and Research budget—with Congress appropriating $298 million and lhe VOA collecting $220 million from industry. The user fee system has been criticized for two reasons: the potential or perceived impact of user fees on the FDA's impartiality, and the fact that the fees are earmarked for new drug apphcation reviews rather than for general activities ar post-marketing safety work. FOARA, however, siso includes provisions for drug safety legislation and pediatrics, specifically lhe Best Pharmaceuticals for Children Act and the Pediatria Research Improvement Act. Based on recent negotiations with lhe pharniaceutical industry, Congress will increase usar fees for new drug applications, to keep drug review largels at 10 months. The FDA can use a substantial part of the fees for post-marketing drug safety and pharmacovigiiance efforts, as well as research on new drug safety tools. This is the most comprehensive reform 01 the FDA in the past decade and Pfizer is actively supportive of this important legislation. Medicara In December 2003, the US Congress passed, and President George W. Bush signed into iaw, the Medicare Modernization Act (MMA) which, for lhe first time, provided prescription drug coverage for American seniors and peopie with disabilities, called Medicam Part D. Pfizer appiauds the Federal government for recognizing that a heaithier society is achievabie by addressing disease and sickness prevention. Medicare Part D is a significant step towards ensuring that lhe country's senior and disabled patient populalions have affordabie access tolhe medicinas they need to hve longer healthy rather than tive longer sick. Without medicine, they pay more for hospitahzations and end-stage disease treatment. 88 J'fi4er 2007 Co'porate Rpon,iluIitv Report is considerable evidence that lhe program is working even better than initially expected, by giving Medicare recipients access to innovative medications at reasonable phces. Recent estimates show that beneficiarias will sáve an a'verage aI $1200 a year, whiie millions of iow-income and s&iousiy iii patients will each save thousands more. One of the reasons for this success is competition. The different pians offered by different insurance companies compete on prerniums and on access to the best, most-commoniy-used medicines. With this successful impiemenlation, Pfizer continues to suppart the roU-oul of lhe Part O benefil. Over 90 percent of America's senior cilizens and younger peaple with disabilities ndw have prescription drug coverage due tolhe new Medicare pescription drug program. We partner with both government a'nd community groups to provide education and assistance and heip improve access to medicines for seniors. Drug importation Prescription drug importation occurs when foreign pharmacies and traders ship medicines, which may or may not be aproved for use in other countries, into lhe US for sele to 4 nerican consumers. Over the past severai years, there have been a number of legislative proposais to amend current l'ealth and safety laws so distributors can import prescription V!dic1nes from other countries Into the US, ar aUow individuais to purchase medications directiy from phannacies in other countries. Aithough importation may sound appealing, itpresents real risks to patients and there is no guarantee that the imported phamiaceuticals would be safe. Federal law an pSscription drug imports reI lects welI-documented concerns aboul the safety of imporbed medicines, and the risk that many of these drugs will be unapproved, adulterated, conlaminated, ar counterfeil (see page 56 for more on counterfeit medicines). Many drugs that consumers befleve are coming from Canadian pharmacies actuaily come from other countries, where lhe supply chain may not be secure. lI lhe US government were to aUow iarge-scale, systematic importation, several federal agencies believe that safety problems would only get worse. lmpórtation not only creales safety risks, II does so without any guarantee of meaningful off-setting cost savings. Italso lhreatens innovation and lhe future deveiopment of dew medicines. Because foreign governments mandale cscounled drug prices, the US market bears more of lhe costs of biomedical research. If markets are unwilling to pay f?r innovation, the flow aI new, innovative medicines will be affected. To heip solve this problem, Pfizer is working hard to find long-term, sustainable solutions to irnprove lhe affordabihty of medicines in lhe US without requiring patients lo incur safety risks from importation. o 1 PUBLIc POLIOY O Supporting Legislation for Smokefree Air Pfizer supports legisiation to eliminate the hazards 01 secondhand smoke from lhe workplace, and other public places. We joined the Campaign for Smokefree Air (CSA), a grassroots coalition, to advance lhis cause for prevention and wellness. Our partnership with the CSA aims to help make Michigan the 3O' state to protect its workers from deadly exposure to secondhand smoke. As a member of the CSA's Steering Commiltee, we are aso the first and only pharmaceutical company actively participating in tinis effort. Secondhand smoke causes severe health repercussions. Michigan absorbs approximately $3.4 billion a year in related productivity losses and spends. through Medicaid, 11.04 billion to cover heaith costs associated with smoking. These are some of lhe reasons why 63 percent of Michigan's registered voters support a new state Iaw to ensure srnokefree workplaces, restaurants and bars. With such support, CSA is aggresslvely pushlng for the passage of Senate BilIs 109 and 110 and House BilI 4163 to secure these smokefree environments. Partners in the 60-member CSA, along with Pfizer, Include lhe American Cancer Sociely, the Nnerican Heart Association, the Arnerican Lung Association of Michigan, lhe Michigan Stale Medical Sociely, lhe Michigan Health and Hospital Association, among other medical provider organizations and health advocacy groups. ' Jldng toExpand Health Insu/ance Goverage The probiàt of the uninsured plagues the American healthcare sysfem, with ppiodrnateiy 47 milllon -. •M1ericnlaçking heeIhcovwage. Progrese on the issué, however, has'been stymied,by lhe vastly d,fferent approaches of vjrioàs stakeholders. But now lhere is a changé. ' F6r lhe past years, Pfizer has participate in a d'verse coalltion of 16 groupa irciudihg heãltháara providers, Irada asociationsand activist groupa determined lo rethink lhe issue and lay out a path for progreas. Together the gsoups devaloped consensus. reconimendatíons for coveririg a significant number o! thõ uninsured and formed lhe Heallh Coverage Coalition for the Unlrisured (HCCIJ) tb rnoe lhese 98 reconjijiendations lorward. On January 18, 2007, lhe ion released sri agreement which alI the partias endorsed. e HCCU agreed to certain key principies: Making coverage vàilabi&tc those who could ReI jdng\ipon incentives and voiuntary approaches Buildln'gon t)e'employer-based system and.,': not weakenlng IncentIves for employers lo provlde coverage 4 Using a comblnation o! pãbiic and approaches to expand covejiTgè - -. 5 Recognizing lhe budgõt challsngè facing most states and . 6 Recognizing the imoorta"of consumar outreach td education on health óoverage options. f R TIie HCCU's recommii,àations advooMe coverage expansion for lhe uninsured Qccurring iri two phases. In Phasé 1, lhe focus would be on children. In Phase li, Die key recommendatíons are teliminate farnily -. status as an éligibility ruirement, and to give states an option to expard coverage lo alI adulta w,th Incomes u l he fed l poveesrteynle eI. In bcoet ho h es,lhe ranodnemendauoenras repr t av balan f £ ubc-ad112r opbons. We are also working with the Coalition to Advence Heaith Retorm. PUBLIC POL1CY Pfi:er 2007 Corpo,&e Respon.U,iüty Repon 89 E .1 EA Strengthening Inteilectual Property Protection We believe that appropriate incentives for biornedicai innovation fuel the discovery and development of new cures and treatments. That's what the track record shows. The research-based pharmaceutical industry depends oi patent rights because they provide needed Incentives to make expensive, high-risk investnients in biomedical discovery and development. This is where new medicines come from. It costs on average about $800 tnillidn to discover, develop and manufacture one approved medicine bef ore it enters the market, with no guarantee of success. Patents guarantee a lirnited period of exclusive marketing rights for approved medicines in order to earn a fair return on such a largo investment. In short, patent protection is the only proven systen, of bringing new medicines to soclety in a timely manner. This is why we are helping emerging markets strengthen their regulatory systems, including inteliectual property rights protection. We believe that strong patent laws, when balanced with reasonable times of exclusive marketing rights, lead to more medicines and, ultimately, less disease. There is a view that patent rights limit access to medicines because they prohibit the unauthorized manufacture and saie of a patented medicine. We disagree that patents are a primary cause of hmited access to medicines. The fact is, 90 percent of the World Flealth Organization's List of Essential Medicines are no longer patented and stili do not reach the people who need them. Further, these medicines were criginally discovered and developed by private industry. As noted in this report, we're working actively to form publicprivate partnerships to improve access to medicines around the world. 90 flar 2007 Qwporate ItcaponsiMitv Repor! Right to Privacy for Patient Information and Physicians The right to privacy is fundamental, but it's being challenged as our society becomes more reliant on electronic forms of cèmmunication and information technology. That's why electronic prescribing, when physicians use electronic rnethods to send prescriptions to pharmacies and hospitais, Is being scrutinized so carefully. We believe that electronic prescribing, cone with proper safeguards, is an inHcreasingiy valuable and important tooi for protecting patient s&fety, enhancing patient treatment and improving overall efficiency. We believe the following guidelines should apply: • Patient and physician needs should drive the deslgn of e-prescribing tools that willl be used at the point of caro. A market-driven approach will best assure the adoption of • systems aligned with the provision of quabty care. • E-prescribing should be provlded through a neutral and open piatforrn and conform to prevailing quality and technicai standards. it should not be designed te advance the commercial interest of any particular participant to the potential detrinient of patient care. Patlent privacy must be protected. •, Ali messages transmitted to physicians and their staffs through e-presiibing systems must be sourced, accurate, and fact-based. E-prescribing technologles should support greater access to data for better clinicai decision-making, including alerts 1 to adverse events and access to formulary information. Such information should not be selectively or competitiveiy pushed to the physician, and the distribution of such information must not diminish the patient's right to appeai. • E-prescribing must not subvert the protections offered to patients in other areas of Medicare. PUBLIC POLIcY Public PoIicy in Europe Healthy Ageing Pfizer Europe has established a 'Healthy Ageing" Platforni to guide "partnering and comrnunicating differently" that aligns with the public's acknowledged desire for staying well. Active work with the EU Commission on a Resolution of "Active and Healthy Ageing" resulted In a partnership toward Healthcare Systems Reform programs. For example: New Approaches to Healthcare In Europe we are changing how we embed the neecis of our stakeholders into the value Pfizer provides them—not only through medical and scientific value, but by siso integrating social value. In practical terrns, we are achieving this by changing how we communicate and partner with our stakehoiders, which, in turn, affects how we operate. We call this "customer facing." For a description of how we implement this in Saies and Marketing through ACE (Aligning Custonier Excollence), please soe page 84. Our transformation is supported by hiring a far more diverso colleague base that comes from the array of social interests in healthcare: patients, pharrnacists, payers, government decision-makers, policyn,akers, economista and NOOs. By allocating our resources to hiring people with these backgrounds, we are embedding the thinking, cuiture and needs of the groups from which they come. Below, and elsewhere in this report, are some results of our Stakehold& Model approach (see pages 10-11): • rhe Luxembourg Sustainable Health Financing StudiesTho Cox Report (named for former President of lhe EU Parilament, Pat Cox)—have been received by lhe EU Health Commission Tho Alliance for Health and The Future works in lhe EU to facilitate rei orms on Health as an lnvestment to keep peopie as productive mombõrs of society. 1 A Pfizer Germany coileague was awarded the Patient Rights Award 2007 by PMI, publisher of several pharmaceutical periodicais, for outstanding work with patient groups to strengthen patient participation and patients' rights. Pfizer Europe Advisory Council Pfizer Europe expanded the Europe Advisory Council, which meets regularly with our management on conimercial goals. To better serve patients, we included diverse social and economic interests, in addition to the medical and scientific lnterests, associated with particular medicines. For example, for Champix, our smoking cessation medicine, we included diverse experts from international organizations, Ministries of Health, patients, tradé unions and others, in addition to medical and scientific experts. Our understanding of how Champlx would serve patients better was enhanced, shilting us from an insular approach to a stakeholder-focused approach. PU DLI C P0 LI CY AWARDS AND RECOGNITION E l'firvr 2007 ( opporu fr Reepr,nibiti!y Rpor 91 E F?3. Public Policy Around the World We are working hard to address public policy chalienges and opportunities around the world. In partnering with governments, communities and many other stakeholders we're cornmitted to working towards policies and prograrns that will help to bring more medicinas to more patients more quickly. 92 Pfiar 9007 Üorporcte Respnnvh.liLv Report PUBLIC POLICY "bEl F13 DPOE PUBLIC POLICY 2007 Cwporate Rospon.nbihty Report 93 PfIzer!sLApproacl$o Sustaii ;e Study in China aw.jt 1 In our view,"sustainability" in the b pharmaceütical sector cj6esbeyond:aíuE Yt1 r and enviionmental renéÂfáI. AtPfiz "How can we help meet thehealth of people today, withàutôohipràrh ability tomeet the healtKneeds of t1r tomorrow9" b We beijava the most workable answer lias fri our dtYI approach: • Sustainabie enterprise—investing in the büsineés • Sustainabie development—investing In the cõrnmunity Sustainabie enterprise includes estabiishinq research partnership agreements local manufacturing capabditles and R&D centers to discover and develop new m&diciti. It aiso means supporting inteliectual property háhis só we ãnd other innovators can help meet the health needs of peopie tornorrow Sustainable development includes working With local government to understand their health priorities a,d then ii forming partnerships to met those needs by rmproving disease awareness, providing needed treaf fZid biiilding ..heaithcarecapacity. Pfizer China is a good exarnple o how our approach to sustainability works. After.entering the rnarket in 1984, We no ee have a presence in more than 50 cities with2,100 employsr We have introduced over 40 medicinas to China and have four state-of the art manufactunng facilities inDaiian Suzhouzi and Wuxi. in 2005 we opened an R&D cantar lnShanghal, and today we have public heaith programs ín six disease areas ranging from 1-11V/AIOS to hypertension. In 2006, Pfizer China was ranked byFottes magazine as one of the niost £}»iT 4 "The dose partnership between Pfizer and our City has truly blossomed in he past deCade, Over this period, of how Pfizer China exemplifies oür partnership has Contributed both to Shanghás de')eIoment and to the health of our Citizens. Looking ahead, we see our association growing strongeç and deeper." ZI-JENG, MAVOR OF SHANGHAI 4; 1 94 P/icr 2cO? C,rporaAc Rn.porictbiWi_v ftçporf 1 -- C POLIGY 0,12lá,PM m1 Sustainable Development Irivesting in the Community : 1. Sustainable Enterprise : ..Investinq:in theBusrness j: •• • JLí• À, > :; iot . E•1 HIV/AiDs PfizeçÇhina has responded to the AIDS epidemic Manutacturing Pfizer Suzhouour arnniai heaíth products inChina bycommittiíT itself to a siate of H1V/AIDS initiatives, facihty, is expariding to become an advanced large scale from training heaithcare professionais tojçomoting ncreased internationai manufactunng and distributuon centeRit empioys !I awareness and education about HiV/AIDS prevention and j advanced rnanufacturing equipment and testing techriotogy treatnient prograíns Pfizer also becarne the first muitinational to produce a vanety of vetennary and agricuitural antubiotic pharmaceutical company in China te issue an H1V/AIOS formuiationsWhen complete manufacturing capacity will i~lkiplace Policy that ensures a work environment free from increase from 800 to 7 000 tons, and producte manufactured j harassment and discrimination for employees living with HIV/ in Suzhou will be exported t55 countried around the world LJL}AlS AI r crN h t T Research & Deveiopment in 2005 Pfizer opened a state-of '"qpF the-art Research and Development Center in Shanghai The 1Hypertension in November 2006 Pfizer began working with 1 Shanghai s Center for Disease Prevention and Control to help Center provides drug developrnent support capabilities and biometnc expertise to China and the Asian region The Center manage and reverse hypertension and related cardiovascular supports study design data management and statistical nsk factors Cardiovascular disease is the leading cause of f tI analysis for global clinical tnals while also training local ?jideath rand disease burden in urban centers in China The Pfizer coileagues in internationally recognized Good Clinical Çfgoal isto fuily utilize the resources and infrastructure of local Practice standards hospitais to irriprove diagnosis and disease management as well as proÃdeducatin and traininá to improve skillat Supply Chain Responsibihty Pfizer sources a number selected hospitais E of raw materiais and active pharniaceuticai ingredients 1 r from suppliers in Chinad this business is growing Stress Management In March 2006 Pfizer China and Song To assure responsibie practices with regard to safety and Jiang University Town launched a joint effort called the Mental the environment we have an active suppher review program11 ? Heaith and &&es Managernent Traning Project The project In 2006 reviews were cone at 22 suppiier facilities in China 1 is designed to rase awareness about mental disorders among Reviews involve onsite visits by Pfizer environmental and university faculty so they can heip recognize and prevent safety experts typically for two days In addition Pfizer has such disordera among their students The project also offers provided training and coaching to key supphers regarding free psychological counseling to the tens of thousands of environment and safety management Effortsincluded students at the eight coileges within the university a five-day training program in November 2006 given tol q 30 managers and engineers from six suppliers on industnal 9 E Smoking Cessation Chin&with approximately 350 niillion hygiene and process safety. smokers, rdudes and consumes more cigarettes than any other country in the world Pfizer China hopes to chalienge Anti-Counterfeiting - in March 2007 Pfizer iaunched a new this trend by conducting a series of community awareness anti-counterfeiting color changing logo for1 viagra® in Chinai and education programs including a three year smoking jEEçE on Consumer Rights Protection Day with planá to repiac cessation initiative at Peking University called Staying Away the current laser anti counterfeiting label globaily This effortgfi [froY Tobadco fora Healthy Life reflects Pfizer 's commitment to patient safety through the4 application of new technoiogies Cataracts Cataracts are one of the leading causes of bhndness in China Pfizer provides support to Lifeline Express E Working with Government In October 2006 the Mayor of a unique traveiing eye hospital train that has provided more Shanghai Han Zheng reaffirmed the city s strong partn&rship than 60,000 free operations to cataract patients in frontier with Pfizer during the first Pfizer Board of Directors meetuigiP and povïrty stricken areas In 2003 Pfizer China donated heid in Shanghai "The dose partnership between Pfizer and neariy 1 100 artificial lenses to heip more than 1,300 cataract our city has truly blossomed in the past decade the Major patients r`e g'en their sight Pfizer China also heiped Lifeline said Over this penod our partnership has contributed both Express host aoadeniic exchanges in rural China to train local to Shanghai $ development and to the heaith of our citizens ophthalniologists and to bring local doctors to Hong Kong Looking ahead we see our association growing stronger and and Guangdong for formal training deeper 1jb1Ib j 1 III PUBLIC POLICY I1L½r007Ga,or41eÉçion9íhftilvR.pci-t 95 Fia 1 r OPDE Making Pfizer a great plaqe to work is a key strategic priority in 2007. Engaged emplõyees are essential: to discoverinp and developing new medicines, and servipg the needs of ali our stakehoiders. They are essential to our success. That's why w&r4 developing a company culture that drives busineSs performance and e innovation through a broaJ diversity of talent and views—where colleagues 6uild their careers, are empowered to make deci ons, have an impact, and are rewarded for achi ving business results. hi 200612007 KEY ACTIONS Managed significant organizational changes with transparency and emphasis on affected coileagues. .e Expanded CEO and senior.management engagement with coileagues, including a global CEO-Colleague Advisory Committee to improve the flow of ideas. Developed a strategic plan endorsed by the Board of Directors to expand Pfizer's global diversity and inclusion. Eliminated dozens of management committeesto push decision-making down into the organization. Expanded Pfizer's employee healthimprovement program, which is based on prevention, early diagnosis and timely treatment. EMPLOYE ES 1 l'firer , 2007 Gorpnrafe Rc*pon,ibitity R.pofl 97 '4 'mnE/4 w Devetoping Talent and Employee Engagement Meaningfui work, an inclusive environment and effective leadership—these are some of the primary drivers of ..colleague engagement," the commitment of eniployees to give their best efforts, stay with Pfizer and say they are proud to do se. We assessed colleague engagement within certain divisions in 2006 and ídentífied a number of key chalienges and opportunities. These included the need for: • Regular, clear and more direct communications during a time of change • Support from managers through change • Focus on retaining and developing commltted employees • Performance-based incentives and career development. riá We addressed some of these chalienges quickly with new solutions. Other challenges we addressed by building on established programs as described throughout this section. In Iate 2007, we will begin an annual ali-colleague survey of colleague engagement using the Gallup survey to assess our progress going forward, Managing Pfizer's Transformation Pfizer currently has 89,000 employees worldwide; In Iate 2006 and early 2007, the company cornrnitted to reducing its workforce by approximately 10 percent of Pfizer's worldwide employee base in fine with evolving changes in the marketplace. Planning for Pfizer's transformation began in early 2005 with teams of colleagues in each division analyzing issues and priorities. As the pace increased in 2006 the chailenges of leading change were met through a robust set of strategies including senior-level communications, colleague focus groups, and providing managers and colleagues; with useful toois to help them deal with the unprecedented pace of change across the company. During this period, we launched several initiatives focused on strengthening supervisors' skills in leading change, colleague retention and building colleague resilience. 98 J'fivir 2007 G;rpt,rate &spon*ihiFity Reptrt Leadership Education and Development Fizer invests in the developrnent of programs to educate and prepare those who supervise others, ensuring a pipeline di "ready now" leaders. The company providas core, coi-nmon and critical leadership development resources for Pizer leaders with a focus on behaviors such as sustaining Arformance, creating an inclusive environment, encouraging oMpen discussion and debate, managing change, developing eople, and aligning across Pfizer. Prorams are based on a three-pronged development strategy that includes coaching, or-the-job experiences, and varlous leaming opportunities. Bátween 2004 and 2006, 2,290 managers across the business graduated from these programs. Olvislonal and Location Education and Training Most of the education and training at Pfizer is conducted a the business levei, where specific quality, technical and research skills are required. For example, our global R&D orànizatioh condúcted more than 50,000 instructor-led fraining classes and nearly 200,000 seif-study events during 2006. Another example is Pfizer's partnership with the University of Michigan, where 160 high-potential R&D colleagues received executive leadership education in 2006. This program complernented a broad curriculum of personal, manager and EM PL OY E ES aM4try ívk1 ffiá r rijM clusion Striving for Enterpnse 1 4 GHML Ji!h 1 sProcesses Diversity and Inclusion is anather key pilíar c engagement Over the past few years mie h nipraved progress in attracting diverse taler campany—particulariy at entry leveis acroas In additian to attracting diversa colleagues is being focused on their deelpment and talented cofleágues ádvanõe to sinior leels Pfizer mindset" ar success profile is being This rneans certain jabs dan t have ta be do have always dane thern ir the past We are af environment in which ali types af calleagL and their ideas and contributions are valued In 2006 Pfizer's Baard ai Director; ando; caniprehensive strategic pian ta expand the culture ai diversity and inclusion gIabaiiyTh designed to attraot, retain and dévelóp the ti talent in the world by creatinâ andhürtüri,i that respects diversity and where ali employ respected and engaged The pIar revolves a foliowing piatf arma 1 examine select HP? pmctices and ire that neither bias nor blacks to pra gress an ta cr4ate progress on ,nclus,an and env,ronment which is percetved as fair comlng s a(nalyzing identifying and addressing ofapportunity acrass Pfizer such as agernent talent planning cornpensatian >es that can be enhanced ta create and iva enviroiiment urrently being evaivated for efficacy is aur which permita any cai eague to present uesansbiems, a ar suggestians directly dership with n w ut fear of ess Maxumization and Groth Leader Education and Accountability We viiii praduce infrmed and engaged Pfiz€ the world who actively deve Diversity & Indo progress and plana in their organiza bons Th ultima tely be responsible for deliverrng speci resulta Senior leader Engagernent and Educatiaftis the Pfizer Diversity & inçiusian strategic frarr the Worldwide DM 0ff ice DIO) began dev, curriculum for Pfizers tolaseniar business la ar the critical rale they play in ereating and inclusive enviranment that optirniz&s índIvdL pertarmance across the entire arganizatiaF ieaders wili be expected ta embrace new be attitudes and cammunicate messages that Pfizer 's arganizatianal culture Pfizer business leaders are each cammitti resaurces ta suppart and suceessfuily rrnplei pians Each business unit lhas identified repri the DM Worldwide Leadership Cammittee meets regularly to pravide executive levei av and gavernance for the campany s DM strati serves an advusary bady ta the Pfizer Execut Tearn and the Worldwide Diversity & Inclusia works in caHaboratuan with the Pfizer Baard Divisions are alsa each identifying DM Busin individuais charged with partnering with iead to crive D&l pians throughout theirghniiaI '(2 DM Worldwide Leadership Committee will work iusiness leadeit t&idéntifj/ and lead efforts that nstmte Um bus,ness value af creating a d'verse and iva enviranrnent Me wdl seek ia partner with key la! organizations ia share aw D&l visson enhance Pfszers tsotíand support our business goa/a ©. uccess dernand that aúr business units retlect the .L .... variety ai perspectives ta respand ta the acceierated ;és in the marketplace and tbe needs af the diverse mera and patients mie serve The Ü&i Worldwide rship Cammittee wiir wark to utilize the D&i pracess ta rt Pfizersbusiness success ir external facus on D&i also apphes to or suppliers, ssspartnersccrnrnunities, and key externai izatians ta hlp drive our business results and share mmitment and progress in the D&l pracess kwLi ti 1 1 EMPLOVEES 1 z,,r2(jó7 ( ry0r4i li i(Pj'( n'nt,i Repod, 99 Diversity and Inclusion Initiatives for Specific Groups or Communities We have programs and initiatves for specific groups or communities who have been historically underrepresented in lhe US. Sorte examples include: Ml 100 PJL-cr 2007 Gorporate fÇcponeihrU&v Report E MP LOTE ES 4E Improving Wellness One way we are striving to hve the heaith principies we promote as a company is through Healthy Pfizer, an integrated, comprehensive heaith-iniprovernent program. Launched to our US colleagues and their farniiies in June 2005 and in Puerto Rico ii, September 2006, the Healthy Pfizer program is designed to increaso heaith awareness and support positivo change based on the principies of prevention, eariy diagnosis and timeiy treatment. Healthy Pfizer's personalized, easy-to-use toois, programrriing and services include a confidentiai, personahzed web portai, onsite health screenings, a heaith risk assessment tooi which inciudes a detailed report on individual risk factors and overali heaith, telephonic and onsite coaching programs designed to help participants reduce risk factor; and rnanage chronic conditions, a 24/7 nursehne, and a physicai activity program. To date: • 22,991 colleagues have conipieted hea]th screenings conducted onsite at Pfizer faciiities throughout the US and Puerto Rico • 84 percent of colleagues and 52 percent of dependents have conipieted the heaith risk assessment tool, the Health Questionnaire • 41 percent of eligible colleagues and 28 percent of eilglbie dependents are enroiied in coaching programs to reduce heaith risk factors and • 20 percent of ehgibie colleagues and dependents are enrolled in programs to heip them betier manage chronic conditions. The program seeks to set a new standard in empioyersponsored heaith programs that is best-in-ciass in usability, customer satisfaction and measurabie heaith outcomes. EMPLOYEES • Communicating Openly \_ CR Open dialogue between colleagues and senior management Ibuiids trust and improves performance, especiafly duringperiõds of change. This is why our CEO and senior rnanagers have iaunched a variety of ways to engago colleagues in interactive communication. in one program, called "On the Road," ,ieaders have been visiting and touring various Pfizer sites, 8hosting town hali meetings and conducting informal iunches with colleagues. Leaders have "gotten out of the office" and are spending significant time with the saies torce and meeting community and state ieaders. As a foliow-up to these events, Reports from frio Road" are posted on our intranet site. These are webcam dispatches in which the CEO shares his informal views on his trips around the company. Two-way communications between senior management and colleagues recentiy improved with the redesign of PfizerWorld, fim company's Intranet-based magazine. The sito now features The Exchange, a forum through which members of the Executivo Leadership Team speak about criticai issues affecting the company—from the canceDation of the torcetrapib clinicai trials (soe pago 27) to Pfizer's reorganization. The Exchange ser-vos as a portai for Pfizer ieaders and colleagues to comniunicate with one another. CoDeagues can siso submit ideas directiy to Chairman and CEO Jeff Kindler. He has received thousands of recommendations, questions and feedback on a range of issues. As another example of new ways of communicating,in 2007, Mr. Kindier created the first Pfizer Coileague Advisory Committee. This global panei of 15 empioyees, from ali leveis and divisions, wiili serve as a sounding board for the CEO and provide input and suggestions from our colleagues who interact directly with customers. In September 2007, every Pfizer colieague in the world wiili participate in the Pfizer Colleague Engagement Survey and action planning. Pfizer utilizes the Galiup G2' survey that measures the most significant drivers of coileague engagenient and inciusion, which directiy relate to productivity, retention and shareholder vaiue. This process inciudes a confidentiai survey with the resuits provided at the supervisor levei which tom, the basis for specific action plans to iitiprove the work environment. it wili siso crive coiieague engagement and a greater sense of inciusion and merit-based icareer advancernent and rewards. ler 2007 t'orporcsh' R,sponsíbüiry R.'port 101 1 Eliminating Bureaucracy AWARDS AND RECOGNITION Making Pfizer a great piace to work includes creating a more agile, flexible and empowered organization to speed decisionmaking. Coileagues kke to get things dono. To that end, we have begun efforts to unieash the talent and potential of our coileagues by: Wrking Mother named Pfizer one of the 100 Best Companies of 2006—the eighth time Pfizer was so honored. • Eliminating bureaucracy and reducing rnanagement Iayers so that leaders are closer to their Pfizer teams and custorners. We are in the midst of reducing the number of Iayers between the top and bottom of the organization from fourteen to eight. This reduction in layers is intended to not oniy bring leaders dosar to customers and patients but will push decision-making down to increase speed and customer focus. • Giving Pfizer coileagues more freedom to make decisions, be more creative, and have clearer accountability. As an exampie, we are in the process of extending the span of control of supervisors with the intent of empowering coileagues and allowing managers to focus on leading and developing their staffs. We are also building a stronger performance-based cultura by reviewing our compensation syètems at ali leveis of the organization in 2007, so there is a more direct hnk betweon rewards, performance and total shareholder roturn. This wilil require improvod performance planning and evaluation, as well as building talent at every levei of the organization. Pfizer is bui?ding on its 2005 succoss of making conipensation more transparent to coileagues by increasing the emphasis on business performance and increasing the differentiation of rewards relative to individual and team performance. :er is ano of 30 companies named to National Association of Female Executivos FE) Top Companies for Executive Women for 2007. Nfikkei Womanin Japan ranked Pfizer as ajnong the top 100 companies for women in 2006. 9fizer earned a perfect score on the Human 9ights Campaign Corporate Equity Index for tI'!e third year in a row. Urban League's New Yark Chapter named fizer a 2007 "Champion of Diversity" for deating and sustaining an environment of inclusion. ..2 o 1 102 flzcr 2007 Corporate Rpo,níbUitr Report F EMPLOYEES 457 (Fia. _ - 4L4 Pfizer is committed to ãssting quality, safety and consistency in the manufacture of our human and animal heaith produçt, while making sure the actions of individuais ad organizations within our supply chain are cçnsi$tent with the highest ersonal ethics. standards of business 2006/2007 KEY ACTIONS Conducted more than 100 onsite reviews at the facilities of contract manufacturers and researchers, key supphers, and outsourced logistic centers in 2006 to assure environment, heaith and safety (EHS) responsibihty of our suppiy chain. Continued to buiida supplier base that reflectis the changing demographics of the consumer marketpiace through a comprehensive Supplier Diversity program. Expanded our Responsibie Contracting initiative across ali Pfizer divisions in the US. C-5 104 JWcer 2007 Gorporcte Repo,nih,/i&v Report improving Quality Quality In everything we do is criticai because our products help people lead healthier lives. Today, every major country or region lias legal requirements that apply to Pfizer products, ircluding sophisticated standards of Good Manufacturing Pactices (GMP) against which regulatory agencies examine ali pharmaceutical companies. These efforts are supported by a number of corporate functions within our Legal Division. Our Corporate Reguiatory Compliance (CRC) organization, ith experts across the globe, verifies compliance through 11 Ariodic audits of Pfizer and selected contractor sites, as well as through measures of quality performance. A risk-based a"naiysis of each site, which considers products, activities, t&chnoiogy, and compliance history, determines the frequency aid duration of audits. Quality performance measures inciude such things as number of recalis and compliance incidents and everits. -h These measures and audit resuits are reviewed by business unit management and rnay be shared with our Chief C,omphance Officer or raised for discussion at our Corporate Compilance Cornmittee meetings. Our Right First Time strategy for manufacturing is màkin a signiflcant contribution to quality assurance and rik mitigation, and reflects our commitment to quality in 1 1erything we do. Right First Time promotes the use of ipnovative technoiogies and a set of toois that wUli improve process understanding and reduce variabihty in manufacturing operations. Manufacturing and CRC coileagues around the world are extensiveiy trained in the use of Right First lime technology and tools and have mede significant improvement in the quality of our processes and products. MANUPACTURING 1 SUPPLY CHAIN Another essential factor in niaintainlng GMP compliance is understanding and infiuencing ever-changing regulatory expectations. Our regulatory monitoring functions gather, evaluate and disseminate emerging regulations and guidance to the Pfizer comrnunity. We have also taken an industryleading role in interacting with the LiS FDA and lhe European Medicines Agency (EMEA) to communicate lhe value of recasting GMP regulations based on scientific and risk nianagement principies. Reducing Costs Pfizer has initiated a Technology and Innovation strategy for its manufacturing facilities to reduce costa by $5 billion avariO years. As part of this strategy we are expioring manufacturing methods foi traditionally found in the pharrnaceutical industry, especially continuous manufacturing processes, and the development of new material options designed to reduce lhe cost of active pharmaceutical ingredients. Improving EHS Performance of Contract Manufacturers and Key Suppliers Our commitment to responsible environrnent, health and safety (EHS) rnanagement goes far beyond our facilities' boundaries. We use stringent environmental performance criteria in assessing and selecting contract manufacturers and key Active Pharrnaceutical Ingredient (API) suppliers We are also committed to heiping our contract manufacturers and key suppliers in the developing world improve their EHS competency. By helping to elevate the EHS performance of these contract manufacturers and suppliers, thair workers and communities benefil, and we protect ourselves against business interniption that could irtipact contractual obligations. To assure EHS responsibility in our suppiy chain, our EHS professionals in 2006 conducted more than 100 onsite reviews at the facilities of contract manufacturers and researchers, key suppliers, and outsourced logistic centers. Reviews were dono in ali regions of the world, with a focus on China and India. The results are communicated to our procurement groups and considered in suppher decisions. Our suppher EHS review program is a key part of our supplier selection criteria. We use a two-tier approach. The top tier includes contract manufacturers and researchers for APIs or finished drug products that contain potent compounds. It also includes key suppliers of drug products and chemicals that are critical tolhe supply chain, such as high-value, unique chemical entity or single source suppliers. The second tier includes contract manufacturers that do not use potent compounds, do not make APIs and are considered Iess critical. MANUFACTURINO 1 SUPPLY CHAIN If suppliers are rated as acceptable with qualifications, the qualifications are shared with lhe suppiier and an action plan is requested to address the arcas of cancern. If a potential new supplier is found to be unacceptable, we will not do business with the entity until the concerns are addressed. If an existing supplier is rated as not acceptable, we typically work with the supplier to improve perforrnance, or we may also and lhe relationship. Pfizer also actively supports EHS management iniprovement at hany suppliers. In November 2006, for example, we sponsored a onc-week intensivo EHS training course in Shanghai, China, focusing on occupational hygiene and process safety. The training was conducted by internationally recognized consuitants, with Pfizer • facilitating discussions. Sixty participants representing six • key suppliers attended lhe course. Integrating EHS Criteria in the Purchase of Goods and Services lntegrating EHS criteria into our purchasing decisions for goods and services can reduce our cosi, improve lhe quality of the product ar service, reduce risks to our business, and reduce environmental degradation. For these reasons we have • been examining categorias of goods and services, identifying opportunities and risks in these purchases, working to develop EHS specifications and defining lhe methods by which we can measure the benefits of such purchases. One example of how such "groen purchasing" benefits Pfizer and the environment is in lhe use of office papar. Sixty-eight percent of the printer and copier paper we purchascd in lhe US in 2005 was recycled papar. The foresting practices used to produce the raw material for the paperwe bought were certified as sustainable under the Sustainable Forestry Initiative. In making this choice we helped save 8,068 trees, 1,645,587 kilowatt hours of energy (enough to power 61 homes for one year), and 321 metric tons of related carbon dioxide (CO2) and olhar atmospheric greenhouse gas emissions (equal to lhe amount of CO2 from lhe operation of 64 cars par year). We are currently purchasing printer and copiar papar with 30 percent post-consurner waste recycied content. Pfizer 2007 (orporate Re,per.,ihititv Rport 105 /%E Ilj (r Ft ... Increasing Supplier Diversity Responsíble Contracting The objective of our Supplier Diversity program isto build a supplier base that reflects the changing dernographics of the consumer marketplace while helping Pfizer increase market share and shareholder valuo. In arder to do this, we have implemented a three-part strategy: To years ego, we iniplemented a Responsible Contracting initiativo in the US for use on ali major capital projecis, sito services and sõMce contracts. Pfizer was the first pharrnaceuticai company to do so. Under the initiative, contractors and ser-vice providers may bid to Pfizer provided tF'ey compiy with "responsibie contracting" prequahfication cltteria that include paying appropriate wages, providing family health insurance and job training, compiying with empioyment laws, and not using independent contractors. The company receives services frorn a broad spectrum of contractors v)ith both union and non-union affihations. Over the past decade, more than $1.2 biiiion, ar approximately 85 percent, our construction doiiars have gane to union contractors. Responsibie Contracting has helpod to expand and diversify Pfizer's servico provider iist, attracting new contractors to our sites and new workers to our communitios. • Creste opportunities through our sourcing process to increase our spending with minority and women-owned businesses. Over the last several years, we have increased such spending by 10 percent a year, well above the pharmaceutical industry average. SmaII businesses, service-disabled veterans and veterans are inciuded in our Supplier Diversity Program. • Provido executive educational prograrns for our diversity suppliers and diversity education training and developmeht for interna! coileagues. For exarnple, over the past three years, we have provided scholarships for minority and women-owned businesses to attend the Tuck Schooi of Business Minority Executive Education Program at Dartmouth Coliege. This program heips entrepreneurs with such issues as buiiding strategic alliances, marketing and organizational development. lnternally, we focus on goal setting and techniques to identify minority and women suppliers. • AIIgn with advocacy organizations, such as the National Minority Supplier Development Council (NMSDC) and the Women's Business Enterprise National Council BENC). Theso leading advocacy and certification organizations provido certification and business development opportunities for minority and women-owned businesses We support these organizations through local and national board memberships and sponsorships of conferences and workshops. 106 JYÜCT 2007 Cvrporafç flrspon,,h,li:v Rpejrt of MANUFACTURINO 1 SUPPLY CHAIN 4oEi Fb AWARDS AND RECOGNITION The Women's Business Enterprihe National Council (WBENC) has recognized Pfizer asone of the 2006 Top Corporations for Wornen's Business Enterprises. This marks the thírd consecutive year Pfizer has received this honor. • . For the fourth consecutive year,[ Pfizer has beenrecognized as the Best Cqrporàtion for Multicultural Business Oppõrtunitiesby DiversityBusiness.com. The online survey of minority and women business énterprises considered such factors as extérnal oútreach, mentoring, and seniormanagement 1 commitment to diversity. M Pfizer's Thane, India manufacturing fadllity von the Sfty, Hlth & Environment Award from the Confederation of Indian-Industries for its education and awareness initiatives 1 :1 MANUFACTURING / SUPPLY CHAIN Pfizer 2007 ('o'poruf Rnponibihtv &pQrL 107 '••! - - OPDE Looking Ahead f We are looking for sustaina!ile.ways to neel healthcare needs aroúnd thé wófld, tomorrow. We help people get••needed treatn and services, while fostering a cliniãtè '6fini thatensures steady progress inbiomediàaI tion Certainly, our work ii.. reserch and dêVélp prevention and wellness, and healthcâre rei helps empower people in their ownheãltha Bút gien the cotnplexities ôf global héalthc issues, we cannot solve problems alone. t, So, we will hsten. learn and change; and 70 hard with responsible business practices; ifl pai tnei ship with our stakeholders to1 hep c a healthier, wealthier world That is our conirnitment. 108 1 Jiw !OO7 Gorporote RcsponeihiTity Report o Global Reporting Initiative (GRI)In4ex The GRI Sustainability Reporting Guidelines provido a framework for organizations to report on thoír social, environmental and ecoromic perfomianco. For more Information, please soe www.globalreporting.org. '/JJerLflht.o porair noporao,t& w n.'poflIu Explanation f. ot me affecls cl anyrestaternent O! atlonplded In earlier reporls. 3.10 1 J tnviitfln,ent, neann fina atety - CI S~evious 1 rabio Identlf4ng the localion cl lhe Standard J9losuresin the mort z. 3.12 Policy and currant practice wilh regard o seeking 3.13 [Jalusuranforlhé report ][0aestt00fte0r9anhzat0n aaewIaa weaa r -T About the Report Ir aarn,ain { CorporateResponsibility and me Board ofblrectors taaca,r - -e.r iIttir Governance and Cornpliance Indicate whether lhe Chair aI lhe highest govemance bodylsalsoan executiva officer 4.2 - ..... GRI Index .... J 4.3 1 Members of lhe highest governance body that are independent and/or non-execut've member 4 4.4 naisa Ertcouraging Sharehoider and Stakehoider Participatior jlte*#lnett' 4.5 ,jtneçeetr .ta,a Linkage between compensation and the organizations perlorniance .1u._Jli. LI. 41 is.— 4 4.6 J LS- Corporate Responsibility and the Board 01 Directora Mechanisms for'shareholders and omp1ayes to provida recomniendations or directio lo the highest governance % Ensuring Soard Independence Processes in placa for lhe highest govemanco body to ensure conflicts of interest are resoived 1 ,..,,r .-,--- r lnstltuling Greater .Accountabitity in Executiva Compensation , Compiylng with PJI Laws, Committed to lhe Highest Ethical Standards cess for deternhining lhe quahflcatlons and expertise l Ensuring Board Independence themember ofthehighestgovernancebodyfor uiding the organization's strategyon econonlic vlronmental and social performance IL IO9,1 t 'tpa. qptert In III 4.8 lnternally dev&oped statement of mission ovalues,L Complying willi Ali Laws, Committed tolhe Highesl codes cl conduct. and principies relavant to eccnomic, Ethical Standards en~mental, and social performance and the status of their irnplementation 1a414s... 4.9 1• — 4.10 k 4.11 lhe hlghest goveranco bodyfor e organizatuon a identifioalion and ang.V -~rn~i o! econonIc, envlron!nentland socla L Corporate Responsibility and the Board 01 Directors Complying with Ali ws Ccmmitted lo the 21 tHlghest Ethical S{anddds r' -------Processes for ovaluating me highest governance bodys cwn performance, particularly with respect to ecanornic, environmental and social perforrnance Ensuring Board Independonce rrr'r r ~pnation cl whether and how lhe precautionary achorprincJple a addressed by tho organtzation Understanding the lnipact of Pharniaceuticals In thEnvlronme Realizlng lhe Proniiseof Greon Chemlstry n., o, a, w,waa,.,aa,,aurat. 4.12 Externally developod economic, environrnental, and social charlers, principies, o' olhar initialives to wtch lhe organization subscnbes or whrch it oridorses 91 2 -- 1 4 iáN , 1' 110 JWcrr 20Õ7 Cerp,rate fltspnrn;h.tity Report Our Colleclive Actions 1 Our Corporate Responsibility Standards 1 and Evaluation Partne,s lncreasrng Scíentufic Coltaborations and Partnerships lnvestinglnHealthi 1Envlronmerit. Health and Safety 1 Sales and Matleting - EU cai INDEX \jr7 r S'gniflcant mirmbershipínoganzaons 1 413 ifl ttirn 1 4.l4W: jL .. kíSt4SLwaiw 415 IOurCoiloctiveAction CborationsandPa,1norshjp r77pwnfl ,r1 Wst 01 stakehoIderrupiengaged bythe organMIjjperatingwith a Now Stakehotder Módel '" F r t tP rMtnwtrnnrTrnn rt!: Basis for identification and selectuon of stakehoIders4tflL øperating w'th a Now Stakeholder Model r---.srtt-&et 416 4.17 Operating w'th a New Stakoboldor Modal Approaches to stakeholder ncluding frequency of engagement by type and b hIHr%i by stakeholder group .... Keytopics and concems that have beon raised through, Changing Ilow We Intograte StakehoIde!Needs2 stakeholder engagernent anã how the oianization has ii $ r responded to those key topics and concerns IncIudin r throughitsreporting <1kincIuding rovenuesoperatir iflconpensation, donations ar retained earnir , jJjProidersànd goveminents EC2 EC3 CS $4SE j Operàng wh a N w Stakeholdet M& NÉ, J. - ex Expenses Consolidated Finanbtal StàSiiiénts i[rinanciai iniplicatuons ando for lhe organizations activiti for 'tc : obligations Change 4qÇ4 r4 ans - EC6 (Partially Càvered) ersity EC7 (Partlalfy Covered) Vide Diversily and Incluslo, Rrfl EC8 1;;--- O RI INDEX Development and services throughcomr benefit ídndersandin 1 H ecdhomlc irii i'fi,er 2007 (.'orprir&v Respon,ibüitv Report 111 Disciosur es - - h. rr ------' - 1 --,Continuing ta Reduce our Footprint: Reducing Por and ~te Ernissions E Materiais used by welght ar volume EN1 :-----1----1 Percentage of materiais used that are recycied input materiais - EN2 r.EN3 (Partially Covered) ( Cantinwng to Reduce our Footprint: Reducng Por andP. ÁA Waste Emissions . -e— Planning for Change J Dprect energyconsumption by prlmary energy source J r L EN4 ÉM lndurect energy consumption by pnmary source k - Energy saved dueto improvernents - EN5 EN6 - - 11-Pus and efflcincy 9 1 Initiatives to provido energy-oflicient ar ranewable energy based products and serices and reductions energy requlrements as a resuil of these initlatives1 Carbon Disclosure ri et—r—r lnitiatives lo reduce tndirect energy consumption and reductions achieved EN7 Planning for ChangeJj Total waterwittidrawalbysource rrsSSamaeasaafla - - aInu!r4e—aSa Water saurces slgn,flcantly affected by wlthdrawai Jlofwater ENB - [ íE EN1O - Water Use and Conservatian MEN 15fl4 ..- I .o Percentage and total volume of water rocycied andreused; Ls ____ EN1? - -- - Chmate Change: Reducung Greenhouse Gases and ng Energy W&y Et Using EnergyWiseiy Ï Er,issions af ozone-depleting subsiances by woight EN20 - NO SO and other significant ak emissions by type and welght iL - _____ — _________ EN27 (Partlally Covered) —, —- Totai water discharge byguality and destinatlon -0 Total weight of waste by type and disposai method - r— awn.nw_a 'r-- -- --------a - initiatives to miligate environrnental impacts oS f products and services, and oxtent ai lmpact mitlgatlon Percentage o! products sald and their packaging materiais that are reclaimed by category - --«-----11 Understanding tho impact ai Pharmaceuticais in the Environment -- fines and totalthumber - ConseMng Water mec..erno4a Saaneaenae—anzwaasassavnan mrsc Contlnuing to Reduce our Footprint: Reducing Por and Waste Ernissions 3 -- - ,,JLan,síLaean o! non-monelary sanctions for non-campliarice with Understanding the lmpact o! Pharmaceuticais in the ESronme2 0j h environmental iaws and regulations Sigcantenvironrnental impacts ai transporting producs and other goods and matertals used for the woMo organízations operations and transporting members 01 1 Continuing to Reduce our Footprint: Reducing Por and Waste Emissions a EN21 — Conl(nulng to Reduce our Footprint: Reduclng Por and flEmissIons EN26 -- rr — rr. Cther reievant lndirect greenhousa 955 emissions Chmate Change. Reducing Greenhouse Gases and r EN1O Ln_. - - «- Total direct and lndírect greenhouse gas emissions by weight • _____________ r EN22 -. - Conserving Water _SS_ ENIO 1 jconservingwater San tasJ eSas j ENB u---- - Plannlng for Change j EHS E J lã - 1 Ciimate Change: Reduclng Greenh Uslng Energy Wsoiy " -L i 112 Pfizer 2007 Corporal, íksponsihriitv Report CRI INDEX E e CRI IND gx Pfirer 2007 Co,w.eo ReApÚn.IihitUy &'pofl 113 $ Pá 114 I'jier 2007 (..p,rote &spirneíh.Jity Report O RI INDEX e 1 Index A Allempo 40 Academic Ailiance Fotindation 43,48 Academy for EducationaJ Deveiopment 36 Active pl,annaceutical ingrediente (API) 8.55,105 Alhcan trypanosomlasis 21 Agency for l-lealthcare Mminislration (Ai-lCA, Florida 47 Age-relaled macular degeneratioà 42 AIOS service organizations (ASOs) 36 Aiignlng Cu~ Excelience Pro9ram (ACE) 12.84.91 Ailergy & respiratory discasse 4 AJIlance for a Healthy Bordar 37 AJliance for Health and lhe Futuro 91 Ailiance to Conserve the Maya Foresl 61 Arnerican Academy of Family Phyaicians 48 Nuerican Cancer Soolety ID, 40,89 M,erlcan Heart Assoclation 10, 89 Mnerican lung Association of Michigan 89 Ajnorican Medical Assoclation 10 Ajmericans with Dlsabilities Aol 100 Amigos en Salud 47 MCHOR 42 Animais in research 29 Animal welfare p0110)' 29 Mn Ajtor B520 Renovation Project 73 Argentino Congress of Clinical Oncology 40 4ornasin° 4 Association o? Businees Communicalors 58 Association of Clinical Oncology 22 Association of tiro Brlllsh Pharrnaceutical Industry 12 Ausielio, MD, Dennis A. (Director) 78. 79 Mitinib° 24 5-2 Balance Ir Oul: Arkansas 46 Biomadcers Consortium, The 30 Biomedical innovalion 21 Blue Book, lhe (Summary o? Pfizer Policies on Buslness Conduct) 77 Boston University School 01 Public l-fealth 9 Brookings lnslitution, lhe 9, 34 Interna Ilonal Volunfeerisrn iniciativa 34 Brown, MD, MichaS S. (Director) 78,79 Bums, Anthony M. (Director) 78,79 Burt, Robeil N. (Director) 78, 79 Buslness Etblcs Conter of Jerjsalem 92 Businesa fora Healthy Society Task Force 45 Busineso Roundlable, lhe 7 IND EX o Caduel° 4 Campalgn for Srnokefree Ar 86, 89 Campaign for Tobacco Free Kids 10 Camptosav° 4 Cance,s 19, 22, 24, 29, 30.40.41 • (aJso soe 'oncology Candidemia 20 Caphri Research Instituto of lhe University of Maastricht 45 Cardiomobile, The 44 Cardiovascular, metaboto and endocrine disoaso 4, 22, 24 Care-A-Van, The 44 Cwing for CIlmale, lhe Business Leadership Platforni 61 Celebrex 4, 54, 84 CEO-Coileague Advisory CoMn,ittee 97, 101 Chagas' disease2l Chantlx (siso Champix°) 4,9,19, 91 Chetnicals in lhe workplace 69 Childhood obesity 41,42,47 Chloroqulne 21,24 Chronic diseases 46 Chronic Obstructive Pulmonar Dlsease (COPD) 45 Chronicle o! Philenthropy, Tire 49 CIO magazine 58 Cleveland Clinic 54 Climate change 62 Clinicai Research Unit, New Haven, CT 73 Clinicai trata 25-26 developing world 26 disclosurw policy 25 ofhical25 phases o! 25 piogress on cornrnitrnenfs 8 quality assura rico 25, 26, 52! 54 trsnsparency 26, 27 Clinton Global Initialive 35 Coalition Aalnst Falte Medicinas 58 Coalition to Advance Health Refonu 89 Commiltee for Medicinal Producls for Human Use 20 Confederalion 01 Indian Industries Safety, Health and Enmnment Aw&d 107 ConnectHlV 34 Connectlon to Cara 48 Conserving waler 65 Conlract manutacturers 105 Cornelia Vlieg ,Association 41 Comwell, Don W. (Director) 78, 79 Corporate ethics and compliarice 77 Corporate Govemance P,inclles 76 Corporate Regulatory Compliance 77,104 Corporate rosponsibllity 5 abouf Lhe report 5 Board o! Okecton' Corporate Governance Cornmitfes 5 integm?Ion o! 5 sfandards and ova luation partners 7 Cox Report 91 CP-945-598 24 D Data and Satety Monitoring 8oard 27 De.mentia 40 Delrol°/Detrol LA 4 Developing lalent 98 Diabetes 18,19,22,24,30,31,38,40.43, 47, 48, 70 Diflucan Partnership Program 36,49 Disabilily Nelworldrig Group IDO Diseases 01 lhe developing world, research for 21 verSty and Inclusion 99 DlversllyBusiness.coni 107 Dow Jones Sustainable Asset Managemeni (DJSAM) 7 Dnig counlerfeiting 56. 92, 95 Drug distribution chain 58 Dmg iniportalion 88 Easter Seals 10,88 Edna McConnell Clark Foundalion 49 Educaling for Inteilectual Property Rights Progran, 92 Educational Grant Disclosure Plan 12 Egypt Health Minialer 93 EHS Critõria for Purchasing Goods and SeMces 105 EHS Guldeline on Proceas Safety 72 Electronic producl code (EPC) 57 Elirninaling bureaucracy 102 Employee education and training 82, 98 Employee engagement 98,99 Employees with disab8ties 100 Energy efllciency credits (or renewable energy credita) 64 Environrnent, heallh and safely (EHS) 61 EPA Climale Leaders 62 EPA Envlronmental Performance Track 61 EPA Presidential Green Chemlstry Award 68 e-prescribing 90 Eraxis° 4,20 Ernst & Yourig 9 EU Health Coqnmission 91 European Medicineb Aency (EM EA) 105 Exceilence in Green Chemistry and Engineering Award 68 l'ftrer 200T Unrporule Reepon,ibiiity Report 115 Ar zrz Executivo compensation 76 Executivo Leadership 'ream (ELO 101 Executivo Medical Review Commlttee 53 Exubera° 4,9.19,31,54 Exxon Mobil 43 F Family I-tealth International 49 FDA Center for Drug Evaluation and Research 88 FDA Critica] Palh Inhtiative 30 FDA Revitajization Ad (FDARA) 88 Feczko, .Joseph (Chio! Medical Olficer) 55 -Fibromyalgia 20 Fleot safety 72 Florida; A Heallhy State 47 Food & Onjg Packaging magazine 58 Foites magazine 94 Foralgn Conupi Practices MI (FCPA) 75.77 Foundation for the National Institutos of Health 30.31 FTSE4Good 7 a Gailup survay 98, 101 Gastrointestinal 24 Gastrointestinal siromel tumor (GIST) 19 Gay, lesbian, bisexual and transgender (GLBT) community 1 00 Genetic Aaaoclatlon lnformalion Network (GAIN) 31 Genitourinary 4,24 Genõtropin° 4 Geodon°/Zeldot 4 Cetfluit 19 Gllead Sciences 43 Glaucoma 42 Global Accountabillty Project (GAR) 7 Global Envonmental Management Initiative (GEMI) 13 Global Health Partners 34, 40 Global lIA Nova 49 Global Manufacturing Active Pharmaceutical Ingrediente 105 Global Reporting lnitiativé (CRI) 5, S. 109 Global Summit o! Women 1 00 Good Clinical Practices (GCP) Guidelines 26 Good Manufacturtng Practices (GMP) 104,105 Governance Metrics lnlen,ational 78 Cray, III, William H. (Directo.) 78, 79 Green buildinga 64 Green chemislry 68 "Green" purchaslng 105 Greon Ribbon Health 46 Greenhousa gases 61.62.63 116 P&er 2r7O C',p,nate Rcspon.ih,lity Reporl H K Han Zheng, Mayor o! Shanghaj 94, 95 Hazardous waste 66 Health Coverage for lhe üninsured (-ICCU) 13,86.89 Health disparities 92 Health Volunteers Inlemational 49 Healthcare Distribution Managenient Association (HDMA) 58 Healthy agoing 91 Healthy Pfier 101 1-11V/AIOS prevention 36 HiV/,AJOS workpIace policy 100 Hong Kong Social Weltare Departnient 49 Honor, Constance J. ead Direaor) 75, 76,78 Hospital Partnership Program 48 Howell, Witiam R. (Director) 78, 79 Human RightsCanipaign 102 Humana Inc. 46 Hungarian Socloly 01 Hypertension 39 Hyporlension 23, 39, 94, 95 Kenya Msoclallon ol lhe Pham,aceutical lndustry 92 Kindlor, Jeff (Chairman, CEO) 2-3, 75, 78, 78, 101 Korean Reaearch Instituto o! Biosolonco and Biolechnology 93 Ibuprofen 54 Improvac 29 In Vitro Testing industrial Plattorm (IVTIP) 29 incubator' at La JolIa 31 Industry strengths and weaknesses 6 lnfectious Disease instituto QDQ 43,48 lnfectious diseases 4, 21.23.24 , lnfectious Diseases Society o! knerica 43,48 lnflammation 4, 24 Instituto for Supply Chain Managehient (ISM) 7 Instituto of Chemical Engineers (iChem ) 68 Crystal Faraday Award for Green Chemlca/ 7âchrológig, UK6S lntellectual prope,ly protectiàn 90,92 International Alllanoo o! Pathents' Organizations 10 Inlemational Mti-Bribery and Mti-Con-uption Corporate Procedure 77 k International Conterence o! Harmonization (10H) 26 International Federalion ol Pharmaceutloal Manufactu,ers and Associations (IFPMA) 26 International LHe Sciences lnslittites/Health and ErMronmental Sciences Instituto 29 International Rescuo Comniittee 49 International Trachoma Initiative (171)36.49 lrlsh National Satety Qrganizatlon 73 L Labs for the 21 st Centu' coliaboralive partnership 73 Lalcec (Argentino League Against Canoer) 40 Latino community 1 00 Leadership in Energy and Environmental Design (LEED) 73 L&shmanlasis 21 Lifeline Expresa 95 Lipilor 4, 84 London School ot Hygiene and Tropical Medicino 35 Lorch, George A. (Director) 78, 79 Lost Time lnjury and lllness Rale 71 Low income radical soheme, South Africa 92 Luxernbourg Sustainable Health Rnanclng Studies 91 Lynca° 4, 20, 23, 68, 84 M Makerere Universily 43,48 Mataria 21,24,36 ~ manta 21 Manufactu.tng/supply chain 103-106 Mead, Dana G. (Director) 78. 79 Medicam Health Support Program (MEIS) 46 Medicam Modernizalion Act (MMA) or Medicam Par: O 46, 88 Medicines Australia 93 Memory Bus 40 Meningitis 26 Monta] Heaith and Stress Managemeni Training Project 95 Mexlcan Diabetes Assoclalion 39 Michigan Health and Hospital Assoclation 89 Michigan Stale Medical Soolety 89 Missouri Waler Environmental Association aold Star Ceitificate' 73 Mobilize A9ainat Mataria 34-35 Monja Mi.nal Foundation 29 Mulago Hospital 48 J Johns Hopkins Bloomberg Sohool 01 PubIic Health 36 IND EX N Q NMCP 48 Naproxe., 54 Nailonal Ailiance for Hispanic HeaIih 48 National Aihance for the Mentally 111 10 National Association of Boards of Phamiacy 58 National Association o? Chain Drug Stores (NACOS) 58 National Association of Community Health Cantora 48 National Association of Fernale Executivos (NAF E) 102 National Business Disability Council 100 National Cancer Instituto (NCI) 29 National Governors Association 48 National Human Genome Advisory Council 31 National Institutos o? Heslth )NIH) 18.30,31 National Minority Supplier Development Council MSDC) 106 National Urban Leaguo 48 Neuropathic pain 20 Neuroscience 4, 23, 24 New stakeholder modal -li Nigeria, Kano 26 Nikkel Woman, Japan 102 Norvasc 4 lo Onchocerciasis 21 Oncology 4,22,24,40 (siso se. cancers Ophthamology 4.24 Organlzation for Economic and Cooperatlon Development (OECD) 10 OSHA VPP 61 OSHAS 14001 and 1800161 Oxfani 10 Ozone depieting con,pounds (ODC) 62, 68, 67 Ozone depletion potential (ODP) 62. 87 P Pain 4, 24 Partners lii Cara Solutions (PICASSO) 45 Pantnorship for Prescription Assistance (PPA) 39, 48 Pantnership for Quality Medicai Oonatlons (POMO) 13 Patient and medical group transparency 12 Patlant pnivacy, night to 90 PEPFAfl 49 Pfizer Mimei Health 4, 29 Pfizer Board cl Diroctors 5,75-79 Pfizer Australia 93 Pfizer Canada 42 Pfizer Canina Tumor Biospeciman Bank 29 Pfizer China 94 lI2J] 4:1 Pfizer Compliance Eduoation Center 77 Pfizer Corporate Connpliance Program 77 Pfizer Europe Msory Council 86,91 Pfizer Foundation 36,40 Pfizer Germany4l Pfizer Global Health Felows 8, 37, 43, 44, Pfizer Global Policy on Interactions with Heallhcare Professionais 83 Pfizer Health Solutions 46, 47 Pfizer Helpful Mswers 9, 39, 48, 84 Pfizer Hong Kong 49 Pfizer Indonesla 42 Pfizer Israel 92 Pfizer Japan 43, 93 Pfizer medical governance 52 Pfizer Policies on Business Conduct 75,77 Pfizer Pra 81, 82 Pfizer SpaIn 42 Pfizer Suzhou 95 Pfizer 'Thailand 92 Pfizer values 3 Pfizer Wornen Summit IDO Pfizer World 101 lhe Exchange 101 Pfizer's Corporate Govemance Commlttee 76 Pfizer's leadlng medicines; 4 Pfizer's PoliUcal Milo,, Report 87 Pfizer's transiormation 98 Phanma Futuros 1112 Pharmaceutical and Medicai ~cos; Ageccy (PM0A), Japen 93 Pharmaceutical Benefits Scheme P85) 93 Pharmaceu cal lndustry Labog Management Association ID Phermacetjtical Research and Manufacturem Association (PhRMA) 26, 30, Pham,aceoticajs in the e,Mronment 68 PhATE Model 68 Philippine Association of Diabetes Educators 43 Photovallalc solar panela 64 PhRMA Discoverers Award 31 Posl-traumatic stress disorder (PTSD) 42 Past-madçeling 53.55 1 commitments 55 swdles 53 fransparency 55 PowderMed Ltd. 21 Prescription Drug Usar Fee Act (PDtJfA) 88 Prescription medicine advertislng 84 Product Medical Review Comrniltee 53 Progresso an 2006 commitments 8-9 Project Hope 49 Project Leonardo 39 Publlc pollcy 85 Around fite World 92 Europe9l United States 87 Publlc-private partnershlps 21,30 QEII Health Sciences Centre Foundation 42 Qua)ity, imprang 104 R Radia frequency identification (1FID) 57 Rebif 4 Reducing casta 104 Reduclng wasto 66, 67 Relpax 4 'Reporta froni the Road 101 Responsible Contracting Initiative 104, 106 Revaflo 4 Right Flrst Time training 98, 104 Research and development 16, 18, 22-24 pipo/iria 22 pipeline transparency 24 Ridley, Or. Rabert 21 S Safety cultura 70 Salas force 81 global coce o! conduct 83 number one mnking 82 ràsfnictuüng 83 San Francisco AIOS Foundalion,/Pangaea Global Foundation 48 Schistosorniasis 21 Scnipps Research Instituto, The 30 S.E.E. Change/Climate Resolve 7 Selzentryi/Celsentni (maravlroc) 18, 20,23 Shanghai Center for Disease Prevention and Control 95 Shanghal Research & Develapment Conter 94,95 Shasing the Caro 48 Sheet Metal Ykrkers Intemational Association 10 Simmons Leadorship Conference 100 Slovenlan Diabetics Assoclation 44 Slovenian Heart Foundation 44 Smoking cessation 19,91,95 Song Jiang Llniversity Town 95 Southem HIV/AIOS Prevention Inlilative 40 Steere, Jr, Wililam C. (Director) 76.78.79 Stenn ceIl 'pclicy 28 Supplier Diversily Program 104,106 Sustainable development 94, 95 Sustainable enterprise 94, 05 Sustainable Forestry Initiative 105 Sutent 4,19,24,31 Pft:er 2007 C orporufe Reeponsibilitv .k.'pofl 117 HSÇ TEM Projeot 41 Tochnology and Innovation Strategy 8 Tho AIOS Subort Organlzation (1'ASO) 48 Therapeutic Arca Medical Revlew Comrniltee 53 Thorapeutic areas (iAs) 24 Torcotrapib 27 Total Injury and Illness Rato 71 Tranzparency International (11)7 Sfeodng Con,miftee on Business Principies for Countering Driber, 7 Troat, Teach, Build, Serve 35-45 Trovan 26 Tuck School 01 Business Minority Executivo Education Program 106 Tufts Conter for the Study o? DnJg Dev&opment 27 Tnisly, Juanita 44 WalerAid 45 Way2Go. For a Healthier Vou 41 llness 101,àWoAse4 Wildlitê Habitat Council 73 Womon Impacting Publlc PIicy 10 Womenin Loadership 100 Woryten's Buslness Enterpdso National Counci (INBENC) 106,107 Worldng Mctlior magazine 102 Workplace safety 69 Wo,ld Health Organization 18, 20,49 Hóafth Evidente No? work 10 11sf of essentiai medioin 90 - •1, 1 - SAFE 35 Special Prog,sm for Reseamh and Training In Tmpiãai DLõses *WHOITDR) 21 World Resources Instituto (MO 63 u linited Nations Global Compact 7, 61 United States ErA Climate Leadors 7, 62 tinited Way o? Micros 48 University o? Michigan 98 Unlversily of Pennsylvania 42 Unlversity of Texas-Pan American 37 I.Jrban League's Charnpion of Diversity Award 102 1!A Vorsipan 82 Vfen& 4, 68 Magra- 4, 56, 57, 95 VcIatLle organic ?ornpounds (VOC) 61, 66, 67 118 Jccr 2007 Q'rpnrate Rcsponaihility Reor! x XaIatanaIao o m 4 -] ................... - - Zilhromax 21, 36;9 Zilhkomíx°/chIo8uid 21, 24 Zmax4 ZoIofr 4, 68 ZonMW45 Zy*leo 84 ZyVOX° 4, 31 INDEX A t A s :4• 9 t !Wx!:r:H.s GLOBAL LE AI) ERSIÍIP POSJTIQNÇ t L - - Largest_Selling Biotechnoloy B grami Enbrel® ir - Number One Antidepressant: Effexor XR® WoHdLead:ng Vaccine - Top.Ranked I.V A Best SeIIing Adult Vitamin: Centrum® : Leading_áIciurn• Supplement Càltrate® • j *by revenue 2007 2 On the Cover -' L Today, children in emerging markets like Mexico and in dozens of other countries around the world are benefiting from the extraor dinary advances in disease prevention that have come from Wyeth Vaccines. Now Wyeth is hard ar work developing next-generation vÍccines to protect both children and adults. r Contents 1 Ãeport to Stockholdors 7 Wyeths øipeline for Innovation 8 MU Highlights from NCR í, Wyeth's Lato-Stage Drug Developnient 10 WyethVaccines: A World to Protect 32 Financial Review •1fl 34 ljirectors and .Officers 3. Wyéth Worldwide 36 Corporate Data IBC Selected Products from Wyeth Wyeth at a Glance Wyeth is one of the world's largest research-based pharmaceuucal and health care produccs companies Ir a leadé} rn the disco?y, developrnent, marketing of pharinaceuticals, manufáãüriáÈ bfotechnology products, vaccines, non-prescription medicines and animal health care products that irnprove the quality of life for people worldwide The Company's major divisions include Wyeth Pharmacedticals, Wyeth Coi'isumcr Healthcare and Fort Dodge Animal Mealth, 4ÕEi Eis REPORT TO STOCKHOLDERS 16 LW w th delivered a very strong financial performance ii 2007, mainly driven by the fast growth of our biotechhology prodJcts Enbrel and Prevnar. We introduced new products - Torisel and Lybrel - and continued our rapid expansion into China, the Middle East and Latin America. We also expanded our aggressive cost-management efforts. As a result, we were able to produce record saies and earnings in 2007 and also were abie to increase our dividend to stockholders. in addition, we implemented important Ieadership changes, effective in janukry 2008, that were well-pianned and efficientiy executed. While we did not secure ali expected new drug approvaIin 2007, the recent approval of Pristiq for major depressive disorder and of Xyntha for hemophilia A points to our abiiity to execute on this fronè. To achieve sustained success, Wyeth Research is undertaking a number of breakthrough initiatives - strategies to address the chalienges posed by an ever-changing regulatory and public health environment aropnd the world. A key outcome of this project isto establish the differntiation of our product candidates to ensure a greater value propositioI,to key stakehoiders: patients, physicians, payors and regulators. The at-risk launch by a generic manufacturer of a generic version ofWyeth's proton pump inhibitor, Protonix, iate in 2007 iii4strates one of the importam chalienges façed by innovation-driven companies like our own. In response to loss of Protonix saies, ia 2008 we irtroduced Project Impact, a corporate-wide initiative to adjust down our infrastructure and reduce our operating costs. Our goai remains to protect and sustain our important ipvestrnents in rcsearch - well illustrated by Wycth's current projects in is fight against / Aliheimer's disease. Research and deveiopment is the engine, that drives our Company and poises us for great possibihty - the oppottunity to make an important difference in the health and well-bein of people around the world. L1 Robert Essncr, Chairinai, of the }oard, and Bernard I'oussnt, Presidenc and Chief Exccicive Officer e 1 Financial H ig h Iig hts Voar Ended Decémber 31, In thousands except per share amounts Net Revenue Net Income Diluted Earnings per Share Dividends per Comm!n Share Total Assets Stockholders' Equity 1 2007 2006 $22,399,798 $20.350.655 4,615,960 4,196,706 3.38 3.08 1.06 1.01 42,717,282 36,478,715 18.210,535 14,652,755 Financial Highlights jtions about the emergence of gene (fexor XR and Zosyn in our plans ur operating resuits for 2007 helpe strong foundation on which to bui. ing a company-wide effort in 2008 to Wyeth's worldwide net revenue for the 'y )st structure, reduce expenses and Euctivity opportunities. Among other 10 percent to $22.4 billion. This was led ive wiii heip guide our Company in growth in Pharmaceuticais, with seven ç force by as mueh as 10 percent over chises each achieving more than $1 biiiii rs. multibiilion-doilar biotechnoiogy produ i1ient organization, with a proven and Prevuar— demonstrated especially s iercoming chalienges. As you will see growth, positioning Wyeth as the world Lnnual Review, our people, our biotech company by revenue. Biotechno resources, our products and our represented more than 35 percent of new product pipeiine provide our 2007 pharmaceuticai revenue, us with a strong base from which to up from 17 percent in 2002. continue building our Company. Consumer Heaithcare revenue - grew 8 percent, and Port Dodge oftransitionan dçrogre Wyeth Pharmaceuticals -' Animal Heaith revenue increased 11 for our Company, as we percent, surpassing $1 billion in saies 2007, Enbrel, marketed for both for the first time in its history. ri ri ,n nrnvwth•1 UfSUO Inrheumatoid arthritis and psoriasis, Wyeth's reported ner income and diiuted earnings per share for 2007 innovation a fl(i ntinue to generated $5 billion in global saies, making ir the industry's largest were $4.6 billion and $3.38, respeco further look for way selling biotechnology brand. Net tiveiy. Before certain significam: saies in North America - where we items, ner income was $4.8 billion, erformance. imprové our co-promote the brand with Amgen with pro forma diiuted earnings Inc. - exceeded $3 billion. Sales per share up 12 percent to $352, a in internationai markets - where we have exclusive rights third consecutive year of double-digit pro forma earnings to the product - grew to more than $2 billion, an growth. An in-depth review of our 2007 financial perin'rease of 36 percent over 2006. formance can be found in the Wyeth 2007 Financial Sales of Effexor, marketed for anxiety and depresReport, which accompanies this Annuai Review. sion, grew to aimost $3.8 billion in 2007, increasing 2 percent over the previous year and maintaining the Outlook for 2008 bdnd's position as the world's iargest seliing antidepressat. This was achieved despite a wide range of view 2008 as a year of transition and progress chiienges, inciuding emerging generic competition to VV for our Company, as we drive growth, pursue th product in some markets. innovation and continue to iook for ways to further In February 2008, we received U.S. Food and Drug improve our performance. Administration (MA) approval to market Pristiq, a A near-term chalienge for the Company is the impact once-daiiy serotonin-norepinephrine reuptake inhibitor, of generic competition for several of our major products, fof the treatment of adult patients with major depressive including Protonix, Effexor XR and Zosyn. For Protonix, we believe our patent, which runs through 2010, is strong. diorder, a serious medical condition that affects more proConfronted with a generic manufacwrer's "at-risk" iaunch th6 120 million adults around the world. Pr!stiq vides efficacy at a simpie, once-daiiy dosage without the of a generic form of Protonix, we decided in January to néed for titration, providing most patients the appropriiaunch our own generic through a designated distributor. We also are vigorousiy pursuing patent iitigation to protect ate thcrapeutic dose right from the start of treatmcnt. We also received approvai for Xyntha, an improved our rights to this importam: product. In addition, we recombinant factor VIII formulation, both for the control atd prevéntion of bleeding episodes and for surgicai proplyiaxis in patients with hemophilia A. O C E frIA :ii Our irnpact on human heaith around the world consaies of $430 miilion, a decrease of 5 percent for tinues to be defined by innovative products iike Prevnar In May, Wyeth received U.S. market clearance for Lybrel, (Prevenar outside the United States), a first-in-ciass vaçthefirst and oniy FDA-approved low-dose combination cine to help prevent invasive pneurnococcai disease in oral contraceptive with unique 365-day dosing, which infantis and chiidren. Globaiiy, Prevnar achieved net saies rnakes it possibie for some wornen to be period-free. 1 of $2.4 biiiion, ao increase of 24 percent. Much of this Torisel was approved in the United States during the growth carne frorn inciusion in national irnrnunization second quarter of 2007 for the treatrnent of advanced prograrns around the world, volume growth in the U.S. renal celi carcinoma. li is the first targeted therapy with a private market and continued geographic expansion. prcven overali survival bdneflt in patients suffering frorn This past year, we produced more this cancer. Torisel uptake in its first than 45 miHion doses of Prevnar. few rnonths has been strong, with The vaccine is availabie in 86 coun$27 rpiihon in 2007 saies. European Qur impact on human tries, 19 of which have inciuded ir Medicines Agency approvai was health around the world received in Novernber, and saies in in their nationai irnrnunization the European Union (EU) have begun. prograrns. In 2007, reguiatory fihings continues to be defined seeicing approvai for Preamar were byinnovative products submitted in China, Russia and Wyeth Nutrition Japan, which, combined, account like Prevnar, a for about 19 rniiiion new births each nTyeth Nutrition is a woridwide help year. In deveioping countries, we In-c!ass vacc me ieader in the deveiopment are working cioseiy with the internaof scientificaiiy advanced nutritionai prevent inva ve tionai health communiry to help products for infants and young chil---4 chiidren gain access to this impordren. A comrnitrnent to research pneumococc / disease tant pubiic heaith intervention. has enabled the Cornpany to achieve r Ifllnf.8fltS8Th chilidren. Wyeth vaccines, inciuding Preamar, numerous annovations, rnost recently are the subject of a speciai report with the first-to-market addition that begins on page 10. of lutein to the prerniurn Go!d product une. In 2007, In 2007, saies of Zosyn, a broad-spectrurn intravenous global saies increased 20 percent to $1.4 biiiiion, with the antibiotic, grew 17 percent to becorne oniy the second G&!d hne accounting for the rnajority of saies. Doubleproduct in its ciass to exceed the Si biilion rnark in digit growth was recorded in each of the three regions in annuai saies. During the year, the Company cornpieted, in which Wyeth Nutrition competes. A key driver for rnost markets around the world, the introduction of a Wteth Nurrition's growth has been its focus on growing new and irnproved Zosyn formuiation designed to rneet markets in Asia, Latin America and the Middie East. To current speciflcations for particuiate matter for injectable met the increasing dernand for high-quaiity formulas, the drugs. Compound patent protection for Zosyn in the Crnpany recently cornpieted nutritionai manufacturing United States and Europe expired ira 2097, and the prodfaciity expansions in Mexico, and íurther expansions are uct is facing generic competition in a number of markets under way in the Philippines and Singapore. A new faciuity in Europe and eisewhere around thc world. aiso is planned in China, which, with growth of 38 percent Tygacil, oijr newest entry in the I.V. antibiotic market, in 12007, becarne the iargest Wyeth Nutrition market. continued its growth, particuiariy for use against drugresistant strains of bacteria. Sales for Tygacil nearly er Healthcare doubied in 2007 to $138 miiiion, and ir now is approved in 66 rnarkets. Regulatory fihings were made during "oral global net saies rose to $2.7 biiiion in 2007, the year for use of Tygacil in cornrnunity-acquired pneuan increase of 8 percent, with international net saies monia, which currentiy accounts for 20 percent of ali! 16 percent. Wyeth Consurner i-Ieaithcare executed in-hospital, I.V.-adrninistered antibiotic usage. ortant brand extensions during the year with the In women's heaith care, 2007 global saies of the roduction of Advil Liqui-Geis on a global basis, Pren,arin farniiy were consistent with the prior year ar jut atrunz Cardio in the United States and Centrum food over $1 biilion. Wyeth contraceptive products dehvered de in China. Overali, key growth drivers inciuded the Advil franchise, which grew 11 percent, in pari: as a result of significant growth in Advil PM;, Centrum viranuns, which grew 7 percent; and the Caltrate brand of calcium suppiements, which saw 16 percent growth. Also driving growth were strong performances in a number of internationai markets, inciuding Brazii, which grew 40 percent; Canada, up neariy 13 percent; and italy, with saies up more thah19 percent. As a result, Wyeth Consumer Heaithcare remains among the top five overthe-counter (OTC) companies in the world, with Advil and Centrum t*o of the top five global OTC brands. b We have outlined a number of late-stage devei meiit highiights in the chart on pages 8 and 9. These incude three novel oncology agents, a monocional antibody to fight Aizheimer's disease, a next-generation vaccine, an antipsychotic, an oral therapy for opioidincuced constipation and a new therapy for river b1idness. We also have programs progressing throiigh deeiornent that seek to expand existing products with ne*iy identified uses and indications. We are hopefui forU.S. approvai in 2008 for Relistor in subcutaneous forkh to treat opioid-induced constipation in patients iri jalliative care settings. We expect that Viviant, being de'eloped for the prevention and treatment of osteoAnimal HealthCare poosis, wili be reviewed ar an FDA advisory committee 1 me Aprela, under investigãtion for postmenopausai ales in 2007 grew 11 percent over 2006, to exceed vaomotor syrnptorns and the treatment of postS $1 bilhon for the first time. Port Dodge significantiy menopausai osteoporosis, is targeted for regutatory enhanced its leadership position in the iúdustry through fiuig in the flrst haif of 2009. the U.S. and European introductions of ProMeris, a new In addition, we are pressing forward on many fronts une of fica and rick products for cats and dogs. in new product deveiopment. For exampie, we have nine lis hvestock product business experienced 12 percent projects in active development for global growth, led by strong saies of improved symptomatic treatments cattie products in the United States or disease modifiers for Aizheimer's and Europe and a fuli year of saies of We are sha rply focused disease, using smali moleçuies, Suvaxyn PCV2, a new swine vaccine. bioiogics and vaccines. We also are onbiologic s. As a result, Aiso achieving signiflcant saies was expioring a wide range of unique the poultry product hne, up 13 pernearly one-thirá of compounds with novel mechanisms cent, with a broadening portfoiio of ofaction for schizophrenia, bipolar is our current vaccines, inciuding an avian influenza disorder, major depressive disorder, vaccine to address the potentiatiy com poied of other cognitive disorders and chronic pandemic Asian HSNI strain. Port pain. Though stiii eariy, these comDodge also remained the overali late nology ca pounds potentialiy offer significam: leader in the U.S. companion animal products and vaccines. improvements compared with biological vaccine market. During the currènt standards of care. In the caryear, an irnportant new registration diovascular arca, we are deveioping was approved for the prevention of a nw compounds that focus on reducing cardiovascular particuiariy virulent strain of cahcivirus in cats. To accomnõrtaiity and the complications of diabetes. In addition, modate future growth, Fort Dodge is epanding its we are investigating innovative therapies in gastrointestiresearch facilities in the Kansas City metropoiitan arca. nal disease and asthma. To address the chalienges of getting new drugs Research and Development approved in an increasingly difficuit environment, Wyeth Rsearch is undertaking a breakthrough initiative. lis yeth's research and deveiopment organization s8ope inciudes ensuring that new product track candidates draws upon expertise in muitipie discovery piatci, ariy demonstrate a vaiue proposition ; deveioping preforms. This means that, in addition to traditionai smàil dictive safety and efíicacy modeis that are the best in the moiecules, we are sharpiy focused on biologics. As a industry; and improving the process for assessing benefitresult, neariy one-third of our current pipehne is composed risk during development. This breakthrough project buiids of biotechnoiogy candidate products and vaccines. on Wyeth's existing R&D productivity initiatives and is intended to formuiate strategies for sustainable success in tie years to come. W E' Social Responsibility Initiatives n everything we do, our goal is to act responsibly - not only for the sake of our stakeho!ders but for the world at !arge. Two examp!es are prominent. The flrst is the ro!lout Prevnar of in the poorest of countries to make this !ife-saving vaccine more accessible over time to mi!!ions 01 chi!dren. In addition, since 1996, we have been working with the World Hea!th Organization to develop moxidectin, a fixst-in-c!ass agem for te treatment - and potentia! eradication - of onchocerciasis or river b!indncss, a disease that is endemic in sub-Saharan Africa as well as in parts of Centra! America and the Midd!e East. More than 125 miltion peop!e worldwide are at risk with more than 17 mil!ion people infected with the disease. In 2007, we contributed approximately $12 million - in products to deve!oping countries, inc!uding about 700,000 doses of Meningitcc vaccine to prevent meningitis C and 25,000 doses of Prevnar to arcas of Peru hard hit by an earthquake earlier in the year. What's more, our U.S. patient assistance programs continue to provide Wyeth products at no charge to those unable to pay. More than 145,000 patients benefited from the program in 2007, with product donations va!ued at over $143 mi!Iion. I Ô BERNARD 11 PoussoT, WYETI-I'S WEW 0W In !ate September 2007, Bernard Poussot was e!ected President and Chief Executive Officer of Wyeth, ffectiveJanuary 1, 2008. Fie succeeds Robert Essner, who announced his plans to retire from the Company. v1r. Essner wi!l continue as Chairman of the Board of Directors for a period of transition. Poussot began bis career at Wyeth in 1986 »s President of Wyeth France. In 1996, he was appointed President of Wyeth-Ayerst lnternational and a year later became President of the worldwide business. In 2002, while continuing President of Wyeth Pharmaceutica!s, he became ecutive Vice Presidem of Wyeth, assuming ditionai responsibiity for Wyeth R&D. In 2006, r. PouSot was promoted to President and Vice iairman of Wyeth and, in january 2007, to the sition of President, Chief Operating Officer and Chairman of te Company. Management Changes n the sidebar to this lene; you can read more abour Iour CEO transition announced during 2007. In addition, we have other changes to report. We're pleased that Robert M. Amen, Chairman and Chief Executive Officer of International Flavors & Fragrances Inc., has joined the Company's Board of Directors, bringing us bis wide-ranging expertise in consumer products. At the same time, we offer our thanks to Wa!ter V. Ship!ey, who stepped down from te Board in 2007 in compliance with te Company's mandatory retirement po!icy, for bis years of devoted service. We also want to express our appreciation to Ivan G. Seidenberg, who afrer bis years aí dedicated service, resigned from the Board. We have made a number of corporate management !eadership changes to prepare Wyeth for continued growth and to capitalize on te executive ta!ent within the Company. Gregory Norden became Senior Vice President and Chief Financial Officer. Fie has been with the Company since 1989 and previously was In announcing this succession, Mr. Essner noted, "Bernard is exceptiona!ly we!l-qualified for this !role, and we have built a wor!d-c!ass management team to support him and te Company. Mis election is a result of the Company's ongoing succession planning process - an important focus ofWyeth's Board of Directors and managernent." Mr. Essner's !eadership helped prope! Wyeth to the top der of the global pharmaceutical industry. During bis tenure as CEO, revenue increased from $14 billion in 2001 co more than $22 bi!lion in 2007, accornpanied by significant increases in earnings per share. Mr. Essner was responsib!e for initiating a transformation of the Company's research and drug dávelopment process, advancing a new model for pharmaceucicat saies in the United States and successfully navigating the Company through significam litigation chailenges. O CFO of Wyeth Pharmaceuticals. Denise M. Peppard was codntries, the lives of hundreds of thousands of children promoted to Senior Vice President, Hunan Resources, evehtuany will be saved. We know that Enbrel aiready with the retirement of Renê R. Le*in, who was instruhasmade an extraordinary difference in the lives of peomental in deveioping a performance-based culture during pie!who have benefited from its use. his 13 years with the Company. Mary Katherine Wo1d To continue and expand this record of achievement, was promoted to Senior Vice President, Finance. The we1 will remam fiexible and resihent in seeking berter ways Board eiected Andrew E Davidson as Vice President, to deliver accessibie and affordabie hea!th care. Internal Audit. Final!)', in February 2008, Timothy P. As *é do aii this, we will be guided by five principies Our vaiues. Science and innovation. Leadership. Sound Cost joined the Company as Senior Vice President, flnhnciai decisions. And belief in our nobie cause Corporate Affairs, bringing to Wyeth many years of imroving the lives of peopie through mediëal advances experience in communications and investor reiations. Mr. Cost repiaces Marily H. Rhudy, who has announced and putting the patient ar the center of everything we do. We thank our coileagues ar Wyeth for their innumerpians to retire. We thahk Ms. Rhudy for her many abie contributions - and for their dedication to reshaping contriburions to our business. There also were a nurnber of organizational changes ourl Company in order to make it stronger. As we iook to the future, we believe that the support and hard work within our business operations. Joseph M. Mahady was of our peopie will help us to grow, to prosper and to promoted to Presidem, Wyeth Pharmaceuticals, and lea'd as we buiid the most trusted and respected health remains Senior Vice Presidem, Wyeth, Geno J. Germano care company in the world. became President, U.S. Pharmaceuticais and Womén's Heaith Care. U!f Wiinberg was promoted to President, EMEA/Canada and BioPharma, and remains Senior Vice Sincereiy, President, Wyeth. Ia the animal heatth division, Richard R. DeLuca, Jr., was named President of Fort Dodge Animal Heaith with the re;mf E. Thomas contributions to Wyeth. Cavan M. Redmond was promoted Bernard Poussot Robert Essner to President, Wyeth Consumer Heaithcare, while Presidem and Chairman aí the Board Douglas A. Rogers became President of U.S. and Global Chief Executive Officer New Business for the division. Wyeth's abi!ity to develop talent, as well as to attract February 29, 2008 new leaders, high!ights the continuity aí cuiture and depth of experience that is critical for our future. We wish ali! those with new responsibi!ities great success and wiil give them our fuil support, and we thank those retiring from the Company for their many contributions over the years. The outstanding ieadership, expertise and experience that: 1 our entire managenlent team brings to Wyeth shouid continue to transiate into successful solutions to importar heaith probiems worldwide. I The RoadAhead e are immensely proud of aii wé have accomplished during the past year and the past decade. The capabilities we have built in R&D and across the Company are de!ivering innovative products to save and improve lives. We hope our work on Alzheimer's disease will rnake a difference for the patients and families who suffer. We believe that as Prevnar is intrp duced in more W 6 Wyeth's PipeÍine for Innovàtiõh During 2007, Wyeth filed four New Drug Apícations (NDA) in the lJnited States, including two that represented new molecular entities. Sincó 2004, Wyeth has delivered on its goal offiling two NDAs each year for new molecular entities. In addition, over the past seven years, 91 new candidate medicines were placed into development, with 72 advancing to human clinical trials.The majority of these have the potential to be first- ar bdt-in-class therapies.Thia chart prescrita a snapshot, as of February 2008, of new drugs ar potential new indications/ fonnulations firam Wyeth the: are in advanced human trials ar uri-der review by regulatory agencies. Wornen's Nealth and fone es and Jnfectious Disease Lybrel/AnyC (levouiorgestrel/EE) Continuous contíaception (EU) (tiúóàyciine) Diabetic foot infections Prernenstrual dysphoric disorder Hspital-acquired pneumonia Pristiq (desvenlafexine succinate) Vasornotor syniptoms of menopausa Puivear 13 Prvention of pneumococcal disease in íinfants and cliildren Mc monfits to fuve years Viviant" (bazedoxifene) Postinenopausal osteoporosis prevention Prevention ci pneumococcal disease in high-risk individuais and adults> age 50 Postmenopausal osteoporosis treatment AprelC (bazedoxifene/cgnjugated estrogens) Posimenopausal osteoporosis occel B vaccifle i of meningococcal disease in ents VasomotorsyTmptoms of menopausa Neuroscience (river blindness), withWHO Bapineuzumab (AAB-001) Alzheimer's disease ACC-001 Alzheimer's diüase Idflaninatorv Disease Pristiq" (desvenlalaxine succinate) Neuropathic pairo Aamkinzumab (IMA-638) Athma Fibromyalgia Oncology/lnirnunotogylHetnophilia SAM-531 Alzheimer's disease lrotuzuniab ozoúamicin (CMC-544). F6lIicular non-Hodgkin's lymphoriia Vabicaserin (SCA-136) Schizophrenia D!iffuse lare B-cell lyniphoma Gastrointestinal inversion in Tiver transplant Relistor (methylnaluexone) Subcutaheous for opioid-induced constipation in advanced medical illness iFact& AF (antihemophilic factorrecombinani) I.V. for post-operative ileus Oral for opioid-induced constipation Mande celI lymphoma (EU) ' Bosutinib (SKl-606) dhroníc myeloid leukomia Breast cancer Neratinib (HKl-212) Rraast rnotar Phase 2 - Oeter,nirtation aI safo and ettectivo dosage for an experimental medicina, goneraily conducted is hundreds 61 patients Pinas. 3 - Oeterrniration si overali berietu/risk ratio for an experimental medicina, generaily conducced is tousands ad patienta Regulatory Revlew - Evaluation ai oafeuy and el5cacy data by govemmental regulitory agencies - «4 ~- Wyeth's development pipeline of new ( therapies continues to grow in breadth, depth innovation Eleven potential newtherapies or uses tor , sigriifiàant existing drugs are in Phase 3 devàlàpment, and another eight currently are awaiting approval in Highlights lrõm Wyeth's Late-Stage Druõ Developmetit Candidate Stage Prevnar 13 Bapinounlmab(AAB_OQI) For infants, childieú and adulta Coilaboration wirh Elan Corporation, plc Phase 3 — Infants and children Phàse>3 Phase 3— first-tine CML Phase 2£ breast cancer Phase 2 Current thera,ies for Alzheimer's disease provide some symptomatic relief but do nor alter the underlyin disease pathology. Thereís a need for safêr and more tolerable therapies capableof inducing tapid and long-lasting remissions in newly diagnosed CML patients. Opioid anatgesics ofiS produce constipation as a sitie effect, which can he a barrier to effective pain management. Currently, chere are no approved medicatidns rhar specifically target OIC's cause. By biiding to ali f rms of beta-amyioid in the brairi, Bosurinih is an orly icvive inhibitor of src and abi kinases, proteins involved in tumor celI growth and níetastasis. Relistor is a selecrive itisiopióid receptor ancagonist that blocks the péripheral side effects of opioid analgesics without interfering with pain relief. This compouud potentia11 offd] ia excellent sitie effect proflie in conparison uiithimarinib and ocher .second-generarion abl kinase inhib itors. In imatinib-resistanrlintolerant patients, hosutinib exhibits response rates comparabte with or hetter than li is designed to rapidly Phase 3 Unmet Medical Need - Mechanism ;( otAction Whats Diffurent For infants ahd children, Frevnar 13 expands protec- The vaccine is designed to induce functonal antibody responses to ali 13 vaccine serotypes, thus prornoting clearârice of the bacteria by antibodies binding to piemüococca1 capsular polysaccharides. For infants and children, ir is expected to be the mostcomplete Wccine for the globa l prevention ofserious pneui'nococcal disease and active otitis media. For adulta, ir is the first conjugate vaccine for adult pneumococcal disease, including pneurnococcal pneumonia, with the potential for long-term protectioi through boosting. 8 Sosutinib (51(1-606) Reuno, Oral forniulation Collahoratkn with Progenics Pharmaceuticals, Inc. Adults tion agaifist aix additionab pneurnococcal diseasecausing serotypes, including 19A. For adulta, ir may provide substantially greater efficacy against pneúrnococcal disease tban current srandards of cate. e f hapineuzuifiàb is thought to help clear dam aging ; beta-amyloid plaques fr?m the brain and also neutralize neuro-tócic forrosof beta-arnyloid, thereby havT ing a fundamental inipact on the disease process. rheipy for A1zheirner' disease thaEiay kàlt 01 modify its course. other second-generation abl kinase inhihitors. reverse OIC without reversing analgesic effects. FtG(W lhe Lhiitéd States orthe European Union. Most important, 75 percent of lhe projects inWyeth's o'erali deveiopment portfoiio, inbiuding those in eariier stages of development are new molecular entities dí NMEs.These represent novel or innovati* cbnipoun and socie drugs or irom Wye .under re that offersignificantvaiueto pótients This chart presents á snapshot of new ,ificaiit new indications/formuiations that are in advanced human triais or v by regulatory aginciü. Vabicaserin (SCA-136) lnotuiúmab ozogarnicin (CMC -544) CoIiaboti&i wirh Coliaboration wirh UCB Group Folticuiar non-Flodgkin's iymphoma (EL NHL) and diffuse large li-deli iymphoma (DL BCL) HER-2 positive meiastatic breast cancer (initiai indication) Phase 3 - EL NUL I'hase2—DLBCL Phase 2 Phase 2 Phase 2 Current treatments couid benefir from reduced toxicities and from improvements in durajion of remission, d,sease-free survivai and quaiity of life as weli as from reduced supportive care costs. In paúents whose nimors recur after treatment wtth trastuzumab (Hercepun) there is a significant need for alternative therapies, shat can hait the concinued growth of the tumor and progression of cancer. Riveriindiess is a devastating parasitic disease predom,nantiy found in Africa thats the secgnd leading infdcrious cause of blindnesk. Current antipsychotics for schizophrenia offer adequate symptdin relief but often have significam side efíects, indàding weight gain and cardiovascular and merabolic problems. The relief of negative - sympcoms and a reduction of cognitive defects remam iinportaiit unmet needs. This anti-Cb22 antibody calicheamicin conjugate binds to thêCD22 receptor expressed by li iyrnphocytës ir' the body. The compiex then is internalized by the ccii, reieasing calicheamicin into the ccli nucleus and inducing celi death. Ir potentially Is an irreversible inhibitor of erbli tyrosine kinass, including HER-2 and EGFR, which are implicat&l in cancer ce11 growth and division. xidectiA ads 5h the BA-A receptor chioride mel cdiinlpidx to disccii niembranes ir' the isite, ultixhateiy leadto às paralysis Inotuzumab ozogimicin, combined with rituximab, has the potential to be the first completeiy targeted treatnient for nonHodgkin's lymphoma, resulting ir' increased efficacy and bettê? safety. Through ar' irreversible inhibition of erbli kinases, use of neratinib tnay resuit in the sustained qppression of associated pathways, thts inhibiting cancer ccii prouiferation. Unlike currenr çreatments thariiãy i4ave serious side cífeas or &n oniy doútroi the ciiseasd', ir has a unique mechanisrh of adián that may resuitjn complete ¶ ehmrntíà, bf the paras ite , ir' endcmiè arcas over tirjie. t, 1 5-HT2C agonists impact iliè activity of serotonin receptors in the btain and differentially moduiate dopaiine reieaè ir' seve key pathways relevam: to schizophrenia. Vabicaserin potentialiy trcats symptomswithout the significant side effects assõbiated with currendy avaiiabie antipsychotics. 9 1 ,,' ç ~ -~ E A Legacy ofAchievement in Preventing Disease T he significam: impact of Wyeth's vaccines - and those of its predecessor companies Lederle Laboratories and Praxis Biologics - dates back more than a century. In theearly 1900s, the Company was involved in the commercial production of smallpox vaccine. Ir later launched Dryvax, a highly advanced version of the vaccine, and revolutionized smallpox vaccine delivery with the introduction of the bifurcated needle. These contributions helped lead to the worldwide eradication o f this 11 devastating disease. In 1906, Lederle became a major supplier of the diphtheria antitoxin and later introduced the first coi1ibined vaccine for preventing diphtheria, pertussis and tetanus. Lederle also produced more than 600 million doses of the firse liye trivalent oral poliovirus vaccine, substantially contributing to the 1994 eradication of polio in the Americas. As vaccine research and development took exciting new direcdons through emerging knowledge about viral and bacterial diseases, Wyeth continued to press forward. Even as many others abandoned vaccine research, Wyeth remained on the Ieaèling edge in vaccine development. In fact, says Jim Connolly, who heads the Company's Global Vaccines business unir, "Wyeth has played a leading role in the introduction of some of the iost significam: vaccine advances over the last century, and otr commitment and excitement about vaccines today are stronger than ever." "One of rny tirst jobs after coming here from Russia was with tire pneumococcal program at Praxis Biologics, whicb later became part of Lederle and then Wyeth. Our goal was tu create a vaccine that woutd work in infants by boosting their immune response. Applying our knowledge tu create such a complex vaccine and malte it effective - that was the cttailenge. Not many people are lucky enough to work on such a project, tu actually set what a vaccine like this can do and then help bring it te the populations that need it most. Tbat's very special7 Maya Koster, Principal Research Scientist, Pharma R&D,Vaccines, and recipiani. National Modal of Tnçhnølogy tor P,ovnar Streptococcus pneumonias, bacteria, magnified 25,000 times, is the pathogen responsible for infections such as bacteremia, sepsis and meningitis as well as middle ear infections and pneumonia. Most at risk are young infants and older adults. EW Greating ConjugateVaccines - In 1989, Wyeth's use of novel conjugation technologies lcd co the introduction of groundbreaking vaccines, ones tiat were effective in young children, ofíered longer protection aüd reduced the rates of disease transmission. In many bacterial diseases, the bacterium expresses a surface coat composed of characreristic polysaccharides, which are long-Iinked súgar molecules. Using conjugation technology, Wyeth scientists linked these polysaccharides to a specific protein called CRM97 a non-toxic variant of diphtheria toxin. Doing so produced vaccines that boosted the body's immune response and in-imune memory, even in very young infants. Three innovative Wyeth conjugate vaccines resulted from this technological breakthrough. The first conjugate vaccine, HibTITER, targeted a bacterium called Haemophilus infiuenzae rype b (Hib), thus he!ping to protect young infants from resulting infectipns that cou!d Iead co severe meningitis, an inflarnmation of the membranes surrounding the brain and spinal cord. A seco rtd vaccine, Meningitec, targers the meningococcal group C bacteiium. This vaccine made a significant contribution to pub1icheaIth in the Iate 1990s, when the United Kingdom experiened an Wyeth's Meningitec, a vaccine against meningitis C, was introduced in the United Kinydom when the country saw an alarming spike in cases, especially in adolescents and young adulta. "Wyeth has played a leading role in the introduction of some of the most significant vaccine advances over the last cenrury, and our commitment and excitement about vaccines today are strongcr than ever." 13 -J4 F alarming increase in group C meningitis. After its 1999 introduction in the United Kingdom, Meningitec, along with follow-on vaccines from other producers, led to the virtual eliminatjon of the disease in that counrry. The third vaccine - Preunar— was launched in 2000 in theUnited States and now is avaílable in 86 countrjes. Prevnar is the first and only pneumococcal polysaccharide-protein conjugate vaccine approved for routine use in infants and young children. As»a result 11 of the extraordinary heakh benefits ir provides, Prevnar has become the global standard in pneumococcal disease prevntion. The vaccine focuses on the seven most prevalent pneumococcal serotypes that cause the majority of disease worldwide. These bacteria can cause severe invasive disease, including baderemia, sepsis and meningitis as well as middle ear infections anã pneumonia. Infants, children under the age of two and older adults are ar highest risk because their immune systems are less capable of fighting the disease. In recognition of the pioneering sciénce employed!by Wyeth in the development of Prevnar as well as its broad publiè health impact, a team of Wyeth scientists was awarded the 2OIJS National Medal ofTechnology - the highest honor the United States can bestow for technological achievement. PrevnarMakes a Significant Impa on Pubtic Health alter Orenstein, M.D., is a world-class infectious disease specialist who today is Associate Director of the Emory Vaccine Center. During bis leaderhip of the Centers for Disease Control and Prevention (CDC) National Immunization Program, Dr. Orenstein was pivotal in dcommending that Prevnar be included in the U.S. national immunization schedule. W 'Tracking of epiderniological trend data predicted a peak in incidente of meningitis C in lhe United Kingdom. In 1992 lhe British govemment had asked ali vaccine suppliers to accelerate development of new vaccines, By November 1999, a national immunization campaign hegan with Menlngltec,the only vaccine available for lhe disease during the critical winter peak months. Meníngitec reduced infections by 76 percent, with an efficacy of 97 percent in adotescents.Today, thanks to ar; effective imrnunization program, meningitis C infections have been reduced dramaticaiIy in lhe United Kingdom7 JufleWiflingharn,Vaccines Groop Product Manager.Wyeth U,K. "The health burden in the United States from pneumosoccal disease in children was substantial ar the time," Dr. Orenstein says. "You had bacteremia, meningitis and pneumonia1i li also was clear that there was a substantial risk for young ch'ildren and that the current pneumococcal polysaccharide vaccine 'as not effective in that group. We looked to pneumococcal cohjugate vaccine for a new answer." Jerome Klein, M.D., now professor of pediatrics ar Boston University School of Medicine, was on the Data Safety Monitor Committee for the Phase 3 trials of Prevnar conducted by Northern California Kaiser Permanente. "The committe broke 14 Thanks toWyeth's Prevnar, mililons of children are protected from the potentiatly devastating effects of serious pneumococcal disease. 3 Fia. the code when 17 cases of invasive pneumococcal disease were identified among children in the triais. Ir was exrraordinar, to recognize within seconds that every child who had received Prcvnar had been protected and that the illness was conflred only to those children who were not vaccinated." At the time of irs approval, Dr. Klein deemed the vaccine "a big win for kid." He recalis, "As soon as Preunar was available, pediatricians enthusiastically grabbed it. lis profile of efficacy and safery was very advantageous. Universal irnmunization soon was recommended." e DPOE Optimally, the vaccine is given in four doses. Dr. Klein explains: "You want to starr as early as possible to capture disease in the very young. After the first dose at two months, you get a minimal 1 anribody rise; at four months, an amplified rise; at six months, a great rise because the infanr's immune system is more çapable ar this time. Ar 12-15 months, a booster is adminisrered— to get another substantial rise of antibodies. This takes you rhiough the period of major vulnerability." David Peristein, M.D., is Associate Medical Director and Ambulatory Pediatric Director ar St. Barnabas Hospitaiin the Bronx, New York. The hospital, located in a neighborhod with explosive pediatric growth, receives more than 75,000 éediatric visirs a year and has 45 pediatricians on staif. Dr. Perlstin remembers what his work was like before the vaccine. Navajo children in lhe southwestern United States, at greater risk of invasiva pneumococcal disease than most of the U.S. population, participated in the clirtical trials that lcd to the introduction of Prevnar. "Before Prevnar, we erred on the sidè of doing everything possible ar the moment - including administering every kind of tesi and giving advanced antibiotics - because we knew the damaje that invasive disease could do to our younger patients. Now oijir whqle practice has been revolutionized. We watch and follow, e4ecially when we know a child has received Prevnar. 1 can't remerhber the last time we had a positive finding of invasive disease tiue to Streptococcus pneumoniae." The CDC recently reported that in 2005 there was a 98 perent reduction in invasive pneumococcal disease caused by the seven serotypes contained in Prevnar and a 77 percent reduction in overali invasive pneumococcal disease in chiidren under ai tive in the United States. "A great deal of the history of infectiôus disease is tied to pneumococcal disease," says William Gruber, M.D., Vice President, Wyeth Vaccines Clinica! Research. 7Being in a position to see such a dramatic reduction in this disease is a wonderfui history to be living." Unexpected Benefit for Adults What's more, there has been an unexpected benfit. "The kicker carne from CDC and Kaiser Permanente data showing that invasive disease among non-imrnunized individuais alsjhad been reduced," Dr. Klein notes. A reservoir of immunity led to the decreased spread of those diseases from infants to olde?siblings, parents and grandparents." So adults are being protected as well. The CDC observed a 76 percent reduction in the incidence of vaccine serotye disease - especially pneumonia - among unvaccinated aduits over age 50. With fewer cases of pneumococcal disease in the overail population, there are fewer chances of transmitting thedisease to those over age 50 and especia11 to those over age 6 whose immune systems becorne less efficient. This remarkableíphenom non, known as "herd immunity," underscores the broad public health impact of the vaccine. i "What's unique about vaccines is that they have both apri individual and a societal effect," says Peter Paradiso, Ph.D., had of Scientific Affairs for Wyeth Vaccines and a scientist wh1b has worked on Prevnar for many years. "Vaccines don't jut prevent disease in the individual, they also protcct society. We hw their power years ago when mass polio vaccinations pSvented an epidemic. "One of the nicest aspects ei vaccine devIopment is 11w almost immediate gratification that follows.Vou have a disease hurden in a poputation,you introduce an efiective vaccine and, in a few years, the disease burden is reduçed substantially.You can seo the lnipact very quickly.The concept ei reducing ar even eliminating seiious iltness and death in infected kids in onty a few years is incredibte." Emilio Ernini, Ph.D.. ExecutiveVice Presidem, vaccine Research and oeveloprnent, Wyeth Pharrnaceuticals "Today," he continues, "Prevnar is the clearest example of a vaccine that has targeted and immunized a population1 that gers a disease and, ar the sarne time, helps stop the spread of thar disease to other cohorts. Indeed, in many ways, the societal benefit of Prevnar is bigger than its direct benetit." 17 4'. Mexico: An Emerging Market Mpdt 1 t is estimatèd that in Latin America, two children die ofinvasive pneumococcai disease every hour. In 2001, Mexico was among the first countries in Látin America - and the first emerging market in the world - to introduce Prevnar. Mexico wili serve as an importam model as the vaccine is introduced in other emerging markets. J Today, nearly 50 percent of ali children in Mexico who 7hould be vaccinated with Prevnar are receiving ir - either ar n9 cost through government hospitais and clinics or through the private sector. By the end of 2008, ir is expected that coverage reach neariy 100 percent. "Ali children born in 2008 wili have the right co be taken to a government hospital and receive the vaccine," says Carlos Fabian Abeiieyra, General Manager for Wyeth in Mexico. "This is a major achievernent for Wyeth and a great benefit for the children of our country." With the addition of Prevnar co Mexico's nationai jmmunization schedule in February 2008, the vaccine has forced a change in the paradigm of how vaccines are viewed. "Basicaliy, chis has éaused the government co take a fresh look ar how ir aliocates its hea1h care doiiars," Abelleyra says. "As you can imagine, in Mexico,1 s it many ocher councries, resources are iimited, and the goverriment must carefully choose its pubiic health prioricies. By including Premiar in its nationai immunization program, the Mexican government has ensured that children wili be protected from a dangerous and potentially deadiy disease. Ir also has affirmed the importance and cost-effectiveness of prevention as a critical component of its national health strategy, as advanced vaccines like Preunar beqefit children and society - today and weli into the future." ..c Early on, the Mexican government created its own co analyses for Prevnar and, as a result, decided to move initial coverage in only the most at-risk popuiations children in rural areas of the country - to universal co Feeling of Hope Emerges Demóstenes Gómez Barrem, M.D., has been a pediatrfdan in Mexico City for the past 30 years. 9 saw many cases of severe pneumonia, bacteremia and meningitis in my practice!So ali of us who treated children understood the need for a vaccine like Prevnar," he says. "We were very happy when ir first was introduced in private practice because we finaily could protect some of our wn patients. But we were even happier," he adds, "when the government started its own vaccination program in grkips of high-risk children." 20 To raise the profile of pneumococcal disease and the benefits of immunizatloatWyeth worked with the Mexican govemment on a mass media campaign, the first ever in Mexico for a vaccine.That allowed us te foster awareness and creste an environment that would facilitate the introduction of Prevnar on a universal basis7 Carlos Faban Abelleyra, General Manager, Wyeth Mexico Ei 1*- Today, Dr. Gómez Barreto believes Preunar is covering most of the serotypes that can cause disease in the country and iJshowing a strong efficacy rate. "Our hope," he says, "is that the most positive impact 111 be seen in villages around the country, where a campaign to vaccinare every chíid is taking piace to reduce mortaliry rates in thse rural areas that have limited access to health care services." AVaccine for the Developing World 7 Today, even with ali the advances that Prcvnar has made, pneumococcal disease still kilis more chiidren than any otheriillness more than AIDS, maIana and measies combined. Yet only a smafl percentage of children in the world ar greatest risk of ding from the disease are getting the vaccine. Starting this year, that picture is expected to begin to change. Wyeth's goal is to work with the internationai heaith community to make Prevnar available to the poorest countries in th'e world as quickly as possible. Thirty-four countries with per capita incomes under $ 1,000 already have indicated an intere 11t in introducing pneumococcai vaccines by 2010. These coufitries account for more than a third of ali the childhood pneumococdl deaths worldwide. The most interest has come from Africa, wl4ich has the highest incidence of pneumococcal disease. Global Impact • Countries whore Prevnarcunontly is available • Çountries whe,e Prevnar also Is on their national immunization schedule C11 21 Orin Levine, Ph.D., au associate professor ar The Johns Hopkins University Bloomberg School of Public Health, leads theeffort to create a bridge to the developing world for pneumococal vaccines. As Executive Director of PneumoADTP, a projet supported by the GAVI Alliance - a unique public/privare partnership of which Wyeth is a member - he is focused ou getting these vaccines to every child who can benefit. DPO Dr. Levine says, "Even though many peoplehaven't heard of ir, pneumococcal disease is the leading vaccine-preventab1 cause of death worldwide. More than 90 percent of those deaths occur in developing countries. So if we want to change the wokd - as we do - then we need to use these vaccines in the countries where children need them the most." In addition to GAVI, a novel funding mechanism cailed the Advance Market Commitments (AMC) is seeking to help ensure that needed vaccines will be taken up by developing cojntries. Designed to create predictable markets in poorer counti4es for future vaccines, the AMC was launched in February 2007, with donors pledging $1.5 billion to support ncxt-genetation pneumococcal vaccines. The AMC goal isto guarantee market for vaccines from producers ar steeply discounted prices and then get those vaccines to countries in need. "We expect pneumococcal vaccines to begin saving líves in developing countries in 2008," Dr. Levine concludés. "?we also expect the impact of Prevnar to be substantial. We should get on with using ir now and have that experience serve as a base for an expanded vaccine. If we can show good results early, we can sustain political support and financing. Success requireS that industry and the public sector demonstrate they can come togecher, deliver the vaccine and measure its health imact." 1 bdiave that raugh roads lead to thelop and tbatthere is no substituta for hard wodcThat's why l'ni proud ta he part ai the Pearl River team that helps produce Prevnar. What a great feeling to know the vaccine we're producing helps san the ligas ei babies around the world." Ernie M, Skinner, Aseplic Set-up Worker, otbVaccines, Peari Rivei. New 'íork Manutacturing One of the :Most Cornplex Bioteçh Products Ever mil the advent of vaccineslike Prevnar, vaccinçproduction often involved growing bacteria, adding certain components to either kill or weaken those bacteria, then filtering and packaging the result. Advanced conjugate vaccines like Prevnar are changing ali that. "Now we're using more biotechnology," says David Zisa, Vice President,Vaccines Product Supply. "We're expressing components of baceria, then performing biochemical rearrangemenis or restrt&turing to actually make the vaccine work." U The result, ar least for Prevnar and for a next-generation Wyeth vaccine that will cover 13 different pneumococ'ai strains, 22 Among other complex production processes, the carrier protein that gives Prevnar some ai its special characteristics is grown atWyeth's Santord, North Carolina, manufacturing facility, where the key focus is quality contraI, increased productivity and efficiency. P13 is increased complexity, longer cycle times and higher costs. "Prcvnar is among the most complex biotech or bioiogid products ever made," says Michael Kamarck, Ph.D., Executive Vice President, Wyeth Technical Operations and Product Supply. "It's a combination vaccine that contains seven giycocorijugates or seven different vaccines in one. li combines, or conjuates, the seven different polysaccharides or sugars found on the cèll coats of each of seven different bacterial strains in the vaccine with a ft carrier protein that enhances their effect." Dr. Kamarck furrher expiains: "At a modern faciliry in Pearl Rivei New York, in a series of fermentation tanks (with separate tanks for each different strain), we start by growing bac&ria using a mixture of nutrients, ali of which support the baUcterial growth. Then we kill the bacteria by adding chemicais that disrupt the celis. After that, we take the ceil coatings that irgeiy are polysaccharides and separate them from other bacterialdebris." Õ A series of steps in a rigorous purification process follows to isolate the poiysaccharide intermediates. Canier Protein Is Key The carrier protein that gives Preunar irs special ability td be identified by an infant's immature immune system and that enhances immune memory also must be grown, a process that takes place ar the Company's Sanford, North Carolina, faciiity. Thdproteiri CRM197— is isolated from the Coryncbacteriunz dipht/nriae bacterium, grown in large quantities, then separated from the bacterium and purified. The purified polysaccharides for each strain in Prevnarare chemically activated and then linked with the carrier pfotein through another biochemical process. Each of the seven resulting glycoconjugates is purified. Ali along the wa4 quality control tests are used to make sure batches are consistent and remain sterile. Finaily, the seven glycoconjugates are combined using !iluminum phosphate to complete the formulation. The final formulated bulk vaccine is fihled into syringes and packaged ata nmber of sites in the United States and Europe for distribution around the World. There are some 1,000 controls in place to ensu#e quality and safety during production. The manufacturing conplexity is unprecedented because 15 individual components de required for Prevnar. To ensure that production facilities can meet the growing demand for Prevnar, Wyeth has invested hundreds of millions of dollars in new facihties and capital improvements. Creating the next-generation pneumococcal vaccine —a 13-valent formulation - will require even more resources, including a new 24 "Our peopte are using their technical skilIs to Iricrease output at our facilities se that we get Prevnarto more and more kids.What reativ motivates people is that they're delivering a lite-saving product. Evorywhere you go in Pead River, Coliegevitie and Santord, you see pictures ei babies - the babies we're trying to save.Actuatly, it*s almost too easy te be a manager in an environment where you're working te cave kids' lives. It just doesn't get any better than this David Zisa,Vice Presiclent, Vaccines Product Supply,Wyeth "Preunar is among the most complex biotech or biologic products ever made. It's a combination vaccine that contains seven glycoconjugates or seven different vaccines in one." process deveiopment facility in Sanford costing $200 miIon as well as investment of near!y $1 biilion ar other Wyeth sités in Andover, Massachusetts; Pear! River, New York; and Gdnge Castie, Ireland. DPCE "We'!1 almost be doubling the compiexiry of the vaccine," Dr. Karnarck says. "There will be 27 discrete steps for analytical assessments. Our job is to manufacture ir perfectly." No wonder employees ar ali the Wyeth facilities invoivedare "absolutely inspired by ir," Dr. Kamarck says. Process irhprovemenes have tripled the output of existing p!ants in the pat four years. And, over the next decade, Wyeth is looking for further increases in manufacturing capacity. Creating a New Generation ofVaccnes toAddress Global Concerns T oday, Wyeth R&D is focusing on the next generation of significant vaccine advances - both to prevene disease and to be used therapeutically to trear ilinesses. The Company's pipeline includes: Prcvnar 13, a 13-valËnt vaccine to prevenr pneumococcal disease in infants and children as Aboriginal children and adults in Australia are arnong the higher-risk groups expected to benetit greatly from Prevnar 13, Wyeth's nextgeneration 13-valent pneun,ococcal conjugate vaccine. well as adults; a vaccine that targets a bacterium that causes significant numbers of meningitis and bloodstream infecions for which no vaccine currently exists; a first-in-class vaccine- being developed in coilaboration with Elan Corporation - to halt the progression of Alzheimer's disease; a vaccine for strep t14-oat; and a vaccine for the staphylococcal infections that have incrased significantly in both hospital and community settings. DPDS Provnar 13 Pediatric The Company has a 13-valent pneumococcal conjugate vaccine in late-stage clinical development for use in infantis and children. This vaccine - called Prevuar 13 - adds protection for sx additional serotypes to the seven already present in Prevna;thus covering approximately 60 percent of the bacterial strains responsible for the remaining pneumococcal disease. Included among those are serotype 19A infections, which have li been on the rise and are responsible for an increasing pr of antibiotic-resistant disease. In addition, the vaccine iiicludes serotypes prevalent in developing countries in Africa and Asia as well as in certain other high-risk populations, includingrNative Americans, Native Alaskans and aborigines in Australi. Targeting serotypes that have begun to repace the sevei original strains, sooner rather than late; is an important part ofthe Prevnar 13 Pediatric vaccine strategy. "The CDC is on recor that 19A is the rnost important emerging serotype in th postPrevnar era in the United States," says Wyeth½ Dr. Gruber. "Two triais - one in Israel and the other in Alaska - are designed to make the case that our vaccine works to protect against 11 this serotype." The deveiopment program for Prsvnar 13 Pediatflc Is crie of the most compiex and chaiienging ever attémpted since, in principie, you're dealing with 13 separata vaccinesAs a result, dia unprecederited efforts by our intenial teams are nothing si1ort of heroic. For exam pie, hundreds ofthousands of tests are expected to be compieted over the nem year alone to assess protectiva lmmuno responses as weli as to demonstrate that this vaccine doesn't interfere with other childhood vaccines7 Kathrin Jansen, Ph.D., SeniorVke Presideni, Early Phase Pl-oyrarn5, 'Wyeth Vaccino Rasearch The trial in Israel will examine how the six additional íerotypes in the 13-valent vaccine will affect colonization by emerging pneumococcal serotypes. With regard to Alaska, Dr. Guber says: "19A has emerged as a very important cause of invasite pneumococcal disease in Native Alaskan infantis and children and may serve as a sentinei for what we might expect to see ove4 time in the population ar large," Dr. Gruber says. "So, in addiion to potentially improving protection in this vulçierable poulation as part of the trial there, we will be better able to predict the global impact of the 13-valent vaccine in reducing disease." "The objective of our 13-valent pediatric pneumococcl conjugate vaccine program is to develop the most complete laccine available for the global prevention of pneumococcal disease and pneumococcal otitis media," says Wyeth's Emilio EmiiÇi, Ph.D., Executive Vice President, Vaccine Research and Develpment. Planned for regulatory submission in 2009, the progdm now is in Phase 3 clinical development. Oposito pago: Chiidren in Kenya wiii be aniong the many who wili benetit as rniliions of doses of Pra vnar are provided to countries in Latin Arnerica, Africa and Asia. 27 e' P13. Prevnar 13Adúlt While Preunar has provided herd irnrnunity to older aduits in many countries by reducing the reservoir of cornmunicable disease that can be spread, pneumococcal disease in adults stili remains a major health burden. Death rates from pneunococc disease in adults between age 50 and age 64 are 10 times higher chan those for one-year-old infants. And for adults over age 65, death rates increase to 27 times greater than for one-year-olds. "CtÍrrentiy, there is a 23-valent, free-poiysaccharide pneuinococcal vaccine available for adults ages 65 and older," Dr. Erninisays. "However," he expiains, "within tive years of administration, the efflcacy of this vaccine declines. And the vaccine cannotbe used to substantiaily boost the irnmune response once an initial dose is administered. Dr. Gruber says: "We expect that Wyeth's Prevnar 13 Adult will provide immunologic memory to permit boosting to maintain protective leveis of antibody throughout adult life. These features of Prevnar 13 Aduit couid extend the age of protection ragainst pneumococcal disease and provide ionger-term protectiôn with repeated dosing or boosters. "Another important objective for the vaccine is to protect the elderly against community-acquired pneumococcal pneumonia, a leading kiiier of older adults," Dr. Gruber adds. Notes Wyeth's Connoily, "The adult vaccine has the opportuniry to transform and reshape the adult pneumococcal areal sarne way Preunar continues to transform pediatric pne'urnococcal disease." The adult clinical program is in Phase 3 trals 'vith regulatory filings expected to begin early in 2010. o Meningococcal BVaccine Next in Wyeth's pipeline is a vaccine targeting meningdcoccus group B, which is an irnportant cause of meningitis and bloodstream infections in very young children and adolescents and for which no vaccine currently is avaiiable. In the United States, a third of ali meningitis cases caused by meningococci are the result of meningococcus group B; in Europe, ailnost rwo-thirds of the iilness is caused by group B. The disease is devastating and has rnortality rates of 10 percent, with 20 percent of those who survive often suffering seere consequences of the disease, including limb ioss and brain damage. "Parents and physicians alike are frightened by this disd'ase. Ir can kill in just 24 to 48 hours,"says Kathrin Jansen, Ph.D., Senior Vice President, Early Phase Programs, Wyeth Vacciqe Research. 28 The development o! conjugate vaccines is a tremendous story about medical as well as public heatth advances. After ali, woildwide, the death rato for pneumococcal disease is about 1 miltion children a year. With hrnader.application of a 13-valent conjugate pneumococcal vaccine, there is the posslbility of preventing up to 750,000 deaths a year. The opportunity is reaU' WIIorn Gruber, M.O.,Vice Presidem. WyethVaccinej Clinical Research Currently in Phase 1 and Phase 2 clinical triais, Wyeth's vaccine works by targeting a surface protein that covers almost ali 'the meningococcus group B strains, eliciting antibodies that kill the bacteria. "Our researchers were hunting for a cross-proteçtive antibody response and discovered a lipoprotein that showd the desired traits," Dr. Jansen adds. "More than 1,000 differekt strains were evaluated to make sure there was enough lipoprotein target on the surface of the ceil so that antibodies made b the vaccine could efficiently kill the bacteria. The bacterium sçeins to actually need this protein so we believe we have found the right target." Alzheimer'sVaccine O Alzheimer's disease affects some IS inillion people worldwide. Wyeth and its partner, Elan Corporation, are engaged in Phase 3 triais for a so-called "passive immunization" approach to attack Alzheimer's disease, based on providing monoclonal antibodies to a patient. In addition, an "active immunization" approach - based on the body's production of antibodies in response to the presence of an antigen - also is being developed. This Wyeth and Elan vaccine - ACC-101 - uses peptid fragments of the beta-amyloid protein conjugated to a protein carrier to elicit an immune response against beta-amyldid plaques presem in the brains of Alzheimer's patients. It!is hoped that the immune response will clear the plaques, thereby stopping progression of the disease or preventing the plaques' iniia1 deposit. The vaccine currently is in Phase 2 triais after demonstrating in mouse modeis that immunization using the vaccine could prevent memory loss. "This would be one of the firsr examples of a therapeutic rather than a preventtive vacine," Dr. Jansen observes. Staphylococcus Aureus Vaccine Staphylococcus aureus is the leading cause of hospital-hcquired "As we have seen an increase in the ove reli pubhc health impact of Prevna,, the cost-effeetiveness of this compex vaccine bécomes even clearer.The need now isto broaden into emerging markets like Mexico and other countries with about 70 million new births each year and to implement mi affordablo and sustainable plan for the vaccine's use in the developing world." Jim Connoily. ExeCutivo Vke P,esider,t and Gene,aI Manager. WyethVaccines infections - more than a haif million cases annually - in the United States. In addition, there has been an alarming ncrease of methicillin-resistant S. aureus or MSRA. S. aureus can cause large boil-like lesions, pneumonia, bloodstream infecrions and even death. A vaccine to address these infectipns is in developrneJ ar Wyeth. This vaccine:includes a bacterial surface component. "jWhile the antibodies generated from the immune system in response to the vaccine can't kill the bacteria directly, they coar the ba'cteria and act in concert with immune components in the blood io gobble up these complexes and destroy the bacteria in the .pràcess," Dr. Jansen says. 29 EI Group A Strep Vaccine While the major burden of group A streptococcus (GAS) infection is strep throat, with more than 600 million cases a year, uitreated or unrecognized GAS infection can result in acute rheurrnhic fever, a disease that is the most common cause of acquirei heart disease in children and adults worldwide. A multi-compdkient vaccine that seeks to prevent GAS infections in young children is in earty development. A large team of scientists at Wyeth works ou the Company's vaccine R&D projects. "We ask a lot from our scientiststhese days, but our people are willing to work more and go the extra mile," Dr. Jansen says proudly. "There is incredible enth'usiasm to bring these programs to the finish tine." L lí Redetining the Possible As head of Wyeth's commercial vaccine business, Jim Connotly spends a good part of bis time looking at new opportunties for what already is one of the ompany's main drivers ofgbwth while also planning for the introduction of new vaccines. j-Ie knows that "the market will pay for innovation but not for mediperity." "It's at the heart of Wyeth's mission to lead the way to a healthier world - and we take that mission very seriously." Says Connolly, "1 believe the success we have achieved ith Prevnar is a direct reflection of the extraordinary va1ueand public health impact of the vaccine. Prevnar has redefirèd the possible when ir comes to meeting significam: unmet m&Iical needs on a large scale. As we look ahead, we will have other assets - advanced vaccines - that could make a drarnatic impact in parts of the world where most of the deaths from invasive disease are occurring. We will do ali we can to make these vaccines available and to do ir in a sustainable and affddab1e way. The key is finding the narrow pathway that meed the needs of our stockholders and the needs of the countries - and the people - who can benefit most. 1 know we will be dble to do that. We simply must. It's at the heart of Wyeth's mssion 1 to lead the way to a healthier world - and we take that mission very seriously." • 1 Wyeth's new 13-valent vaccine Prevnar 13— now is being developed to more tully address invasivo pneumococcal disease in vuinerable populations, including infants and children as well as older adults. 30 H SELECTED FINANCIAL DATA (boilar amounts in thousands except per share arWountst .YeárEndédDeceznber3l, Net revenue Research and develàpnient expenses Net income Diluted earnings per share Dividends per commonshare Capital expenditures Total assets Number of employees ar year end Wages and sálaries o 2006 2005 2004 ),655 $22,399,798 3,255,785 ,109,060 3 4,615,960 4,196,706 3 08 338 1.06 1.01 /J 1,289,784 1 390 668 $42.717.282 $36,478,715 50,060 50.527 $ 3,488,510 $ 3,765,604 $18,755,790 2,749,390 3,656,298 270 0.94 1,081,291 $35,841,126 49,732 $ .3,434,476 $ 17,358,028 2,460,610 1,233,997 091 0.92 1,255 275 $33,629,704 51,401 $ 3,280,328 2007 COMPANY DATA BY RÉPORTABLESEG.MENt (In millibns) Net Revenue from Cusú,niers Pharmaceuticals Consumer Healthcare Animal Health Consolidated total $18,622.0 2,736.1 1,040 $223998 Income (Loss) before Iricome Taxes Pharmaceuticals Consumer Healthcare Animal Health ., Corporate Consolidated total $ 6,164.5 519.2 194.1 (421.1) $64567 r Depreciation and Amoruzation hxptnsc Pharmaceuticals Consumer Healthcare Animal Health Corporate Consolidated total $ $ 800.5 35.1 32.6 50.5 918.7 ëípenditures for Long-Lived Assets Pharmaceuticals ConsumerHSlthcare Animal Heakh Corporate Consolidated total $ 1,4106 72.2 42.4 g4.i 1 6 $ _ ,2 Total Assets at December3 1, Pharmaceuticals Consumer Healthcare Animal Health . Corporate Consolidated total $18,814.9 1,833.4 1,569.4 20,499.6 $42.717.3 32 2005 2004 $16,884.2 2,530.2 936.3 $20,350.7 $15,321.1 2,553.9 880.8 $18,7558 $13,964.1 2,557.4 836.5 $17,3580 $ 5,186À 516.2 163.7 (436.4) $ 5,4299 $ 4,544.9 574.3 139.4 (478.0) $ -4,780.6 $ 4,040.1 578.6 134.8 (4,883.3 $ (129.8 2006 2007 Vear Ended December 31 1 ,. - 11 ] , $ 719.9 20.0 32.7 $ $ 803.0 $ 1 682.0 40.8 30.3 33.8 786.9 $ $ 529.5 45.7 29.9 17.3 622.4 $ 1,228 3 15.3 37.2 72.0 1,3728 L_ $ 1,0779 28.4 45.0 47.1 $ 111984 $ 1,226.5 33.2 40.0 83,4 $ 1,3831 $17,171.6 1,492.9 1,430.0. 16,384.2 $36,478.7 $15,770.2 1,463.2 1,326.7 17,281.0 $3s,841.1 $15,771.2 1,701.4 1,340.9 14,816.2 $33,629.7 jn // WORLDWIDE NET REVENUE BY PRODUCt (In miltions) Pharmaceucicals Effexor Prevnar Enbrel Frotonix Nutricion ZosynfTazàcin Premarin famll$' Oral contraceptives I3enevix Raparnune rhBMP-2 ReFacto Tygatil Zoton Tortsêl Alliance revenue Ocher Total Pharmaceuticals Consumer Healtbcare Centru,n Advil Caltrate Robitussin ChapStick Preparation H AdvilCo!d&Sinus Ditnetapp Alavert Other Total Consumer Healthcare Animal Health Livescockproducts Companion animal products Equineproducts Poúltryproducts Total Animal Health 2007 2006 2005 2004 $ 3,793.9 2,439.1 2,044.6 1,911.2 1,443.0 1.137.2 1.055.3 433.9 432.6 364.8 358.9 334.9 137.9 93.3 26.6 1,294.2 1,320.6 $18,622.0 $ 3,722.1 1,9613 1,499,6 1,795.0 1,200.8 972.0 1,050.9 454.9 357.6 336.9 308.0 305.6 71.5 130.8 0.0 1,339.2 1,378.0 $16,884.2 $ 3,458.8 1,508.3 1,083.7 1,684.9 1,040.9 891.6 908.9 525.3 343.3 300.2 236.3 268.4 10.0 3752 0.0 1,146.5 1,538.3 $15,321.1 $ 3,347.4 1,053.6 680.0 1,590.6 943.3 760.3 880.2 590.1 301.5 259.0 165.3 249.4 0.0 447.7 0.0 789.9 1,905.8 $13,964.1 704.9 684.1 225.9 220.3 139.7 109.7 73.7 72.6 56.0 449.2 $ 2.736.1 $ $ 634.0 514.0 189.2 253.2 134.4 104.8 122.4 80.4 49.5 472.0 $ 2,553.9 616.6 490.4 179.0 237.9 123.2 102.3 129.7 87.8 56.0 534.5 $ 2,557.4 $ 452.4 317.9 145.3 126.1 $ 1,041.7 $ , 657.1 620.2 19..Ï 225.5 127.9 103.1 61.0 81.7 i 49.8 408.8 - $ 2,530.2 $ $ 405.5 283.9 135.5 111.4 936.3 $ $ 377.2 257.8 138.2 107.6 880.8 $ $ $ 351.0 252.6 138.2 94.7 836.5 33 DJRECT9RS AND OFFIcERS Principal Division a Board of Dlrectors Principal Corporate Officers Robert Essner Chairman Robert Essner Chairman &rnard Poussot' Presidem and Chief Executivo Officer Bernard Poussor 7,1,9,1411 Presidem and Chief Executivo Officer Robert M. Amen 2,112 Chairrnan and Chief Executivo Officer International Elavors & Fragrances Inc. John D. Feerick 2,3 Professor of Law Fordham Univeraity School aí Law Timothy P. Cost "a" Senior Vice Presidem, Corporate Affairs Frances D. Fergússon, Ph.D. 4.5,1 President Emeritus Vassar Coilege Victor F. Ganzi 1.1,3,12 Presidem and Chiei Executivo Officer The Hearat Corporation Robert Langer, Sc.D. Instituto Professor Massacbusetts Instituce ofTechnology John P. Mascotte 1.2, '3,12 Retired Presidem and Chief Execudve Officer Elue Cross and Blue Shield of Kansas City, Inc. Raymond J. McGuire " Co'Head, Global lnvesrment Banking Citi Mary Lake Polan, MD., Ph.D., M.P.H. a' Professor and Chair Enieritus Deparenient of Obsterrics and Gynecology Scanford Universicy School of Medicine Gary L. Rogers 2,3 Former Vice Chairman General Electric Company Thomas Hofstaetter, Ph.D. " Senior Vice President Corporate business Development Joseph M. Mahady 7, Senior Vice President Gregory Norden 7,0,9,10,11 Senior Vice President and Chieí Financial Officer Denise M. Peppard Senior Vice Presidem Human Resources Marily H. Rhudy Senior Vice Presidem Public Affairs Robert R. Ruffolo, Jr., Ph.D. Senoor Vice Presidem Lawrence V. Stein Senior Vice President and General Counsel UlfWiinberg " Senior Vice President Mary Katherine Wold "°" Senior Vice President Finance Subsidiary Officers Andrew E. Davidson Vice Presidem liiternal Atidit Wyeth Pharmaceuticals Joseph M. Mahady Presidem Douglas A. Dworkin' Vice President and Deputy General Counsel Wyeth Pharmaceuticals Asia/Pacific and Nutritionals Mark M. Larsen' President 0' leo C. Jardot Vice President Government Relationa Paul J. Jones •. Vice Presidem and Controlier Jeffrey E. Keisling Vice Presidem Corporate Information Services and Chiei Information Officer Wyeth Pharmaceuticals Latin America Eduardo G. Nieto' President: E' John C. Kelly Vice Presidem Finance Operations 11 Eileen M. Lach' Vice Presidem, Corporate Secretary and Associate General Counsel bavici A. Manspeizer vice Presidem Intellectual Property and Associate General Counsel 11 JamesJ. Pohlman .ice Presidem 1Corporate Strategic Initiatives Steven A. Tasher a Vice Presidem and Associate General Counsel in R. Victoria 8.9 President lar Relations erv E. Landry, Jr. Wyeth Pharmaceuticals Teci-mica! Operations and Product Supply Charles A. Portwood President Wyeth Pharmaceuticals U.S. Pharmaceuticals and Women's Health Care GenoJ. Germano' Presidem Wyeth Research Robert R. Ruffolo, Jr., Ph.D.'°"° Presidem Port Dodge Animal Health Richard R. DeLuca, Jr. . lJ Presidem Wyeth Consumer Healthcare Cavan M. Redmond 2,1,9.10 President Wyeth Consumer Healthcare - United States and Global New Business Douglas A. Rogers' President Wyeth Consumer Healthcare - Internacional Etienne N. Actar' Presidem Johfo R. Toreli lI1 Parmer Core Capital Group, LLC 1 Execuçive Comoniittt 2 Audit Comaoittee 3 Compenaaaion and Bendita Conaanittee 4 Corporate Isoun Conmitue Nominating and Governonce Conmittee 6 Scienct and Tec}nology Committee 7 Managemen e Co,nn'ttee 5 34 Wyeth Pharmaceuticals EMEA/Canada and BioPharma UlfWiinberg ' Presidem t.aw/Regulatory Review Conmictce 9 Operaeinna Conninee O lluaianResonrces.nd Benefiti Conaninte Renrenleni Committee Ia Deiignated cobe a FinanciaI Expert' ai defined in applicable sec noMa '8 WYETH WORLDWIDE Pharmaceuticals Consumer Healthcãre Animal Health Affihiate & General Manager AfSliate & General Manager Regional Managers John Wyeth and Brother Ltd. (United Kingdom) Palie H. Chrisrensen Wyeth Consumer Healthcare Inc. (Canada) Suneer Varma Wyeth Industria Farmaceutica Ltda. (Brazil) Carlos Cesar Sampaio &ent A. Standridge Senior Vice President North America Sales and Marketing Wyeth Pharma GmbH (Germany) Andreas Krebs Wyeth Consumer Healthcare S.p.A. Iltaly) Massimo GalIo Wyeth Taiwan Corporation (Taiwan) Jessica Yeh Whitehall-Much GmbH (Germany) Frank Kube Wyeth Consumer Healthcare Ltd. (Puerto Rico Branch) (Puerto Rico/Caribbean) Alberto R. Fernandez-Comas o yeth South Africa (Proprietary) Ltd. ksouth Africa) Luciano dePortu Luis E Andrade Senior Vice Presidem and Managing Director, Lârin America, Japan, and Global Poultry Wyeth Pharmaceuticals France (France) Emmanuelle Quiles Wyeth Lederle S.p.A. (Italy) Mathieu W. Simon, M.D. Wyeth Farma S.A. (Spain/Portugal) Elvira Sana Wyeth K.K. Uapan Region) Susumu Kurata Wyeth AB (Nordic Region) Vacant Wyeth S.A. de C.V. (Mexico) Carlos Fabian Abelleyra Wyeth Pharinaceutical Co., Ltd. (China/1-Iong Kong) Dr. Xiaobing Wu Wyeth Australia Pty. Limited (AustralialNew Zealand) Erica Mann Wyeth Pharinaceutical Co., Ltd. (China) John Choü Wyeth Consumer Healthcare (Eastern and Central Europe/ Commonwealth of Independent States/Middle East/Africa/Balkans) Luciano dePortu Rob Barclay Senior Vice President and Managing Directo; Asia/Pacific Ugo Cosentino Vice President and Managing Director, Euiope and Emerging Markets Whitehal! Laboratories Limited (England/lreland) John R. Smith Wyeth Consumer Healthcare Pty. Ltd. (Australia) Alian R. Franz Wyeth S.A. de C.V. (Mexico) Arturo Sanchez Wyeth Canada (Canada) Arnour Ploos vais Ajustei Wyeth Consumer Healthcare Ltd. (Colombia Rranch) (Colombia) Camilo Tedde Wyeth Philippines, Inc. (Philippines) Andrew Ericson L. Santos Wyeth Sagre Familiale (France) Faissal Tahiri Wyeth Pharmaceuticals FZ-LLC (Middle East/North Africa) Joseph 1-lenein Wyeth Philippines, Ind. (Philippines) Edgardo B. Meridoza Wyeth Pharmaceuticals B.V. (Netherlands) Edward Lysen Wyeth-Lederle Pharma GmbH (Austria/CLE Region) Mark Heseiton 35 CORPORATE DATA Executiva Offices Wyeth Five Giralda Farms Madison, NJ 07940 (973) 660-5000 www.wyech.com StockTrading Information Wyeth stock is listed on the New York Stock Exchange (ticker symbol: WYE). Independent Registered Publie Accounting Piaui PricewaterhouseCoopers LLP 400 Campus Drive Fiorham Park, NJ 07932 Annual Mõeting The Annual Mecting of Stockholdets will be bebi on Thursday, April 24, 2008 ar the Hyatt Morriscown in Morristown, New Jersey. StockbolderAccount Information The Banir of New York Melion is the transfer agent, registra; dividend disbursing agent and dividend reinvestxnent agent for the Companjr. Stockholders of record with questions about lost certificares, lost or missing dividend checks, or notification of change of address should contact: Wyeth elo INY Melion Shareowner Services P0 Box 358015 Pittsburgh, PA 15252-8015 (800) 565-2067 (Inside the United States and Canada) (201) 680-6578 (Outside the United States and Canada) For the hearing impaired: (200) 231-5469 (TDD) Internet address: www.bnymellon.com/shareowner/isd BuyDIRECT Stocic Purchase and Safe Plan The BuyDIRECT plan provides stockholders of recordand n&w investors with a convenient way to make cash purchases of theCompàny' common stock and to automatically re?nvest dividends inquiries should be directed to The Bank of New York Melion. ReportsAvailable ft The Company's 2007 Annual Report on Form 10-K and ali Company fihings with the Secuiities and Exchange Commission canbe accssed on our Web site ar www.wyeth.çom Alternarively, a printed copy of the Cornpany's 2007 Annual Report on Forn 10-K and other Company hlings rnay be obtained by any stockholder without charge through Wyeth by caliing (877) 552-4744. Equal Employnient Opportunity Our established affirmtive action and equal ernpioyment prograins demonstrate our long-standini commitment to provide job and promotional opportunities for ali qualifled persons regardiess of age, coto; disability/national origin, race, religion, sex, sexual orientation or status as a vete±an. Environment, Health and Safety Information on the Corbpany's environrnentai, health and safety (EI-IS) performance and its EI-IS Policy is available on the Web ar http://www.wyeth.con-Jaboutwyethl cicizenship/ehs. EHS inÍbrmatión also is included in Corp'orato Citizenship 2006— Living Our Values, which is available on the Web ar http://www.wyeth.comaboutwyeth/ cirizenship. A copy of the EI-IS Poiicy may be obtainedtpon written request to: Wyeth Deparcinent of Environment, Health and Sáfety Five Giralda Farms Madison, NJ 07940 This papa is FSC (Foresr Stewardship Councit) certified from weIl-managed foresta, contro!ted sources and recycted wood offiber. 36 Coiporate Citizenship Ccnporate Citizenship 2006 Living 0w' Values, a report describing the Company's efforts in the arcas of governance, empioyee development, support for our communities, and protection of the environment and the health and safety of our employees, is availabie on the Web ar http://www.wyeth.com/ahoutwyethcitizenship or via written request to: Wyeth Pubiic Affairs Five Giralda Farms Madison, NJ 07940 Tradein aiics Product designations appearing in diíferentiated type are vradernarks. Trademarks for products that have not received final regulatory approval are subject to change. Cautionary Statement The information in this Annual Revi~ is a summary and does not provide complete information; ir should be considered along with the information contained in the Company's 2007 Financial Report, 2007 Annual Report on Form 1 0-K and oth& periodic fiuings with the Securities and Exchange Commission. This Annual Review inciudes forward-iooking statements. Ali statements that are not historical facts are forward-iooking statements. Ali forwardlooking statements address macters invoiving numerous assumptions, risks and uncertainties that could cause actual resulrs to differ materially frõm those expressed or implied by those statements. In particular, the Company encourages the reader co review che risks and uncer tainties described under the heading "Item IA. RISK FACTORS" in the Company's 2007 Annual Report on Form 10-1<. The forward-looking statements in this Annual Review are qualified by these risl< factors. Accordingly, the Company cautions the reader not to place undue reliance on these forward-looking statements, which speak oniy as of the date on which they were made, and the Company undertakes no obligation to update or revise any of these statements, whether as a result of new information, future deveiopments or otherwise. SEIECttD PRÕiCTS ,0 5 t Wyeth Phamiaceuticals 1 Consumer ØQ Fort Dodge Animal Health thcare ft Nutntionals Cardiovascular and Gastrointestinal o Nursoy v, Progresa Protonix Protonix,,l.V, Zoton !romise Promise Gold 5-26 5-26 Gold' Hesnophilia BcneHX ReFacto Xyntha PM -X Vaccgnes Immunology and Oncolóiy Çold & Sirfús p, Meningitc Prevnar/Prevenar Mylotarg Neumega Rapamune, Torisd4 i - Néd Nutritional Supplements - Caitrate Centrum Çentrurn Cardio Centrum Select Centruin Silver o ase Vitasprint S12 Women's Health Care 7 lnfecticuá Disoase Tygacil Zosyn/1a?ocin Inflamrnatory Diseass Enbrel Dimetapp Robitiissin Loecte Lybrel : Minesse rrernarin Premarin Vaginal Cream Premphase Prempro/Premetie Totetie Other Products Anhesol erCon" Néuroscience., .1 EffexõrlEfexor Effexor XR Co.rornoted wicF. Amgen mc: Me fle bove produc; areidcntifi,d as rrade:na,k u;ed byysth and ics'shiidtariea. ti: JI Broifëhi-ShieId Bursine 4 : ÇaJid Cydectixf Duramune Fe!0:Vauf1entofe1 .Fluãd ,.LymeVíx' Nolvan "Polyfle3f" Poulvac, ProHeartiGuardian ProMeris Pyritnid Quest/Equest 1Rabarri i lII iij S uvaxyn Synovex Tela zoi TODAY TOIÇIORRQW Tobugesic[rorbutroI Triangie West Nile-Innovator Wyeth Five Giralda Farms Madison, NJ 07940 UR XUP / MINISTÉRIO DA JUSTIÇA SECRETARIA DE (DIREITO ECONÔMICO OFICIO N° Q /2009/SDE/GAB Brasília, 16 de fevereiro de 2009. fl A Sua Senhoria o Senhor ARTHUR BADIN Presidente do Conselho Administrativo de Defesa Econômica Ministério da Justiça Brasília - DF Senhor Presidente, De ordem, encaminho a V-,', Sa., nos termos do § 41 do art. 54 da Lei n° 8.884/94, a documentação, inclusive confidencial, referente ao Ato de Concentração no 08012.001157/2009-71, de interesse das requ&entes PFZIER, INC. ("PFIZER") e WYETH VEDO MINISTERIO DA JUSTIÇA SECRETARIA DE DIREITO ECONÔMICO GABINETE DO SECRETÁRIO ,l't) OFICIO N° [Z; ) 12009/SDE/GAB Brasília, 16 de fevereiro de 2009. A Sua Senhoria o Senhor ANTÔNIO HENRIQUE PINHEIRO SIL Secretário de Acompanhmento Econômico Ministério da Fazenda Ed. Sede, Bloco "P", 3° andar, sala 324 70048-900 - BRASÍLIA/DF Senhor Secretário, De ordem, encaminho a V! Sa., nos termos do § 4° do art. 54 da Lei-n" 8.884/94, a documentação, inclusive confidencial, referente ao Ato de Concentração n° 08012.001157/2009-71, de interesse das requerentes PFZIER, INC. ("PFIZER") e WYETH ("WYETH"). Atenciosamente, REGINA Chefe MINISTÉRIO Dà JUSTIÇA SECRETARIA DE DIREITO ECONÔMICO GABINETE Em 11 de fevereiro de 2009 . Determino a divulgação dos seguintes atos de concentração econômica protocolados N° nos termos do art. 54, da Lei n°8.884/94 e do art. 13, da Portaria n° 5/96/SDE: ft AC n° 08012.001157/2009-71. Rqtes: PFIZER, INC. ("PFIZER") e WYETH ("WYETH"). Operação: aquisição, pela PFZIER, da WYETH. setor de atividade envolvido na operação é o 1, de Indústria Farmacêutica - Produtos Farmacêutics e Veterinários. Á S OVN Chefe de Gabi ENVIADO Á PUBLICAÇÃO MPLC/OABNETE/DESPACHOS/ACs 17022009 1; MINISTÉRIO DA! JUSTIÇA SECRETARIA DE! DIREITO ECONOMICO GABINETE DESPACHO DO CHEFE DE GABINETE h Em-IV de fevereiro de 2009 N° Q ? . Ref.: Ato de! Concentração n° 0012.001157/2009-71. De ordem da Senhora Secretária de Direito Econômico, ao Departamento de Proteção e Defesa Econômica - DPDE, para que se manifeste, preliminarmente à .autüação, sobre o pedido das! reuerehtes de tratamentõ confidencial dó parte da doúmèhtaãoque instrui a prdente notificação. hN4S Chefe de abinet 513 stituto 4 -17 ( OZ f F. ft 28 ISSIV /677-7012 Diário Oficial da União - seção 1 SECRETARIA NACIONAL DE JUSTIÇA DEPARTAMENTO DE ESTRANGEIROS DIVISÃO DE PERMANÊNCIA DE ESTRANGEIROS DESPACHOS DO DIRETOR .cooitri,iirào Mitistio do Tnbalbo Dispute di mia' - o_____. e.......4 • uti.a..i. . ..r,, ib os..noasiur , N 34, quina-feira. IS de fevatim de 2009 Tmdo os vista goto ficou demormtndii efetiva eecasídide di maswbasçio do aEitgefro si Oi.peaa. rorasdairodo que o p. sate Oe owsofl.Ie imbuido na forros di lei e. drisre da isfeomiio do Mirdsrtio do Trt.IIso e Essupteto. DEFIRO o Pedido de PonosogaÇio de Estada no Pais - 24/09/2010.. Poocaoo 0° 09000.0I223I/2-33 - Olivia tive Bourely Tosdo os - que ficou dososndia dEIrva nidade da miouleuiclo do aovraein na mirpoma. cosa.ldcnndo que o pego. & Psusopçao de Emd. rIo Pus .54 14/08)2010.. Processo n° 080I24I7ç2008-92 - Autuo Rodolfo Afta Creia Tardo ao viola que ficou dosoeotrala 1 efetiva neccoaladi à o do aüarSm na mosos. aS&aado cato o eec- Eocaasbshe-uc o feito no Dfretoi do Dqsrtumo.lo de Esmr,gàoo pan ddboaclo. atolado que soja m.nOido o tIo is&faiotno de fis. 40, lado no voas. isto.rpasivid.de do pedido.Pro t E8000.012728'2008-3l 3iana. Huaiag e W. lUto - LUCIANO PESTANA BARDOSA Ii DESPACHOS DO CHEFE i - MARIANA TAVARES DE ARAUJO DESPACHO DO CHEFE DE GABINETE Eu lide fevereiro de 1 .109 74° 86 - DaSo i dMoçk dimo ~ .do co.EotaçIo emitira petoocoisdos mc lassa do itt 54. di 04 ? L88Q94 e do itt II. à Paisana 0° SI9SSDEi AC 0° 01012001157/2009-71. Rqtea: PFIZEB, INC. rPFlZER°) e WYETH (WYETH1. Opaiçio: .quiuiçleh pela PFEIER. da WYETH. O neste de ilividade owolvido ou eçuaaçlet o de Irãiaia Fasssractustca - Prodiooea Ftomacbulicoe e t/dasuina NELSON CAMPOS DEPARTAMENTO DE PROTEÇÃO E DEFESA DO CONSUMIDOR DECISÀO N° II, DE li DE FEVEREIRO DE 2009 Processo Aóskujsostivo o 040l2.00413512002-97. Rqiee- Assodaçio Denileisa dia Peodidoem de Cii. Repaimotado(s): Miiaaç,io Mfnego Lak Asamvooc Coloe.Çio no morado de produlo Snprdçeio ao conom.o. Em ir000in.moeo as raSa tic cabataridada - Nom Tderdc. mupta. .dotiodo-a meto rnoouv.çio e. dose modo. coceidoando . goavidide e e eutemlo da IM. oss.da . milhirar de mmtuvide.ss mli iodo o pais. • v.ntisn. .asfaida. bar, meto • mndiçao atedmie. à eTasa. nos lama do rsjgo 37 do 14a tOltAlO e da not 23. II e III e 2& III e VI do Deaao, 1181)97. splieo à repoamitaS • n'oçio de mula. no vila de ES 82.800.00 (oitaoo. e dois mil e oitocona nos), de'urdo o vilce defiosovo ser dquaitude as fava do Fundo de ~ de Direitos D'Suom neo truta à Raoluçio MD n. 16. de (8 de miTço de 2005. ceaoiote delcusiso. o noflo 29 do basto .2.181/97. RICARDO MORISPOITA WADA Direter DESPACHOS DO DIRETOR Em li de faicreasu de 2009 P4' 19 -. Trago a público u decido de arquivar o Procano Adm&tsEauvo de ouúmao 08012.004128/2002-95. mm iisnd.reto sri Noqa e. M. CGAJ/DPDl que ee oicorba pulidi aos pecava ia 74° 20 - ltoio a público i decido de arquivar o Pto Admadvo de sõrnero 080I1084I3412002-41. mm ftradommto a Noou a 47. CGAJIDPDC/1®9, que ar mmsra joda um po_vei P4' 21 - Processo Admlelsuallvo .0° 08012004147/2002-I1. Regreimitaste: Aisociaçio Boanleisu dei Produtora de Cal. Repeoatsdar Lindasalva Almeida D. & C. AannsOo: Propinas de Q. Itd.dedoCutH,&ila. Ceirçiolasdo os aula. vosSos qoir o .anon apostando pela eepesteasdo é soepativo. assa no e4amv.do o peito asbcleeido pelo capa do misto 49 do Deasto a° 118097. boa cine - situo 39 do Là .° Ç7$4/99 toonlda.nIo que o on'uss iotposoo on' as. sou bojo os rolamos asgosnlo.00s já aprceindoo e redoádos a decido pisfroide mmc Peocauo Adouinisfritiv, rito vgo rato para eecoaidai-Ie. Dossio do aposto e - que maio doo iodos rasou, recebo o matoso no efeto nasatoeo os edicto is ascOen inopoalsa, nos larram do ciSmes» no prigosfo fatia do aoL 61 da Lá u. 9784/99 edo tiL 49 do Dwmo 1881)97. ccrsido. que bá receio de poçrulro de dificil ou mata. eqsasçlo à rqarso.tad. ato a dedelo leis refoomai.. RICARDO MORISHITA WADA Tardo «ri vista que ficou dosoatidi efelivi noEooidode 0 POsà mtoçio do onnrãro las empema. osmidoando en a.se honda a teia di IS e. diaaooe di miamaçao no uuilsosaw no 'mono e otgo. urnonu o pauto do Proerog.Çio do Estada a Pois itt l0to3,20I11.-Po .0° OSao.012163t201l-00 - Momin lan Z.jic Tado os vista que Som dossooauadn a efetiva necessidade do anulado do obSo nu oiuprno, comidaoodo que o pien'te poocaso anota-se isisoisuldo a tossa di lã e. diva di teamaçio do Misisofaio do Tuteslbo e Esgorego. DEFIRO o pedido de Pieeroesçto de Estada no Pus itt DVD7,201t- Procoso ot 011rtuO.011(06i.200847 - Sa.niolsw Mordia Diante doo nova etosota connta. ao asile e. coosiderando i ir,fcemaçio do Mininotio do Teatulho e EmpeEgo. mono husabsbooale o aio irodefoildoio publicado os Dufio Ohicial de 28/12,2008. pan DEFERIR o pedido de Recomidauçlo concederodo • Franzido de Prezo do estada .04 0105r200t- Proemno ro° (8000/011995/2088-10 rabio ESta Fano.da ~j~ Deda Maria Ba,sojo MteaaoePsbloFossssdaBamojo O To.do em do viola que Soou dosoaoads a efetiva necasitisde àmaasaasçio muaegao na arsçuma. coraidaindo que o pieomito peocano eoscoosua-se imwutdo 015 forma da lei e. disite à àofoemaçlo do Ministdrio do Trabulho e Emprego. DEFIRO o Podido de Trirafoomaçio de \/OsOo lar' V pan Pormrerroa- Precioso 0° c8303.o2382Q1®t-a9 - iahs ADoto CSny Posso, e Miou Dei Pilar Acevolo Cruz Tmde os vista que ficou doc000ulnda a efetiva ,itde do manhorçio do aorgdeo na o.ravma, misdondo que o pieiate precato crceuoa..e SOtaldo a tossa do IS e. disst do ofoemaçlo do Minosotio do Taubsllas e Enrprcga DEFIRO o Pedido de Proorogoçio do Estado no Pais até 12)18/2010.- Processo ef 0t.0I30S4/200849 - Bapisrd Wicling, Fito Wieling. Heidras sc.esaoura WloIürg Diolulroff e Mito Whel.eg Tardo as vista que ficou dosoatada i efeolvi neonoidade di manançio do atuorgeiro na osgoemi, cosõdetiodo que o pisommc pat ossonba.e t.toddo a fossa de iit e. baste de iofasmçio do Mirmisttsio do Tsabaftio e Enspeego. DEFIRO o Pedido de Pmemsaçio de Estada no PS sf4 03/11/2010.- Procoso n° 0t0l&%5377,2008-% - Gerando Primitivo Rasando Omaoa Tardo ais vista que ficou domomenda n efetiva roecosidade do us.mçlo do ae.ngaro Sri empossa. cosoidorsndo que o pIelote peteato oieoistw iiIa.oldo na fosso. do lei e. discute da iofecmaçlo do Mioistdrio do Trabalho e Enspreao. DEFIRO o Pedido de Preorogaçio de Estado no Pais - 09/IMola- Processo t 0110I2.®5533/2008-26 - Dhot Goodirlr lo Tel no visa. que ficeni doso_rada n efetiva ncocoiàde da usarataçio do osEsngoto ti amplmi considerando qone o posososie phocano arestos-se Imbuido ira domas di lei e, diarte à isfamnçio de Minisotio do Trabalho. Eosspr000u DEFIRO o Pedido de Proerogoçio de Estuda no Pias itt 29/10/2009.- Processo n' 08.0l305G'201lS-24 - feio Rioloard Bladley To.do no vso que ficou derocrorreda a efetiva oidide di m.çio do aea. na oaa. co.aidoiodo qie O 88nosle pa aoconfl-se mentido na tesas da lo e. drinte da infoossaçio do Minfsodoio do TsbsIlro e Esrpsto. DEFIRO o Pedido do Proorogaçio do Estada no Pais alt 03/01/2011.- Ptocoso V 0O0l3032/200O-l3 . Minonu 1)0.0 e Tomoko Uo.o Toado osi vista que ficou das000asonda e efeiiv. oeeatdsde da masusooçio do anssgáso na empoa aaidaasdo que o n..e toauuido ri forma da lei e. diante da - pe afetomiçio do Mao do Trabalho e Easporgo. DEFIRO o Podido do Ptoorogaçio de Esteda no Pata itt 28/11/2010. - Pmenoo t t8tl&009034'2008-48 - flooea Paul time Baia Ccile Ddeootb Male Douret. Claroat J.eqoaa Mede DoereI No.oIsit LasSo Amea.e Mede 000,6 Ntuhis e Saoduisc Catamooa DoureI Noubin Tardo co visa. que fies.. ~trela. efetiva necessidade do isiroteoçlo do ataogelm 5. osspomt considerando que o pieaote aoeoss o.eoofra-ae hiat.ldo ri bossa da lei e, dnoOe da Sfausraçio do Mirisodijo do Trabalho e Emprego. DEFIRO o Pedido de Prereogaçio de Estada no Pais .58 22/01/0011. - Ps a° 080111.03337V2008.31 - Cbada CaoS Dwioo e tassoe MaS Bo.tlota -E - 08a0u264'2008-76 Peter Paula. Cliadin daik Pouna e Lotos P000ser Outrossim. iiotosssso que a mhiogdroi poe stgfr o disposto no AoL '23, XVI di Lá do Denodo 86.715/81. 48 Tando os vista que Soto.. dosoemuada da mastoaçio do coossipoiro na oroao. ao ocioso processo encosta-se irsualdo ri temi Introroaçio do Miointãio do Tesbilho e Empre1 do Prorropçlo de Estada os Pilo iii 07/01 08008/012723i2008-29 Rudiga Wostwoa e --G~ ~que a aoaogeira dovos na.jtades por irditargiro disposto a AoL 123, XVI da Lei 6.815/80 e/e Aat 6Z §13- do Decrat 86.715/81. Tardo ao vista que já deeaisos opino nqaaler ao da atada nohlcitsda, ~imo. ARQUIVAMENTO do Pedido de Pleerogiçlo do Estada no Pula-Procaso 0° 03097.002772)2008-lI - Estoban Mastro de Fruia ? - FERNANDA t SALDANILA DE AZEVEDO INDEFIRO o praias pedido de pamnanfeisa para o mil cicio! chiada QOAN 11), por tio la sido localizado no adoeço fresecido na turco. 0,55500 a oiciooil ttias HUANC Y1JXIN. deoassioo o ARQUIVAMENTU rendo ao vasta a perda do objeto.. Precato 0° (8503011191)2%4-lI . Qian lo Detamano o snpuivnmento do(s) praote(o) procasE(o). ia. do os vem o falecior.00qn de(s) rmpaamote(n). Procnoo P4' 08260.00095G'2006-89 . SsJv.dor Musa (3ailego MARIA ol.MA !I, DE MIRANDA ALVES Subilitoli Fia de diliginein procodida pelo Dqrato do Policia Fedaal. DEFIRO o proaute pedido de pa~ no que rouca. prendo pie o(s) atungeto(s) 'oras 5 poole benoleima rb ia guria e dqsadb.oa mcerãmica. nostúrdo-s social e aeeabrsaoe. Procoso N° 08241.35,2007-0l . C.nvo Sotia la Processo 74' 011387080289/0038-47- Hino Viooeim Rossatd FoosliS Precato P4' 08433.001739/2008-16. Matias tgroaclo Fiemira BInoiIb Poceato P4' 0S491007194fl007-76- Diata Cabulei FIleOcn FIielIa e Crus Boisia Coret Fossa Pro P4' 0R503009646)2H38-49 - Maio Piloy Ayala, Alma Doniela Ba.. Beta. Laia. alisto Wlardo Proc000 N° 0E303010838)2001-o6 - Felix Maio Mimaai Ana)m e I0rin. Soledad Rojuo Raia Procato N°08503.010844/20(8-35 - Evaisto R. Ceadai Tarmpsi e Baoolict Trqse Nocero 74° 05u503.01087D208843 - licitei Ramt Pioa Processo P4' u8505,010954)2001-17 - Ditoso Mas..i Orlia, Priroiuva Mimosa de Mitsui e Victor Mamas MamaS - - Processo P4' 08505.010989/2008-56- Alce Osigwe e lvlus, Eluwe Dikr P000ecio P4' 08305.013239/0088-36 - Robalo Cororul Fiorota e Horoetirida Cavala Pera Proonoo N5 0t305.0I333a/2-I9 - Ovidio Diet.a Sitia Zctrslloa e Eta MiaraS Samnioio Promo 10 083030108 14,2008.37 - Vieste 00050 Mmmii Qulsose, Alvaiso ~ii Mmmi Mamsni e relia taise MimaS Qumçe Procoso 14' 0003.02Ol2088-60 - 1.1 11 leso Poste. Clara Adelino Soarys Porte e Sylvie AndaS Rlaad Po.00e Potaso 740 oa303.02l0002008-a4 - Jnomiurg Hong e Ymgza 01 Procaso N° 08505024 103,2008-13 - AsaS lCsOla Condool. Fr Pralina Quo.alisoa PnDI e iowa! Eotnaa KalIa Queoullata Psoceauo N5 09503.023703t200a-26 - Y.00borg Ztom e Quaoyiog flis Precate P4' 08505026670/20011-42 - Rouasudo Hareru iran e Ssià Romolo Oretisa Flora Proavo 14' 08305.026742/2088-51 - listo!. Wang e S. 'is. 0P1 ! MINISTÉRIO DA JUSTIÇA SECRETARIA DE DIREITO ECONÔMICO DEPARTAMENTO DE PROTEÇÃO E DEFESA ECONÔMICA COORDENAÇÃO-GERAL DE CONTROLE DE MERCADO Nota sobre Pedido de Tratamento Confidencial Ato de Concentração n° 08012.00115712009-71 Requerentes: - PFIZER, INC. ("PFIZER") - WYETH (-WYETH") Consta dos autos pedido de tratamento confidencial de informações e/ou documentos. Em conformidade com os artigos 26 a 30 da Pbrtaria MJ no 4/2006, sugiro: r ___________(i) (X) o deferimento do pedido, com a aütuação em apartado confidencial dos seguintes dãüiüëiifdC ` - Versão confidencial do formulário Anexo 1, em relação aos itens 1.9, 111.1 e VI.!; - Cópia do Agreement and Plan ofMerger —item III.1 do formulário Anexo 1. documentos e informações descritos abaixo. As (ii) (X) o indeferiniento do pedido, referente 05 (cinco) dias, nova versão pública do Anexo 1 ,requerentes devem ser intimadas a apresentar da Resolução 15/98 do CADE. A versão púbi de informações percentuais deve ser apresentada em intervalos de 10 pontos percentuais. - Versão confidencial do formulário Anexo em relação ao item IV. 3; - Relação dos produtos comercializados pc PFIZER e pela WYETH no Brasil - item IV.3 do formulário Anexo 1 - Anexos 1 e II. À consideração superior. Brãsília4 de de 2009. PICCOLI L. CAVALCANTI Asses1ora Técnica M De acordo. Após a certificação nos autos, comunique-se às requerentes, à SEAE e ao CADE. Publique-se. 1 1 Brasília, de de 2009. RAYVI KUUSTQ1)E ABREU C. MADRUGA 11 Cooid6ador Geral MINISTERIO DA JUSTIÇA SECRETARIA DE DIREITO ECONÔMICO DEPARTAMENTO DE PROTEÇÃO E DEFESA ECONÔMICA DESPACHO DA COORDÉNADORA Em 20 de fvereiro de 2009 N°. 067. Ref. Ato de Concentração n°08012.001157/2009-71. Requerentes: Pfizer, Inc e Wyeth. Advs: José Inácio Gonzaga Franceschini e O?tros. Em conformidade com a Lei n° 8.884/94 e o Capítulo VIII da Portaria/Mi n°. 4, de 06 de janeiro de 2006, defiro, parcialmente, o pedido de tratamento confidencial solicitado. Intimen-se as Requerentes a cumprirem à diligência solicitada, no prazo de 05 (cinco) dias, nos )termos da nota técnica de fis. Dê-se ciência ao Conselho Administrativo de Defesa Econômica - CADE e a Secretaria de Acompanhamento Econômico - SEAE. Publique-se. VERA LÚCIA 11 Coordenadora Geral de S NARITA NUNES de de Mercado, Substituta RomiIdajt67SIClLO-DIL-PÇIZER X WYETH . 200209 ENVIADO A PUBLICAÇÃO r t-. iy 0 o MIN 'SECRETAR DEPARTAMENTO D Êsplanada dós Mnitérios Fone: 61.3223-3909/3. Oficio n` (116:1 STÉRIO DA JUSTIÇA A DE DIRLIT(.) FCO\Ô\IICO PRO FEÇÃO E DEFESA EC ONÔMJCA d. Sede -- 5° andar - Sala 552 - Cep: 70064-900 23-8916/3429-3396 - Fax: 6,1 3226-5772 L'UAB - : Brasília, de fevereiro de 2009 .Ao Senhor .ANTQNIO IIENRIQL 'E PINHEiRO SILVEIRA £ 1 ,Secretario de Acornpinharnento Lconõrnico do \linistério da Fazenda-SEÁE, Interino Ed. Sede. Bloco E. 3' andar - sala 324 70048-900 --Brasília,DF Assunto: Comunica Confidencialidat xl Senhor Secretário, JÁ Comunico a\10ss3 Sen oriao d Ç' ferirnento do pedido de tratamento confidencial referente ao Ato de Concentração n° 8012.001157/2009-71 em que figuramcorno requerentes asempresas Pfiier, Inc e Wveth. coni rme notd técnica em anexo. Atenciosamente,, VERA LUC NARITANtINES de Mercado, Substituta SEAE-SIGILO : - -c MIN 1Sf USTIÇA SECRETARIA DE Dl tEITO ECONÔMICO DEPARTAMENTO DE PROTE ;ÃO E DEFESA ECONÔMICA Esplanada dos Ministérios - Ed. Sede 5° andar — Sala 552— Cep: 70064-900 Fone: 61.3223-3909/3223-891 3429-3396 — Fax: 61.226-5772 Oficio n° 17 Z'c' /2009/CGCM/DPDEIGAB Brasília, c ') de fevereiro de 2009 Ao Senhor ARTHUR BADIN - Presidente do Conselho Setor Comercial Norte - Q. lfl - Projeção C Brasília/DF strativo de Defesa Econômica - CADE Assunto: Comunica Confidencialidade. Senhor Presidente, Comunico a Vossa Senhoria o dferimento do pedido de tratamento confidencial referente ao Ato de Concentração n° 08012.001157/2009-71, em que figuram como requerentes as empresas Pfizer, Inc e Wyeth, conforme notd'técnica em anexo. Atenciosamente, VERÁ LÚCIA PkgÍtÀS NARITA NUNES Coordenadora Geral de donkol e de Mercado, Substituta CADE-SIGIW 36 - Diário Oficial da 1ssx1677-704r2 SECRETARIA DE DIREITO ECONÓMICO DFSPACHOS DA SEM FÁRIA E. 19 do leveraro de 2000 P4' 97-Ato de Concentração 5' 080l2.037/2009-57. Requeretua: BHP liilhios Pio, Rio tinto Pie e Richardi Da7 Minerais e bise Ilorisce Innessrcenca 41 Limiled. Mvi: Dimane Lima Cominho e Ouimt Pelos principias da economia processual e da rflcilncis da Adminianaçio Publica. nos Iremos do (1' do antigo 50 da Lei 9.784/90, e lendo em viola o Teimo de Coopenaçio Técnrco-Openacional firmado entre a Psncwadoria do Cooaelina Adminiatisuivo de Defesa Ecotsimia es Secretina de Direito Ecoodoico e publicado no DOU, em 20 de aoslo de 2007. concordo com olmedo parecer da Secrelazuidc Acnnsponhienenro Económico, do Mpnlnitno da Fazenda. cujos termos pemaan. irma,rear essa decido, conto sua molivaçio. Opino, come- r Ii Seção 1 2003-ló. Ri~leirasMagathaese noma do Deaula Mtmee, sina razoes à es visa à oedem ecoE em sede dc Nt 104- Ptocmsinseoto Aàsiniitvioivs a' O presesnie: Unilever Bona ii Lida. Represesi dustiusleComercial Lide. Mvogadcs: Cano ouna Acolho alloeaTdcssicador fia., apre panainesno de ProteçIo e Defesa Ecoodanioi secos futcrono(I'doaet50,da Lei9.714/ presente dec~ iriclinin, como usa mooiv' denuncia em indEne nazi. indicio. minimo nimica, e com vistas a garantir o ano ema inclino de oficio, determino. lnat.aaraçlo e nos termos do artigo ilda Lei tI. 1.584/94. fundamentos e'poueo. na Moo Técnica eia Proocçio e Defesa Ecoodmira. emendo que dlcioadc irifraçini ordem económica toifitil Processe Adminialralívo. Por esse motivo. da presaste Aterigliaçio Preliminar, recortes Na 37, quanla-fcinu. 25 de fevereiro de 2009 SECRETARIA NACIONAL DE JUSTIÇA DEPARTAMENTO DE ESTRANGEIROS DIVISÃO DE PERMANÊNCIA DE ESTRANGEIROS DESPAChOS DO CHEFE • Tendo em 'sua que ficou dononiirsda efetiva necessidade da ntmulettçao do etasalgeiro na empina.. considerando qosopeesensa P0 I03-A.eslgas o? v'siiarit04OI2,0l0849r1005-i7. Repesnasiuuier MisSiuoPúUiendoEstedodeidfrasGaaklepe,meudo General Moina do lhiI Lida. Ata,: Lesoado Pausa da Roda e Silva e id C Ri- mos planam a in.ewn nua isentas, 500W asIa riintsvaçso. Up.Im coloeqiosleniente, sprovsçlo do pio, denSo mie processo na encaminhado ao Ceitelbo Admininleadvo de Defesa EconômicaCADE, em cumprimento ao disposto ao 5 6' do M. 54 da Lei 5,884/94. - P4' 100. Aio de Concentraçio 5' 0801201161/2001-73. Roque' fl: Bexosvoobil Marina LimltM e Esse Brasileira de Peorolso Limitada. Ata: loS Alexandre Doais Neto e Outros. Pelei peincipina da economia punocenual e da eficiência da Adasslnislnçao Pú. bIses, na lermos do Ir do aedgo SOda Lei 9.7141* e lendo em vista o lhano de Cooperado Técnico-Operacioral rimado mire. Procsndteia do Conselho Adminisarsflvo de Defesa Econômica e a Sectotaoia de Direito Económico e publicado no D.aU. em 20 de igeno de 2007. concordo com o imr do parecer da Secretatta de Aconçuebamessio Ecenérnico, do Miniauério da Fasenda, cujos terusa pintam a nsse asa decido, ma motins opino. coas lamente, alurovaçio do ano, devendo _ encaresabado ao Conaelho Adminiasraeivo dc Defesae CADE, um esaispiunento ao dlaposao no 5 6' do L 54 da IS - r,ner - P0 101 Ato da Cooceoaraclo nu 0i012.00006112004-16. RemsaresIna: Lubeizol Advancrd Material,, Inc e lhe Doar Chemical Cotapanyd. tIo Aacaat de Antiasde e On/0os, Pelos pri~ da ecoeicmla processual e da eficidocia da Adoniniutraçao Pública, nos lermos do 5' do amigo 50 da Lei 9.784/99, e tendo em vista o Termo de Cooperas Tdcstico-Opeoacional firmado ente a Pato.' ratais do Conselho Admlniaurativo de Defesa econõmica e a secrelarla de Direito Econômico e publicado no D'O_o, em 10 de agonio de 2007, cnocoido com o teor do patecer da Secretsrii de Acompasbansenio leondirico, do Ministério da Fs,xsda. csajna termoa passam a integrar esta decisão. conto sua moliveçao. Opino. conaseqaenlesnmsr, pela nprosnaç5o do sto, devendo este processo ter escanhado ao Conselho Administrativo de Defesa Eeooõn,ica CADE, em cuntproasserito ao disposto no * 6' do aro. 54 da i.ei 5884/94. - P4' 102' Ato de Conceuirsçiã n' OiOIl.000231,2009-32. Roquenotar Desusuult Avigion SÃ, Alcaaet.Lsaceio e Tbaleu S.A. Advu: elMo Ei Plol. Regia. PenomietIo Pugtiene Amar.l de Pelos princlsioe da ecascosia processual e da efi. cidnciasAdmiuütaçaoPúb)ica,noalennoadolrdoauigosoda Lei 9.784/99, e senda ens vises o Termo de Coepesaçio Técnico. Opmacionul firmado asic. a Pnocusadooia do Conselho Adousuiuuadvo de Defesa Econdessica e a Seana.ia de Direito bcenãn,ico publicado ao IXO.U. as 20 de agosto de 2007. «ffiOrd0 cm o t. do parecer da Secretas de A ipasbamenlo Econômico, do Mininsério da Fazenxis, estio. aeemoa us a ir.tegn-tr essa decido, conto atas moslvts Opino, aIo, devendo esie processe ser encaminhado ao tatuo da Defesa Lcondmica CADE, em cumprisnsenio ao disposto no IS' do art. 54 da Lei 8.084°94. . co0ae0Ientaseoie.rdo - - N' 103 Ano de Concrmtrsçio a' 0I0I2.000799/1009.53. Reqiie' rentes: Flore.nsl 26 de Novembro' Flnoestnmento e Reflorestamento Ltd... Florestal ltupirattge Fliresurmenlo, e Reflorestar.tenio Lida, e Muita Sà , Adva: Tão AmaraS do Andrsde e Outrou. Pelos pote' clpiia de economis processual e da eficiência da Admmninorruçlo Pibltes, no. ta.. do * P do artigo 50 da Lei 9.784/99. e tendo em vista o Termo do Coopençeo Tecniro-Operacional formado cena a Procuradoria do co.lho Adminuauaiivn de Defesa Econômica es Seesuiria de Direito Ececismico r publicado no DOU, em 20 de agosto de 2007, ceescoedo com o leor do parecer da Secresaoia de Acomspaslsmessto Econdenico, do Minioiério da Fazenda, cujna ter, atos psa.ams a isíegrar nau. decido como sua moeivaçio. Opino, cnnneqiossenamoe, pela aprovado do aio, devendo este poscaro ser encaminhado ao Conselho Adrnisian.tivo de Defesa Econômica CADE, em cunweimmmo ao disposto no5 V do agi. 34 da Lei 1.584'94, - MARIANA TAVARES DE ARAWO 1 DESPACHO DO CHEFE DE GABINETE Em 2/Ide faveoeiro de 2000 - N'IS Determlnoa divulgaçio doaae8iuinueaatea dc concenuriçioeconómica prneocoladoa nos teimo. do ato. 5414 Lei t5.814/04e do sri. 3 da poep,e3p e' 5/p'JSDE: AÇ a' 010t2,001236/2000.12. Rqla: EVIALIS DO BRASIL NUTRIÇAO ANIMAL LTDA. ('EVIALIS') e MALTA CLrnON DO ORASIL SÃ. ('MALTA'). Operaçao: aquiniçio, EVIALIS, de parte do capalal ,ocial da MALTA. O setor de atividade envolvido na operaçiol Psoãkia e Ptoduçao Aniul Raçom.r - - • AC 01o12.no1321/2009.41. Rqtean COMPANHIA DE PARtiCIPA' ÇÕES EM CONCESSÕES ('CPCl, BRISA, PARTICIPAÇÕES E EMPREENDIMEN7tS LTDA.CBRlSA' CARLOS SEABRA SUAREZ, ABIGAILSILVASUAREZ,ISABELASILVASUAREZ,Ai4APAULA SUAREZ e GABRIEL SILVA SUABEZ, Operação: aquisiçio, 'CPC'CBRISA'de, ieapedivaanenie.50%dasaçãaadinisiasr 100% dnsçtesprefaenclaSdocsesãaisocsldamNlROLkts.&rContro- - é°nç°'is DIEGO FALECE DEPARTAMENTO DE PROTEÇÃO E DEFESA ECONÓMICA COORDENAÇÃO-GERAL DE CONTROLE DE MERCADO DESPACOtOS DA COoRDrNDORA-cERAL Em 19 de fevereiro do 2009 ti, 1,064- Alo de Conceniraçio a' 001I2.091079/2®9.13. Requennleu Proteger Brasil S.A Tnnsponadors de Velame Segurança. Prosegsr Siaiernas de Segurança Lada, Ccniúns Sinsenusu de Segurança Ilda e Cmir/u-ia Coendrrio e Serniçm Ltd. Advt: liso Amsrul da Andrade e (Miou. Em conformidade roma Lei nf 8.884/94 e o Capliulo VIII da Ponarl&Wt4.de%dajaneirodaltoô,defwoopedtdodeníaínrstoconfldcttcialaolicilsdo. - - - P65' Ato de Caacenlraçto ir 00012.07I020/2009-17. Raquertuler Prosegor Tecnologia em Sistema, do Segursnçs Eletrônica. Iscindio Lidae SeiS Indústria Eleutaica Lida Ad,,: lua Mninsl da Psadrade a Outros. Etas conformidade com a Lei a' 5184/04 ao Capltsalo VIII da PooiarMi5'4,de00dejanekodo20Q&defkoopedldodev.w confidmeal aolicitado. es P66' Ato de Corsotauraçio ir 00012.00106/2009-40. Requerentes: Uniln Brasil Lida e Mucolo Broehers Limitará. Ad,,: José Inicio Oottzaga Franaschimi e Outros. Em coaifomiidade coes a Lei nt 1.814,94 ao Capitulo VIII da Poeaaoialsej n. 4. do 06 de Janeiro de 2006, defirso pedidode tratamento coalidencial nolicitada, Em 20 de fevereiro de 2009 ti P067- Ato de Concentração n' 08012.001157/2009-71. Requerenter PArir, Inc. Wyeüt. Advs: José Inicio Gonaga Fmncerchini e Outros, Em conformidada com a Lei a' 8.884/94 e o Capitulo VIII da Portariw3liít4,daoidejaneirodell0ó, defino, psrcsaknenie,npcdidode lrstansenno confidencial solicitado. lnlimsm-ie si Requerentes a cumprirem à diligdscta totícttida, no peno da 05 (cinco) dias, nos latinos da nota técnica de A. VERA LÚCIA PRI'flASNARITANUNFS Subslil.uis -_ pçao na EMana no raia alt UjRflt2iflY.' moo 0461000742/200-8. Miolsel Senos Boftgtoan Tendo em tinia que ficou dasaonasrade a efetiva caem .unaiéetnçio do estrangeiro na empeca, coauidcoando qsm o processo encontra-se inatruldo na faina da lei e.diante da tal do Miniaidolo do Trabalho e Empren DEFIRO o Pedido 4 gaçio de Estada no Pais alI 22104'20t1.- Pron OIala,000843/200I-94 Teodnlo Drilon Ajanre TeSoemvj.'j que ficou demssdaaefaiva manntentçao do eaintogcÍro na empresa, considerando que o processo ot,conln-,e instwdo na foenia dalei e, diante de liii do Ministério do Trabalho e Emprego, DEHRO o Pedido 4 gaçlo de Estada no Pais ind 30/06/2009.' Pato I1000.009443/200842 Tom Seque Dela Cruz Tendo em vlsi. que ficou demosaimdaaefetiva necea InSiulenÇiO do estrangeiro na empresa, considerando que o processo encontra-se n'traido na forma da lei e, diante da mi do Ministério do Trabalho e Emprego. DEFIRO o Pedido do gado de Estada no Pais and 09/1012010.. Pron 000l5.005469/2008'13 -GeoegeTurntbull 'bem vias. pie ficou demonstrada a efetiva meca manutenção do eltrnagrno na empresa, conaiderando nua, o processo enconline innstsuldona ranina da lei e, dianseda iii do Mit/elO do Trabalho e Emprego. DEFIRO o Pedido do gafe de Estada co Pais até 05/10/2010.- Pino 01000.0126l91200a.34 Mauayisid Fulosenara Tendo em viela que Sena demoesiradaaefellva ueca marnoleraçio do esbangeieo na empresa, considerando que o processo meantes-se ivalnsaldo na forma da lei e, diaasse da IS do Ministério do Trabalho e Emprego, DEFIRO o Pedido di gaçio de Estada no Psiu até 20/11/2010,- Prec' 01018.009115/2001-48 Jsoatbsn CortezSuganob Tendo em vista que flceudcmooniradaaefetivanecar ssanuurmçlo do estrangeiro na empeesa, muulderarsio que o processo erscnolra-ae intimido na forma da lei e, dias. da mi do Mhuisnétlo do Trabalho e Emprego. DEFIRO o Pedido di g,çb° de Esísda no Pata sol 13/03/2010.- Pino 08000.01485/2001-34 Brian Frsncis Donohoe Tendo em viola que ficou demcoslrtdaaefctiva neces manutençio do estrangeiro na empresa, coanldarando que o procesaoenconhrn.eetnuuwdonaformsdalele,dianledainl M Ministério do Trabalho e Emprego, DEFIRO o Pedido di Estada no Pala até 26/09/2009.- Pino g•fe o8000.006247/2008.I5- Cari Flensing Slefan leigos Tendo em viste que ficou demonstrada a efetiva necas menuiençio do estrangeiro na empaasa, considerando que o processo encontra-se insizuldo na fama da lei e, dinnte da ml doMininnésiodoTrabalboeEmprego,DEFtROoPedldodi gsçao de rasada no Pais ali 26/98/2009.- Fruo 0l0lS.009.03/200&13. DssyIl Buemavidez Viatavilia Temdoemvistaquc rídoiandaaernivaonca ma.esençao do easasgesuo na empinas. considetando que o pIocaloIts-te mesozsaldo Isa faina da lei, diaaíe da lã do Misiatdgio do Trab.sho e Emprego, DEFIRO o Pedido da gaflo de Essas no Pala and 18/024011.. Pesca 01013.005467/2008-24 - Jeeom Harmen Modernas Temdoemvssia que ficou demoosuada .cfetivn linces maniateoçao do essosaigetro na empress, corelderando que o processoencoutia-te mnsuruldo na foomada lei e, diante da iii do Ministério de Trabalho e Emprego, DEFIRO o Pedido do gaç5o de Estada no Pala até 28/11/2009.' Feto 01280.02915I02007.37'RamonNooaioAnoyaveciraldo Tendo em viam que ficou doncatttsada a efetiva meca manuienfo do esarangelro na em considerando que o processo rncastra.ae lmtnaldi na da lei e, diante da lei do Ministério do Trabalho e Empregn, DEFIRO o Pedido do gaçao de estada no Pele ind 26/11/2010.- I'mnn 08011.009693/2001-84 - Gerbard Clemens Devenier . . - - FRANCËSCHINI e MIRANDA Advogados 1 José Inácio Gonzaga Franceschini Custodio da Piedade U. Miranda Fernando Eduardo F. Ferreira -Thays R. Martins Fontes Moreira José Alberto Gonçalves da Moita Giannl Nunes 08 Araujo Ana Carolina Pinto Couri Paulo Messias Pedrassoli Waiter Basilio Bacco Júnior Camila Castanho Girardi Sandra Gomes Esteves Maria Eu gênia Dei Nero Poietti Camila Pimentei Porto Dona Fiávia Maria Peiliciari Cristhiane Helena Lopes Ferrero André Pissolito Campos Clâudla Nastari Capanema MarcosPaulo Amorim Patricia Bandouk Carvalho Av Brig. Feia Lima, 1451-13° anda- São Paulo. SP -01. Tal. + 5511 3095-2566-Fax: • 5511 3813.9693 sv-ftne*n-advoqadosn.& - - SECRETARIA DE DEFESA ECONÔMICA SDE DEPARTAMENTO DE PROTEÇÃO E DEFESA ECO - DPDE- -- --- SDEJGAB/CAPRO Coordensçlo de Apele Processual MikIlCTrPlfl flA II ITIflA ' ''' • ' IIIIIlIIIIlIIIlIlIIIttIIIIIIIIIIIIIIII 11111 III Iliflulil UlI 11111111 IIIUIlII 1111 b 08012.001360/2009-48 ! Ato de Concentração n°08012.001157/200971 1. WYETH, empresa devidamente qualificada nos Ato de Concentração em referência, er que também é Requerente PFIZER, vem, respeitosamente, por seus advogados, requerer a retificação e conseqüente substituição das informações constante°s dos itens 1.1 B e 1.4 do Anexo 1, de 13 de fevereiro de 2009, nos termos que segdem: lnformase1i em relação ao item 1.1, que o Representante Legâldá WYETH é o se!nhor Aryeh Friedman. e No tocante à informação prestada no item 14, informase que a--WYETH tem suas ações negociadas na Bolsã de Valores de Nova lorque e encontram-se pulverizadas, não sendo controlada, em última instância, por qualquer pessoa jurídica ou indivíduo. E Por fim, protesta-se pela posterior juntada do A Procesisual instrumento de mandato, para os devidos fins de direito. Junb3-e. SS8,jjc)2/dr Termos em que, Pede beferimento, De São Paulo para Brasília, 20 de fevereiro de 20 Pp._ José OAB/SP n° 28.711 coordenador CGSIIDPDEISDEJMJ Camila Castanho Girardi OAB/SP n° 175.500 9,2 OAB/bF n° 26.634 ) li FRANGESÇHINI e MIRANDA Advogados José Inácio Gonzaga Franceschini Custodio da Piedade U. Miranda Fernando Eduardo F. Ferreira Thays R. Martins Fontes Moreira José Alberto Gonçalves da Motta Gianni Nunes de Araujo Ana Carolina Pinto Couri Paulo Messias Podrassoli Walter Basilio Bacco Júnior Camila Castanho Girardi Sandra Gomos Esteves Maria Eugênia Dei Neto Poletti Camila Pimentel Porto Dona Flávia Maria Pelilciari Cristhiane Helena Lopes Ferreno André Pissohto Campos Cláudia Nastari Capanema Marcos Paulo Amonim Patricia Bandouk Carvalho / SECRETARIA DE Av, Brig. Faria Lima, 1461-13' andar- São Paulo - SP - 01480-900 're11L + 5511 3095-2566 - Fax + 5511 3613-9693 adv-!meh1l-ad'oQadoS. com .br ECONÔMICA - SDE II -. DEPARTAMENTO DE PROTEÇAO E DEFESA ECONOMICA 1VL7CAPRJ - DPDE Coardrn.çto de Apoio Procenu.l MINISTÉRIO DA /UsTIÇA - MJ 08C12.001561/2009.45 Ato de Concentração n° 08012.001157I2009-71 Recebido em_c 3__Vlas Servidor / PFIZER, INC. e WYETH, devidamente qualificadas nos autos do Ato de Concentração em referência, por seus advogados, vêm, respeitosamente, em 3 (três) vis, requerer a juntada das anexas cópias dos instrumentos de mandato por elàs outorgados, bem como o envio de uma via 11 para o CADE e outra para a SEAE, para os devidos fins de direito. ,-% jai fl9 a /Termos em que, •Pedem Deferimento, De São Pauto para Brasília, 02 de Março de 2009. ga pwjÂiigustoA.C. / CGSUDPDE!SDEIM.J PFIZER, INC. WYETH II II Pp._ — José Inácio OAB/SP ne 28.711 / Pp. Camila Castanho Girardi OABISP n° 175.500 dia Nastari Capanema OABIDF n° 26.634 E: PROCURAÇÃO POWER OF ATÜORNEY • meio do presente instrumento particular, a presa PFIZER, INC., (doravante designada torgante), constituída e existente conforme as de Delaware, com escritôrio-sede em 235 KNOW ALL MEN B"( THESE PRESENTS that PFIZER, INC., a corporation duly organlsed and validly existing under the laws of Delaware and having its principal place of buslness in 235 East t 42 Street, Nova iorque (NY) 10017, EUA, rieia e constitui seus bastantes procuradores Srs.: 42 Street, New York (NY) 10017, EUA, hereby appoints and constitutes its attomeys: 0 José Inácio Gonzaga Franceschlni, Custodio da Piedade U. Miranda, Camila Pimentel Porto Dona Giannl Nunes de Araujo, Càmila Castanho Girardi, Cristhlane Helena Lopes Ferrero CPFIMF 160.105.278-21, CPFÍMF 254.527.028-81, CPF!MF 221.923.918-70, 28.711, 22.122, OABISP OAB/SP 172.50013, OABISP 130.569, OABISP 175.500, OABISP 252.787, Marcos Paulo Amorim Claudia Nastari Cananema Patrícia Bandouk Carvalho CPF)MF 038.713.756-40. CPF!MF 296.416.146-86. CPFIMF 329.289.728-97 OAB/SP OAB/SP OAB/SP ali Brazilian citizens, attomeys-at-law, members of the iàw firm FRANCESCHINI E MIRANDA-ADVOGADOS, registered witfl Brazilian Bar Association, Seccion São Paulo, under no 2143, with offices aí Av. Brigadeiro Faria Lima, 1461, 1 Sth. floor, São Paulo, State of São Paulo, Brazil, Zip Code 01451-904, granting the forenanied Grantees, on behalf and stead of me Grantor, joint and severally, regardless of the appointment order, ali spedal powers to represent me Grantor's interests in ali and any administrativa proceedings, inciuding acts of concentratiori, before the Brazilian Secretariat of Economic Controi (Secretaria de Acompanhamento Econômico - SEAE), of me Ministiy of Finance, me Secretariat of Economic Law (Secretaria de Direito Econômico - SDE) and its Department of Economic Protection and Deferice (Departamento de Proteção e Defesa Econômica - DPDE), of the Ministry of Justice, and the Administrativa Council for Economic Defence (Conselho Administrativo de Defesa Econômica CADE), the Grantees beíng further empowered to CPFÍMF 197426.148-49, CPF(MF 346.147.538-68, CPFIMF 277.153.008-29, OABISP 202.543, 26.634. 281.994 brasileiros, todos advogados e integrantes do escritório FRANCESCHINI E MIRANDA ADVOGADOS, sociedade inscrita na Ordem dos Advogados do Brasil, Secção de São Paulo, sob 2143, com escritório à Av. Brigadeiro Faria Lima, no 1461, 130 andar - Torre Sul, CEP 01451904, São Paulo, Capital, outorgando-lhes todos os poderes contidos na Cláusula Ad Judicia et Extra, para o fim de, em conjunto ou separadamente, independentemente da ordem de nomeação, defenderem os direitos e interesses da OUTORGANTE em qualquer Procedimento, Processo Sindicância, Averiguação, ir ' Administrativo ou Ato de Concentração perante a Secretaria de Acompanhamento Económico SEAE, do Ministério da Fazenda, Secretaria de Direito Econômico - SDE ou seu Departamento de Proteção e Defesa Econômica (DPDE), do Ministério da Justiça, e o Egrégio Conselho Administrativo de Defesa Econômica . CADE; podendo, ainda, tomar ciência de despachos, prestar declarações, receber contatos e notificações e todos os demais atos judiciais ou 4- ' 1" jJ\ conipromise and to receive notifications, to follow up said procÕedings, to cornply wlth requests of and to subi information to such cornpefltion euthorities, to acknowledge opinions of the mentioned proceeding, and decisions of and orders from CADE, to have access to the relevant records, to subgrant powers and, in general, to do ali acts necessary to the fulfilment of the present and specially to represei Lhe Grantor on the submission of the transaction which involves PFIZER and WYETH through Administrative Council of Economic Defence CADE. São Paulo, Februa 20',2009 Marc Brotman PFIZER, INC. extrajudiciais que se fizerem necessários para o firme e valioso cumprimento deste instrumento realizar o particular de mandato, acompanhamento processual dos mencionados inclusive Administrativos; e Frocessos substabelecer, no todo ou em parte, especificando no respectivo Instrumento os poderes substabelecidos, e, especialmente, para representar a OUTORGANTE na submissão ao Conselho Administrativo de Direito da Concorrência - CADE do Ato de Concentração nvolendo a PFIZER, INC., e a empresa ãoO de Fevefeiro Marc Brotrnan PFIZER, INC. 4,. "0. PROCURAÇÃO POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS that WYETH, a corporation duly organised and Validly existing under the laws of DELAWARE and • Por meio do presente instrumento particular, a mprésa WYETH, (doravante designada Outorgante), constituída e existente conforme as 11 having its principal place of business in NEW eis DELAWARE, possuindo seu escritório-sede 11 pm NEW JERSEY, nomeia e constitui seus JERSEY, hereby appoints and constitutes its bastantes procuradores os Srs.: attorneys: José Inácio Gonzaga Franceschini, Custodio da Piedade U. Miranda, Camila Pimentel Porto Dona CPF/MF 197.426.148-49, OAB/SP 28.711, CPFMF 346.147.538-68, OAB/SP 22.122, CPFMF 277.153.008-29, OAB/SP 172.50013, Glannl Nunes de Araujo, CPFIMF 160.105.278-21, OAB/SP 130.569, Camila Castanho Girardi, OAB/SP 175.500, ÔPF!MF 221.923.918-70, OAB/SP 252.787, Crlsthlane Helena Lopes Ferrero Marcos Paulo Amorim Claudia Nastani Capanema Patrícia Bandouk Carvalho CPF/MF 254.527.028-81, CPF)'MF 038.713.756-40, OAB/SP 202.543. CPFIMF 296.416.148-86. OAB/SP 26.634. CPF/MF 329.289.728-97 OAB/SP 281.994 ali Brazilian citizens, attorneys-at-law, mernbers brasileiros, todos advogados e integrantes do of the law firm FRANCESCHJNI E MIRANDA-- Lcritório FRANCESCHINI E MIRANDA. ADVOGADOS, registered with Brazilian Bar ADVOGADOS, sociedade inscrita na Ordem dos Association, Seccion São Paulo, under n° 2143, Advogados do Brasil, Secção de São Paulo, sob with offices ai Av. Brigadeiro Faria Lima, 1461, I nO 2143, com escritório à Av. Brigadeiro Faria 1 3th. floor, São Paulo, State of São Paulo, Brazil, Zip Code 01451-904, granting the forenamed Lima, n°1461, 13° andar - Torre Sul, CEP 01451904, São Paulo, Capital, outorgando-lhes todos os poderes contidos na Cláusula Ad Judicia et Grantees, on behalf and stead of the Grantor, joint and severally, regardless of the appointment Extra, para o fim de, em conjunto ou order, ali special powers to represent file :separadamente, independentemente da ordem de Grantor's interests in ali and any administrative nomeação, defenderem os direitos e interesses proceedings, inciuding acts of concentration, da OUTORGANTE em qualquer Procedimento, Sindicância, Averiguação, Processo Administrativo ou Ato de Concentração perante a Secretaria de Acompanhamento Econômico - before the Brazilian Secretariat of Economic Control (Secretaria de Acompanhamento Econômico - SEAE), of the Ministry of Finance, the Secretariat of Economic Law (Secretaria de ÉAE, do Ministério da Fazenda, Secretaria de Direito Econõmico - SDE) and its Department of Protection Economic and Deíence Direito Econômico - SDE ou seu Departamento (Departamento de Proteção e Defesa Econômica - DPDE), of the Ministry of Justice, and the Adrninistrative Councfl for Economic Defence (Conselho Administrativo de Defesa Econômica CADE), lhe Grantees being further ernpowered to e Proteção e Defesa Econômica (DPDE), do Ministério da Justiça, e o Egrégio Conselho Administrativo de Defesa Econômica - CADE; podendo, ainda, tomar ciência de despachos, prestar declarações, receber contatos e notificações e todos os demais atos judiciais ou •- ------ J• ÇC ; ir compromise and to receive notifications. to follow etrajudiciais que se fizerem necessários para o up said proceedings, to comply with requesta of and to submit information to such cornpetition authorities, to ackno'Medge opinions of the mentioned proceedirig, and decisions of and firme e valioso cumprimento deste instrumento particular mandato, realizar o yocessos Administrativos; e inclusive substabelecer, no todo ou em parte, especificando no respectivo instrumento os general, to do ali acts necessary to Lhe futfilment doderes substabelecidos, e, especialmente, para of Lhe present and specially to rõpresent Lhe Grantor on Lhe submission of Lhe transaction which involves PLEASE INFORM and PLEASE epresentar a OUTORGANTE na submissão ao Economic Defence - CADE. Conselho Administrativo de Direito da Concorrência - CADE do Ato de Concentração envolvendo a FAVOR INFORMAR e a empresa FAVOR INFORMAR 1 ,aJ.4-a h de acompanhamento processual dos mencionados orders trom CADE, to have access to lhe relevant records, to subgrant powers and, in INFORM through Administrativa Council ai - . Location and Date e Data Coilegeville, PA, USA February 20, 2009 / i MINISTÉRIO DA JUSTIÇA SECRETARIA DE DIREITO ECONÔMICO GABINETE DO SECRETÁRIO OFÍCIO N*3?5 /2009/SDE/GAB Brasília, 03 de março de 2009. A Sua Senhoria o Senhor ARTLIURBADIN Presidente do Conselho Administrativo de Defesa Econômica Ministério da Justiça Brasília — DF 4 - -. Senhor Presidente, De ordem, encaminho a V. Sa. doc..a1en ção de interesse da empresa PFIZER, INC rPFIZER" E WYETH ("W7VETH"), referente ao Ato de Concentração n° 08012.001157/2009-71. Atenciosamente, REGINA Ct Chefe do AZEVEDO - Ministério da Justiça -Bloco T - 50 andar -sala 538 -0 Fone: 613321-780013321!'8195 - e-mail: sdeíhnj.ov.br MINISTÉRIO DA JUSTIÇA SECRETARIA DE DIREITO ECONÔMICO GABINETE DO SECRETÁRIO OFÍCIO N° W AR 3R 6 /2009ISDE/GAB Brasília, 03 de março de 2009. A Sua Senhoria o Senhor ANTÔNIO HENRIQUE PINHEIRO SILVEIRA Secretário de Acompanhamento Econômico Ministério da Fazenda Ed. Sede, Bloco "P", 3 ° andar, sala 324 70048-900 - BRASÍLIAJDF RECEBIDO às(érdOhr Em 03 : O)) 05 Senhor Secretário De ordem, encaminho a PFIZER, INC ("PFIZER") E WYETH ( 08012.001157/2009-71. Sa. documentação de interesse da empresa 'ETH"), referente ao Ato de Concentração n° Atenciosamente, REGINA CÉLIA AZEVEDO Chefe do Prol as Ministério dá Fone: 61 3321 0TU 50 andar ~ sala 538— Cep: 70064-900 - Brasília-DF 195—e-mail: sde)mi.ov.br SOE FRANCESÇHINI e MIRANDA José Inâclo Gonzaga Franceschini Custodio da Piedade U. Miranda Fernando Eduardo E. Ferreira Thays R. Martins Fontes Moreira José Alberto Gonçalves da Moita Gianni Nunes de Araujo Ana Carolina Pinto Couri Paulo Messias Pedrassoli Walter Basilio Bacco Júnior Camila Castanho Girardi Sandra Comes Esteves Maria Eugênia Dei Nero Poletti Camila Pirnentel Porto Dona Flávia Maria Pelliciari Cristhiane Helena Lopes Ferreiro André Pissolito Campos Cláudia Nastari Capanema Marcos Paulo Amorim Patricia Bandouk Carvalho Av, Brig. Faria Lima, 1461-13' andar- São Paulo SP - 01480-900 Tal: + 5511 3095-2566 - Fax: + 5511 3813-9693 adv-fmefm-aôooãdOs.c1, br ECONÔMICA - SDE SECRETARIA DE DEPARTAMENTO - DPDE o PROTEÇÃO E DEFESA ECONÔMICA VGIRO CoordeniçiO de Apoio Procr,suai MINISTÉRIO DA JU ID HI tINI 11111 WIfl 11111 I I I 08012.001562/2009.90 Ato de Concentração n°08012.001 ri Recebido en,.._-21.—' Servidor PFIZER, INC. [e WYETH, devidamente qualificadas nos autos do Ato de Concentração em referência, por seus advogados, vêm, respeitosamente, em atenção ao Despacho n° 67, publicado no Diário Oficial da União, de 25 de fevereiro de 2009, informar que deixa de submeter nova versão pública do Anexo 1, diante do indeferimento parcial do pedido de confidencialidade formulado na Inicial, tendo em vista que o conteúdo do item -lV.3 encontra-se disponível versão públiáa já apresentada e os Anexos 1 e II são documentos independentes, de sorte que igualmente poderão ser utilizados para compor o volume público dos autos. A Termos em que, Pedem Deferimento tz 888, °"cc), g'52 De São Paulo para Brasília, 2 de março de 2009. Coordenador /7 CGSWDPDEIs{Jfr' -1'52' —yPFIZER, INC. Pp. _—, Jqs-IuâioGonz_a'í Franceschini OAB/SP n° 28.711 Camila Castanho Girard OAB/SP n° 175.500 1 MINISTÉRIO, DA JUSTIÇA SECRETARIA DE DIREITO ECONÔMICO GABINETE DO SECRETÁRIO OFÍCIO W j /2009/SDE/GAB Brasília, 03 de março de 2009. A Sua Senhoria o Senhor ARTHUR BADIN Presidente do Conselho Administrativo de Ministério da Justiça Brasília - DF Econômica - -a-',- - CADE/MJ 08700.000814/2009_1 3 Senhor Presidente, De ordem, encaminho a Vli Sa. documentação de interesse da empresa PFIZER, INC ("PFIZER") E WYETH ("WYETH"), referente ao Ato de Concentração n° 08012.001157/2009-71. Atenciosamente, REGINA Cf Chefe do AZEVEDO Esplanada dos Ministérios -'- Ministério da Justiça - Bloco T _5° andar— sala 538— Ccp: 70064-900 - Brasília-DF Fone; 61 3321-7800/3321-8195 - e-mail: sde(ámi.2ov.br !lt 1 Ma. Jf L ai? e MINtStÉR1) DA JUSTIÇA SECRETARIA DE DIREITO ECONÔMICO GABINETE 6o SECRETÁRIO OFÍCIO N-293 12009/SDE/GAB Brasília, 03 de março de 2009. o, A Sua Senhoria o Senhor ANTÔNIO HENRIQUE PINHEIRO SILVEIRA Secretário de Acompanhamento Econômico Ministério da Fazenda Ed. Sede, Bloco "P", 3 ° andar, sala 324 70048-900 - BRASÍLIA/DF RECESIDO às /tdhr Em&/jjO9 Senhor Secretário Fone: 61 3321-7800/3321-8195 - e-mail: sdecmj.govbr - 7 MINISTÉRIO DA JUSTIÇA SECRETARIA DE DIREITO ECONÔMICO GABINETE DÓ SECRETÁRIO 51- /2009ISDE/GAB OFICIO N°J ? ¶ A Sua Senhoria o Senhor Arthur Badin Presidente do Conselho Administrativo de Ministério da Justiça Brasília - DF Brasília, 12 de março de 2009. ;sa Econômica CADE/MJ 08700.00100012009-98 Senhor Presidente, De ordem, encaminho a V. Sa. documentação de interesse das empresas. PFIZER, INC. ("PFIZER"), referente ao Ato' de Concentração n°08012.001157/2009-71. Atenciosamente, 69 La FRANCECHINI eMIRA'4DA dvogados José Inácio Gonzaga Franceschini Custodio da Piedade U. Miranda Fernando Eduardo F. Ferreira Thays R. Martins Fontes Moreira José Alberto Gonçalves da Motta Gianni Nunes de Araujo Ana Carolina Pinto Couri Paulo Messias Pedrassoli Walter Basilio Bacco Júnior Camila Castanho Girardi Sandra Gomes Esteves Maria Eugênia Dei Nero Poletti Camila Pimentel Porto Dona Flávia Maria Pelliciari Cristhiane Helena Lopes Ferrero André Pissolito Campos Ciãudia Nastari Capanema Marcos Paulo Amorim Patricia Bandouk Carvalho 4 Av, Bnig. Faria Lima. 1461-13' andâr- São Paulo -5 TaL: + 5511 3095-2568 - Fax: + 5511 381: sdv4mhn-advooados. com br SECRETARIA DE DEFESA ECONÔMICA - SDE DEPARTAMENTO DE PROTEÇÃO E DEFESA ECONOMICA - DPDE Vias Recebido MINISTÉRIO DA JUSTIÇA - MJ Ser clor YW Ato de Concentração! n° 08012.001157/2009-71 -SDvG/cAPRo - coordenaçto da Apoio Proceooual lfl Uli lUI I I lI I Jli fllHI I IlI 08012,001800/2009-67 PFIZER, INC.,' devidamente7jDliticada nos autoso Ato de Concentração em referência, em que também é interessada WYETH, por seus advogados, vem, respeitosamentJ, em 3 (três) vias, requerer, para os devidos fins de direito, a juntada de 01 (uma) via original e 02 (duas) vias autenticadas do comprovante de reáolhimentõ da Taxa Processual de Apresentação de Ato de Concentração, nos termos da Lei n.° 9.781, de 19 de janeiro de 1999. Termos em que, requerendo dessa d. SDE o envio da via autenticada à d. SEAE e a original aoE. CADE. Pede Juntada e Deferimento, De São Paulo pára Brasília, 11 de março de 2009. INC. aga Franceschini n°28.711 n Camila Castanho Girardi OAB/SP n° 175.500 - A Procesgaj Claudia NastiriCapanema RavvtAilwío A. C. Madruga coordenador CGSUDPDE!SDW 1 Ii e 4, i C6digo de Recolhimento - MINISTÉRIO DA FAZENDA 14500-9 Ndmero de Referência 1 SECRETARIADO TESOURO NACIONAL Competência Guia de Recolhimento da União - GRU 0212009 Vencimento 12/0212009 Nome do Contribuinte / Recolhedor: Francoschini e Miranda Advogados CNPJ ou CPF do Contribuinte Nome da Unidade Favorecida: CONSELHO ADMINISTRATIVO DE DEFESA ECONOMICA UG (Gestão 68.314.343(0001-54 303001 /30211 Valor do Principal Instruções: As informações inseridas nessa guia são de exclusiva responsabilidade do contribuinte, que deverá, em caso de dúvidas, consultar a Unidade Favorecida dos recursos. 45.000,00 (-) Desconto/Abatimento (-)Outras deduções Mora / Multa GRU SIMPLES Pagamento exclusivo no Banco do Brasil S.A. [STNFFD7144BB5CE4D4B5BEFB7FC1 2816AB0] (+5 Juros/Encargos (5 Outros Acréscimos - Valor Total - -.,& 45.000 89990000450-9 00000001 01 0-3 955231 61 450-5 00453523008-0 111111111111111111 1111111 1- 1 j/02/2009 - D'ANGU DO BRASII\ - \ 14:58:38 0450 - '- COMPROVANTE DE PAGAMENTOS COM COO BARRA - Convento GRU-CUIA RECOLHhI UMIAO 899900004509 00000001010-3 Codiqo de Barras 00453523008-0 95523ib1450-5 t 10/02/2009 Data do pagamento 1 NRO de Referencia 02/2009 Competencia MM/AAAA 12/02/2009 Bata de Vencimento 68314343/0001-64:- .& ' ÇNPJ 45 000,00 Valor Principal 45000,00 " Valor Total NR AIJTEIITICACÃO O F5A 487 275 F71 F9E -J---- 001 FRANCESCHINI e ML Av. Bng Faria Lima 1461 - 13o andar- São Paulo. SP -01 Tal.. • 5511 3095.2566. Fax: • 5511 3613-9693 adv-fntfrn-advoaados cornbr José Inácio Gonzaga Franceschini Custodio da Piedade U. Miranda Fernando Eduardo F Ferreira Thays R Martins Fontes Moreira José Alberto Gonçalves da Motia Ana Carolina Pinto Couri Paulo Messias Pedrassoli Walier Basilio Bacco Júnior Camila Castanho Girardi Maria Eugénia Dei Nero Polelti Camila Pimentel Porto Corja Flávia Mana Pelticiari Crislhiane Helena Lopes Ferrero André Pissolito Campos Cláudia Nastari Capanema Marcos Paulo Amorim Patricia Bandouk Carvalho SECRETARIA DE DEFESA ECONÓMICA - SDE DEPARTAMENTO DE PROTEÇÃO E DEFESA ECONÔMICA 1 SDEJGAB:CÁPRO - DPDE Coordeniçio de Apoio Proce,rtal J MINISTÉRIO DA JUSTIÇA - MJ 08012001990/200912 APENASVERSAO PUBLICA Ato de Concentração n° 08012.00115712009-71 Recebid mG? Vias ar! WYETH, devidamente qualificada nos autos do Ato de Concentração em referência, em que também é Requerente PFIZER, INC, por seus advogados, vem, respeitosamjnte, em 3 (três) vias, requerer, para os devidos fins de direito, a juntada da cópia autenticada do instrumento de mandato por ela outorgado. § Termos em que, requerendo dessa d. SDE o envio de 1 (uma) via à d. SEAE e 1 (uma) ao E. COIDE. Pede Juntada e Deferimento, De São Paulo para Brasília, 16 de março de 2009. _—t7 WYETH Pp. Joseinacio Gopzaga Franceschini C.. OAB/SP n° 28.711 L. IL.y Cristhiane Helena Lopes Ferrero OAB/SP n° 252.787-SP Camila Castanho Girardi OAB/SP 175.500 P.p.________________________ 1 Claudiã Nastari Capnema OAB/DF n° 26.634 A Prcc*nt jrt 4 Jt!! it3t.4 o Auiusto4. C. mmga cá a23 o:-- POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS WYETH, a corporation duly organised and validly Por meio do presente instrumento partictitaa empresa WYETH, (doravante designada existing under the laws of DELAWARE and Outorgante), constituída e existente conforme as leis DELAWARE, possuindo seu escritório-sede having its principal place of business in NEW em NEW JERSEY, nomeia e constitui seus JERSEY, hereby appoints and constitutes its bastantes procuradores os Srs.: attorneys: José Inácio Gonzaga Franceschini, Custodio da Piedade U. Miranda, CPF/MF 197.426.148-49, CPF/MF 346.147.538-68, OAB/SP 28.711, OABISP 22,122, Camila Pimentel Porto Dona CPFJMF 277.153.008-29, OAB/SP 172.500B, Cianni Nunes do Araujo, CPF/MF 160.105.278-21, OABISP 130.569, Camila Castanho Girardi, CPF/MF 254.527,028-81, OAB/SP 175.500, Cristhiane Helena Lopes Ferrero CPF/MF 221.923.918-70, OABISP 252.787, Marcos Paulo Amorim CPF/MF 038.713.756-40. OAB/SP 202.543. Claudia Nastari Cananema CPF/MF 296.416.148-86. OABISP 26.634. Patrícia Bandouk Carvalho CPF/MF 329.289.728-97 OABISP 281.994 ali Brazilian citizens, attorneys-at-law, diembers of the law firm FRANCESCHINI E MIRANDA - brasileiros, todos advogados e integrantes do escritório FRANCESCHINI E MIRANDA - ADVOGADOS, registered with Brazilian Bar ADVOGADOS, sociedade inscrita na Ordem dos Association, Seccion São Paulo, under n° 2143, with offices at Av. Brigadeiro Faria Lima, 1461, Advogados do Brasil, Secção de São Paulo, sob ri0 2143, com escritório à Av. Brigadeiro Faria Lima, n°1461, 130 andar - Torre Sul, CEP 01451- 1 3th. floor, São Paulo, State of São Paulo, Brazil, Zip Code 01451-904, granting the forenarned Grantees, on behalf and stead of the Grantor, joint and severally, regardless of the appointm&nt 904, São Paulo, Capital, outorgando-lhes todos os poderes contidos na Cláusula Ad Judicia et Extra, para o fim de, em conjunto ou order, ali special powers to represent the Grantors interests in ali and any administrative separadamente, independentemente da ordem de proceedings, including acts of concentration, da OUTORGANTE em qualquer Procedimento, Sindicância, Averiguação, Processo Administrativo ou Ato de Concentração perante a before the Brazilian Secretariat of Econo4ilc Control (Secretaria de AcompanhameÇto Econômico - SEAE), of the Ministry of Finan6, the Secretarial: of Economic Law (Secretaria de Direito Econômico - SDE) and its Departmenof Economic Protection and Defence (Departamento de Proteção e Defesa Econômca - DPDE), of the Ministry of Justice, and the Administrativa Council for Economic Defence nomeação, defenderem os direitos e interesses Secretaria de Acompanhamento Econômico SEAE, do Ministério da Fazenda, Secretaria de Direito Econômico - SDE ou seu Departamento de Proteção e Defesa Econômica (DPDE), do Ministério da Justiça, e o Egrégio Conselho Administrativo de Defesa Econômica - CADE; (Conselho Administrativo de Defesa Econômija - podendo, ainda, tomar ciência de despachos, prestar declarações, receber contatos e CADE), the Grantees being further empowered to notificqcãep todos os demais atos judiciais ou esta rs,vj jÇQÃo/0l) 3817700 compromise and to receive notifications, to foflow extrajudiciais que se fizerem necessárksra up said proceedings, to comply with requests of firme e valioso cumprimento deste insiruti3'' and to submit information to such competition particular mandato, realizar —ÔIO authorities, to acknowiedge opinions of the acompanhamento processual dos mencionados mentioned proceeding, and decisions of and Processos Administrativos; e inclusive orders from CADE, to have access to the substabelecer, no todo ou em parte, relevant records, to subgrant powers and, in especificando no respectivo instrumento os general, to do ali acts necessary to the fulfilnent poderes substabelecidos, e, especialmente, para of lhe present and specially to represent the representar a OUTORGANTE na submissão ao Grantor on lhe submission of the transaction Conselho Administrativo de Direito da whjch invoives PLEASE INFORM and PLEASE Concorrência - CADE do Ato de Concentração INFORM lhrough Adminir""' Economic Defence - CADE. Location and Date Coliegeville, PA, USA February 20, 2009 ÇÁ - de AR e a empresa MINISTÉRIO DA JUSTIÇA SECRETARIA DE DÍRÉITO ECONÔMICO GABINETE DO SECRETÁRIO OFÍCIO N° 2/67 /2009/SDE/GAB Brasília, 18 de março de 2009. A Sua Senhoria o Senhor ANTÔNIO HENRIQUE PINHEIRO SILVEIRA Secretário de Acompanhamento Econômico Ministério da Fazenda Ed. Sede, Bloco 'P", 30 andar, sala 324 70048-900 - BRASÍLIA/DF MF/SEAE ASS RECEBI O ORIGINAL hs Em/ti os aí Senhor Secretário De ordem, encaminho a V. Sa. documentação de interesse das empresas, =TH. ("~TH"), referente ao Ato de Concentração n°08012.001157/2009-71. Atenciosamentc REGINA Chefe Esplanada dos Ministérios - Ministério da Justiça - Bloco T —5° andar - sala 538— Cep: 70064-900 - Brasília-DF Fone: 613321-790013321-8195 - e-mail: sde(mj.2ov,bT a a 087 CAD 00001 MINISTÉRIO DA JUSTIÇA SECRETARIA DE DIREITO ECONÔMICO GABINETE DO SECRETÁRIO OFÍCIO N°'1 /2009/SDE/GAB Brasffia, 18 de março de 2009. r.. A Sua Senhoria o Senhor Arthur Badin Presidente do Conselho Administrativo de Ministério da Justiça Brasília - DF o Econômica LI Senhor Presidente, De ordem, encaminho a V. WYETH. ("WYETH"), referente ao Ato de C documentação de interesse das empresas, rntração n°08012.001157/2009-71. Atenciosamente, REGINA CÉL DE OLIVEIRA AZEVEDO Chefe do Esplanada dos Ministério da Justiça —Bloco T— 50 andar— sala 538— Ccp: 70064-900 -Brasília-DF Fone: 61 3321-7800/3321-8195 - e-mail: sdeami.2ov.br FIs.j JUSTIÇA [O ECONÔMICO MINISTÉRIO SECRETARIA DE E DEFESA ECONÔMICA DEPARTAMENTO DE o Referência n" oOS-0eJ153 /o- 7i Partes: [INFOR)%AR A ARTE QUE REPRESENTA, SE APLICÁVEL] 11 Solicitante: [NOME / DOCUMENTO DE IDENTIFICAÇÃO] Volume dos autos: ..F&iJJflA_o ti Ç€tt}fltl2 [N° DO VOLUME FLS.] Brasília (DF), em &93 de 1 [ASSINATURA] _de 2009 M00P/Pf10TO AUÇADt) NO MtLS FRANCESCHINI e MIRAt4DA Advogados José Inácio Gonzaga Franceschinl Custodio da Piedade U. Miranda Fernando Eduardo F. Ferreira Thays R. Marfins Fontes Moreira José Alberto Gonçalves da Moita Gianni Nunes de Araujo Ana Carolina Pinto Couri Paulo Messias Pedrassoli Walter Basilio Bacco Júnior Camila Castanho Girardi Sandra Comes Esteves Maria Eugênia Dei Nero Poletti Camila Pimenlel Porto Dona Flávia Maria Petticiari Cristhiane Helena Lopes Ferrero André Pissolito Campos Cláudia Nastani Capanema Marcos Paulo Amonim Patricia Bandoulç Carvalho Av. Brig, Faria Lima, 1461— 13' andar- São Pa11- SP: Tal.: +5511 3095-2566-Fax: +5511 31 C SECRETARIA DE DEFESA ECONOMICA - SDE DEPARTAMENTO DE PROTEÇÃO E DEFESA ECONÔMICA -DPbÉ MINIStÉRIO DA JUSTIÇA - MJ AProcSY" APENAS VERSAO.PÚBUCm o) / a Râvvi usIoA.0 Coordénador-Geral DPDEJ$DEIMJ Í! 1 Ato de Concentração n° 0801200115712009-71 9 SDOAB/CAPRO - E) O A0 -ja: .0 oordlfltÇ110 de Apoto ?rOCtlIUhl o801 2.00223012009-22 1 451 PFIZER, INC (doravante designada "?FIZER"), devidamente qualificada nos autos do Ato de Concentração em referência, em que também é Requerente WYETH, porseus advogados que esta subscrevem, vem, respeitosamente, para os devidos fins de direito, em 3 (três) vias, requerer a juntada dos seguintes documentos: (1) tradução para o vernáculo do CONTRATO E PLANO DE INCORPORAÇÃO ("Merger Agreehient"), bem como do respectivo Termo de Responsabilidade firmado pela tradutora; e 1 Protesta-se pela posterior juntada da tradução juramentada, caso entendam os órgãos do SBDC ser esta necessária. s - —--rC- SZ flÀNèEscrnNI eMIRANDA Advnoadti (ii) cópia jautenticâda do instrumento de mandato outorgádo pelaPFlZER; Termos em que; requerendo dessa d. SDE o envio de .1 (urna) viaà d. SEAE é 1(úma) ao ECADE. Pede Juntada 4D?ferimento, be Sãõ Pàulo para Brasília, 26 de março de 2009. IZERJ; INC. WYETH P. José Inácio Gonzaga Franceschini OAB/SP n° 28.711 Pp.— Cristhiane Helena topes Ferrero OAB/SP n° 252.787-SP • P.. Camila Castanho Girardi OAB/SP 175.500 aets Claudia Nastari Capanema OAB/DF no 26.634 2 -- —: L FIs,,..3 PROCURAÇÃO POWER OF ATFORNEY KNOW ALL MEN 6V THESE PRESENTS that PFIZER, INC., a corporation duly organised and validly existing under the laws of Delaware and having its principal place of business in 235 East Por meio do presente instrumento particuIar,'a. empresa PFIZER, INC., (doravante designada Outorgante), constituída e existente conforme as leis de Delaware, com escritório-sede em 235 42 Street, New York (NY) 10017, EUA, hereby East 42 Street, Nova lorque (NY) 10017, EUA, nomeia e constitui seus bastantes procuradores appoints and constitutes its attorneys: os Srs.: José Inácio Gonzaga Franceschini, Custodio da Piedade U. Miranda, Camila.Pimentel Porto Dona Gianni Nunes de Araujo, Camila Castanho Girardi, Cristhiane Helena Lopes Ferrero CPF/MF 197.426.148-49, CPF/MF 346.147.538-68, CPF/MF 277.153.008-29, CPF/MF 160.105.278-21, CPF/MF 254.527.028-81, CPF/MF 221.923.918-70, OAB/SP 28.711, OABISP 22.122, OAB/SP 172.500121, OAB/SP 130.569, OAB/SP 175.500, OAB/SP 252.787, Marcos Paulo Amorim Claudia Nastari Cananema Patrícia Bandouk Carvalho CPF/MF 038.713.756-40. CPF/MF 296.416.148-86. CPF/MF 329.289.728-97 OAB/SP OAB/SP OAB/SP 202.543. 26.634. 281.994 ali Brazilian citizens, attorneys-at-law, members of the law firm FRANCESCHINI E MIRANDA - brasileiros, todos advogados e integrantes do escritório FRANCESCHINI E MIRANDA - ADVOGADOS, registered with Brazilian Bar ADVOGADOS, sociedade inscrita na Ordem dos Association, Seccion São Paulo, under n° 2143, Advogados do Brasil, Secção de São Paulo, sob with offices aí Av. Brigadeiro Faria Lima, 1461, n° 2143, com escritório à Av. Brigadeiro Fária 13th. floor, São Paulo, State of São Paulo, Brazil, Lima, n° 1461, 130 andar - Torre Sul, CEP 01451904, São Paulo, Capital, outorgando-lhes todos Zip Code 01451-904, granting the forenamed Grantees, on behalf and stead of the Grantor, joint and severally, regardless of the appointment os poderes contidos na Cláusula Ad Judicia et order, ali special powers to represent the separadamente, independentemente da ordem de Grantor's interests in ali and any administrative nomeação, defendérem os direitos e interesses proceedings, ihcluding acts of concentration, da OUTORGANTE em qualquer Procedimento, before the Brazilian Secretariat of Economic Control (Secretaria de Acompanhamento Sindicância, Econômico - SEAE), of the Ministry of Financé, the Secretariat of Economic Law (Secretaria de Direito Econômico - SDE) and its Department of Economic Protection LDeTnc t ' and (Departamento de Proteção e DeMsaEèonômica - DPDE), o! the Ministry o! Justice, and the Administrativa Council for Economic Defence (Conselho Administrativo de Defesa Econômica CADE)[the Grantees being further empowered to Extra, para o fim de, em conjunto ou Averiguação, Processo Administrativo ou Ato dê Concentração perante a Secretaria de Acompanhamento Econômico SEAE, do Ministério da Fazenda, Secretaria de Direito Econômico - SDE ou seu Departamento de Proteção e Defesa Econômica (DPDE), do c compromise and to receive notifications, to follow extrajudiciais que se fizerem necessários para up said proceedings, to comply with requests of firme e valioso cumprimento deste inshentl mandato, realizar '—e de particular and to submit information to such competition authorities, to acknowIedge opinions of the mentioned proceeding, and decisions of and acompanhamento processual dos mencionados inclusive Administrativos; e Processos orders from CADE, to have access to the retevant records, to subgrant powers and, in substabelecer, no todo ou em parte, general, to do ali acts necessary to the fulfilment of the present and specially to represent the poderes substabelecidos, e, especialmente, para Grantor on the submission of the transadtion Conselho Administrativo de Direito da which involves PFIZER and WYETH through Administrative Council of Economic Defence — Concorrência — CADE do Ato de Concentração envolvendo a PFIZER, INC., e a empresa CADE. WYETH. São Pauto, ua 2O 9 especificando no respectivo instrumento os representar a OUTORGANTE na submissão ao São Pgujg,Q0 de Fev iro de 009 -. Marc Brotman Marc Brotman PFIZER, INC. MADÂ[h:A. PINHEIROS urna. 7' pio, (II) 3816.7700 IlTEflçAç, Esa cópia expedida P0I - dite com o crginai. Dou M. MAR 2009 por -e (EL. O24í Termo de'Responsabilidade Nara Maria Salomão Ribeiro, portadora de cédula de identidade e 5.880.888-7, inscritd no CPF sob o n" 029.221.548-74, residente e domiciliada na cidade de São Paulo, estado de São Paulo, atesta, para fins de comprovação 'perante o Conselho Administrativo de Defesa Econômica - CADE, qdè a presente tradução, de sua lavra, reproduz, na sua integridade e com total fidelidade, o conteúdo de documento original que a acompanha, concebido em idioma estrangeiro. Reconhece, ademais, estar plenamente ciente das conseqüências deste ato, inclusive quanto às sanções aplicáveis, sejam de caráter administrativo, sejam de índole criminal. São Paulo, 19 dè março de 2009 Nara Maná Sâlomão Ribeiro Nome e assinatura do résponsável pela tradução MINISTÉRIO DA JUSTIÇA SECRETARIA DE DIREITO ECONÔMICO GABINETE DÓ SECRETÁRIO OFÍCIO N0335L4 /2009/SDE/GAB Brasília, 27 de março de 2009. A Sua Senhoria o Senhor ANTÔNIO HENRIQUE PINHEIRO SIL Secretário de Acompanhamento Econômico Ministério da Fazenda Ed. Sede, Bloco "P", 3' andar, sala 324 70048-900 - BRASÍLIA!DF Senhor Secretário De ordem, encaminho a V. Sa. documentação de interesse da empresa, PFIZER, INC ("PFIZER"), referente ao Ato Concentração n°08012.001157/2009-71. Atenciosamente, REGINA CË Chefe do AZEVEDO RECEBI O C 4bL Em j-03— Esplanada dos Ministérios - Ministério da Justiça - Bloco T — 50 andar -sala 538 — Ci Fone: 613321-7800/3321-8195 - e-mail: sdemi.eov.br Brasília-DF t CADE/MJ 1p SECRETARIA DE 78. P3700.001193/2 ,j..._. DAJUSTIÇZ. tEITO ECONÔMICO SECRETÁRIO OFICIO N°S65 /2009/SDEIGAE Brasília, 27 de março de 2009. A Sua Senhoria o Senhor ARTIIURBADIN Presidente do Conselho Administrativo de Defesa Econômica Ministério da Justiça Brasília DF - Senhor Presidente, De ordem, encaminho a V. USa. documentação de interesse da empr PFIZER, INC ("PFIZER"), referente ao Ato de Concentração n°08012.001157/2009-71. Atenciosamente, REGINA CÉL4I$tËVOLIVEIRA AZEVEDO Chefe do PT'otocololProcessual/SDE Esplanada dos Ministérios - Ministério da Justiça~ Bloco 9-5° andar -sala 538— Cep: 70064-900 - Brasília-DF Fone: 61 3321-7800/3321-8195 - e-mail: sdeCrni.gov.br r -Y MINISTERIO DA JUSTIÇA SECRETARIA DE DIREITO ECONÔMICO GABINETE 1*) SECRETÁRIO 2 OFÍCIO N',9(-, Brasília, 25 de fevereiro de 2009. A Sua Senhoria o Senhor ANTÔNIO HENRIQUE PINHEIRO SILVEIRA Secretário de Acompanhamento Econômico Ministério da Fazenda Ed. Sede, Bloco "P", 3 ° andar, sala 324 70048-900 - BRASÍLIA/DF Senhor Secretário De ordem, encaminho a V. Sa. documentação de interesse das empresas WYETH e PFIZER, INC., referente ao Ato de Concentração n°08012.001157/2009-71. Atenciosamente, AZEVEDO • MINISTÉRIO DA JUSTIÇA SECRETARIA DE DÏREITO ECONÔMICO GABINETE DO SECRETÁRIO OFÍCIO N° 3 ((j /2009ISDE/GAB Brasilia, 25 de fevereiro de 2009. A Sua Senhoria o Senhor ARTIIUR BADIN Presidente do Conselho Administrativo de Defesa Econômica Ministério da Justiça Brasília - DF Senhor Presidente, De ordem, encaminho a V. Sa. documentação de interesse das empresas - WYETH e PFIZER, INC., referente ao Ato de Concentração n9 08012.001157/2009-71. Atenciosament( REGINA CEUA DE OLIVEIRA AZEVEDO .Chefe do Protocolo/Processual/SOE Esplanada dos Ministérios -Ministério da Justiça -Bloco T -5' andar— sala 538— Cep: 70064-900 - Brasília-DF FRANCESCHIN]I e MIRANDA Advcados José inácio Gonzaga Franceschini Custodio da Piedade U. Miranda Fernando Eduardo F. Ferreira Thays R. Martins Fontes Moreira José Alberto Gonçalves da Motia Paulo Messias Pedrassoli Walter Basilio Bacco Júnior Camila Castanho Girardi Sandra Gomes Estoves Maria Eugênia Dei Nem Poietti Camila Pimentel Porto Daria Flávia Maria Pelliciari Cristhiane Helena Lopes Ferrero André Pissolito Campos Dávio Antonio Prado Zarzana Renata S. Tormim Av. Biig.Fana Una 1461 _j3'asar.Toq Sul . São Paulo .$P-01451-9O4 Tel.: + 5511 3095-2566 - Fax: + 5511 3613-9693 adv-fnefm-advad.nbr COORDENAÇÃO-GERAL DE CONTROLE DE ESTRUTURA DE MERCADOS COGCE p SECRETARIA DE ACOMPANHAMENTO ECONÔMICO SEAE A p,JU1t9ÉRIO DAFAZENDA - MF Jun3-se s RawiAugusto& C. Coordeirador-Gerl da SDVGABIC*pRo Ato de ConcentraçaEi78O12.001157I2 Coordeniçio de Apoio Proce,sg.j I I11111111111111111111111 08012.005I3958 PFIZER, INC. e autos do Ato de Coticentração em E advogados, requerer a juntada do anexo direito, requerendo-se, ademais, o envic apresentados à d. SDE e ao E. CADE. ETH, devidamente qualificadas nos vêm, respeitosamente, por seus belecimento, para os devidos fins de J rmos em que, dem DeferimE De São .\1 / o Rio e Janeiro, 02 Camila ho Girardi 175.500 julho de 2009. -_ - - FRANCESCEINI fi MIRANDA Advogados José Inácio Gonzaga Franceschini Custodio da Piedade U. Miranda Fernando Eduardo F. Ferreira Thays R. Mal-Uns Fontes Moreira José Alberto Gonçalves da Motia Paulo Messias Pedrassoli Walter Basilio Bacco Júnior Camila Castanho Girardi Sandra Comes Esteves Maria Eugênia Dei Nero Polelti Camila Pimenlel Porto Daria Flávia Maria Peiliciari Cristhiane Helena Lopes Ferrero André Pissolito Campos Dávio Antonio Prado Zarzana Renata S. Tormim andar-Tcfte Sul - São Paulo - SP - 01451-904 Ai. B,ig. Feia Lina 1461.13Tel.: + 5511 3095-2566 - Fax. +5511 3813-9693 adv-frS5fm-advodOSm.br - COORDENAÇÃO-GERAL DE CONTROLE DE ESTRUTURA Ir DE MERCADOS - COGCE - SECRETARIA DE ACOMPANHAMENTO ECONOMICO SEAE II ~ÈÜO DA FAZENDA - MF A Fiffi § ' t- Jufl -Se. ___ ENASVERSAO PUBLICA1 re RawtAugustokC.Mad Coordenador-Geral da Z'G/CRO Ato de Concentraç&tRflO8O12.001157i2OO9-7l Coord.nçja de Apoia Procosuti IøhII lihItiI I I I Ii itifti i (I I li! 0801 1005130/200958 PFIZER, INC. ei WYETH, devidamente qualificadas nos autos. do Ato de Concentração em epígrafe, vêm, respeitosamente, por seus advogados, requerer a juntada do anexo S!jbstabelecimento, para os devidos fins de direito, requerendo-se, ademais, o en' apresentados à d. SDE e ao E. CAbE. irmos em que, em DefõrimE De São Pàulo/para o'Rio 02 n Camila iho Girardi 175.500 julho de 2009. Cl SUBSTAB ..ECIMENTO ti Substabeleço, com reserva de iguai para mim, na pessoa da advogada RENATA SEMIN TÕRMIN, CPF/MF 25.894.668-97, OAB/SP n.° 235.664, integrante do escritório FRANCESI HINI E MIRANDA - ADVOGADOS, sociedade inscrita na Ordem dos / Ivogados do Brasil, Secção de São Paulo, sob n° 2143, com escritório li calizado na cidade de São Paulo/SP, Av. Brigadeiro Faria Lima no 1461, 13 andar - Torre Sul, os poderes que me foram conferidos por PFIZER, INC e WYETH, nos autos do Ato de Concentração n° 08012.001157/200 -71, em, trâmite perante o Sistema Brasileiro de Defesa da Concorrênc a - SBDC, para os devidos fins de direito. De São FauIo para o Rio de CamiI Castánho Gira OA/SP h° 175.500 a. de julho de 2009. MINISTERIO DA JUSTIÇA SECREAR1A DE MRZrrO ECONÓMICO li DEPAILTAMINTO DE PROTEÇÃO E DEFESA ECONÓMICA s 1P9J a. A PARTE QUE REPRESENTA SE APLICÁVEL] (NOME / DOCUMENTO DE Volume dos amos: x JjfrM.O ti [N DO VOLUME / ÉL S.] 1 Bmsfluz (DF), em de [ASSINATURA] De ordem, defiro conforme Em; • MINISTÉRIO DA JUSTIÇA - — Leiie de Fur da CGPj - SECRETARIA DE DIREITO ECONÔMICO -- De ordem, defiro conforme solicitado. Em, -1f 2009 e MINISTÉRIO DA JUSTIÇA 11 SECRETARIA DE DIREITO ECONÔMICO Secretaria de Direito Econômico DPDE Ministério da Justiça Referência - 08012.001157/2009-71 Requerentá: Akzo por seu representante legal abaixo assinado, vérn a presençâde Voêsa Ser requerer. Cópia das flsts nn4q. (preenchimento obrigatórIo) Nestes termos pede Deferimento Procuração: Brasltiá-DF, 14 de Julho 2009 José Alberto Gonçalves da Motta (Nome do representante legal por xtenso e de forma legível) Fone: 3327-65-41 OAB: II4DF 1: (Assinatura) PARA O - Justificativa: Vafoc-R$ Deferido N° de Folhas: Requerente: N° de •Wtor. R$ 2009 RECIBO gkrO DE PROTEÇÂÕ E DEFESA ECONÔMICA DA SECRETARIA DE DIREITO ECONÔMICO o cÓPIAnoSaUTo5 E] CARGA DOS AUTOS Brasllla-DP 07 de 2009 de __ (Assinatura) ATENÇÃO: O prazo de carga dos processos é de 24 (vinte e quatro) De ordem, defiro conforme solicitado. - - - - 1 à MINISTÉRIO DA JUSTIÇA li SECRETARIA DE DIREITO ECONÔMICO Secretaria de Direito Econômico DPDE Ministério da Justiça 08012.00115712009-71 Referência Requerente: Akzo por seu representante legal abaixo assinado, vem a presença de Vossa Senhoria requerer: Cópia das - - -- r03L( C (preenchimento obrigatório) Nestes termos pede Deferimento Procuração: Brasília-DF, 14 de Julho de i 2009 José Alberto Gonçalves da Motta (Nome do representante legal por extenso e de forma legivel) Fone: 3327-65-41 OAB: I14DF - (Assinatura) INFORMAÇÕES PARA O RECOLHIMENTO DA GRU Deferido N° de Folhas: Jütificativa: Valor R$ ROVANT,EDE\RECOLHIMENTO DO VALOR RELATIVO À EXTRAÇÃO DE Requerente: No de' T VÁ ~R o r: $ Vt RECIBO id:2OO9 "TO DE PROTEÇÃO E DEFESA ECONÔMICA DA SECRETARIA DE DIREITO ECONÔMICO E] COPIAS-DOS AUTOS D CARGA DOS AUTOS Brasllia-DF L 5 de __ de 2009 (Assinatura) ATENÇÃO: O prazo de carga doa processos é de 24 (vinte e quatro) De ordem, defiro conforme solicitado. E . Q 2009 , //a4JgjduedeF0fl; MINISTÉRIO DA JUSTIÇA da COM SECRETARIA DE DIREITO ECONÔMICO Secretaria de Direito Econômico DPDE Ministério da Justiça - ( Referência - 08012.1157/2009-71 U Requerente: André Alencar Porto por seu representante legal abaixo assinado, vem a presença de Vossa Senhoria requerer: cópia integral da versão pública dO4n/ 4 (preenchimento obrigatório) Nestes termos pede Deferimento 1 Procuração: Brasllia-DF, 24 de 2009 Setembro dei André Alencar Porto (Nome do representante legal por lextenso e de forma legível) Fone: 32022825 OAB: DF 25103 (Assihatura) INFORMAÇÕES PARA O RECOLHIMENTO DA CRU Deferido N° de Folhas: Justificativa: Valor. R$ COMPROVANTE DE RECOLHIMENTO DO VALOR RELATIVO À EXTRAÇÃO DE CÓPIAS Ç Requerente: ________ Valor. R$ fr 1 /f 4 Servidor RECI DO E] COPIAS TOS o CARGA AUTOS Brasllia-DF, ATENÇÃO: \ t2 O( Bsb, em b / de 2009 RTAMENTO DE PROTEÇÃO E DEFESA ECONóMICA DA SECRETARIA DE DIREITO ECONóMICO cot de ___________ de 2009 O prazo de carga dos processos é de 24 (vi j te e quatro) MN1STÉffltYDkJ1JSTIÇA SECRETARIA DE DIREITO ECONÔMICO DEPARTAMENTO DE PROTEÇÂÓ E DEFESA ECONÔMICA REGISTRO DE VISTA DÉ AUTOS PÚBLICOS Referência n° Partes: A PARTE QUE A, SE APLICÁVEL) DE Volume dos autos:. 10 (N° DO VOLUME/FLS) ;rí1iC@F),ern 2 de 5 ALSSINATUIRA) de 2010 FRANCESCHINI e MIRANDà José inácio Gonzaga Franceschini Custodio da Piedade li. Miranda Fernando Eduardo F. Ferreira Thays R. Martins Fontes Moreira José Alberto Gonçalves da Motta Paulo Messias Pedrassoli Walter Basilio Bacco Júnior Sandra Gomes Esteves Maria Eugênia Dei Nero Poletti Flávia Maria Pelilciari Cristhiane Helena Lopes Ferrero André Pissoiito Campos Renata S. Torn,in Hannali Manuela Galvão Pereira Regis Coppini Meireles de Lima Av. Brig. Fada Lima, 1461 -lYandw TeL .5511 3095-2566 sctamefm.advQoados wm br Jj DE DEPARTAMENTO ECONÔMICA DPDE PROTEÇÃO E DEFESA - SECRETARIA DE DIREITO ECONÔMICO SDE Recebido em--& - MINISTÉRIO DAJUSTIÇA—MJ L PENASVERSÂO PÚBLICR - SDE/GAB/CAPRO CoordtniÇtO de Apoio Proce,iUtI Ato de Concentração n.° 08012.001157/2009-71 08012.002663/2011-01 Pfizer, Inc. por seus advogados que esta subscrevem, devidamente qualificada nos autos do Ato de Concentração em epígrafe, vem, respeitosamente, requerer a juntada dos inclusos Instrumentos de Renúncias, para os devidos fins de direito. Requer-se sejam' as respectivas vias remetidas à d. Secrõtaria de Acompanhamento Econômico Administrativo de Defesa Econômica CADE. - SEAE e ao E. Conselho - A Processual. Junte-se BSB_LLJ.JJL Termos em que, Pede juntada e deferimento. Luis CLaditIma Pinhelryj Subsbhjto De São Paulo para Brasília; 15 de fevereiro de INC. Pp. José Inácio Gonzaga Franceschini OAB/SP 28.711 PP- AU-A IA J4Q~Mo Hannah Manuela Galvão Pereira OAB/SP 297.613 e RENUNCIA Eu, CAMILA PIMENTEL PORTO DORIA, inscrita na Ordem dos Advogados da Brasil sob o n.° 172.500 e no CPF/MF sob o n.° 277.153.008-29, por intermédio do presente ato venho apresentar RENUNCIA, nós termos do artigo 45 do Código de Processo Civil, aos poderes que me foram outorgados pela empresa Pfizer, Inc para atuar em seu nome perante o Sistema Brasileiro de Defesa da Concorrência - SBDC, em especiàl no Ato de Concentração n° 08012.001157/2009-71. Em face da existência de outros procuradores, faz-se desnecessár a notificação da mandante, bem como a continuidade da repre ntação pelo prazo de dez dias, previstos no artigo 45 do Código de kocesso Civil. Sãà Paulo, 14 de janeiro de 2011. a Camila PimentelPorto Dona OAB/SP n.° 172.500 RENUNCIA 0 Eu, CAMILA CASTANHO GIRARDI, inscrita na Ordem dos Advogados do Brasil sob o n;° 175.500 e no CPF/MF sob o n.° 254.527.028-81, por intermédio do presente ato venho apresentar RENUNCIA, nos termos do artigo 45 do Código de Processo Civil, aos poderes que me foram outorgpdos pela empresa Pfizer, Inc. para atuar em seu nome perante o Sistema Brasileiro de Defesa da Concorrência - SBDC, em especiàl no Ato de Concentração n° 08012.001157/2009-71. Em face procuradores, faz-se desne bem como a continuidade da previstos no artig da existência de outros i a notificação da mandante, ntãção pelo prazo de dez dias, MINISTERIO DA JUSTIÇA SECRETARIA DE DIREITO ECONÔMICO GABINETE DO SECRETÁRIO OFÍCIO N° )si 1_ /2011/SDE/GAB Brasília, 04 de março de 2011. A Sua Senhoria o Senhor ANTÔNIO HENRIQUE PINHEIRO o MA D) Íf41 Secretário de Acompanhamento Econômico Ministério da Fazenda Ed. Sede, Bloco "P", 3 ° andar, sala 324 70048-900 - BRASILLAJDF SE.AJM Senhor Secretário De ordem, encaminho a V versão pública, de interesse da empresa 08012.001157/2009-71. gh Documentação de n° 08012.002663/2011-01, R, INC. referente ao Ato de Concentração n° Atenciosamente, JONAS IYELNIÃN BIS1tO]Y OTJ Chefe do Pr4oc6IoIProcessuaI/SDE MINISTÉRIO DA JUSTIÇA SECRETARIA DE DIREITO ECONÔMICO GABINETE DO SECRETÁRIO OFÍCIO N° /2011/SDE/GAB Brasília, 04 de março de 2011. A Sua Senhoria o Senhor ANTÔNIO HENRIQUE PINHEIRO Secretário de Acompanhamento Econômico Ministério da Fazenda Ed. Sede, Bloco "P", 3° andar, sala 324 70048-900 - BRASÍLIA/DF ILtIJI o Lii! SEAWMF RECEBhlT -f Senhor Secretário De ordem, encaminho a versão pública, de interesse da empresa 08012.001157/2009-71. À Documentação de n° 08012.002663/2011-01, R, INC. referente ao Ato de Concentração,?4_ ? J Atenciosamente, JONAS Chefe & Esplanada dos Ministérios - Ministério da Justiça Fone: 61; 3321-7800/3: 1 - 5 andar—sala 538 - Cep: 70064900— Brasília-L)F 5— e-mail: sde1rni.pov.br lia MINISTÉRIO DA JUSTIÇA SECRETARIA DÉ DIREITO ECONÔMICO GABINETE DO SECRETÁRIO I OFICIO N° ' /2011/SDE/GAB Brasília, 04 de março de 201f? L A Sua Senhoria o Senhor FERNANDO DE MAGALHÃES FURL Presidente do Conselho Administrativo de Ministério da Justiça Brasília - DF 0 jEconômica 85 3- CADE/MJ 08700001379/201151 0% £4 Senhor Presidente, De ordem, encaminho a V versão pública, de interesse da empresa 08012.001157/2009-71. Documentação de n° 08012.002663/2011-01, R, INC. referente ao Ato de Concentração n Atenciosamente, S JONASi Chefe do SOUSA uM! SDE - Ministério da Justiça - E )T-5° andar — sala 538—Cep: 70064-900Fone: 613321-78001332 195—e-mail: sdeinjgov.br à MLNISTEWO DA JUSTIÇA SECRETARIA DE DIREITO ECONÔMICO GABINETE DO SECRETÁRIO OFÍCIO N° '1 /2011/SDE/GAB Brasifia, 04 de março de 201* A Sua Senhoria o Senhor FERNANDO DE MAGALHÃES FURLAN Presidente do Conselho Administrativo de Dei a Econômica Ministério da Justiça Brasília - DF -- - a CADE/MJ 08700001379/201151 li Senhor Presidente, De ordem, encaminho a V versão pública, de interesse da empresa P 08012.001157/2009-71. Documentação de n° 08012.002663/2011-01, R, INC. referente ao Ato de Concentração n° Atenciosamente, JONATtE1Ãfl1$4ttii buJX Chefe do Prbtocol6/ Processual! SDE 7 a e Ministério da Justiça - TERMO DE ENCERRAMENTO DE VOLUME 11 SISTEMA DE GERENCIAMENTO DE DOCUMENTOS/PROCESSOS MJDOC SDE/GAB/CAPRO - Coordenação de Apoioasw TERMO DE DE VOLUME Pública Ao(s) 12 dia(s) do mês de Julho de1 2011, procede o encerramento deste volume, no do Processo 08012.001157/2009-71, contendo 248 folhas, abrindo-se em seguida o volume n°2. Para constar, eu NILCEIA MARTINS DE SOUZA, sobrescrevo e assino. Carimbo e iTéiMartins de So Agente Administrativo e Mat. 0161048 1 1 .ti Emitido por NILCEIA MARTINS DE souzAI: Data: 12/07/2011 Hora: 17:21 Ministério da Justiça Página 1 de 1 a Ministério da Justiça DE VOLUME TERMO DE DE GEFENCIA14ENTO DE DOCUMENTOS/PROCESSOS MJDOC SPE/GAB/CAPRO - Coordenação de ApoioajuE DE VOLUME TERMO DE 2011, procede o encerramento deste volume, abrindo-se em seguida o volume no 2. , sobrescrevo e assino. Julho Ao(s) 12 dia(s) do mês de n° do Processo 08012.001157/2009-71, contendo 248 Para constar, eu NILCEIA MARTINS DË S Carimbo e .céta Martrn$ de Souza Agente Admi4istrativo y Mat. 016048 ,1 Data: 12/07/2011 Emitido por: NILCEIA MARTINS DE SOUZA Hora: 17:21 Ministério da Justiça li Página 1 de 1